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Alzheimer’s disease is a progressive neurodegenerative condition that is 
characterised by distinct neuropathological changes. Within the last decade post 
mortem human brain samples have been used to show that there are robust 
epigenetic changes occurring in the brain during disease. However, as these 
samples are collected shortly after death they are a reflection of only the very end 
stages of disease. 
 
Through the exposure of differentiated adult cells to exogenous reprogramming 
factors it is now possible to generate induced pluripotent stem cells which have 
the potential to differentiate into any cell type in the body. Over recent years 
reseach has moved towards using these stem cells to generate neurons or 
microglia in order to study diseases of ageing such as Alzheimer’s disease. 
However, there are relatively few epigenetic studies that have been undertaken 
using induced pluripotent stem cells. As there are global cellular epigenetic 
changes occurring during the induction of pluripotency and re-differentiation it is 
critical to ensure we understand the DNA methylation changes occurring during 
normal neuronal differentiation before using these as a model of Alzheimer’s 
disease or other diseases of ageing.  
 
The aim of this thesis is to first characterise the DNA methylation changes that 
are occurring in neuronal and microglial models that are exposed to AD-relevant 
exposures such as differentiation and maturation, drug treatment and immune 
challenge. This will largely be achieved through measuring DNA methylation 
using the Illumina Infinium HumanMethylationEPIC BeadChip array which 
provides information on the DNA methylation levels at over 850,000 loci across 
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This chapter reviews research that has been undertaken in the field of 
Alzheimer’s disease (AD), with a particular emphasis on epigenetic studies and 
work in induced pluripotent stem cells (iPSCs) to date. The work presented in this 
chapter reviewing iPSCs to study epigenetic variation in AD is based on a 
published review, on which I am first author [1], which can be found in Appendix 
A. 
 
1.1 Alzheimer’s Disease (AD) 
Dementia is an umbrella term that covers several diseases that all have similar 
symptoms, which are associated with neurodegeneration. AD is the most 
prevalent neurodegenerative disorder and accounts for approximately 60-80% of 
all dementia cases worldwide [2]. The disease is characterised by the 
accumulation of amyloid beta (Aβ) plaques, intracellular neurofibrillary tangles 
(NFTs) of hyperphosphorylated tau [3] and loss of synaptic connections [4];  taken 
together these lead to neuronal cell death. This is accompanied by cognitive and 
behavioural changes, such as memory impairments, language disturbance and 
hallucinations. The early cognitive decline in AD can be attributed to the 
degeneration of cholinergic neuronal cells found in the cortical and limbic brain 
regions such as the hippocampus [5] and the basal forebrain [6]. 
 
1.1.1 Types of AD  
AD can be broken down into two subtypes, early onset AD (EOAD) and late onset 
AD (LOAD). EOAD accounts for relatively few cases, between to 1-5% and the 
disease has a  symptomatic onset of before 65 years of age [7]. EOAD is usually 
attributed to autosomal dominant mutations in three genes, which are amyloid 
precursor protein (APP), presenilin1 (PSEN1) and presenilin2 (PSEN2). 
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Therefore these cases of EOAD can be inherited and so are often termed familial 
AD (FAD).  
 
Most AD cases are late-onset, starting after the age of 65, and sporadic, with no 
defined aetiology. However, in recent years, large cohort collections and the 
relatively inexpensive cost of assessing genetic variation through genome-wide 
association studies (GWAS) has allowed the identification of common variants 
associated with risk of developing LOAD. These studies have demonstrated that 
LOAD is multifactorial with many different genes and single nucleotide 
polymorphisms (SNPs) being implicated in, and contributing to, disease onset 
and progression [8].  
 
1.1.2 Prevalence and Financial Burden 
It is estimated that 46.8 million people worldwide are affected by dementia, with 
this set to double every 20 years, reaching 131.5 million people in 2050 [9]. 
Despite 5.2% of people over the age of 60 living with dementia only around 1 in 
4 people with AD have been diagnosed [10]. Furthermore, due to the rising 
number of AD cases the economic burden of the disease is also increasing; it has 
been calculated that the global cost of dementia was $818 billion in 2015, with 
this set to become $2 trillion by 2030. Some regions have seen large increases 
in cost with the greatest being an increase by ~300% in sub-Saharan Africa, 
whilst overall the worldwide increase is ~35% [10]. This is because the life 
expectancy of developing countries is increasing and the number of people aged 




1.1.3 Disease Progression and Pathological Hallmarks 
Despite LOAD and EOAD having different causes and ages of onset, the 
progression and pathology of these subtypes are broadly the same. As previously 
stated AD can be characterised by the accumulation of Aβ plaques and NFTs of 
hyperphosphorylated tau. The deposition of these tangles does not occur at 
random, but follows a distinct and characteristic pattern [12-15], starting in the 
neocortex and then the hippocampus [16], whilst other regions, such as the 
cerebellum, remain relatively unaffected [17]. This specific topographical 
distribution correlates with, and explains, the characteristic symptoms of AD; the 
hippocampus and neocortex are well known for being involved in controlling 
emotions, memory and higher brain function [18, 19]. The cerebellum on the other 
hand is responsible for the coordination, motor and voluntary movements, and 
there are far fewer aberrations in these in AD patients when compared with the 
prevalence of other symptoms [20]. There is already considerable pathology 
before the disease is diagnosed [21], with the onset of symptoms sometimes 
occurring at least 10 years after Aβ is first deposited [22]. This apparent delay in 
the appearance of symptoms is caused by there being a threshold of cholinergic 
loss before the brain can no longer compensate and ameliorate the deficit [16]. 
 
1.1.4 Causes of LOAD 
Despite decades of molecular research into LOAD aetiology, relatively little is 
known about the exact mechanisms that initiate AD pathology or drive AD 
progression. Whilst it is known that certain genetic mutations can increase one’s 
risk of disease (see section 1.1.4.4), it is unclear through which mechanism these 
are acting. In general, there are three hypotheses that try and explain AD 
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aetiology. These are the amyloid hypothesis, the tau tangle hypothesis, and the 
inflammatory hypothesis. 
 
1.1.4.1 The Amyloid Hypothesis 
As previously stated, it is known that certain mutations within the APP, PSEN1 
and PSEN2 genes are disease causing. The proteins that these genes code for 
are all involved in the proteolytic cleavage of APP into several different proteins. 
APP can be processed through two pathways: the amyloidogenic and non-
amyloidogenic pathway, and it is the amyloidogenic pathway that produces 
several isoforms of Aβ (figure 1.1) [23]. In the non-amyloidogenic pathway APP 
is first cleaved by α-secretase (encoded for by ADAM10) followed by γ-secretase, 
forming AICD, sAPPα and p3. However, in the amyloidogenic pathway APP is 
cleaved by β-secretase (encoded for by BACE1) and then γ-secretase to form 
sAPPβ, AICD and Aβ. Interestingly, PSEN1 and PSEN2 both encode for proteins 
that are subunits of the γ-secretase complex [24-26]. 
 
Whilst Aβ has normal cellular functions such as playing a role in synaptic plasticity 
[27], kinase activation [28] and oxidative stress protection [29], too much causes 
aggregation and the formation of plaques. Interestingly, the aggregation rate 
varies between the different isoforms of Aβ, for example the fastest aggregation 
rate can be attributed to Aβ1-42 and so this isoform is more likely to form neurotoxic 
amyloid plaques [30]. These mutations (in APP, PSEN1 and PSEN2) shift the 
balance of APP processing more towards the amyloidogenic pathway, therefore 
changing the Aβ42/Aβ40 ratio. This has been shown to cause an increase in the 















Figure 1.1. Proteolytic cleavage of APP through the amyloidogenic and non-amyloidogenic pathways. 
In the non-amyloidogenic pathway APP is first cleaved by α-secretase followed by γ-secretase, forming AICD, sAPPα and p3. However, in the 
amyloidogenic pathway APP is cleaved by β-secretase and then γ-secretase to form sAPPβ, AICD and amyloid-β (Aβ). Mutations in APP, PSEN1 
or PSEN2 that shift the balance towards the amyloidogenic pathway result in the formation of more oligomers and plaques made of Aβ. 
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1.1.4.2 The Tau Tangle Hypothesis 
Tau, which is encoded for by the microtubule associated protein tau (MAPT) 
gene, plays important physiological roles in microtubule assembly and 
stabilisation [32]. Altogether there are six isoforms in the brain, which vary in 
length, the number of microtubule binding domains (3R or 4R) and inserts of 29 
amino acids in the N-terminus (0N, 1N or 2N) they contain [33].  In three of the 
isoforms of Tau there are three microtubule binding domains (0N3R, 1N3R, 
2N3R) and in the other three there are four microtubule binding domains (0N4R, 
1N4R, 2N4R) [33].  
 
Alongside Aβ plaques, the accumulation of intracellular Tau into NFTs is another 
hallmark of AD. The exact mechanisms through which these NFTs develop are 
still un-clear, but the phosphorylation and de-phosphorylation of Tau is thought 
to play a critical role (figure 1.2). NFTs in the brains of AD patients compared to 
non-AD patients are enriched for abnormally hyperphosphorylated Tau (p-Tau) 
[34]. This p-Tau is unable to bind to tubulin, therefore preventing microtubule 
assembly, alongside this it can also disrupt the microtubules directly [35, 36]. 
Dysfunctional networks of microtubules within neurons cause disturbances to 
critical cellular functions such as axonal transport [37] and synaptic integrity [38]. 
P-Tau is also able to sequester normal physiological Tau causing further cellular 
disruption [39]. The progression of p-Tau accumulation within the brain, 
measured as Braak staging (figure 1.3), correlates with disease severity [40] and 
is therefore thought to play a key role in the initiation and progression of disease. 
Tau deposition first begins in prodromal AD in the transentorhinal cortex (stages 
I/II) before spreading further during mid-stage AD into the limbic regions (stage 
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III/IV) and finally during late stage disease is widespread throughout the 
neocortex (stage V/VI). 
 
Whilst there have been no mutations in MAPT implicated in AD, MAPT mutations 
are sufficient to cause diseases such as frontotemporal dementia (FTD). The 
MAPT mutations linked to FTD have been shown to be missense or deletion 
mutations that reside either in the coding region or intronic region located close 
to the splice donor site of the intron following exon ten [41-43]. These mutations 
are believed to affect how tau interacts with microtubules, reducing their stability 
and ability to form [44-47]. Intronic mutations are generally located at positions 
+3, +13, +14 and +16 within the intron following the alternatively spliced exon 10 
[48, 49]. Using exon trapping it has been shown that intronic mutations lead to 
increased splicing of exon ten which can also be seen in brain tissue from patients 
known to have intronic MAPT mutations [50, 51]. This is reflected by a change in 
the 3R to 4R isoform ratio creating an overproduction of the 4R isoform [42, 52]. 
Exploring these mutations and the effects they have is of importance for AD as it 
can help the understanding of how tau pathology may lead to neurodegeneration. 
Until relatively recently it was believed that it was not possible to develop AD 
without the presence of Aβ plaques. However, imaging studies have shown that 
tau tangles do occur in the absence of amyloid. Using positron emission 
tomography (PET) to look at the presence of both Aβ plaques and tau and their 
association with cognitive performance it was shown that in the absence of tau 
memory, language and executive function were unaffected even in the presence 
of Aβ plaques [53]. This suggests that it is in fact tau that causes cognitive 
















Figure 1.2. Schematic diagram to illustrate the hyperphosphorylation of Tau.  
Within neuronal cells Tau mediates the stabilisation of microtubules by binding to tubulin dimers. If hyperphosphorylated Tau dissociates from the 
microtubules, this causes them to destabilise. Hyperphosphorylated Tau is prone to aggregation first into paired helical filaments and then 




Figure 1.3. Schematic diagram to illustrate the spread of Tau throughout the 








In the prodromal phases of disease (stage I/II) Tau deposition can be seen in the 
transentorhinal regions of the brain, before spreading to the limbic areas during the 
mid-stage (stage III/IV) , and finally into the neocortex in late stage AD (stage V/VI). 
Where the shade of blue indicates the level of tau deposition from light blue = least 
deposition to dark blue = considerable deposition. Image adapted from BioRender.  
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1.1.4.3 Innate Immunity and AD 
Of increasing interest is the involvement of the innate immune system in AD, 
particularly the role of microglia. Microglia are the resident immune cells in the 
brain and spinal cord, and play important roles in neurodevelopment, immune 
surveillance, disease and homeostasis [54]. Unlike neurons and other glial cell 
types, microglia are of haematopoietic lineage, arise early during development 
[55], and are derived from erythromyeloid progenitors (EMPs) in the yolk sac  [56].  
There is increasing evidence to suggest that microglia play a key role in AD risk 
and pathogenesis [57]. Under normal physiological conditions they are highly 
ramified and their function is highly regulated by molecular factors in the central 
nervous system (CNS) [58]. Upon activation microglia become less ramified, 
develop a more rounded cell body with shorter processes and express a wide 
range of different mediators [59]. Through chronic/recurrent activation of 
microglia during ageing, or the presence of Aβ plaques in AD, this can trigger 
morphological changes and alterations in intracellular and cell surface antigens 
reminiscent of an activated cell [60]. These microglia are said to be “primed” and 
are in a pre-activated state [61, 62]. These primed microglia have increased 
expression of inflammatory markers such as major histocompatibility complex 
(MHC) class II molecules, complement receptor 3 (CR3) and are also less 
ramified [63-66] (figure 1.4). Once primed, microglia give a heighted response to 
inflammatory stimuli [60]. This exaggerated immune reaction activation is 
accompanied by the secretion of inflammatory molecules, which can be 
detrimental to surrounding neurons [67] (figure 1.4).  However, microglial priming 
by Aβ does not necessarily only occur after Aβ deposition, but can also occur 
before plaques are even formed; Maezawa and colleagues have shown that 
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nanomolar concentrations of Aβ oligomers can activate microglia and induce 
microglial-mediated neuronal cell death [68].  
 
To date, anti-inflammatory drugs have proved unsuccessful in ameliorating the 
microglia-induced neuronal death [69]. This is because the relationship between 
the innate immune system and AD is incredibly complex, and the immune 
response to plaques can be beneficial or damaging depending on the context [70-
72]. It is also likely that these studies were also undertaken too late, once the 
priming and damage had already occurred, but it has been suggested that long 
term non-steroidal anti-inflammatory drugs (NSAIDs) can give a decreased risk 






















Figure 1.4. Schematic illustrating the role of microglial activation in AD. 
 
Under physiological conditions microglia have a highly ramified morphology. Throughout ageing microglia are repetitively stimulated, and also as a 
response to chronic Aβ in AD they become primed. Following this priming, when they encounter secondary stimuli such as inflammatory mediators 
as a response to a systemic infection they undergo a heightened response. This response results in the release of proinflammatory, excitatory and 





1.1.4.4 Genetics of LOAD 
The mutations known to cause FAD are within genes that are all involved in the 
APP processing pathway. On the other hand, the causes of LOAD are far less 
defined; despite there being a genetic component to LOAD there are no 
mutations/SNPs that are sufficient to cause disease alone. From GWAS it has 
been shown that the gene most robustly associated with LOAD is Apolipoprotein 
E (APOE), which encodes a polymorphic glycoprotein that is involved in the 
transport of cholesterol and other lipids [74] alongside neuronal growth [75] and 
tissue repair [76]. There are three isoforms of APOE that all correspond to allelic 
variation at a single locus, ɛ2, ɛ3 and ɛ4, which can be distinguished by cysteine 
to arginine substitutions at the amino acid positions 112 and 158 [77]. The ɛ4 
variant confers increased risk of developing LOAD, with each additional copy of 
the risk allele lowering the mean age of onset [78]. Whilst APOE ɛ4 accounts for 
approximately 20% of genetic risk for developing LOAD it cannot explain all of 
disease incidence, as not everyone who is homozygous for ɛ4 develops AD [79]. 
Aside from APOE there are numerous other SNPs that have been implicated in 
LOAD from numerous GWAS. In 2013, there was a meta-analysis of nearly 
75,000 individuals which nominated 19 common genetic variants, of which 11 
were novel disease loci [80] (see table 1.1). Interestingly, many of the GWAS loci 
nominated for AD can be linked to amyloid processing or inflammation. More 
recently, two larger meta-analyses of AD GWAS were published; Kunkle and 
colleagues identified 25 risk loci in ~95,000 individuals [81], whilst Jansen et al 
nominated 29 risk variants, implicating over 200 genes, by analysing >450,000 
individuals, by using an AD-by-proxy phenotype [82]. The genes identified were 
in pathways relating to immune regulation, lipid related processes and 





been identified from GWAS only confer a relatively modest effect size, with odds 
ratios (ORs) between 0.73 and 1.22 per loci investigated [83], it is thought that 
these could act cumulatively to cause the onset of degeneration. Scientists have 
generated polygenic risk scores (PRS) for AD, which combine the effects of many 
disease-associated SNPs to predict disease risk [84] and recently it has been 
reported that the PRS prediction captures nearly all common genetic risk for AD 
[85].  However, another study has demonstrated that collectively common SNPs 
for AD only account for a third of phenotypic variance in AD [86]. Recent efforts 
to explain the missing heritability of AD have used sequencing approaches to 
identify rare variants, with a larger effect size, with SNPs in PLD3, TREM2, 




















Table 1.1. Summary table of SNPs associated with AD, which reach genome wide 
significance in Lambert et al, 2013 [80] 
 
 
SNP Chr:Position Closest Gene Odds Ratio 
rs6656401 
 1:207692049 CR1 1.18 
rs6733839 
 2:127892810 BIN1 1.22 
rs10948363 
 6:47487762 CD2AP 1.10 
rs11771145 
 7:143110762 EPHA1 0.90 
rs9331896 
 8:27467686 CLU 0.86 
rs983392 
 11:59923508 MS4A6A 0.90 
rs10792832 
 11:85867875 PICALM 0.87 
rs4147929 
 19:1063443 ABCA7 1.15 
rs3865444 
 19:51727962 CD33 0.94 
rs9271192 
 6:32578530 HLA-DRB5– HLA-DRB1 1.11 
rs28834970 
 8:27195121 PTK2B 1.10 
rs11218343 
 11:121435587 SORL1 0.77 
rs10498633 
 14:92926952 SLC24A4 RIN3 0.91 
rs8093731 
 18:29088958 DSG2 0.73 
rs35349669 
 2:234068476 INPP5D 1.08 
rs190982 
 5:88223420 MEF2C 0.93 
rs2718058 
 7:37841534 NME8 0.93 
rs1476679 
 7:100004446 ZCWPW1 0.91 
rs10838725 
 11:47557871 CELF1 1.08 
rs17125944 
 14:53400629 FERMT2 1.14 
rs7274581 
 20:55018260 CASS4 0.88 





1.2 Genomic Regulation 
Epigenetic processes mediate the reversible regulation of gene expression, 
occurring independently of DNA sequence, acting principally through chemical 
modifications to DNA and nucleosomal histone proteins [92]. Epigenetic 
modifications serve to inform the transcriptional machinery whether a gene is to 
be transcribed or not. It is epigenetic processes that allows every cell type in the 
body to express different proteins and have distinct morphologies and functions, 
despite containing the same genetic material [93]. There are several epigenetic 
mechanisms, including DNA modifications, histone modifications and microRNA-





















 (A) Regulation of chromatic structure through post-translational modifications to 
histone proteins. This can include: acetylation, methylation, SUMOylation, 
ubiquitylation, citrullination and ADP-ribosylation. (B) Addition of chemical tags to DNA 
to the 5’ end of a cytosine nucleotide. This creates 5-methylcytosine (5-mC) – the most 
commonly studied epigenetic mark, 5-hydroxymethylcytosine (5-hmC), 5-
carboxylcytosine (5-caC) and 5-formycytosine (5-fC). (C) Small RNA molecules, such 
as microRNA (miRNA) can also affect gene expression either through degrading mRNA 





1.2.1 DNA Modifications 
The most widely studied epigenetic modification in human studies is that of DNA 
methylation, given it is the most stable and longest lasting change [94, 95]. This 
is because it can be robustly assessed using extracted genomic DNA, thus 
meaning it has been the focus of many human epidemiological epigenetic studies 
to date [96]. 5-methylcytosine (5-mC) is formed when a methyl group (CH3) is 
added to the 5’ position of the pyrimidine ring of a cytosine within a CpG 
dinucleotide by DNA methyltransferases (DNMT). 5-mC has been shown to block 
transcription by preventing the binding of transcription factors (TFs) and 
promoting methyl-binding proteins to initiate chromatin compaction [97]. 
However, it is not always the case that DNA methylation leads to gene silencing. 
More recently it has been demonstrated that methylation that lies within the gene 
body itself may be associated with transcriptional activation [98-100]. 
 
DNA methylation is not the only cytosine modification, 5-hydroxymethylcytosine 
(5-hmC) [101, 102], 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caC) [103, 
104] have all been described in recent years and are formed from the sequential  
oxidation of 5-mC by ten eleven translocation (TET) enzymes (figure 1.6). These 
modifications, 5-hmC in particular, has been shown to be enriched in certain 
areas of the brain [105-107] and also in stem cells [108], with between 0.4-0.7% 
[106] and 4-6% [109] total nucleotides being hydroxymethylated respectively. 
Lowering TET levels within stem cells, and therefore also 5-hmC levels, has been 
shown to impair self renewal and promote the loss of the stem cell phenotype 
[110, 111]. Interestingly, in contrast to 5-mC it has been demonstrated that 5-










Cytosine is first methylated, to 5-mC, by a DNA methyl transferase enzyme (DNMT). 
This can then be sequentially oxidised into 5-hmC, 5-fC and 5-caC by ten eleven 





1.2.2 Other Epigenetic Mechanisms 
Alongside cytosine modifications, histone modifications and small RNA based 
mechanisms also alter the expression of genes. As with DNA modifications there 
are several different chemical marks which can be added to histones to alter their 
function.  
 
As the focus of this PhD thesis is on DNA methylation I have chosen to focus on 
this epigenetic mechanism only. However, I do acknowledge that there are other 
epigenetic mechanisms that may play a role in the onset and progression of AD.  
 
1.2.3 DNA Methylation Studies in AD 
Initial studies investigating DNA modifications in AD focussed on global 
methylation analyses using immunofluorescence. These were inconsistent in 
findings; Mastroeni and colleagues demonstrated a significant decrease in 5-mC 
and 5-hmC in entorhinal cortex neurons and glia in AD patients when compared 
to controls [113, 114]. They have also shown that the affected twin in a 
monozygotic twin pair had decreased DNA methylation in cortical neurons [115] 
and decreased 5-mC and 5-hmC in hippocampal neurons and glia [113] 
compared to the unaffected twin. However, other studies have shown increased 
global 5-mC and 5-hmC in AD patients [116] and in AD neurons [117]. Due to the 
inconsistencies between studies attention has changed to investigating 5-mC and 
5-hmC change at single nucleotide resolution.  
 
One way in which this was achieved was through the use of array based 
methodologies. The earliest array based technologies assessed AD-associated 





methylation BeadChip array (27K array). One study, which identified 948 CpG 
sites (mapped to 918 unique genes) showed nominally significant AD-associated 
DNA methylation changes [118]. Sanchez-Mut et al also used this array and 
investigated hippocampal DNA methylation in five Braak stage I-II cases, five 
Braak stage III-IV cases, five Braak stage V-VI and five controls (Braak stage 0). 
They identified Braak-associated DNA methylation at four loci, two of which 
resided within the DUSP22 gene and one each in the CLDN15 and QSCN6 genes 
[119].  
 
The 27K array has since been superseded by the Illumina Infinium 450K 
methylation BeadChip array (450K array), which can determine the DNA 
methylation status of >485,000 loci across the genome. It is this technology that 
has been most widely used to assess epigenetic variation in AD. In 2014, two 
independent papers were published back to back that both identified four 
overlapping signals (ANK1, RPL13, RHBDF2 and CDH23), which had not 
previously been associated with AD [120, 121]. Interestingly, in the Lunnon et al 
paper, two of the top four most significant differentially methylated positions 
(DMPs) resided in the ANK1 gene, located only 91bp apart. These changes were 
found only in brain regions known to be affected by AD, such as the prefrontal 
cortex, entorhinal cortex and superior temporal gyrus, but not other unaffected 
brain regions such as the cerebellum [120]. However, a recent study has used 
pyrosequencing to assess DNA methylation across an 119bp region of the ANK1 
gene, which includes those two CpG sites, in a range of different brain regions in 
different dementias and showed ANK1 hypermethylation in AD cerebellum, 
although not at the two sites covered by the 450K array [122]. Interestingly, this 





in AD, Huntington’s disease (HD) and Parkinson’s disease (PD). In individuals 
with Dementia with lewy bodies (DLB), or Vascular dementia (VaD), DNA 
hypermethylation was only seen in individuals with co-exisiting AD pathology. 
The same group have also recently shown robust neuropathology-associated 
DNA methylation in the HOXA gene cluster. In this study they used the 450K 
array to identify a 48kb region, spanning 208 CpGs, which demonstrated 
increased DNA methylation in the prefrontal cortex and superior temporal gyrus 
tissue. The top ranked probe within the HOXA3 gene was also validated in two 
independent cohorts [123]. Taken together, these studies have provided the first 
robust and replicable evidence of an association between differential DNA 
methylation and AD. 
 
Whilst these studies have undoubtedly provided valuable insight into the role of 
epigenetic dysfunction in AD, they were performed on bulk brain tissue. Having 
multiple cell types present within each tissue sample can add noise to the data 
and whilst this can be controlled to some extent in the analysis, this is not ideal. 
Furthermore, AD is characterised by alterations in the abundance of neurons and 
glia, which further confounds the problem. In order to try and combat this issue, 
Gasparoni et al, performed the first epigenome-wide association study (EWAS) 
on FACS sorted neuronal and non-neuronal (glia) nuclei from post mortem brain 
[124]. They were able to show Braak-associated changes in neurons and glia that 
replicate the previous findings, and confirms the cell type of origin of the ANK1 
(glia) and HOXA3 (neuron) signals. 
 
The latest iteration of the methylation array is the Illumina Infinium EPIC array 





genome wide at single nucleotide resolution. One study by Marioni et al used this 
newest array to investigate the relationship between accelerated DNA 
methylation, or epigenetic age, and AD risk factors relating to lifestyle, genetics 
and cognitive reserve. DNA methylation at certain loci has shown to change 
robustly with age and based on this there have been numerous algorithms 
developed which are able to predict biological age from an individuals methylome 
[125, 126].  Using epigenome-wide DNA methylation data from 5,100 people they 
reported significant associations between epigenetic age acceleration and body 
mass index (BMI), socioeconomic status, high blood pressure and smoking [127]. 
This study highlights the potential importance of specific lifestyle factors in the 
onset of AD and suggests that modifying these may lower AD risk, although more 
longitudinal studies are needed to disentangle these relationships further.  
 
Overall through many studies, some of which are discussed here, it has been 
shown that specific DNA methylation changes are consistently and robustly 
associated with AD pathology. However, these relationships are complex and 
further studies need to be undertaken in order to elucidate the precise 
mechanisms and establish whether these epigenetic changes are causative or 












1.3 Modelling AD 
There are a number of different model organisms that have been used to 
investigate AD-associated changes including rodent models, Drosophila 
melanogaster and neuronal cell culture models. In this section I will initially focus 
on rodent models, as these have been the most widely utilised. Subsequently, I 
will discuss newer methodologies involving stem cell models and how these are 
being used to model AD. 
 
1.3.1 Rodent Models of AD 
To fully understand and characterise a disease, extensive modelling must take 
place to elucidate the mechanisms underlying disease aetiology. Traditionally, 
this has been achieved by several methods, including both animal (murine) 
models and primary patient cell lines. Whilst both approaches have their own 
merits, they can prove inconvenient and do not completely and accurately reflect 
human disease. At present, the AD research field has had a heavy focus on 
disease modelling through the use of transgenic mouse models [128], as there is 
a well-developed understanding of genetic manipulation techniques in this 
organism. Furthermore, mice are more phylo-genetically related to humans than 
other simpler model organisms such as Drosophila melanogaster 
and Caenorhabditis elegans, although these do allow for more experimental 
control than mice. Due to the close relation of mice to humans they also have 
great utility in studying familial AD using transgenic mice containing mutations in 
the APP and PSEN genes. This has led to advances in our understanding of 
multiple aspects of AD, in particular amyloid pathology and the differential effects 
of the various Aβ peptides. However, despite the extensive use of these 





mice do not display overt neurodegeneration [129-131], have amyloid plaques 
[132], nor do they model sporadic LOAD.  
 
Whilst they have proven useful for modelling autosomal disease, such as familial 
AD, the mouse models do not have extensive utility for studying sporadic AD, 
which has both polygenic and environmental components. Even if it were possible 
to model the genetics of sporadic AD in transgenic mice the effect sizes of each 
associated variant would be small and therefore difficult to determine phenotypic 
outcome. However, there have been murine studies that have targeted 
replacement of the endogenous murine Apoe gene with human APOE-ε4. These 
mice demonstrated reduced spatial learning and a reduction in dendritic spine 
density in the medial entorhinal cortex [133]. In another study where APOE (both 
ε3/ε3 and ε4/ε4) mice were crossed with mice containing a mutant human form 
of APP, the APOE-ε4xAPP mice displayed significantly worse spatial memory 
performance than their APOE-ε3xAPP counterparts, but this was also associated 
with insulin dysfunction [134].  
 
1.3.2 iPSCs and iPSC-derived Neurons as Models 
A more promising avenue for modelling SNPs in complex diseases, such as 
sporadic AD, is using stem cell technology. Embryonic stem cells (ESCs), which 
are derived from the inner cell mass of an embryo (blastocyst), have the ability to 
differentiate into any cell in the body [135]. Due to their inherent plasticity, and as 
genomic variation can be assessed relatively inexpensively through polymerase 
chain reaction (PCR), microarray, or sequencing technology, there is the potential 
that they could be used to study the effect of disease-associated SNPs on the 





implicated with using embryo derived ESCs are numerous. Recent advances in 
stem cell technology have allowed the production of stem cells derived from adult 
tissue, such as blood, urine and fibroblasts (figure 1.7) [136]. These iPSCs have 
almost identical characteristics to ESCs: they share the same morphology, can 
differentiate into any cell type in the body, have unlimited growth and have the 
same expression pattern of genes [137]; potentially making them a very powerful 
tool in research. One concern of using iPSCs is that of X-inactivation in female 
cells, whereby one of the X chromosomes is randomly inactivated. It was 
previously a concern that iPSCs may not consistently and efficiently undergo X-
inactivation. However, a recent study investigated X-inactivation in ESCs and 
iPSCs using over 700 high-throughput sequencing samples. They demonstrated 
that whilst there is heterogeneity in X-inactivation and XIST expression in the 
ESCs this was not the case for iPSCs which maintained an inactivated X 
chromosome [138]. 
 
The most common method of using stem cells to study neurological diseases is 
by differentiating iPSCs into neurons (figure 1.8). Through this process different 
growth factors are added into the culture media to promote cellular differentiation 
to neuronal cell types. Two growth factors in particular are used to differentiate 
iPSCs into a neuronal cell type, SB431542 (SB) and LDN193189 (LDN), through 
a process named dual SMAD inhibition. Dual SMAD inhibition rapidly 
differentiates iPSCs into early neuroectoderm [139] by blocking two signalling 
pathways. These pathways use two SMADs, bone morphogenic (BMP) and 
transforming growth factor-beta (TGF-β), for signal transduction. By blocking 
these pathways OCT4 expression decreases and PAX6 expression increases, 






Whilst these two growth factors are common to most neuronal differentiation 
protocols, there are numerous other growth factors and small molecules used in 
order to terminally differentiation and mature iPSC derived-neurons [141]. For 
example, glial cell line-derived neurotrophic factor (GDNF), brain derived 
neurotrophic factor (BDNF) and ascorbic acid (AA) can be used. These three 
factors have been shown to support the survival and promote the growth and 
differentiation of new synapses and neurons [142-144].   
 
Many of the methodologies used to generate iPSC-derived neurons were 
developed in order to generate specific neuronal cell types and few have been 
created in order to enhance and accelerate functional maturation. One which has 
been created with this in mind is the synaptojuice medias developed by Kemp et 
al [145]. Their differentiation protocol requires the serial addition of two 
supplemented medias in order to enhance the two phases of neuronal 
development, neurogenesis and synaptogenesis. A list of all the growth factors 
used in these two medias (SCM1 and SCM2) can be found below in figure 1.8. 
Cells matured through this protocol exhibit comparatively larger cellular 
capacitance and relatively hyperpolarised resting membrane potentials. Not only 
this, but functionally mature neurons can be generated within 21 days, roughly 
half the time it would take with other methods [145]. However, whilst this 
methodology does decrease differentiation time, it does not promote the growth 







Whilst it is now possible to create iPSC-derived neurons of different subtypes the 
earliest studies using iPSC-derived neurons simply served to try and recapitulate 
AD findings from other models such as post-mortem human brain and rodent 
models. From these studies it was demonstrated that neuronal survival and 
function were comprised when the iPSC-derived neurons were treated with 
exogenous Aβ [146-150]. Alongside this, iPSC-derived neurons which were 
derived from both LOAD and EOAD patients had increased Aβ1-42 production and 
elevated Aβ1-40/Aβ1-42 ratio [151-156]. For example, iPSC-derived cortical 
neurons containing the PSEN2 N141I mutation demonstrated both an increase 
in Aβ1-40/Aβ1-42 ratio and a decrease in the maximum number of spikes following 
depolarising injection, both of which were ameliorated in isogenic controls [153]. 
Besides aberrant Aβ production there are also aggregates of 
hyperphosphorylated tau in AD. During the normal timeframe of neuronal 
differentiation in culture, iPSC-derived neurons do not express the mature 4R 
isoform of tau. It is not until they were cultured for extended periods, ~360 days 
in vitro, that the mature 4R isoform was co-expressed alongside 3R tau [157]. 
Despite this, even without the mature 4R isoform, EOAD neurons harbouring an  
APP duplication had increased GSK-3β activity and a concomitant increase in 







Figure 1.7. A simplified schematic representing the reprogramming of 
differentiated adult cells into iPSCs.  
This technique, as first described by Takahashi and Yamanaka in 2006, uses four 
reprogramming factors to de-differentiate adult somatic cells into iPSCs. Lin28 and 





















The medias and growth factors used to promote neuronal differentiation are shown. 
These include; two SMAD inhibitors: SB and LDN and IWR1 which inhibits the WNT 
signalling pathway. The components for SCM1/2 were formulated to promote 
neurogenesis and synaptogenesis [145]. 
 







1.3.3 iPSC-derived Microglia 
Until recently, it had been difficult to generate iPSC-derived microglia, with much 
scepticism for the reported studies as the microglia were made from induced 
hematopoietic stem cells (HSCs). HSCs have the potential to give rise to other 
cell types such as blood derived macrophages and as already stated microglia 
arise from EMPs (see section 1.1.4.3). In order to generate EMPs from the iPSCs, 
Muffat et al developed a serum free media that contains high levels of IL-34 and 
colony stimulating factor 1 (CSF1) [159]. These conditions were chosen as the 
media mimics the brain cerebrospinal fluid and the factors have been shown to 
be necessary for microglia differentiation and maintenance. These cells were 
shown to express many of the cell surface markers of microglia including 
TMEM118, P2RTY12/13, HEXB and GPR34. Alongside this, the resulting cells 
were also highly phagocytic and a transcriptomic analysis showed they resemble 
human primary foetal and adult microglia [159]. This is not the only protocol that 
has been developed to generate iPSC-derived microglia, and there are now 
several different methods available [160-163]. 
 
Since the development of these protocols there has been significant interest in 
using the resulting cells to study the impact of various immune-related AD-
associated SNPs; one such mutation is the R47H mutation of TREM2. 
Interestingly, in knock-in mice harbouring the human R47H mutation in TREM2 
was aberrantly spliced, however, this was not found to be the case in human 
primary and iPSC-derived microglial models [164]. Other functional studies have 
also demonstrated that missense mutations cause TREM2 to accumulate in its 
immature form, meaning it is not processed normally and therefore is not 





differentiation and are able to perform phagocytosis and still respond to immune 
stimuli [165]. This suggests that certain TREM2 mutations can have subtle 
effects, perhaps reflecting the later onset of disease [165].  Alongside TREM2, 
iPSC-derived microglia have also been used to further investigate the relationship 
between APOE genotype and AD. A study by Lin et al demonstrated that APOE 
status was linked to the gene expression in biological pathways such as lipid 
metabolism or immune responses [166]. In addition to this cells carrying the 
APOE4 variant were shown to have impaired Aβ42 clearance when compared to 
isogenic controls [166]. 
 
1.3.4 Other Cellular Models used to Investigate AD 
To overcome some of the caveats of iPSC-derived neurons, in particular those 
related to cellular immaturity, other ways of modelling neurological disorders such 
as AD have emerged. One of these are induced neurons (iNs), which are similar 
to iPSC-derived neurons in that they are generated from differentiated adult 
tissue, but differ in the fact that they do not pass through a stem cell intermediate 
phase [167]. As iNs do not pass through this intermediate stage they have been 
shown to retain the epigenetic, metabolomic and transcriptomic age of the 
fibroblasts they were derived from [168, 169]. Alongside this, iNs are easier to 
make, quicker to produce, taking only a couple of few weeks, and are much 
cheaper than iPSC-derived cells. Whilst this maintenance of age and cost-
effectiveness have obvious advantages for studying diseases of ageing there are 
a few limitations which means they have not been widely adopted. Firstly, their 
major limitation is that the number of iNs you can generate is finite as there are 
no stages within reprogramming that are expandable. This means that iNs are 





screens [170]. Secondly, it has been shown that the original culture conditions of 
the fibroblasts can impact on the resulting neurons and therefore cause 
interindividual heterogeneity or mosaicism when compared to the clonal nature 
of iPSC-derived cells [171]. Finally, whilst it is possible to generate iPSC-derived 
neurons from a variety of differentiated tissues including but not limited to 
fibroblasts [136], keratinocytes [172] and blood cells [173] the same cannot be 
said for iNs. Currently only pericytes and skin fibroblasts have been used to 
successfully derive iNs from adult tissue, but as pericytes are quite hard to obtain 
from donors, fibroblasts remain the only feasible option for generating iNs. 
 
The other cellular model being used increasingly more frequent to study 
neurological diseases such as AD are those of cerebral organoids. Cerebral 
organoids are conceptually very similar to iPSC-derived cells as they are too are 
derived from iPSCs, the main difference is that the organoids are grown in 3D 
rather than the traditional 2D culture used for iPSC-derived neurons [174]. The 
creation of organoids relies upon the ability of iPSCs to self-organise, and through 
the use of exogenous factors form organised structures resembling distinct 
regions of the brain [174]. One recent study demonstrated that organoids derived 
from both down syndrome and EOAD patients displayed progressive 
accumulation of Aβ and tau into structures resembling plaques and NFTs, but 
that these aggregations were absent from control organoids [175]. Alongside 
monoculture organoid models triculture models have also been developed to 
increase physiological relevance. Using this system organoids containing 
neurons, astrocytes and microglia to model AD pathophysiology and the model 
displayed Aβ aggregation, tau hyperphosphorylation, neuroinflammatory activity 





relevant organoid models do have their limitations. One limitation to modelling AD 
with organoids relates to the maturity of the resulting cells, much like iPSC-
derived neurons grown in 2D, cerebral organoids have been shown to have a 
transcriptional profile representative of a prenatal brain [175, 177]. Alongside this 
another limitation is that of the lack of vascularisation, which can result in 
insufficient neuronal maturation and overall limits the amount of time the 




























1.4 Using iPSCs to Model Epigenetic Changes 
 
1.4.1 Epigenetic Changes Associated with Inducing Pluripotency 
Associated with inducing pluripotency are the global cellular epigenetic changes 
that allow the cells to alter gene expression and become iPSCs. These changes 
to epigenetic mechanisms, such as DNA methylation, are known to regulate 
which parts of the DNA are transcribed and change throughout development and 
differentiation in order to restrict what types of cells the precursors can become 
(figure 1.9) [179].  
 
Despite being functionally identical, several groups report that iPSCs have 
different DNA methylation profiles and gene expression patterns to ESCs [180-
183]. Similarly, whilst grown in 3D, cerebral organoids too have been 
demonstrated to have the epigenetic signature of fetal human brain, but their 
development does seem to parallel that of human cortical development [184]. 
Some groups attribute this variation due to an ‘epigenetic memory’ where iPSCs 
show residual DNA methylation patterns that are typical of the tissue they 
originate from [185]. These differentially methylated regions (DMRs) were shown 
to affect the differentiation potential of the newly formed iPSCs. For example, 
iPSCs derived from neural and fibroblast progenitors maintained DNA 
methylation marks at sites associated with haematopoietic lineages, which 
decreased the potential for these iPSCs to form blood cells. Subsequently, it is 
possible to reverse these restricting methyl marks by increasing the cells passage 
number or treatment with chromatin modifying compounds [185]. This treatment 
is associated with a decrease in DNA methylation at haematopoietic loci and 





appear that this epigenetic memory can affect the differentiation potential of cells 
initially, this effect is actually only transient. It has also been observed that certain 
subsets of cells can become stuck in a partially reprogrammed state. This is due 
to inefficient DNA demethylation at certain sites or the incomplete repression of 
TFs [186]. Despite this, these aberrations can be rectified using RNA inhibition of 
TFs or treatment with DNA methylase inhibitors. Another potential source of 
epigenetic variation between ESCs and iPSCs is the microenvironment in which 
the iPSCs have been generated. Cooper and Newman have demonstrated that 
there is some correlation between cells’ gene expression patterns and the 
laboratory the cell lines are derived from [187, 188]. This demonstrates that the 
environment can affect the epigenome and therefore downstream gene 
expression of cell lines. To fully assess the differences in the epigenomes 
between iPSCs and ESCs, Lister et al, utilized a shotgun bisulphite sequencing 
technique (MethylIC-seq) to look at the whole-genome DNA methylome at single 
base-pair resolution [189]. This demonstrated that, overall, ESCs and iPSCs are 
similar, but that there are some inherent differences between their DNA 
methylomes. The reprogramming of somatic cells generated hundreds of DMRs 
that could be attributed to both memory from the somatic cell and iPSC-specific 
DNA methylation patterns that are susceptible during the reprogramming process 
as many DMRs were consistent across independent iPSC lines [181]. All of these 
studies demonstrate that there are fundamental differences in both the 
epigenome and gene expression patterns of ESCs and iPSCs. However, there 
are ways to rectify some of these differences meaning that iPSCs still have utility 

















In order to create iPSCs from differentiated adult tissue such as fibroblasts global cellular 
changes to epigenetic mechanisms, such as DNA methylation, are necessary as these 
epigenetic mechanisms regulate cell fate and differentiation. Undifferentiated pluripotent 
cells, such as iPSCs, start at the top of the landscape, and throughout differentiation they 
move further down the landscape becoming more specialised and undergoing epigenetic 
changes which reflect this. To reprogramme differentiated cells such as fibroblasts back 
into the pluripotent state you have to reset these epigenetic marks, effectively pushing the 






Through the use of GWAS in human samples and studies in rodent models clear 
links between genetic variation and disease progression have been established 
[80, 82, 128-134]. However, in the case of LOAD, genetic variation is not sufficient 
in all cases to cause disease, as exemplified by the fact that approximately 40% 
of monozygotic twins are discordant for AD [190].  In recent years EWAS studies 
have been undertaken to understand the contribution of non-genetic factors to 
AD onset and progression [120, 121, 123]. Whilst these studies have provided 
clear and robust evidence for epigenetic dysfunction in AD the majority have been 
performed using postmortem brain tissue, which only offer a snapshot of DNA 
methylation profiles at the very end stages of life. Furthermore, these studies 
simply highlight an association with disease, and do not show whether nominated 
loci are actually causal in the disease process. Although rodent models can be 
utilised to study AD longitudinally, these are all models of FAD, which have limited 
utility for studying sporadic disease that has both genetic and environmental 
contributions. In order to establish how DNA methylation changes throughout the 
life course and in diseases it is now important to use human based models which 
can be followed over time to track these changes, such as iPSC-derived neuronal 
models and human derived cell lines. This thesis aims to characterise a number 











1.6 Hypothesis and Aims  
As it has previously been demonstrated that there is epigenetic dysfunction 
occurring in AD, this thesis hypothesises that there are methylomic changes 
occurring within neuronal and microglial cells when they are exposed to AD-
relevant exposures and that these changes can be linked to relevant biological 
pathways. 
 
In order to address this hypothesis this thesis aims to: 
1. Investigate the epigenomic changes that occur during iPSC differentiation 
and maturation into neurons. 
2. Investigate the epigenomic changes induced by epigenetic modulators in 
iPSC-derived neurons and microglia. 
3. Investigate the epigenomic changes induced by Lipopolysaccharide (LPS) 






























2.1 Cell Culture 
This section outlines the general methods that were used to culture cells on a 
regular basis. For cell line specific culture and differentiation methodology please 
see the relevant chapter. Please see table 2.1 for more information on the cell 
lines used in each chapter. 
 
All work done in this section was undertaken in a class II laminar flow hood that 
had been turned on and allowed to equilibrate for at least half an hour before use. 
During this time any appropriate reagents were warmed either through use of a 
water bath or drying oven set to 37oC. Once equilibrated the laminar flow hood 
was thoroughly decontaminated by spraying and wiping down all surfaces and 
side panels with 70% ethanol. At least once a week the laminar was also deep 
cleaned (by using 1% Rely+On Virkon (12358667, Fisher Scientific) solution 
followed by 70% ethanol). Before being placed into the laminar flow hood all items 
and equipment were thoroughly sterilised first by being sprayed with 70% ethanol. 
After completion of cell culture work the laminar flow hood was again sterilised 























3 33Q Fibroblasts Female Lentivirus - 3x Technical  - [191] 
4 
CTR M3 36S Keratinocytes Male Sendai virus  - 3x Technical  300,000 [192] 
SFC840-03-03 Fibroblasts Female Sendai virus  - 3x Biological  750,000 [193] 
5 SV40 Primary microglia Male 
Lenti‐SV40 
lentivirus 6 3x Technical  100,000 - 
Table 2.1. Information on cell lines used in each chapter. 
Detailed information for the cell line(s) used in each chapter. The chapter the cell line was used in, the name of the line, the tissue it was 
derived from, the sex of the person the line was derived from, the transformation method, passage number at which they were used, 





2.1.1 Thawing and Recovery 
Cells in long term storage were kept in liquid nitrogen using Cryostor (Sigma 
Aldrich). Cells were defrosted by partially immersing the cryovial into a 37oC 
water bath until only a small ice crystal remained. Once defrosted the cryovial 
was transferred into the laminar flow hood where all cell culture work was 
undertaken. The cell suspension was then transferred into a 15mL falcon tube 
containing the relevant pre-warmed media. Cells were pelleted by centrifugation 
for three minutes at 1,000rpm (Megafuge 16R, Thermo Fisher), and the resulting 
pellet resuspended in media containing 1xRevitacellTM cell supplement (1:100, 
Gibco). Resuspended cells were placed into the correct size flask or culture plate 
and kept in a humidified incubator at 37oC, with 5% CO2. RevitacellTM supplement 
was removed after 24 hours by changing the media on the cells.  
 
2.1.2 Changing Media 
The relevant media was first warmed to 37oC in a water bath or drying oven. Once 
up to temperature media and relevant equipment were sterilised with 70% ethanol 
and placed into the laminar flow hood. Following this, cells were then carefully 
moved from the incubator into the laminar flow hood, being sprayed with ethanol 
before being placed into the laminar flow hood. Using good aseptic technique, 
the lid of the flask was removed and spent media removed using a stripette and 
pipet aid. Waste media was then placed into a flask containing 1% Virkon in order 
to kill any free-floating cells. Fresh media was then placed into the relevant 
wells/flasks, being careful not to wash it over the culture and dislodge the cells. 






2.1.3 Cryopreserving Cells 
To freeze down cells they were first washed in phosphate buffered saline (PBS; 
Gibco), treated with Ethylenediaminetetraacetic acid (EDTA; Gibco) or Accutase 
(Gibco) (depending on cell type/stage) and washed with media as described in 
section 2.1.2. After washing, cells were detached from the base of the well using 
1mL Cryostor/well and the suspension placed into a cryovial. Vials of cells were 
placed into isopropanol tubs for the first 48 hours before being moved to liquid 























2.2 DNA Extraction 
This section outlines in detail the method used to extract DNA from cell pellets in 
Chapters 4, 5 and 6. All plastic-ware used during this protocol were sterile and 
DNase free. Before starting the laboratory benches were cleaned using Alconox 
(Sigma Aldrich) and 70% ethanol to remove contaminants and any DNases 
present.  The DNA extraction workflow is depicted in figure 2.1 below. 
 
2.2.1 Overview of DNA Isolation using a Phenol Chloroform Based Protocol 
Extracting genomic DNA using a phenol-chloroform method has been widely 
used and has been shown to yield high quality DNA for downstream purposes 
[194]. The method below is an adaptation of the phenol-chloroform method 
developed by Sambrook et al. [194]. Reagents used for the extraction can be 
found in tables 2.2, 2.3 and 2.4. 
 
2.2.2 Lysis and Digestion of Cells 
Cell pellets were resuspended in 1mL lysis buffer (table 2.2). Subsequently, to 
degrade any RNA present, 2μL of RNase-A (working concentration 20µg/mL; 
Fisher Scientific) was added to each sample and these were then incubated at 
37oC for two hours. To facilitate protein degradation, 20μL of Proteinase K 
(20mg/mL; Sigma Aldrich) was added and the sample was incubated for a further 
two to three hours at 50oC. The sample was then cooled to room temperature 






2.2.3 Purification of Nucleic Acids 
Phase lock tubes were prepared by adding vacuum grease to the lid of a 2mL 
Eppendorf tube and centrifuging the tube at room temperature (RT) for 10 
minutes at 3,000 rpm. The cooled lysed cell suspension prepared in section 2.2.2 
was then added to the phase lock tube, before being topped up with 
Phenol:Chloroform:Isopropyl alcohol (PCI). The tube was then inverted 20x to 
mix and was centrifuged at 13,000 rpm for 15 minutes at RT. The top layer was 
then transferred to a new 2mL Eppendorf and 1mL of chloroform was added. The 
tube was inverted 20x to mix and was then centrifuged at 13,000 rpm for 15 
minutes at RT. The top aqueous layer was carefully transferred to a new tube 
and the chloroform extraction step was repeated.  
 
2.2.4 Precipitation of DNA  
Sufficient 100% ice-cold ethanol was added to the purified nucleic acid solution 
to fill the Eppendorf tube. Subsequently, the samples were placed at -20oC 
overnight. After 12-16 hours the samples were centrifuged at 13,000 rpm for 15 
minutes at RT, the DNA was precipitated, forming a white pellet at the base of 
the tube. The supernatant was removed and the pellet was carefully washed with 
1mL 70% ethanol so as not to dislodge the pellet. The sample was then 
centrifuged at 13,000 rpm for 10 minutes, before repeating the 70% ethanol wash 
step. The supernatant was removed by pipetting and the sample was left to air 
dry for 30 minutes. Finally, the pellet was resuspended in 200μL Tris-EDTA (Te) 
buffer (table 2.3) and left to dissolve overnight. Once dissolved DNA was stored 






Once collected and pelleted the cells were lysed using RNase A and proteinase K. The nucleic acids were then purified from this lysed cell 
solution through the concurrent addition of PCI and chloroform spinning whilst centrifuging between each addition. Once purified the DNA was 
precipitated using ice-cold 100% ethanol. Following precipitation, the DNA was pelleted and dissolved in Te. 





2.2.5 Determining the Quantity of Extracted DNA 
2μL of DNA was used to quantify DNA using spectrophotometry (NanoDrop 8000) and 
check quality. The quality was assessed by checking the 260/280 and 230/280 ratios, 





















Name Storage pH Final Concentration Supplier Catalogue No. 
NaCl RT - 75mM Sigma Aldrich S3014 
Tris-HCl RT 8 10mM VWR 733-1654 






RT - th final volume Sigma Aldrich L3771 
H20 RT - - - - 
Table 2.2. Reagents required to make lysis buffer.  
 





Name Storage pH Volume (mL) Supplier Catalogue No. 
1M Tris-
HCl 
RT 8 10 VWR 733-1654 
0.5M EDTA RT 8 0.2 Fisher Scientific 11568896 
H20 RT - 990 - - 
Where RT signifies room temperature. 
The solution was filtered with a 0.5micron filter and autoclaved before use. Where RT 










Name Storage Concentration Supplier Catalogue No. 











Isoamyl Alcohol (PCI) 































2.3 DNA Sodium Bisulphite (BS) Treatment  
BS treatment, which was originally described in 1992 by Frommer et al. [195] is a 
methodology that allows you to accurately measure DNA modifications at the base-
pair level. Through this method un-modified cytosines are converted into uracils, and 
so after PCR amplification the uracils become a thymine. However, if a cytosine is 
modified, i.e. contains a methyl or hydroxymethyl group, it is protected from conversion 
and so will not become a thymine. It is this difference that allows you to distinguish 
whether a cytosine was originally modified or not. BS treatment using the EZ-96 DNA 
Methylation-GoldTM Kit (Zymo D5007) requires 500ng of high quality DNA (in a volume 
of 20μL) to provide enough starting material to profile cytosine modifications using the 
Illumina Infinium Methylation bead arrays, which is the profiling methodology used in 
all data chapters of this thesis. The method outlined below is an adaptation of the BS 




2.3.1 Starting Material 
500ng (25ng/μL in 20μL) of DNA was added to each well of a 96 well PCR plate. 
  
2.3.2 Sodium BS Conversion 
To each DNA sample in the 96 well plate, 130μL CT conversion reagent (table 2.5) 
was added and mixed by pipetting. The PCR plate was sealed and transferred to a 





10 minutes, 64oC for 2.5 hours and then 4oC for up to 24 hours. Once the cycle was 
completed, 600μL of M-binding buffer was added to the wells of a Zymo-SpinTM I-96 
binding plate mounted on a collection plate. The samples were transferred from the 
conversion plate into the Zymo-SpinTM I-96 binding plate and mixed by pipetting. The 
plate was centrifuged at 3,000 x g for 5 minutes and the flow through was discarded. 
Subsequently, 400μL of M-wash buffer (table 2.6) was added to each well and the 
plate was centrifuged again at 3,000 x g for 5 minutes. Following this, 200μL of M-
desulphonation buffer was added to each well and the plate was incubated at room 
temperature for 15 minutes. The plate was then centrifuged at 3,000 x g for 5 minutes 
and the flow through was discarded. Samples were washed using 400μL of M-wash 
buffer, centrifuged at 3,000 x g for 5 minutes and the flow through discarded. A further 
400μL of M-wash buffer was added to the samples, which were then centrifuged at 
3,000 x g for 10 minutes. The Zymo-SpinTM I-96 binding plate was placed onto an 
elution plate and 15μL of M-elution buffer was added directly onto each well of the 
binding plate. The plate was incubated at room temperature for 5 minutes and then 
centrifuged at 4,000 x g for 3 minutes. Subsequently, a further 15μL of M-elution buffer 
was added to the plate and the incubation and centrifugation step was repeated. The 
eluted DNA could then be used immediately for downstream analysis, or store at -











Reagent Volume (mL) Supplier 
M-dissolving buffer 0.5 Zymo 
M-dilution buffer 3 Zymo 
CT conversion reagent Bottle provided Zymo 
Ultra-pure H2O 9 User 
Table 2.5. CT conversion reagent required for BS conversion using the Zymo EZ-96 





Reagent Volume (mL) Supplier 
M-wash buffer 36 Zymo 
100% ethanol 144 User 
Table 2.6. Reagents required to make the M-wash buffer for BS conversion using the 






The CT conversion reagent is provided as a powder and must be dissolved prior to use 





2.4 Infinium Human Methylation EPIC BeadChip Array  
By combining whole genome amplification of BS treated DNA with array based scoring 
of CpG loci, the EPIC array makes it possible to assess 5mC levels of 863,904 loci 
across the genome [196]. The EPIC array builds on the previous iteration of this 
technology, the Illumina Infinium Human Methylation 450K array, and contains >90% 
of the original CpGs plus an additional 413,743 CpGs [197]. Importantly, the EPIC 
array covers 99% of the Reference Sequence (RefSeq) database genes, and includes 
coverage of important regulatory regions such as CpG islands (CGIs) (>95% covered), 
shores (>90% covered), shelves (>80% covered), 3’ and 5’ untranslated regions 
(UTRs), promoters, enhancers and CpGs within gene bodies [196].  
 
In order to quantify 5-mC levels, the signal intensity of each probe is measured using 
an Illumina iScan by generating beta values, a measure of DNA methylation. Within 
the BeadChip there are two different types of probe used to assess methylation, these 
are termed type I and type II probes (figure 2.3). Type I probes have two separate 
probe sequences per CpG one each to cover the methylated and unmethylated CpG. 
The hybridisation of an unmethylated BS converted DNA strand to an unmethylated 
bead allows for the single base pair extension and incorporation of a labelled ddNTP 
nucleotide which matches the nucleotide which is immediately upstream of the CpG. 
However, if an unmethylated DNA strand hybridises to a methylated bead then there 
is a 3’ mismatch pairing at the probe and single base pair extension is not possible. 
The same method/steps is used for the detection of methylated BS treated DNA, but 
in reverse. Whereas, the same bead is used to measure both methylated and 





match both the BS treated methylated and unmethylated DNA sequences. This is 
achieved by allowing the cytosine of interest, the target of the single base pair 
extension and replacing the rest of the cytosines within the probe sequence with 
degenerate R bases that can hybridise to both C and T bases (where C represents 
methylated and T represents unmethylated loci). 
 
2.4.1 EPIC Array Protocol  
In this section I will describe the methodology required to perform the Illumina Infinium 
HumanMethylationEPIC BeadChip Array. All reagents described are provided as part 
of the array kit, unless otherwise stated. Please see figure 2.2 for the experimental 
workflow. 
 
2.4.1.1 Preparation for amplification 
In the first stage of this protocol the BS DNA is denatured and neutralised in order to 
prepare it for overnight amplification. First, 20μL of MA1 reagent was pipetted into 
each well of an MSA4 plate, before 7μL of BS DNA from the BS elution plate was 
added in to the corresponding wells of the MSA4 plate. Following this, 4μL of 0.1M 
NaOH was added to each well and the MSA4 plate was sealed using a 96-well cap 
mat, having ensured that the orientation of the cap matches that of the plate. Each 
plate was then vortexed for one minute and centrifuged at 280 x g for one minute. The 
plate was then incubated for ten minutes at room temperature. After this incubation, 
68μL of RPM solution and 75μL of MSM solution was added into each well and the 
plate was re-sealed with the 96-well cap mat. The plate was then mixed by inverting it 
ten times, before centrifuging at 280 x g for one minute. The plate was then incubated 






2.4.1.2 Fragmentation of DNA 
The MSA4 plate was removed from the hybridisation oven and centrifuged at 50 x g 
for one minute. Following this, 50μL of FMS solution was added to each well and the 
plate was sealed with a 96-well cap mat. The plate was then vortexed for one minute 
at 1,600 rpm before being centrifuged at 50 x g for one minute. The sealed plates were 
then placed on a heat block set to 37oC for one hour.  
 
2.4.1.3 Precipitation of DNA 
After the DNA had been fragmented, the plate was removed from the heat block and 
100μL of PM1 was added to each well and the plate sealed with a 96-well cap mat. 
The samples were then vortexed at 1,600rpm for one minute followed by a 37oC 
incubation for five minutes. After this incubation step, the samples were centrifuged at 
50 x g at 22oC for one minute. Subsequently, 300μL of 100% 2-propanol (Sigma 
Aldrich) was added to each well, the plate was carefully sealed with a new 96-well cap 
mat, inverted at least ten times to mix the contents thoroughly and then incubated at 
4oC for 30 minutes. Following this incubation stage the plate was centrifuged at 3,000 
x g for 20 minutes at 4oC. The cap mat was then discarded, the supernatant removed 
and the plate was left uncovered and inverted for one hour at room temperature to air 
dry the pellet.  
 
2.4.1.4 Resuspension of DNA 
26μL of RA1 reagent was added to each pellet and then the plate was heat sealed 





for one hour. After this incubation stage, the plate was vortexed at 1,800 rpm for one 
minute and then centrifuged at 280 x g for one minute.  
 
2.4.1.5 Hybridisation to BeadChip 
Before hybridisation can begin the hybridisation chambers were first prepared as 
follows. First, the hybridisation chambers were placed into the corresponding gaskets 
and then 800μL of PB2 solution was placed into the reservoir of each chamber. Once 
the reservoirs were filled the chamber lid was replaced and kept at room temperature 
until needed.  
 
The resuspended samples in the MSA4 plate were placed on the heat block at 95oC 
for 20 minutes to denature the samples. After this incubation step, the plate was 
removed from the heat block and allowed to cool to room temperature for 30 minutes. 
Once cooled, the plate was pulse centrifuged at 280 x g for one minute and the 
BeadChips were removed from 2-8oC storage 15μL of each DNA sample was pipetted 
onto the appropriate BeadChip section, the hybridisation inserts containing the 
BeadChips were loaded into the hybridisation chamber, the chamber was closed and 
placed in a hybridisation oven at 48oC with continuous movement for 16-24 hours.  
 
2.4.1.6 Washing the BeadChip 
The hybridisation chambers were removed from the oven and allowed to cool for 25 
minutes. During this time two wash dishes were prepared, containing 200mL of PB1, 
the multi-sample BeadChip alignment fixture filled with 150mL of PB1 solution and the-
flow through chamber. Once cooled the BeadChips were removed from the chambers 





into the wash rack and submerging them fully into the PB1 solution. Once all the 
BeadChips were in the wash rack, the rack was then moved up and down for one 
minute with slow gentle agitation. Subsequently, the wash rack was moved to another 
wash dish containing fresh PB1, again ensuring the BeadChips were fully submerged.  
 
2.4.1.7 Assembly of Flow-Through Chambers 
Each BeadChip was placed into a black frame that had been set up in the multi-sample 
BeadChip alignment fixture pre-filled with PB1 solution aligning the barcode with the 
ridges in the fixture, placing a clear spacer onto the top of each BeadChip and a clean 
glass back plate on top of the clear spacer. The metal clamps were attached to the 
flow through chamber and the clear plastic spacers were trimmed from the flow 
through chamber assembly.  
 
2.4.1.8 Single Base Pair Extension and Staining 
The water circulator was filled to the appropriate level and set so the chamber rack 
reached a temperature of 44oC. Once the chamber rack had reached this temperature 
each flow through chamber was placed in the chamber rack and then the following 
steps were undertaken using the Tecan dilution robot: 
1. 150μL of RA1 was dispensed and incubated for 30 seconds.  
a. This step was repeated five times 
2. 450μL of XC1 was dispensed and incubated for ten minutes 
3. 450μL of XC2 was dispensed and incubated for ten minutes 
4. 200μL of TEM was dispensed and incubated for 15 minutes 






a. This step was then repeated 
6. The temperature of the chamber rack was changed to the temperature stated 
on the side of the STM tube, which is normally 32oC. 
7. 450μL of XC3 was dispensed and incubated for one minute.  
a. This step was then repeated 
8. 250μL of STM was dispensed and incubated for ten minutes 
9. 450μL of XC3 was dispensed and incubated for one minute 
a. This step was repeated after which five minutes were waited before 
moving on. 
10. 250μL of ATM was dispensed and incubated for ten minutes  
11.  450μL of XC3 was dispensed and incubated for one minute 
a. This step was repeated after which five minutes were waited before 
moving on. 
12. 250μL of STM was dispensed and incubated for ten minutes 
13. 450μL of XC3 was dispensed and incubated for one minute 
a. This step was repeated after which five minutes were waited before 
moving on. 
14. 250μL of ATM was dispensed and incubated for ten minutes 
15. 450μL of XC3 was dispensed and incubated for one minute 
a. This step was repeated after which five minutes were waited before 
moving on. 
16. 250μL of STM was dispensed and incubated for ten minutes 
17. 450μL of XC3 was dispensed and incubated for one minute 






18. 450μL of XC3 was dispensed and incubated for five minutes 
19. Incubate for a further five minutes 
Once this staining was completed, the flow through chambers were immediately 
removed and placed horizontally on the lab bench. 
 
2.4.1.9 Washing and Coating the BeadChips 
A wash dish containing a wash rack was filled with PB1 reagent. Each flow through 
chamber was sequentially dismantled and each BeadChip was immediately placed 
into the wash rack, before slowly moving the wash rack up and down in the solution 
ten times and then soaking the BeadChips for five minutes. The BeadChips in the 
wash rack were then transferred to a second wash dish containing XC4 solution, and 
the rack was moved slowly up and down ten times, before soaking the BeadChips for 
five minutes. The BeadChips were removed from the XC4 and placed horizontally to 
dry in a vacuum desiccator for one hour at 508mmHg (0.68 bar), or until the XC4 was 
completely dry on the arrays. Once dry, the underside of each BeadChip was cleaned 
with 70% ethanol. 
 
2.4.1.10 Imaging the BeadChips 
Four BeadChips at a time were loaded into the Illumina iScan and the Methylation 







Figure 2.2. Diagram to illustrate the Illumina EPIC array workflow.
Diagram to illustrate the various experimental steps throughout the EPIC array protocol. After the DNA is bisulfite converted it is denatured 
and amplified by PCR before being fragmented and precipitated. Following this the precipitates DNA is re-suspended and hybridised to the 























On the EPIC BeadChip there are two probe types: type I, which uses two probe sequences 
per CpG and type II which uses just one probe per CpG. For type I probes the U bead 
measures the unmethylated signal and the M bead measures the methylated signal. The 







2.4.2 Data Quality Control (QC) and Normalisation 
The DNA methylation level at each CpG locus was determined by generating β-
values, which represent the ratio of the intensity of the fluorescent signal for the 
methylated and unmethylated beads. The β-values for each probe lies between 
zero (all cytosines at that loci are unmethylated) and one (all cytosines at that loci 
are methylated). The β-values can be calculated using the following equation:  
𝛽 =  
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑀
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑀 + 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑈 + 100 
 
2.4.2.1 Assessing Median Methylated and Unmethylated Signal Intensity 
The median methylated and unmethylated sample intensity for each sample were 
calculated and plotted against one another in order to ensure that the 
hybridisation to the BeadChip was successful and that the signal intensities for 
each sample were above background levels. Median sample intensities were 
coloured both by chip and position on each BeadChip to check whether these 
were having any effect on intensity. 
 
2.4.2.2 Determining Bisulfite Conversion Efficiency  
Another way to assess data quality is to determine the bisulfite conversion 
efficiency. The “bscon” function in the wateRmelon package [198] uses the 
sample intensities of the fully methylated control probes on the array to calculate 
the percentage bisulfite conversion of each sample. This percentage can be used 
to determine how well the bisulfite conversion went during the DNA preparation. 






2.4.2.3 Determining Epigenetic and Mitotic Age 
In order to calculate the epigenetic or biological age of samples the Horvath 
coefficients were extracted. There are 391 probes on the EPIC array whose DNA 
methylation profile has been shown to robustly change throughout ageing, these 
probes were used to generate an algorithm which can be used to predict the 
biological age of samples from methylation data [126]. This data was then 
uploaded and submitted to the latest version of the Horvath epigenetic age 
calculator at https://dnamage.genetics.ucla.edu/home [126]. 
 
To determine the mitotic age of samples the MiAge calculator was used. This is 
an algorithm that uses the methylation profile of 268 probes to predict the number 
of cellular divisions a cell has undergone [199]. The 268 probes relevant to the 
MiAge calculator were extracted and used in conjunction with MiAge algorithm to 
generate estimates of the number of cellular divisions.  
 
2.4.2.4 Pfilter 
To filter samples and probes by detection p-value the “pfilter” function in the 
wateRmelon package was used [198]. This removes samples that contain more 
than one percent (by default) of probes above the 0.05 detection p-value 
threshold and probes with any samples with a beadcount less than three or more 
than one percent above the p-value threshold.  
 
2.4.2.5 Normalisation using Dasen  
Normalisation was performed using the “dasen” function within the wateRmelon 
package [198]. Dasen uses quantile normalisation, which normalises by type I 






One limitation of the EPIC BeadChip array technology is the difference in 
performance between the two bead types [200]. More specifically, the β-values 
which are generated from the type I probes are in general more reliable and 
accurate than the values generated from the type II probes. In order to address 
this there have been a number of data normalisation methods developed. The 
wateRmelon package within R offers a range of different normalisation methods 
[198], of which Dasen was used within this thesis as it has consistently been 
shown to be the best performing method in our group.  
 
Another caveat of the BeadChip array is the presence of SNPs in close proximity 
to the CpG of interest, which have been shown to confound the data generated 
[201, 202], meaning therefore that the 5-mC levels detected may be a reflection 
of the underlying genetic variation. Furthermore, a proportion of the probes on 
the array have been shown to cross hybridise with other genomic locations and 
as a result do not accurately reflect the DNA methylation at the specific loci of 
interest [201, 202]. In order to overcome this any probes which have been 
identified as cross-hybridising or contain SNP variation were removed prior to any 
analysis, using the probe annotations provided by McCartney et al [203]. 
 
Further details on data QC and on specific analytical methods or pipelines can 









CHAPTER 3 : CHARACTERISATION OF DNA 
































The work presented in this chapter is based on work submitted for publication 
and is currently under review at Epigenomics (Imm et al, 2020).  A copy of the 
submitted manuscript can be found in Appendix C. 
 
3.1 Introduction 
The process of ageing very heterogeneous with some people developing age-
related conditions far earlier than others. Not only do age-related changes affect 
tissues and organs but also affect cells and their organelles [204]. These changes 
can include changes to mitochondrial function [205], the extracellular matrix [206] 
and also transcriptional and epigenetic changes [207-209]. In the introduction to 
this chapter I will briefly introduce the cellular changes that occur during ageing 
and focus on DNA methylation changes over time especially within the brain.  
 
3.1.1 Cellular Changes Associated with Ageing 
As we age one of the organelles that is particularly affected is the mitochondria. 
With time the electron transport chain (ETC) becomes less efficient, causing more 
reactive oxygen species (ROS) to leak into the cell and also reduced production 
of ATP [210].  This increase in ROS causes further mitochondrial damage and 
globally more cellular damage [211]. Whilst it is believed that ROS can have 
homeostatic functions and are released as a stress mechanism in order to 
promote cellular survival at some point during ageing, the levels of ROS can 
ultimately elicit more harm than good and begin to cause age-associated cellular 
damage [212]. 
 
Another hallmark of ageing is cellular senescence, which is the stable arrest of 






the shortening of telomeres [216] there are other mechanisms that cause 
senescence, including DNA damage to the INK4/ARF genes [215]. The levels of 
INK4a and ARF have been shown to correlate robustly with chronological age in 
the vast majority of tissues analysed in both humans and mice [217, 218] and 
have been linked to many different pathologies, including AD, through GWAS 
[219]. 
 
Ageing can also be characterised by deregulation or changes in alternative 
splicing [220]. Alternative splicing is a key mechanism for cellular homeostasis 
and survival, and is dysregulated in diseases of ageing such as AD [221-223]. 
One example of how alternative splicing can result or affect ageing is at the LMNA 
gene which encodes for LamininA/C. A mutation within this protein (C608T) 
causes a new 5’ splice site to be generated and therefore causes the formation 
of truncated form of the protein which is associated with the disease Hutchinson-
Gilford progeria syndrome [224, 225]. Progeria is a disease of accelerated ageing 
where the people who have the disease display age related phenotypes much 
earlier in life such as atherosclerosis, hardening of the arteries and cardiovascular 
diseases [226]. Another way in which alternative splicing can affect ageing is 
through the dysregulated splicing of DNA repair genes. This leads to increased 
DNA damage and cellular stress and therefore to cellular ageing [227].  
 
3.1.2 DNA Methylation Changes associated with Ageing 
Recent evidence suggests that epigenetic mechanisms such as DNA methylation 
may play a role in ageing [228-232]. Changes in DNA methylation at particular 






methylation changes over time [233-235] and these can used to accurately 
predict age in a variety of tissues [125, 236-238]. DNA methylation changes begin 
very early in life, with longitudinal studies in blood showing that during the first 
five years in early life there are large increases in DNA methylation, and that 
these changes in methylation occur even within the first year of life [239, 240]. 
Studies of DNA methylation throughout ageing within monozygotic twins have 
also demonstrated that changes to DNA methylation are independent of 
genotype, as the twins have diverging patterns of methylation over time, 
demonstrating that these epigenetic changes at least in part are influenced by 
our environment [241, 242]. “Epigenetic drift” is one mechanism that is theorised 
to play a role in cellular ageing and refers to stochastic alterations to the DNA 
methylome over time with age. This drift leads to inter-individual divergence in 
DNA methylation over time and is likely caused by accumulation of epigenetic 
changes brought on by environmental exposures [241, 242]. Characteristic 
robust and reproducible DNA methylation changes at specific loci over time as a 
result of age have now been used to derive an epigenetic clock which is able to 
predict biological age from epigenetic profiles [125].  
 
3.1.3 DNA Methylation Changes associated within the Ageing CNS 
DNA methylation is known to regulate early neuronal development as increased 
promoter methylation at pluripotency and germ-line specific genes ultimately 
determines pluripotency repression in progenitors [243]. For the first few years 
after birth there are large increases in DNA methylation at 16 of 50 genes which 
have been determined to be important in CNS development and growth with 
changes within the cerebral cortex being involved specifically in neuronal 






throughout early development and childhood, each age period are distinct from 
one another in terms of methylation changes within the prefrontal cortex [245]. 
The most dramatic changes occur during the prenatal period, slowing down 
considerably after birth and then continuing to slow further throughout life. 
Interestingly, the transition between postnatal to foetal is characterised by 
prenatal demethylation to postnatal methylation.  
 
One of the hallmarks of advancing age is the slow decline of cognitive function, 
including aberrations in memory [246]. Generally it is believed that there is a 
global decrease in DNA methylation with increased age, but that this is dependent 
on the context and the loci in question [247, 248]. In the mature CNS it has been 
shown that long-term memory and synaptic plasticity are modulated by the 
activity of DNMTs in the hippocampus and that these processes can be affected 
by the deregulation of methylation [249]. The decreased capacity for 
neurogenesis throughout ageing has been attributed to the global 
hypomethylation that is seen in the brain [250]. DNMTs mediate the DNA 
methylation process and have also been shown to be linked to memory and 
cognitive function. Using young and aged mice it has been shown that Dnmt3a2 
expression in the hippocampus decreases throughout ageing and that recovery 
of the Dnmt3a2 levels rescues cognitive functioning [251]. Taken together these 









3.1.4 Modelling Cellular Trajectory 
Genome-wide “omics” datasets, such as for DNA methylation provide an 
opportunity to study dynamic cellular processes such as cell cycle, cellular 
activation and differentiation [252, 253]. Using epigenomics data it is possible to 
computationally study these processes using trajectory inference (TI) modelling 
or pseudotime analysis. TI methods order the cells/samples based on patterns in 
the data, for example, based on the changes in DNA methylation profile [254]. 
Through the creation of lineage trajectories using TI methods it is possible to 
untangle dynamic processes and work out which changes are contributing to the 
trajectory.  
 
There are now over 70 TI methods available all with differing underlying 
characteristics and algorithms. Generally, there are two main differences 
between methods, which are (1) the type of trajectory they are able to detect and 
(2) whether they fix the topology of the trajectory. Early methodologies relied upon 
the user to input the topology parameters or the topologies to be fixed using 
algorithms [255-257]. However, more recent methods, such as SCORPIUS, are 
able to also infer the trajectory, which is computationally more complex [258].  
 
3.1.5 Using iPSC-derived Neurons to Model Diseases of Ageing 
In order to best model any disease, such as diseases of ageing, it is important 
that we select the most appropriate model possible. Over recent years one model 
system that has garnered considerably more use for modelling diseases of 
ageing, is that of iPSC-derived neurons. These iPSCs have been shown to be 
functional, expressing neuron specific proteins and having the ability to fire 






other model systems, it is important to also recognise their potential limitations. 
For example, although they have been shown to be electrophysiologically mature 
[145], with numerous protocols having now been developed to accelerate this 
electrophysiological maturity, they have also been shown to be transcriptomically 
immature [259].  
 
To utilise iPSC-derived neurons to study epigenomic aberrations in disease fully 
it is important to first have an understanding of what is happening under disease-
free conditions. This should include identifying an epigenetic trajectory signature 
associated with neuronal differentiation and maturation and to assess the 
epigenetic maturity of the resultant neurons. This data will then be able to inform 
future studies, allowing the better interpretation of disease specific epigenomic 
dysfunction, as well as allowing the identification of specific limitations that would 



















3.2 Hypothesis and Aims 
As epigenetic mechanisms are known to regulate cell fate and differentiation this 
chapter hypothesises that there are methylomic changes occurring as iPSCs 
differentiate and mature into neurons and that these changes are occurring in 
cellular pathways functionally relevant to the neuronal cell type.  
 
In order to address this hypothesis the aims of this chapter are: 
1. To determine the biological age of differentiated iPSC-derived neuronal 
cells. 
2. To identify the biological pathways that are changing throughout neuronal 
differentiation. 
3. To use DNA methylation patterns to create a cellular trajectory throughout 
differentiation and maturation. 
4. To use the loci important within the trajectory to look at gene-gene 


















3.3.1 Cell culture 
Information in this section covers the conditions needed to grow, maintain and 
differentiate iPSCs into mature neurons.  
 
3.3.1.1 Sources of Cells 
Cells referred to within this project as “33Q” were a gift from Professor Nicholas 
Allen at the University of Cardiff. These cells were generated and validated 
externally (HD33i.8) by Mattis et al [260].  
 
3.3.1.2 Neuralisation and Expansion into Neuronal Precursors 
Neurogenesis was conducted using a 2D-monolayer based system, through the 
addition of regulatory signalling molecules (table 3.1, figure 1.8) to iPSCs at a 
high confluency. Day 0-7, differentiation was first induced using SLI media which 
contained 2% NeuroBrew-21 without retinoic acid, 10µM SB, 1µM LDN and 
1.5µM IWR1. Media was changed daily, and cells were passaged 1:2 on day 8. 
On day 8, after passaging, cells were changed to LI media containing 2% 
NeuroBrew-21 without retinoic acid, 200nM LDN and 1.5µM IWR1. Media was 
changed daily between days 8 and 16. Following these differentiation steps NPCs 
were formed which could be expanded in NPC expansion media, terminally 
differentiated or frozen down for later use. 
 
3.3.1.3 Terminal Differentiation into Neurons 
To plated day 16 NPCs, SCM1 medium was added for the first 7 days post 






NeuroBrew21 (Miltenyi Biotec), 2µM PD0332991 (Selleckchem), 10µM DAPT 
(Sigma-Aldrich), 0.6mM CaCl2 (to give 1.8 mM total CaCl2 in final complete 
medium; Sigma-Aldrich), 200µM ascorbic acid (Sigma Aldrich), 10ng/mL brain-
derived neurotrophic factor (BDNF, Miltenyi Biotec), 1µM LM22A4 (Tocris 
Bioscience), 10µM forskolin (Tocris Bioscience), 3µM CHIR 99021 (Tocris 
Bioscience), and 300µM gamma-aminobutyric acid (GABA, Tocris Bioscience). 
From 8 days post plating, the NPCs were cultured in SCM2 medium, which 
contained 1:1 Advanced DMEM/F-12 (with Glutamax):Neurobasal A (Life 
Technologies), 2% NeuroBrew21 with retinoic acid (Miltenyi Biotec), 2µM 
PD0332991 (Selleckchem), 3µM CHIR 99021 (Tocris Bioscience), 0.3mM CaCl2 
(to give 1.8 mM total CaCl2 in final complete medium; Sigma-Aldrich), 200µM 
ascorbic acid (Sigma-Aldrich), 10ng/mL BDNF (Miltenyi Biotec), and 1µM 
LM22A4 (Tocris Bioscience). This media was generated as part of a rapid 
maturation protocol outlined in [261]. 
 







3.3.1.4 Media Used for Each Cellular Stage 
 
Cell 
Stage Media Name Media Components Working Concentration Supplier 
Catalogue 
Number 
iPSC Essential 8 Essential 8 basal medium - Life Technologies A1517001 Essential 8 supplement 1x Life Technologies A1517001 
D1-7 
NPC SLI 
Advanced DMEM/F-12 + Glutamax - Life Technologies 11524436 
NeuroBrew-21 without retinoic Acid 2% Miltenyi Biotec 130-097-263 
SB431542 10μM Abcam ab120163 
LDN193189 1μM Sigma Aldrich SML0559-5MG 
IWR1 1.5μM Tocris 3532 
D8-15 
NPC LI 
Advanced DMEM/F-12 + Glutamax - Life Technologies 11524436 
NeuroBrew-21 without retinoic Acid 2% Miltenyi Biotec 130097263 
LDN193189 200nM Sigma Aldrich SML0559-5MG 





Advanced DMEM/F-12 + Glutamax - Life Technologies 11524436 
NeuroBrew-21 with retinoic Acid 2% Miltenyi Biotec 130-093-566 
FGF2 20ng/mL Fisher Scientific 10222253 
D1-7 
TDN SCM1 
Advanced DMEM/F-12 + Glutamax - Life Technologies 11524436 
NeuroBrew-21 without retinoic Acid 2% Miltenyi Biotec 130097263 
PD0332991 2μM Tocris Biotechne 4786 
DAPT 10μM Tocris Biotechne 2634 
CaCl2 1.8mM Sigma Aldrich 449709 
Ascorbic Acid 200μM Sigma Aldrich BP461 
BDNF 10ng/mL Tocris Biotechne 248-BD-025/CF 
Forskolin 10μM Tocris Biotechne 1099 
LM22A4 1μM Tocris Biotechne 4607 
CHIR 99021 3μM Tocris Biotechne 4423 
GABA 300μM Tocris Biotechne 344 






NeuroBrew-21 with retinoic Acid 2% Miltenyi Biotec 130097263 
PD0332991 2μM Tocris Biotechne 4786 
CHIR 99021 3μM Tocris Biotechne 4423 
CaCl2 1.8mM Sigma Aldrich 449709 
Ascorbic Acid 200μM Sigma Aldrich BP461 
BDNF 10ng/mL Tocris Biotechne 248-BD-025/CF 
LM22A4 1μM Tocris Biotechne 4607 









Where D1-7 NPC is the media used for the first seven days of differentiation into neuronal precursors, D8-15 NPC is the media used for day 
8-15 of differentiation into neuronal precursors, D16 NPC is the media to maintain and expand the cells at the neuronal precursor stage, D1-
7 TDN is the media used for the first seven days of terminal differentiation into neurons, and D8- TDN is the media used to complete terminal 





















Figure 3.1. Diagram outlining the experimental workflow. 
33Q iPSCs were plated out at day -4 and allowed to grow in culture for four days before being collected. The remaining cells then began 
neuralisation and were collected on day 16 once neuronal progenitors had been formed. Following this, the final cells were terminally 
differentiated and collected after either a further 37 or 58 days. The diagram above illustrates the days the cells were collected at which cellular 






3.3.2 DNA Extraction and Methylation Profiling and Quantification 
DNA was extracted from cell pellets and bisulfite treated prior to quantification of DNA 
methylation using the Illumina EPIC array. Please refer to sections 2.2 for information 
on DNA extraction, section 2.3 for details on bisulfite conversion and section 2.4 or 
figure 2.2 for a detailed outline of the EPIC array protocol. 
 
3.3.3 Data QC 
For an outline of the QC and normalisation methods used in this chapter please see 
sections 2.4.2. All data analyses in this chapter were performed using R version 3.4.3. 
Signal intensities were imported into R using the methylumi package [262]. Initial QC 
checks were conducted using functions within the methylumi and wateRmelon 
packages [198, 262].  
 
Using the default setting of one percent, the “pfilter” function detected two samples 
and 12,962 probes and 7,170 sites to be above the detection threshold. The two 
samples which failed this metric, were the iPSC samples labelled “D4_2” and “D4_3”. 
These samples were removed at this point. 
 
3.3.4 Data Analysis  
Outlined in this section are the analysis steps conducted in order to assess and 








3.3.4.1 Correlation between Epigenetic and Mitotic Age 
In order to assess the correlation between the epigenetic and mitotic age Pearson’s 
product-moment correlation was used. This was using the “cor.test” function within the 
default statistics package of R. 
 
3.3.4.2 Weighted Gene Correlation Network Analysis (WGCNA) 
Network analysis was performed on normalized DNA methylation (β)-values using 
WGCNA [263]. Pair-wise correlations were used to identify modules of highly co-
methylated probes. An unsigned network was created using the “blockwiseModules” 
function from the WGCNA package [264] based on a block size of 10,000 and using 
a soft threshold parameter of 20. Each module was then labelled with a unique colour 
identifier. Module-trait relationship was determined using linear regression, and four 
modules were shown to be significant after multiple test correction (blue, black, 
greenyellow and red).  
 
Pathway analysis was used to give biological or functional meaning to the CpG sites 
that contributed the most to each significant module. This was achieved using the 
“gometh” function from the missMethyl package [265] alongside the Gene Onotology 
(GO) repository. The “gometh” function was chosen as it adjusts for the number of 
CpGs per gene. Probes were sorted by module membership in each module and the 
top 15% were used for pathway analysis. Briefly, pathways were downloaded from the 
GO website (http://geneontology.org/) and genes with at least one Illumina probe 
annotated to it and which mapped to at least one GO pathway were included. 
Pathways were filtered to those containing between 10 and 2,000 genes and a list of 






3.3.4.3 Probe Filtering and Dimensionality Reduction 
In order to robustly determine variable CpG sites median absolute deviation (MAD) 
was calculated and the upper fifth percentile was used as a cut off to determine the 
most variable probes throughout differentiation and maturation. Principal component 
analysis (PCA) without scaling probes by their variance was then used to reduce the 
number of dimensions within the dataset whilst maintaining as much relevant 
information as possible. 
 
3.3.4.4 Pseudotime Trajectory Analysis 
To create a pseudotime trajectory throughout the different cellular stage the 
“infer_trajectory” and “draw_trajectory_plot” functions of the SCORPIOUS package 
[258] were used, respectively. The first two principal components of the methylation 
data were subjected as the coordinate of the samples to the “infer_trajectory” function, 
which performs k-means clustering. This calculates the distance matrix between 
cluster centres and finds the shortest path that connects all cluster centres using a 
custom distance function before finally fitting a curve to the given data using principal 
curves [258]. 
 
Next, to identify the loci with the largest contribution to the trajectory, I regressed each 
CpG sites methylation values on the pseudotime variable that had been in the 
trajectory modelling, using a general additive model (GAM). This allowed the detection 
of non-linear methylation patters occurring throughout neuronal differentiation. The 
CpG loci which remained significant after Bonferroni multiple testing correction were 







3.3.4.5 Calculating Euclidean Distance 
Euclidean distance was calculated prior to the trajectory modelling in order to cluster 
the samples to identify their similarity to one another. This information was then 
represented as a dendrogram. 
 
3.3.4.6 Gene Ontology (GO) Enrichment Analysis 
Pathway analysis was used to give biological or functional meaning to the CpG sites 
that contributed the most to the trajectory analysis. This was achieved using the 
“gometh” function from the missMethyl package [265] alongside the GO repository. 
The “gometh” function was chosen as it adjusts for the number of CpGs per gene.  
 
In order to add additional meaning to the pathway analysis outputs the online platform 
REVIGO was used (available at: http://revigo.irb.hr/) [267]. The significantly altered 
pathways (determined by GO ID) and p-value significance values were added to the 
online portal with the GO term database being set to Homo sapien and the semantic 
similarity measure as Resnik. Once analysed the treemaps for the altered biological 
processes (BP), molecular functions (MF) and cellular components (CC) were 
generated and created. 
 
3.3.4.7 Gene-gene Interaction Network Analysis 
I used Metacore (Clarivate Analytics) to obtain a set of functional regulatory 
interactions between the unique genes that were annotated to the CpG sites with the 
largest contribution to the trajectory inference model. The Metacore database is a 
repository of manually curated and experimentally validated directed gene-gene 






validation enables us to create highly confident interaction network maps. The network 
reconstruction was restricted to interactions contained within the categories of 
“transcriptional regulation”, “influence on expression”, “co-regulation of transcription” 
and “regulation", which have all been reported in humans. When available the type of 
interaction, i.e. activation or inhibition, was provided. Next, the igraph package (version 
1.1.2) [268] was used to calculate the strongly connected component (SCC) from the 
network obtained through the Metacore database. Following this the “network 
analyser” tool from Cytoscape (version 3.4.0) [269] was employed to conduct the 




















3.4.1 Outcome of the QC Pipeline 
The results in this section outline the quality control process undertaken in order to 
ensure the data was of sufficient quality before undertaking any downstream analyses.  
 
3.4.1.1 Median Sample Intensities Highlight Potential Problems 
To check the signal intensities for each sample were above background level the 
methylumi package was used to extract and quantify the fluorescent intensities for 
each probe. Following this, the median methylated and unmethylated signal intensities 
for each sample were calculated (table 3.2). By plotting the median methylated signal 
intensity against the median unmethylated signal intensity (figure 3.2) If was able to 
determine whether the median signal intensities are above the background level of 
intensity, which is generally assigned a value of 1000. Two iPSC samples in our 
dataset, D4_2 and D4_3, have signal intensities which are close to or around the 
background signal intensity level and were therefore considered for exclusion from the 
study. However, as they were close to the cut off threshold, they were kept in so I 
could see if they also failed on any other QC metrics. 
 
Next, I assessed whether there was any variation introduced into the data by the 
BeadChip the samples were on or the position within the BeadChip. To do this the 
samples were coloured by BeadChip and position on the BeadChip and methylated 
and unmethylated signal intensities were plotted (figure 3.3). In the data whilst the 
BeadChip itself doesn’t affect the signal intensities (figure 3.3B) the position of the 






were located on row1 coloumn1 (R01C01) and row2 column1 (R02C01) have lower 
methylated and unmethylated median signal intensity than any other of the positions. 
























Cell Stage Day of Differentiation Replicate Sample ID Median Methylated Intensity Median Unmethylated Intensity 
iPSC 4 
1 D4_1 2320 1429 
2 D4_2 1136 1032 
3 D4_3 992 811 
4 D4_4 1781 1146 
NPC 16 
1 D16_1 4369 2199 
2 D16_2 3769 2001 
3 D16_3 3645 1667 
4 D16_4 3105 1632 
Neuron-D37 37 
1 D37_1 3394 1767 
2 D37_2 3298 1572 
3 D37_3 3637 1496 
4 D37_4 3633 1403 
Neuron-D58 58 
1 D58_1 3315 1819 
2 D58_2 3476 1789 
3 D58_3 2748 1232 
4 D58_4 3407 1480 
Table 3.2. Median methylated and unmethylated intensities for each sample. 
 
 
Using the methylumi package [262] the signal intensities for sample were extracted and the medians calculated. For each sample shown 
above is the sample ID, day of differentiation, replicate number, the corresponding cell stage, median methylated intensity and median 


























Figure 3.2. Median methylated and unmethylated signal intensities. 
 Using the methylumi package [262] the signal intensities for sample were extracted and 
the medians calculated. Scatterplot showing the median methylated and unmethylated 
















Median methylated and unmethylated sample intensities were calculated for each BeadChip and 
each of the eight positions on the BeadChip. (A) Median signal intensities coloured by position 
as a scatterplot and boxplot. (B) Median signal intensities coloured by Chip ID as a scatterplot 






3.4.1.2 All Samples have a Good Bisulfite Conversion Efficiency 
Bisulfite conversion is the process which converts unmethylated cytosines to uracils 
and consequently to thymines during PCR allowing unmethylated and methylated 
cytosines to be distinguished from one another once the EPIC array has been run. 
Therefore, it is of great importance that the bisulfite conversion efficiency is high and 
is detecting the true levels of methylated and unmethylated loci. Within the EPIC array 
there are several loci which are known to be fully methylated, using the “bscon” 
function of the wateRmelon package [198] within R it is possible to convert the 
fluorescence intensity of these probes for each sample into an easy to understand 
percentage conversion efficiency. The lowest generally accepted bisulfite conversion 
efficiency is 80% and any samples that have a percentage conversion less than this 
should be removed. All of the samples within this study have a bisulfite conversion 
efficiency of greater than 90% and therefore do not need to be removed based on this 


























Figure 3.4. Bisulfite conversion efficiency and β-density plot. 
 
 
(A) Using the fully methylated probes within the array the bisulfite conversion efficiency of each sample was calculated and represented in a 
histogram. (B) The DNA methylation level at each locus was determined using β -values, which are the ratio of fluorescence signal intensity for 






3.4.1.3 β-Density Demonstrates Bimodal Distribution of Methylation 
To determine the methylation level at each locus on the EPIC array β-values for each 
locus are generated. β-values are calculated by taking the ratio of the intensity for the 
fluorescent signal for the methylated and unmethylated beads. As this value is a ratio 
the β-value for each probe lies between zero and one, where zero indicates all 
cytosines at this locus are unmethylated and a value of one means all cytosines at this 
locus are methylated. The majority of loci within the genome will either be almost 
completely fully methylated or completely unmethylated, depending on whether the 
gene they are annotated to is being expressed or not. To check that our data falls in 
line with this the β-values for each sample were plotted on a density plot (figure 3.4B). 
It is clear that for the vast majority of samples and loci that this holds true. However, it 
is of note that for some of the iPSC samples there is an increase in hemi-methylation 
(having a β-value between 0.2 and 0.8) and a decrease in fully methylated loci. This 
would suggest that there is more hemi-methylation present in the iPSC samples over 
the more differentiated cell types.  
 
3.4.1.4 Two Samples are Removed by P-filtering 
The final stage in the QC pipeline is to filter samples and probes by detection p-value. 
This was achieved using the “pfilter” function in the wateRmelon package [198], which 
removes samples that contain more than one percent (by default) of probes above the 
0.05 detection p-value threshold and probes with any samples with a beadcount less 
than three or more than one percent above the p-value threshold. Using the default 
setting of one percent, the pfilter function identified two samples, 12,962 sites with a 
beadcount count less than three and 7,170 sites having 1% samples with a detection 






the D4_2 and D4_3 samples which also had low median signal intensities. Due to 
these samples failing the pfilter test and also being on the borderline of having too low 
signal intensities it was decided that they should be removed from the study.  
 
3.4.2 Dasen Normalisation of Methylation Data 
In order to make meaningful comparisons between the samples within the dataset the 
data needs to be transformed using normalisation. Normalisation was performed using 
the “dasen” function within the wateRmelon package [198]. Dasen involves quantile 
normalisation that normalises by type I and type II probe background levels first. After 
dasen normalisation the median methylated and unmethylated signal intensities 
become much closer together and consistent across samples (table 3.3; figure 3.5).  
 
By plotting the normalised β-values it is possible to see that when plotting all probes 
on the array the peaks which are towards the extremes (i.e. fully methylated and fully 
unmethylated loci) are much tighter, this is especially true for the fully methylated 
probes (figure 3.6A). By plotting β-values by probe type it is clear that the type I probes 
contribute more to the fully unmethylated peak (figure 3.6B) and the type II probes 










Cell Stage Day of Differentiation Replicate Sample ID Median Methylated Intensity Median Unmethylated Intensity 
iPSC 4 
1 D4_1 3340.000 1636.643 
4 D4_4 3340.000 1636.643 
NPC 16 
1 D16_1 3340.000 1636.643 
2 D16_2 3340.214 1636.643 
3 D16_3 3339.943 1636.643 
4 D16_4 3340.214 1697.286 
Neuron-D37 37 
1 D37_1 3340.357 1636.500 
2 D37_2 3340.357 1637.214 
3 D37_3 3340.429 1637.214 
4 D37_4 3339.786 1637.500 
Neuron-D58 58 
1 D58_1 3340.429 1637.168 
2 D58_2 3340.357 1637.500 
3 D58_3 3340.214 1637.500 
4 D58_4 3340.429 1636.643 
Table 3.3. Median methylated and unmethylated intensities after dasen normalisation. 
 
Using the wateRmelon package [198] dasen quantile normalisation was performed and the median intensities calculated. For each sample 
shown above is the corresponding cell stage, day of differentiation, replicate number, sample ID, day of differentiation, the corresponding cell 





























Quantile normalisation was performed using dasen [198] to generate the normalised 
median methylated and unmethylated signal intensities. Graphical representation of 












Normalised β-values were generated and plotted using dasen quantile normalisation (A). Probes were separated based on whether they 






3.4.3 Assessing Metrics of Maturity throughout Neuronal Differentiation 
In this section I have used DNA methylation at numerous loci to examine/assess 
metrics of maturity within the different cellular stages throughout differentiation and 
maturation. 
 
3.4.3.1 iPSC-derived Neuronal Cells have an Immature Epigenome  
One concern when using iPSC-derived neurons to study diseases of advanced age is 
the biological age of the neurons. I have used the Horvath epigenetic age calculator 
to predict epigenetic age based on DNA methylation profiles assessed by the EPIC 
array [126]. This is an algorithm which takes the DNA methylation levels of 391 loci in 
order to give a prediction of biological age. The biological age of each sample can be 
seen in table 3.4 and these have been plotted in figure 3.7. From this analysis it is 
possible to see that whilst the epigenetic age of the cells increases with differentiation 
and maturation, even the most mature samples still have a negative biological age  
This demonstrates that the even the oldest iPSC-derived neurons in this study still 
have an epigenomic profile representative of foetal neurons.  
 
3.4.3.2 Mitotic Age Stops Increasing after Terminal Differentiation  
An important metric of ageing is the number of cell divisions a cell has been through. 
Assessing this in our samples is particularly of interest as differentiated neurons are 
post-mitotic and should therefore cease dividing and replicating. In order to determine 
the number of cellular divisions I used the MiAge calculator [199]; this algorithm is able 
to predict mitotic age using the DNA methylation profile of 268 probes from the 
methylation array. Similarly to the epigenetic ages, our data shows an increase in 






epigenetic age it plateaus or slightly decreases between the two terminally 





















Cell Stage Day of Differentiation Replicate Sample ID Epigenetic Age (years) No. of Cell Divisions 
iPSC 4 
1 D4_1 -0.534 472.08 
4 D4_4 -0.755 429.273 
NPC 16 
1 D16_1 -0.665 679.434 
2 D16_2 -0.552 647.998 
3 D16_3 -0.584 652.024 
4 D16_4 -0.439 566.607 
Neuron-D37 37 
1 D37_1 -0.407 828.816 
2 D37_2 -0.487 1003.885 
3 D37_3 -0.445 776.052 
4 D37_4 -0.588 817.212 
Neuron-D58 58 
1 D58_1 -0.412 733.566 
2 D58_2 -0.427 698.652 
3 D58_3 -0.392 718.764 
4 D58_4 -0.566 779.269 






Using the Horvath epigenetic age calculator [126] and MiAge calculator [199], the epigenetic age, i.e. years, and mitotic age, i.e.  number of 
cell divisions were calculated for each sample. For each sample shown above is the corresponding cell stage, day of differentiation, replicate 




















Using the latest iteration of the Horvath epigenetic age calculator online [126], the 
epigenetic ages of each sample were calculated. Where red represents the iPSC stage, 
purple the NPC stage, blue the neurons differentiated for 37 days post terminal 
differentiation and green the neurons differentiated for 58 days post terminal differentiation. 




































Using the coefficients of the MiAge calculator [199] the mitotic ages of each sample were 
derived. Where red represents the iPSC stage, purple the NPC stage, blue the neurons 
differentiated for 37 days post terminal differentiation and green the neurons differentiated 






 3.4.3.3 There is No Correlation between Epigenetic and Mitotic Age 
To test whether there is any correlation between epigenetic age and the number of 
divisions a cell has gone through Person’s correlation was used. From this it is clear 
that whilst there is some correlation between epigenetic and mitotic age this correlation 
is not significant (figure 3.9; r value=0.426, p=0.129). Interestingly, representing the 
data in this way it is possible to see that on the whole the neuronal D37 samples have 
undergone more cell divisions than the neuronal D58 samples.  As cell division is 
known to stop once terminal differentiation has occurred I also wanted to test whether 
the correlation improved if the D58 neuronal samples were not included. However, 

























Using Pearson’s product-moment correlation the relationship between epigenetic age and 
mitotic age was assessed and the results plotted. Where red indicates the iPSC samples, 
purple the NPCs, blue the neurons differentiated for 37 days post terminal differentiation 
and green the neurons differentiated for 58 days post terminal differentiation. The line of 






3.4.4 Non-CpG Loci are more Hemi-methylated in iPSCs 
As depicted in figure 3.4B there is an increase in hemi-methylation in the iPSC 
samples. It has previously been demonstrated that stem cells contain more CpH hemi-
methylation (where H stands for any base other than cytosine) [270] and so to 
determine whether this was the case in these iPSC samples probes were grouped on 
the basis of whether they were CpG or CpH. After this it was possible to plot only the 
hemi-methylated CpG and CpH probes (having a β-value between 0.2 and 0.8) to 
ascertain where the hemi-methylation was present (figure 3.10). From this analysis it 
is possible to see that for the most part the CpG probes on the array have higher β-
values than the non-CpG probes on the array, but also that within the non-CpG group 






































After dasen normalisation probes were grouped on the basis of whether they were a 
CpG or CpH probe. Probes containing β-values between 0.2 and 0.8 (hemi-methylated 
probes) were then plotted, where red represents the iPSC stage, purple the NPC stage, 
blue the neurons differentiated for 37 days post terminal differentiation and green the 






3.4.5 Biological Function of DNA Methylation Levels 
In this section I will describe and analyse the methods used in order to provide 
biological meaning to the DNA methylation changes occurring during neuronal 
differentiation and maturation. This has been achieved using WGCNA and pathway 
analysis. 
 
3.4.5.1 WGCNA Identifies Four Modules of Co-Methylated Loci 
To identify groups of probes that have similar methylation changes over time WGCNA 
was used. Briefly, after the construction of blockwise modules of 10,000 probes 
pairwise correlations were used to identify groups of linearly co-methylated loci. This 
analysis identified 26 modules of co-methylated probes, eight of which are modules of 
progressive hypomethylation and fourteen of which are modules of progressive 
hypermethylation throughout differentiation. Of these 26 modules four remained 
significant after correction for multiple testing (figure 3.11). These were the black, blue 
greenyellow and red modules (p=0.001, p=2.00x10-4, p=4.00x10-6 and p=3.00x10-6, 
respectively). The blue, black and greenyellow modules were modules of 
hypomethylation over time (figure 3.11B-D) and the red module was made of probes 
becoming hypermethylated throughout differentiation (figure 3.11E). For the most part 
the iPSC, NPC and day 58 terminally differentiated groups have relatively little 
methylation variation according to the module eigengene, with the day 37 terminally 
differentiated neurons having a larger amount of variation within the group. This would 
suggest that there are still large amounts of DNA methylation level variation within the 





















Figure 3.11. WGCNA identifies four significant modules across differentiation. 
 WGCNA was used to identify modules or groups of loci that had similar linear changes in DNA methylation throughout differentiation. (A) This 
analysis identified 26 modules, four of which still remained significant after multiple testing correction. These are the black, blue, greenyellow 
and red modules which are highlighted with an *, where red signifies an increase in methylation over time and green signifies decreasing 
methylation over time. (B)-(E) Boxplots depicting the change in methylation of the module eigengene throughout neuronal differentiation for 






3.4.5.2 Pathway Analysis Implicates Neuronal Differentiation, Neurogenesis 
and Transcriptional Regulation 
In order to provide biological meaning to the modules identified during WGCNA GO 
pathway analysis was performed on the top 15% probes within the module (based on 
module membership). After the top 15% probes were extracted there were 2,005, 
3,410, 1,266 and 2,037 probes in the black, blue, greenyellow and red modules, 
respectively. The GO repository allows us to input the genes annotated to each loci 
within each module and provides us with the various biological pathways that are 
enriched in these modules. The top ten pathways for each module are provided in 
tables 3.5 to 3.8. The black module is associated with biological pathways which are 
associated with becoming a neuron (table 3.5). This includes FDR significant 
pathways such as neuron differentiation, generation of neurons and neurogenesis. As 
I was differentiating the cells into neurons this is encouraging and is perhaps to be 
expected. The blue module is also associated with becoming a neuron and pulls out 
similar biological pathways, although the genes within these pathways are distinct from 
those in the black module (table 3.6). On the other hand, the greenyellow module is 
made up of pathways involved in response to ions, transcriptional repression, 
regulatory DNA binding and signal transduction (table 3.7). This suggest that this 
module is involved more in the underlying processes required to make neurons such 
as gene expression changes and intracellular signalling rather than the physical 
changes. It is however worth noting that unlike the other modules, none of the 
pathways identified in the greenyellow module passed FDR correction. Finally, 
similarly to the black and blue modules, the red module is also associated with 






interestingly the red module is made of probes becoming hypermethylated rather than 






GO Term Description No. of Genes in Pathway 
No. of Genes 
in Module P-Value FDR 
GO:0030182 neuron differentiation 1222 127 4.18 x10
-6 0.034 
GO:0048699 generation of neurons 1342 134 1.25 x10
-5 0.043 
GO:0022008 neurogenesis 1439 140 1.55 x10-5 0.043 
GO:0048666 neuron development 972 106 3.67 x10-5 0.076 
GO:0008092 cytoskeletal protein binding 836 88 9.99 x10
-5 0.143 
GO:0031175 neuron projection development 827 93 1.06 x10
-3 0.143 
GO:0048468 cell development 1884 164 1.21 x10-3 0.143 
GO:0030030 cell projection organization 1328 124 2.34 x10
-3 0.241 
GO:0007409 axonogenesis 422 55 2.98 x10-3 0.273 
GO:1902259 
regulation of delayed 
rectifier potassium 
channel activity 
15 6 3.95 x10-3 0.316 








GO Term Description No. of Genes in Pathway 
No. of Genes in 
Module P-Value FDR 
GO:0030182 neuron differentiation 1222 228 4.17 x10
-16 3.44x10-12 
GO:0048699 generation of neurons 1342 242 1.17 x10
-15 4.83x10-12 
GO:0022008 neurogenesis 1439 252 2.34 x10-15 5.55x10-12 






827 169 8.05 x10-13 1.33x10-9 
GO:0048468 cell development 1884 287 6.93 x10
-12 9.52x10-9 
GO:0048858 cell projection morphogenesis 583 131 2.21 x10
-11 2.48x10-8 
GO:0016358 dendrite development 195 63 2.40 x10
-11 2.48x10-8 






568 128 3.13 x10-11 2.58x10-8 
Shown for each pathway is the corresponding GO ID, pathway descriptor number of genes 
annotated to the pathway, the number of genes in our list in the pathway, uncorrected p-
value and false discovery rate (FDR)-adjusted p-value. Pathways are ordered by 
significance. 
Shown for each pathway is the corresponding GO ID, pathway descriptor number of genes 
annotated to the pathway, the number of genes in our list in the pathway, uncorrected p-























GO Term Description No. of Genes in Pathway 
No. of Genes in 
Module P-Value FDR 









176 18 0.001 1 
GO:0044212 transcription regulatory region DNA binding 769 53 0.001 1 
GO:0000975 regulatory region DNA binding 771 53 0.001 1 





648 45 0.002 1 
GO:0023019 
signal transduction 
involved in regulation of 
gene expression 
18 4 0.002 1 
GO:0071889 14-3-3 protein binding 23 6 0.003 1 





32 5 0.003 1 
Shown for each pathway is the corresponding GO ID, pathway descriptor number of genes 
annotated to the pathway, the number of genes in our list in the pathway, uncorrected p-






















GO Term Description No. of Genes in Pathway 
No. of Genes 
in Module P-Value FDR 
GO:0030182 neuron differentiation 1222 165 4.88x10
-10 2.01 x10-6 
GO:0022008 neurogenesis 1439 185 5.60x10-10 2.01 x10-6 
GO:0048699 generation of neurons 1342 176 7.30x10
-10 2.01 x10-6 
GO:0045595 regulation of cell differentiation 1483 170 5.41x10
-8 1.11 x10-3 
GO:0048666 neuron development 972 134 7.46x10















753 106 2.68x10-7 2.68x10-3 
GO:0050767 regulation of neurogenesis 665 96 2.94x10
-7 2.68x10-3 
GO:0048468 cell development 1884 209 3.77x10-7 2.68x10-3 
Shown for each pathway is the corresponding GO ID, pathway descriptor number of genes 
annotated to the pathway, the number of genes in our list in the pathway, uncorrected p-







3.4.6 Trajectory Modelling 
This section of the results covers the creation of the trajectory network, the 
identification of biological pathways that are contributing to this network and the gene 
interactions within the network. 
 
3.4.6.1 Trajectory Inference  
To further explore how DNA methylation changes throughout neuronal differentiation 
I undertook trajectory inference modelling to create a cellular lineage trajectory and 
create groups of probes which were becoming hyper- or hypomethylated throughout 
differentiation. To generate the lineage trajectory (figure 3.12A) principal component 
analysis was used to reduce the number of dimensions within the dataset whilst 
maintaining as much information as possible. The dataset was reduced to only contain 
the five percent most variable CpG probes (41,811 loci) and 14 principal components, 
of which the first two components explained 78% of the variation in the data. Once this 
was completed the pseudotime of the trajectory was estimated. The first two principal 
components were then used alongside pseudotime to plot the samples according to 
stage of differentiation/maturation (figure 3.12A). Samples within each cellular stage 
clustered together, with the exception of one Day 37 neuron sample, which clustered 
with the Day 58 neuron samples.  This could indicate that this sample had aged quicker 
than the others in the same group; however, when I checked the “epigenetic age” of 
this sample, it was surprisingly the second youngest of the four Day 37 neuronal 
samples. To ensure this sample was not a general outlier I clustered all 14 samples 
based on Euclidean distance (prior to the trajectory inference analysis). This 
highlighted that this Day 37 sample was not an outlier in general and clustered together 






Using the pseudotime created in the lineage trajectory a GAM was fitted to cluster 
together and order probes by whether they are becoming progressively 
hypomethylated or hypermethylated throughout differentiation. Where blue represents 
progressive hypomethylation and red progressive hypermethylation it is not surprising 
to see that there are large numbers of probes that have progressive methylation 
changes over time (figure 3.12B). There are 4,206 probes becoming hypomethylated 
with time and 1,662 probes becoming hypermethylated across neuronal 
differentiation. The probe that undergoes the largest DNA methylation change over 
time is one that becomes progressively hypomethylated during differentiation and is 
not annotated to a gene using the University of California Santa Cruz (UCSC) 
repository (figure 3.12C) [271]. However, using the Genomic Regions Enrichment of 
Annotations Tool (GREAT) it was possible to determine the closest gene to this loci is 






















Figure 3.12. Trajectory modelling and module construction. 
 (A) To create the trajectory model dimensionality reduction was first performed, using PCA, followed by estimating pseudo-time to model the 
lineage trajectory using k-means clustering, a custom distance algorithm and principal curves. (B) Using the pseudo-time estimation a 
generalised additive model was used to determine which probes were becoming hypo-methylated (blue) or hyper-methylated (red) over time. 
(C) DNA methylation changes occurring at the top differentially methylated probe throughout differentiation. Left: plot of β-value (y-axis) against 






















cg00908292 ↓ 1.71 x10-13 7.16 x10-9 17 38699009 - CCR7 (+22714) 
cg15190241 ↓ 1.11 x10-12 4.67 x10-8 1 168368506 - TBX19 (+118229) 
cg14171824 ↓ 2.02 x10-12 8.47 x10-8 1 2006656 PRKCZ PRKCZ (+24748) 
cg25653165 ↓ 3.16 x10-12 1.32 x10-7 5 179569548 RASGEF1C RASGEF1C (-4200) 
cg21105928 ↓ 3.17 x10-12 1.32 x10-7 15 40143956 GPR176 GPR176 (+69136) 
cg04901527 ↓ 3.49 x10-12 1.46 x10-7 10 117832870 GFRA1 GFRA1 (+200108) 
cg01933515 ↓ 4.67 x10-12 1.95 x10-7 14 96532698 C14orf132 C14orf132 (+27038) 
cg24737914 ↓ 4.82 x10-12 2.02 x10-7 7 5739289 RNF216 RNF216 (+82080) 
cg00177101 ↓ 5.46 x10-12 2.29 x10-7 9 120545390 - TLR4 (+78741) 
cg02331902 ↓ 5.82 x10-12 2.44 x10-7 5 90610303 - ARRDC3 (+68872) 
cg11702768 ↓ 9.47 x10-12 3.96 x10-7 9 34567202 CNTFR-AS1 CNTFR (+22532) 
cg20109624 ↓ 1.04 x10-11 4.36 x10-7 16 81254265 PKD1L2 BCMO1 (-17787) 
cg02268851 ↓ 1.23 x10-11 5.13 x10-7 11 47545207 CELF1 CELF1 (+332) 
cg02603875 ↓ 1.27 x10-11 5.33 x10-7 5 152871549 GRIA1 GRIA1 (-182) 
cg26181096 ↓ 1.39 x10-11 5.80 x10-7 22 41876619 ACO2 ACO2 (+11491) 
cg01170387 ↓ 1.58 x10-11 6.62 x10-7 16 31076818 ZNF668 ZNF668 (-443) 
cg17957761 ↓ 1.69 x10-11 7.09 x10-7 19 46478879 - NOVA2 (-2076) 
cg04314308 ↑ 1.99 x10-11 8.32 x10-7 19 19336150 NCAN NCAN (+13369) 
cg03534428 ↓ 2.14 x10-11 8.96 x10-7 19 42972740 LIPE-AS1 CXCL17 (-25541) 
cg03724874 ↓ 2.22 x10-11 9.28 x10-7 3 111719291 TAGLN3 TAGLN3 (+1706) 
cg13313697 ↓ 2.26 x10-11 9.44 x10-7 5 152870740 GRIA1 GRIA1 (-991) 
cg12379611 ↓ 2.85 x10-11 1.19 x10-6 10 17045387 CUBN CUBN (+126442) 
cg13617441 ↓ 2.87 x10-11 1.20 x10-6 3 34886005 - ARPP21 (-795872) 
cg21762380 ↓ 3.10 x10-11 1.30 x10-6 9 93063697 LINC01508 DIRAS2 (+341688) 






cg00622618 ↓ 3.50 x10-11 1.46 x10-6 6 38288376 BTBD9 BTBD9 (+319323) 
cg10859605 ↑ 3.61 x10-11 1.51 x10-6 8 30255368 RBPMS RBPMS (+13342) 
cg15167636 ↓ 3.62 x10-11 1.51 x10-6 12 90485193 - ATP2B1 (-382586) 
cg20780998 ↓ 3.71 x10-11 1.55 x10-6 X 12996931 - TMSB4X (+3703) 
cg08332866 ↓ 4.02 x10-11 1.68 x10-6 17 35017916 - MRM1 (+59916) 
cg16627786 ↑ 4.45 x10-11 1.86 x10-6 22 19711051 GP1BB GP1BB (+584) 
cg24135615 ↓ 4.71 x10-11 1.97 x10-6 17 37042201 LASP1 LASP1 (+16090) 
cg08960385 ↓ 4.74 x10-11 1.98 x10-6 20 43367613 - KCNK15 (-6807) 
cg01956293 ↓ 4.76 x10-11 1.99 x10-6 2 145212605 ZEB2 ZEB2 (+66015) 
cg02494279 ↓ 5.47 x10-11 2.29 x10-6 18 23395233 - SS18 (+275355) 
cg01079726 ↓ 5.71 x10-11 2.39 x10-6 14 100485682 - EVL (-45932) 
cg08811227 ↓ 6.15 x10-11 2.57 x10-6 16 24697469 - TNRC6A (-43564) 
cg19902443 ↓ 6.58 x10-11 2.75 x10-6 20 11899807 BTBD3 BTBD3 (+28332) 
cg04122918 ↓ 6.63 x10-11 2.77 x10-6 14 73146313 DPF3 DPF3 (+214495) 
cg27587033 ↓ 6.76 x10-11 2.83 x10-6 1 2006032 PRKCZ PRKCZ (+24124) 
cg24692861 ↓ 7.49 x10-11 3.13 x10-6 3 155524344 C3orf33 C3orf33 (-290) 
cg02879029 ↓ 7.62 x10-11 3.19 x10-6 8 10829962 XKR6 PINX1 (-132577) 
cg17835180 ↓ 8.07 x10-11 3.38 x10-6 X 12995592 - TMSB4X (+2364) 
cg16306978 ↑ 8.55 x10-11 3.58 x10-6 2 21266953 APOB APOB (-9) 
cg07584840 ↓ 8.84 x10-11 3.70 x10-6 12 94579928 PLXNC1 PLXNC1 (+37430) 
cg06538238 ↓ 9.78 x10-11 4.09 x10-6 6 29588575 GABBR1 GABBR1 (+12386) 
cg22334705 ↓ 1.04 x10-10 4.34 x10-6 14 60174988 RTN1 RTN1 (+162695) 
cg18630264 ↓ 1.04 x10-10 4.36 x10-6 4 140707850 MAML3 MGST2 (+120929) 
cg09972881 ↑ 1.05 x10-10 4.39 x10-6 12 53298822 KRT8 KRT8 (+21430) 
cg13053505 ↑ 1.09 x10-10 4.57 x10-6 4 4854459 - MSX1 (-6933) 
Table 3.9. The top 50 of 5,866 probes comprising the epigenetic trajectory signature identified through general additive modelling.
Shown for each loci are its probe ID, direction of change (i.e. increasing(↑) or decreasing(↓) methylation), uncorrected p-value, bonferroni 
corrected p-value, the chromosome it resides on, its genomic position, the gene it is annotated to according to the Illumina (UCSC) manifest 


















By calculating and clustering samples based on their Euclidean difference (prior to 
trajectory inference) it is clear that the D37 sample which clusters with the D58 samples is 






3.4.6.2 Pathway Analysis Implicates Development, Signalling and 
Transcription 
In order to give meaning to the trajectory model and determine the functional 
implications of the probes on which it is based I used GO pathway analysis to identify 
the cellular pathways which are undergoing change during differentiation. To do this 
the loci that had the most significant methylation changes throughout differentiation 
were grouped together according to whether they were becoming progressively 
hypomethylated or hypermethylated over time (4,206 and 1,662 probes, respectively). 
The genes annotated to these probes were then searched in the GO repositories in 
order to find biological processes in which these genes are enriched. The 
progressively hypermethylated loci resided in genes that featured in pathways relating 
to head development, signalling, cell surface receptor signalling, transcriptional activity 
and cell-cell junctions (figures 3.14; table 3.10). The progressively hypomethylated loci 
were associated with neuron projection development, synaptic activity and gated 
















Table 3.10. Results of GO pathway analysis of loci that become progressively hypermethylated through differentiation. 
 
GO Term GO Descriptor Ontology No. genes in pathway 
No. genes in our 
list P-value FDR Genes 
GO:0000976 transcription regulatory region sequence-specific DNA binding MF 777 71 6.45 x10
-9 2.99 x10-5 
NFAT5; SIX2; VAX1; JDP2; 
NACC2; GLIS1; DNMT3A; ELF3; 
FOXK1; FOXS1; 
GO:0000977 RNA polymerase II regulatory region sequence-specific DNA binding MF 725 67 1.12 x10
-8 2.99 x10-5 
NFAT5; SIX2; VAX1; JDP2; 
NACC2; GLIS1; DNMT3A; ELF3; 
FOXK1; FOXS1; 
GO:0043565 sequence-specific DNA binding MF 1088 86 1.31 x10-8 2.99 x10-5 
NFAT5; SIX2; VAX1; FOXN3; 
FOXP4; JDP2; NACC2; GLIS1; 
DNMT3A; ELF3; 
GO:1990837 sequence-specific double-stranded DNA binding MF 819 72 1.53 x10
-8 2.99 x10-5 
NFAT5; SIX2; VAX1; JDP2; 
NACC2; GLIS1; DNMT3A; ELF3; 
FOXK1; FOXS1; 
GO:0001012 RNA polymerase II regulatory region DNA binding MF 731 67 1.69 x10
-8 2.99 x10-5 
NFAT5; SIX2; VAX1; JDP2; 
NACC2; GLIS1; DNMT3A; ELF3; 
FOXK1; FOXS1; 
GO:0044212 transcription regulatory region DNA binding MF 891 76 3.33 x10
-8 4.80 x10-5 
NFAT5; SIX2; RAI1; VAX1; JDP2; 
GABPB2; NACC2; GLIS1; 
DNMT3A; ELF3; 
GO:0001067 regulatory region nucleic acid binding MF 893 76 3.80 x10
-8 4.80 x10-5 
NFAT5; SIX2; RAI1; VAX1; JDP2; 
GABPB2; NACC2; GLIS1; 
DNMT3A; ELF3; 
GO:0098609 cell-cell adhesion BP 811 71 1.31 x10-7 1.27 x10-3 
PTPRU; CDH16; MAD2L2; 
COL13A1; UNC5D; CLDN19; 
CTNND2; DSP; DTX1; GPC4 
GO:0003690 double-stranded DNA binding MF 909 74 1.32 x10-7 1.27 x10-3 
NFAT5; SIX2; VAX1; JDP2; 
NACC2; GLIS1; DNMT3A; ELF3; 
FOXK1; FOXS1; 
GO:0007155 cell adhesion BP 1384 107 1.43x10-7 1.27 x10-3 
PTPRU; EDIL3; CDH16; PLXNC1; 
EFS; SPON2; SPON1; MAD2L2; 
EMID1; COL13A1; 
Shown is the top ten pathways identified through GO pathway analysis. For each pathway is the GO ID, pathway descriptor, number of genes 
annotated to the pathway, the number of genes in our list in the pathway, uncorrected p-value and false discovery rate (FDR)-adjusted p-value. 













Figure 3.14. Pathway analysis of loci becoming progressively hypermethylated 
throughout differentiation.
Gene ontology (GO) enrichment analysis was performed on the 1,662 loci shown to 
become progressively hypermethylated throughout neuronal differentiation. 
Treemaps illustrating the pathways relating to (A) biological pathways (BP), (B) 
cellular components (CC) and (C) molecular functions (MF) that are changing 
throughout differentiation are shown. For each treemap, terms relating to the same 
pathway are grouped together and have been given the same colour, the term that 







GO Term GO Descriptor Ontology No. genes in pathway 
No. genes in 
our list P-value FDR Genes 
GO:0097458 neuron part CC 1686 293 3.46 x10-11 3.06 x10-7 CDH13; FARP1; KATNB1; CACNG3; BASP1; BAIAP2; ADCY2; PPARGC1A; STMN2; CIT; 
GO:0045202 synapse CC 1152 220 4.77 x10-10 2.11 x10-6 GPC6; CDH11; CDH13; FARP1; WASF2; APC2; RTN3; CACNG3; BAIAP2; NRG3; 
GO:0048666 neuron development BP 1069 209 1.09 x10-9 3.21 x10-6 FOXO6; CDH4; CDH11; FRY; PLXNC1; FARP1; UBE4B; CDKN1C; KATNB1; ADARB1; 
GO:0043005 neuron projection CC 1286 228 1.51 x10-9 3.35 x10-6 
CDH13; FARP1; KATNB1; CACNG3; BASP1; 
BAIAP2; ADCY2; PPARGC1A; STMN2; 
FAM107A; 
GO:0048858 cell projection morphogenesis BP 635 142 2.58 x10-8 3.91 x10-5 CDH4; CDH11; PLXNC1; FARP1; WASF2; ADARB1; BAIAP2; SEMA4D; SEMA3C; B3GNT2; 
GO:0048812 neuron projection morphogenesis BP 620 139 2.70 x10
-8 3.91 x10-5 CDH4; CDH11; PLXNC1; FARP1; ADARB1; BAIAP2; SEMA4D; SEMA3C; B3GNT2; ZFYVE27; 
GO:0120039 plasma membrane bounded cell projection morphogenesis BP 634 141 3.80 x10
-8 3.91 x10-5 CDH4; CDH11; PLXNC1; FARP1; WASF2; ADARB1; BAIAP2; SEMA4D; SEMA3C; B3GNT2; 
GO:0031175 neuron projection development BP 939 183 3.89 x10-8 3.91 x10-5 FOXO6; CDH4; CDH11; FRY; PLXNC1; FARP1; UBE4B; KATNB1; ADARB1; SEC24B; 
GO:0036477 somatodendritic compartment CC 819 152 3.97 x10-8 3.91 x10-5 FARP1; KATNB1; CACNG3; BAIAP2; ADCY2; PPARGC1A; STMN2; CIT; CHRM5; TRIM9; 
GO:0032990 cell part morphogenesis BP 654 142 8.98 x10-8 7.46 x10-5 CDH4; CDH11; PLXNC1; FARP1; WASF2; ADARB1; BAIAP2; SEMA4D; SEMA3C; B3GNT2; 
Table 3.11. Results of GO pathway analysis of loci that become progressively hypomethylated through differentiation. 
 
Shown is the top ten pathways identified through GO pathway analysis. For each pathway is the GO ID, pathway descriptor, number of genes 
annotated to the pathway, the number of genes in our list in the pathway, uncorrected p-value and false discovery rate (FDR)-adjusted p-value. 


















Figure 3.15. Pathway analysis of loci becoming progressively hypomethylated 
throughout differentiation. 
 
Gene ontology (GO) enrichment analysis was performed on the 4,206 loci shown to 
become progressively hypomethylated throughout neuronal differentiation. Treemaps 
illustrating the pathways relating to (A) biological pathways (BP), (B) cellular 
components (CC) and (C) molecular functions (MF) that are changing throughout 
differentiation are shown. For each treemap, terms relating to the same pathway are 
grouped together and have been given the same colour, the term that summarises 






3.4.6.3 Transcriptional Regulation is a Highly Interconnected Process 
during Neuronal Differentiation 
To explore the connectivity between key genes that display progressive DNA 
methylomic changes through differentiation gene-gene interaction analyses were 
performed on the Bonferroni significant loci. Out of the 5,874 significant loci 2,352 
loci were annotated to unique genes. From this a prior knowledge network (PKN) 
was obtained, which contained 602 genes and 1,158 interactions between these 
genes. Within this PKN there was only one SCC which was comprised of 50 
genes and 138 interactions between them, so that every gene within the SCC 
can be reached through any other gene in the network (figure 3.16; table 3.12). 
This network analysis highlighted key genes within the network based on 
particular characteristics including their out-degree (the set of targets they 
regulate), in-degree (set of upstream regulating genes), betweenness centrality 
(most influential genes as determined by the shortest path lengths in the network) 
and their clustering coefficient (measure of tendency to cluster with other genes 
in the network). Interestingly, STAT3, TCF7L2 and LHX2 are the top genes based 
on their edge counts (number of upstream regulators) and their out-degree 
(number of downstream target genes). STAT3 also has the highest betweenness 
centrality of 0.043 which suggests that it plays a large role within the network. 
 
In order to ascertain more information about the functions of the top 50 most 
connected genes in the network a manual function search for each gene was 
undertaken. Of these top 50 genes 36 (72%) are involved in transcriptional 
regulation and include genes coding for proteins that are transcriptional 
activators, repressors and hormone receptor transcriptional regulators. Of these 






top 50 most connected genes. Interestingly, of the 22% of genes in the network 
that aren’t involved in transcriptional regulation 14% are genes that are known to 
































Connectivity Outdegree Function 
STAT3 0.04345 0.37748 0.01997 71 9 9.43 62 Transcription factor 
LHX2 0.01637 0.35092 0.00186 66 3 3.32 63 Transcription factor 
CDKN1A 0.00058 1 0.0161 60 58 10.68 2 Cell cycle regulator 
TCF7L2 0.0191 0.34628 0.01481 56 4 8.73 52 Transcription factor 
ETS1 0.01263 0.29362 0.00716 52 4 6.37 48 Transcription factor 
RUNX1 0.01469 0.30945 0.01568 43 7 8.5 36 Transcription factor 
GATA4 0.01931 0.25409 0.03409 34 14 14.39 20 Transcription factor 
SMAD3 0.00844 0.26041 0.0252 32 4 10.19 28 Transcriptional regulator 
PAX6 0.01644 0.29865 0.02381 31 10 11.43 21 Transcription factor 
SMARCA4 0.00607 0.30651 0.02094 30 1 10.86 29 Chromatin remodellor 
KDM6B 0.00588 0.24575 0.01984 28 2 10.29 26 Histone demethylase 
NR5A2 0.01974 0.2422 0.00833 26 4 7.84 22 Transcription factor 
THRB 0 0.24009 0.00395 23 0 4 23 NHTR 
BCL6 0.01245 0.28388 0.04978 23 11 16.64 12 Transcription factor 
PPARGC1A 0.02024 0.25271 0.05952 22 11 17.52 11 Transcriptional coactivator 
NFATC1 0.00469 0.24691 0.03095 22 6 13.24 16 Transcription factor 
BMI1 0.00515 0.27404 0.02381 21 4 14.33 17 Chromatin remodellor 
RARB 0.00132 1 0.00952 21 16 9.14 5 NHTR 
ATF3 0.02981 0.31245 0.06053 21 11 17.3 10 Transcription factor 
THRA 0 0.25391 0.00952 21 0 6.67 21 NHTR 
BCL2 0 0 0.07368 20 20 22.15 0 Apoptosis inhibitor 






SALL4 0.00992 0.28897 0.0719 19 6 18.67 13 Transcription factor 
NR4A1 0.00078 0.91667 0.04248 18 8 11.78 10 Transcription factor 
ZBTB20 0.00028 0.23217 0.00327 18 1 7.17 17 Transcription factor 
DNMT3B 0.00226 0.26586 0.03309 17 1 13.76 16 DNA methyltransferase 
MEIS1 0.00807 0.26122 0.02917 17 9 13.19 8 Transcriptional activator 
PBX1 0.01088 0.30764 0.07143 16 5 19.4 11 Transcription factor 
HDAC4 0.00233 0.19141 0.01429 15 1 10.73 14 Histone deacetylase 
NCOA2 0.0013 0.20809 0.01648 14 1 12.93 13 Transcriptional coactivator 
CD44 0 0 0.09341 14 14 26.29 0 Cell surface receptor 
COL2A1 0 0 0.00549 14 14 11.79 0 Component of collagen 
BCL11B 0.01648 0.28445 0.02564 13 2 17.85 11 Transcriptional repressor 
CHD7 0.00272 0.1532 0.01282 13 3 7.38 10 Chromatin remodellor 
TEAD1 0.00104 0.17285 0.01923 13 1 9 12 Transcription factor 
PAX3 0.00911 0.22896 0.02564 13 8 14.54 5 Transcription factor 
KDM2B 0 0.26348 0 13 0 6.46 13 Histone demethylase 
NCOR2 0.0005 0.20172 0.03846 13 2 14.69 11 Transcriptional corepressor 
NR2F1 0.00139 0.23343 0.02273 12 1 11.92 11 NHTR 
ERG 0.00477 0.26419 0.03788 12 3 14.75 9 Transcription factor 
ESRRG 0.0016 0.2032 0.03636 12 4 13.09 8 NHTR 
EGFR 0 0 0.05303 12 12 25.33 0 Cell surface receptor 
EBF1 0.00132 0.17466 0.01515 12 4 12.58 8 Transcription factor 
TCF4 0.00199 0.17328 0.04545 11 2 16.27 9 Transcription factor 
ZBTB16 0.00846 0.26485 0.02727 11 7 12.18 4 Transcription factor 
COL1A2 0 0 0.07273 11 11 23.82 0 Component of collagen 






NR4A2 0.00108 0.68 0.02727 11 2 10.91 9 Transcription factor 
SREBF2 0 1 0 11 0 2 11 Transcription factor 
SOX5 0.00004 0.8125 0.00909 11 1 4.45 10 Transcription factor 
Table 3.12. A subnetwork of 50 genes constituting the strongly connected component (SCC) in the gene-gene interaction network, 
highlighting the methylomic changes occuring throughout neuronal differentiation. 
 
Using Cytoscape a SCC comprised of 50 genes was identified alongside information on the key features of these 50 genes. Shown for each gene 
is the betweenness centrality, closeness centrality, clustering coefficient, edge count, indegree, neighbourhood connectivity, outdegree and 






Figure 3.16. Network interactions of top 50 connected genes. 








Interaction map depicting the connections between the top 50 most connected 
Bonferroni significant differentially methylated genes. Where orange lines indicate an 
inhibitory interaction, green lines indicate an activating interaction, blue ovals indicate 
genes becoming progressively hypomethylated, red ovals indicate genes becoming 
progressively hypermethylated and grey ovals indicate genes that have more than 







In this chapter I have undertaken epigenome wide analyses at base-pair 
resolution of the DNA methylation changes that occur as iPSCs differentiate into 
and then mature as neurons. To facilitate this samples from different cellular 
stages were collected, had DNA extracted and then run on the Illumina EPIC 
array to quantify DNA methylation levels at over 850,000 loci.  
 
One of the first results of this study showed that stem cell derived neurons have 
an immature epigenome. This was determined using the Horvath epigenetic age 
calculator provides a biological age based on DNA methylation data. The highest 
epigenetic age from any sample from this study was -0.41 years, which would be 
representative of neurons of an embryo. This result is particularly interesting as 
neurons derived from this same iPSC line have been shown to be functionally 
mature and are able to fire mature action potentials at the time points used within 
this study [145]. In a study conducted by Mertens et al, they demonstrated that 
there are age-related expression changes to RANBP17 and that neurons derived 
from stem cells had expression levels of RANBP17, which were comparable to 
embryonic or immature neurons. However, this was not the case with iNs, which 
are neurons generated directly from fibroblasts and do not undergo an 
intermediate stem cell phase [273]. Alongside the age-related expression 
changes to RANBP17 iNs have also been shown to maintain their epigenetic age 
unlike the iPSC-derived neurons [169]. Another way it was originally believed may 
increase or accelerate the epigenetic age of iPSC-derived neurons was to use 
3D or organoid models. It’s reasonable to think that having the 3D interactions 
with cells neurons around them, which is more physiologically representative of 






genome-wide, base-pair resolution DNA methylomic sequencing it has since 
been demonstrated that cerebral organoid models have a foetal methylomic 
profile [184]. This included the accumulation of methylation at non-CG loci in 
super-enhancers which corresponded to forthcoming transcriptional repression 
in the adult brain and the identification of demethylated regions during organoid 
development which overlapped with foetal brain regulatory elements [184]. 
 
Another important marker of maturity for cells is the number of cell divisions they 
have gone through. This is particularly of interest for this study as neurons are 
post-mitotic and therefore should no longer be undergoing cell division. To 
estimate the number of cell divisions the cells had undergone I used the MiAge 
calculator developed by Youn and Wang. This analysis demonstrated that after 
terminal differentiation the cells do indeed stop dividing which is as expected. 
This suggests that the terminal differentiation of these cells was successful and I 
have generated neurons which no longer undergo cell division. However, as the 
D37 samples in general had undergone more cell divisions than the D58 samples 
it could indicate some technical variation and perhaps suggest that the D37 and 
D58 samples were plated at different times and that the D37 samples spent 
longer as NPCs therefore undergoing more rounds of cell division. 
 
It would be interesting to be able to extend this study to further time points to 
determine whether the epigenetic age of these cells will increase further whilst 
the mitotic age remains stable. In future studies using iPSC-derived neurons to 
study diseases of ageing it will be important to consider these metrics of maturity 







Another finding to come from this chapter is that there is elevated CpH hemi-
methylation in iPSCs when compared to the NPCs and terminally differentiated 
neurons, which is in concordance with previous literature [181, 274]. This may be 
a reflection that there are more dynamic gene expression changes occurring 
during the stem cell stage. However, hemi-methylation of non-CpG loci is also 
known to occur in neurons and is thought to accumulate during development 
[275-277]. The fact that it is not possible to see this hemi-methylation in the 
neuronal cells used in this chapter perhaps adds further evidence to the 
epigenetic immaturity of the neurons.  
 
To understand the biological consequences of changing DNA methylation 
throughout differentiation WGCNA and pathway analyses were used to first group 
together modules of co-methylated loci and then to interrogate the function of 
these modules. These analyses produced four modules of co-methylated probes, 
three of which were modules enriched for pathways involved in the generation of 
neurons. This is to be expected and confirms that the cells I created through were 
neurons. What is interesting is that the red module, which is made up of genes 
becoming hypermethylated over time, has very similar pathways coming out to 
those within the black and blue models, which are made up of progressively 
hypomethylating genes. As hypomethylation is generally associated with 
increases in expression hypermethylation associated with decreases in gene 
expression it would suggest that there are several pathways which are associated 
with the development of neurons are undergoing increases and decreases in 
gene expression. This would make sense as there are many different processes 
and many large-scale changes which are necessary to create neurons. In 






methylation on gene expression is context dependent and hypermethylation and 
so it is somewhat generalisable to predict that DNA hypermethylation leads to 
gene silencing [278, 279]. The other module pulled out through WGCNA and 
pathway analysis is the greenyellow module. Unlike the other three significant 
modules this module is associated with biological pathways involved in 
transcriptional regulation and signalling. As this module is associated with 
progressive hypomethylation over time it would suggest that there are many 
genes within these pathways becoming more expressed over time. This is 
intuitive as the genes that are expressed and the signalling pathways that are 
used within stem cells are very different from those expressed and used by 
neurons. It is however worth noting that none of the pathways in the greenyellow 
module passed FDR correction. 
 
One interesting finding from the creation of the lineage network was that one of 
the day 37 terminally differentiated neurons clustered more closely with the day 
58 terminally differentiated neurons over the other samples within the same 
cellular stage. This would suggest that this sample has aged quicker than the 
other samples in the group and is therefore more epigenetically mature. However, 
this may not be the case as this sample has the second lowest epigenetic age 
and lowest mitotic age of the day 37 neurons. This could mean that the probes 
used to determine epigenetic age are not contributing to or do not have a large 
part in distinguishing between the different cellular stages. This is somewhat 
logical considering the DNA methylation profile of 391 probes are used to 
estimate epigenetic age and I generated the trajectory model of the fifth percentile 
most variable probes, which equates to approximately 42,000 loci. On the other 






indistinguishable from the D58 samples is also to be expected; if this sample has 
matured quicker than the rest of the samples in this group, it is intuitive that it 
undergone fewer cell divisions. 
 
Similarly to the pathways highlighted in the WGCNA analysis, the pathways 
highlighted in the hypermethylating and hypomethylating probes in the lineage 
network are also largely involved in gene regulation and processes important to 
becoming a neuron. As the majority of Bonferroni significant differentially 
methylated loci are progressively hypomethylated over time it would suggest that 
there are more genes becoming expressed at an increased level as cells become 
more neuronal, although as discussed earlier this is context dependent and 
depends where the methylation falls within the gene. 
 
From the gene-gene interaction network analysis I was able to generate a 
network of the 50 most connected genes which played an important role in the 
generation of the lineage trajectory. Of these genes STAT3, TCF7L2 and LHX2 
were shown to be the most connected and therefore key genes in the network. 
These genes have been shown to play vital roles in neuronal survival and 
function. For example, STAT3 and other members of the JAK/STAT pathway 
have been shown to play key roles in the control of neuronal proliferation, survival 
and differentiation [280, 281]. Cells which have been treated with STAT3 
inhibitors were shown to be highly susceptible to these even at low concentrations 
[280]. TCF7L2 is a transcription factor within the Wnt signalling pathway has been 
shown to play a crucial role in forebrain development and the regulation of 






has been shown to suppress astrogliogenesis in the developing hippocampus, 
thereby promoting neurogenesis [283] and has also been implicated in the 
regulation of β-catenin dependent cortical neurogenesis [284]. The implication of 
these genes in the gene-gene interaction network shows that there are many 
neuronal specific genes or genes that are highly involved in neuronal 
differentiation and survival that are key to creating the lineage trajectory and 























3.6 Conclusion  
In this chapter I have characterised genome wide patterns of DNA methylation in 
order to further understand the epigenomic changes that are occurring 
throughout neuronal differentiation from iPSCs. I have shown that despite being 
functionally mature, the resultant neurons still have an immature epigenetic age 
but also that this epigenetic age does increase throughout differentiation. 
Although not epigenetically mature the terminally differentiated neurons do 
appear to have stopped dividing as the estimated number of cell divisions they 
have undergone does appear to have plateaued, although further time points 
would be needed to confirm this. In order to provide information on the functional 
implications of changing DNA methylation patterns I used trajectory inference and 
pathway analysis. Through these analyses it is clear that there are large amounts 
of loci undergoing significant DNA methylation changes over time, which are 
affecting gene regulation within the differentiating cells and that these loci are 
highly interconnected with one another. 
 
Overall I have identified an epigenomic trajectory signature characteristic of 
neuronal differentiation and maturation. I have also demonstrated that there are 
several considerations when modelling epigenetic changes associated with age 












CHAPTER 4 : DETERMINING THE EFFECT OF 
EPIGENETIC MODULATORS ON DNA METHYLATION IN 































4.1.1 Histone Proteins 
Within the nuclei of all eukaryotic cells can be found a complex interplay of DNA 
that is wound around octamers of core histone proteins which form nucleosomes. 
The wrapping of DNA around these histone proteins allows for the 10,000-
20,000-fold reduction in DNA size which is necessary to fit the genome into the 
nucleus [285].  This level of chromatin compaction and therefore transcriptional 
ability is regulated by conformational changes to the histone proteins including, 
but not limited to, modifications such as methylation, acetylation, 
phosphorylation, ubiquitination and sumoylation [286]. These histone tail 
modifications regulate how easily accessible the transcription start sites (TSS) 
and other promoter regions within the DNA are to transcription factors and other 
cellular machinery that are necessary for the transcription of genes. This is 
achieved through the compaction (heterochromatin) or opening (euchromatin) of 
chromatin [287]. Methylation and acetylation of the histone tails are the most 
widely studies modifications. In general histone acetylation is associated with 
increased gene expression as the positive charge of the acetyl group repels the 
negative DNA causing it to have a more open conformation [288]. Histone 
methylation on the other hand can activate and repress gene expression 
depending on which amino acid has been methylated and how many methyl 
groups there are on the amino acids [289].  
 
4.1.2 Epigenetic Modulators 
There are numerous compounds that have been shown to have an effect through 






changes caused by different epigenetic modulators I have subsequently 
described the targets of each group of modulators that are studied in this chapter.  
 
4.1.2.1 Bromodomains 
A bromodomain (BRD) is a small (approximately 110) amino acid protein domain 
that has a conserved three-dimensional structure. Bromodomains recognise 
acetylated lysines on the N-terminal tails of histone proteins [290]. The domains 
adopt a bundle of four alpha helices and the differences in the loops can 
determine the specificity and affinity for different histone peptides and inhibitors 
[290]. There are 61 BRDs which are expressed in the human proteome, most of 
which recognise acetylated histone marks however, there are some BRDs that 
contain atypical domains that have little or no activity towards acetylated histone 
marks [291].  
 
The modular nature and the diversity in domains has meant that studying the 
function of BRD-containing proteins has been quite difficult. They can contain a 
number of distinct reader domains in addition to having enzymatic functionality 
and playing the role of scaffolding proteins in the chromatin modifying complexes. 
However, using highly specific BRD inhibitors it is possible to untangle their 
complex biology and functional effects [291]. BRD inhibitors are a class of drugs 
that reversibly bind to the BRD regions of the Bromodomain and extra-terminal 
(BET) motif proteins BRD2, BRD3, BRD4 and BRDT and prevent the protein-
protein interaction between the BET proteins and relevant transcription factors 
[292, 293]. This disruption of action can affect gene transcription and regulation. 






function and unravel the relationships between histone modifications, chromatin 
biology and DNA methylation.  
 
To date the greatest success in designing BRD inhibitors has been against the 
BET subfamily of BRD containing proteins. This is largely due to their therapeutic 
potential for treating diseases such as cancer [294, 295]. The first of these 
inhibitors to be published was (+)-JQ1, which is a competitive inhibitor of 
acetylated lysine reading BRDs [296]. There are many more BRD inhibitors that 
have now published, including, but not limited to, SGC-BP30 which inhibits BRDs 
present in the histone acetyltransferase (HAT) p300 [297, 298], BI-9564 an 
inhibitor of the chromatin remodelling complexes BRD7 and BRD9 [299], and 
BAZ2-ICR which has been shown to inhibit the bromodomain adjacent to zinc-
finger domain (BAZ2) chromatin remodelling complex [300].    
 
4.1.2.2 Histone Protein Methyltransferases 
Histone modifications, such as methylation, have been shown to be largely 
localised to areas of the genome that are actively transcribed, which could 
suggest their function is linked to polymerase activity [301-304]. These 
modifications also occur in a highly cell type specific manner at enhancers; 
although there does seem to be similar patterns of histone modifications at 
promoters between cell types [305]. This could suggest that enhancers are the 
most variable element of the transcriptional machinery and are what ultimately 
drives cell type specific gene expression patterns.  
 
Mono-, di-, or tri-methylation of the histone tails has been shown to both induce 






that is methylated and also the level of methylation [306]. For example, in general 
lysine tri-methylation at histone 3 lysine 24 (H3K24), H3K36 and H3K79 have all 
been shown to be associated with active transcription and gene expression 
whereas lysine di-methylation at H3K9 is a known marker for transcriptional 
repression [307]. Arginine side chains can be modified through the addition of 
one methyl group or two methyl groups either symmetrically or asymmetrically. 
These lysine and arginine modifications are generally carried out by one of two 
protein families [306]. PR and SET domain proteins are protein lysine 
methyltransferases (PKMT) and methylate lysines on histone tails whilst the 
protein arginine methyltransferases (PRMT) such as the Rossman fold proteins 
modify arginines [308].   
 
4.1.2.3 WD Repeat-Containing Proteins 
WD repeat domain proteins are minimally conserved regions of approximately 
40-60 amino acids that usually end with a tryptophan and aspartic acid (WD). 
They are involved in a variety of cellular processes including cell cycle 
progression, signal transduction, apoptosis and gene regulation.  
 
In terms of epigenetic mechanisms, WD repeat domain 5 (WRD5) is the best 
characterised protein in terms of its interactions and binding partners. WRD5 has 
been shown to be a part of the mixed lineage leukaemia complex (MLL). As it is 
a part of the MLL complex it is involved in the methylation and demethylation of 
H3K4 [309], which represents a significant epigenetic tag for gene transcriptional 
activation. Interestingly, alone the WRD5-MLL proteins show little histone 
methylation activity, but this is greatly increased upon the formation of a larger 






to directly bind to WRD5, and this interaction is known to be responsible for the 
tri-methylation at the promoters of MLL target genes, which includes HOXA2 
[311]. Alongside binding proteins, WRD5 also has a RNA binding pocket that 
binds long non-coding RNAs, such as HOTTIP and NeST, facilitating gene 
transcription [312-314].  
 
One known small molecule inhibitor of WRD5-MLL protein-protein interactions is 
OICR 9429 [315]. OICR 9429 has been shown to bind in the WRD5-interacting 
(WIN) peptide binding pocket, therefore disrupting WRD5’s interaction with MLL 
at this same binding pocket [315]. OICR 9429 has demonstrated selective binding 
to WRD5 compared to other histone methyltransferases (HMTs) or 
pharmacologically relevant targets and can reduce the proliferation and even 
induce growth arrest in p30-overexpressing cancer cells [315]. 
 
4.1.2.4 Methyl Lysine Readers 
Methyl lysine readers (KMR) recognise the methylated tails of histone proteins 
and are associated with transcriptional repression [316]. One common feature 
between the different proteins of the KMR family is the methylated lysine binding 
pocket that contains an “aromatic cage” of amino acids [317]. The KMR family is 
large, diverse, and has been shown to have relatively weak interactions with 
histones and not to have any enzymatic activity. As such it has made them a 
challenging family of proteins to develop chemical inhibitors for [318]. However, 
one KMR that now has a chemical probe inhibitor is lethal(3)malignant brain 
tumour-like protein 3 (L3MBTL3) [288]. L3MBTL3 has been shown to play a role 
in haematopoiesis [319] and its deletion has also been implicated in diseases 






to an arginine residue within the “aromatic cage” binding pocket thus inhibiting its 
ability to bind methylated lysine residues [288].   
 
4.1.2.5 Histone Lysine Demethylases (HKDM) 
The first evidence that histone lysines underwent dynamic regulation in terms of 
their methylation came from Shi et al. in 2004, when they demonstrated that LSD1 
uses flavin adenine dinucleotide as a cofactor to oxidise the methyl group on the 
histone tails into formaldehyde [321]. In this study it was also shown that LSD1 is 
relatively specific and only demethylates H3K4me1/2, but not H3K4me3 or other 
H3 lysine residues [321]. Genome-wide chromatin immunoprecipitation mapping 
has highlighted that LSD1 binds to the promoter and enhancer regions of genes 
regulating their expression [322, 323]. Through this regulation it is thought that 
LSD1 plays a role in numerous cellular functions including differentiation and 
stemness [308, 322, 323], senescence [324], and it has even been implicated in 
neurodegenerative disorders [325, 326].  
 
The other HKDM targeted within this chapter is the Jumanji domain containing-3 
(JMJD3) protein, which catalyses the demethylation of H3K27me2/3 and 
therefore is associated with increased expression of the genes regulated by that 
chromatin mark [327, 328]. Interestingly, JMJD3 is essential for stem cell 
differentiation into neuronal lineages; in the developing spinal cord H3K27me3 
regulates the activity of BMP causing the interaction of JMJD3 with the SMAD1/4 
transcription factors activating the BMP antagonist Noggin [329]. GSKJ4, an 
inhibitor of JMJD3, has been shown to mimic α-ketoglutarate binding to JMJD3 






macrophages had reduced LPS-induced cytokine production therefore 
































4.2 Hypothesis and Aims 
Previous work has demonstrated that the epigenetic modulators used in this 
chapter are known to inhibit proteins involved in different epigenetic mechanisms. 
Despite this, the epigenomic consequences of these compounds are unknown. 
Therefore, the hypothesis of this chapter is that these compounds have 
methylomic consequences on neurons and microglia and that these changes 
have functional implications on biological pathways.  
 
In order to address this hypothesis this aims of this chapter are: 
1. To treat two iPSC cell models with different drugs known to modulate 
epigenetic mechanisms. 
2. To provide the first insight into the DNA methylation changes that are 
caused by these modulators. 




















4.3.1 Cell Culture  
The information in this section contains all the information necessary to grow, 
maintain and split the iPSC-derived neurons and microglia used in this chapter. 
 
4.3.1.1 Sources of Cells 
The iPSC-derived neuronal cells used in this study were grown, maintained and 
treated by Dr Elena Ribe and her team at the University of Oxford, UK in 
conjunction with collaborators at the Alzheimer’s Research UK Oxford Drug 
Discovery Institute (ARUK ODDI), according to the protocol below.  
 
The iPSC-derived microglial cells used in this study were grown, maintained and 
treated by Dr Sally Cowley and her team at the University of Oxford, UK in 
conjunction with collaborators at the ARUK ODDI, according to the protocol 
below. 
 
4.3.1.2 Generation of Human iPSC-Derived Cortical Neurons 
In this section I will describe the methods used to culture, maintain and 
differentiate iPSCs into neuronal cells. To generate the cortical neurons we used 
the iPSC line CTR M3 36S, which were derived from keratinocytes from a middle 
aged neurotypical male at Kings College London. The keratinocytes were 
reprogrammed into iPSCs using sendai virus and differentiated into cortical 







4.3.1.2.1 iPSC Culture 
iPSCs were cultured at 37oC with 5% CO2 under feeder-free conditions. iPSCs 
were cultured on 6-well plates (Nunc) that had been coated with Geltrex (Life 
Technologies) prior to plating and were maintained in 2mL E8F media (Life 
Technologies). Colonies were passaged when the culture reached approximately 
80% confluency. To passage the cells the media was removed and the cells were 
washed with PBS, and detached using dispase (Life Technologies) by incubating 
at 37oC for three to four minutes. After this time the dispase was removed and 
the cells were gently washed with 2mL pre-warmed E8F media. To remove the 
cells from the base of the well they were gently scraped and pipetted up and down 
to break up the colonies, but not to reduce them to single cells. The cells were 
plated at approximately 10,000 cells per cm2, after which they were returned to 
the incubator and left for a minimum of 48 hours before handling.  
 
4.3.1.2.2 Neuronal Differentiation 
The protocol for neuronal differentiation was adapted from Shi et al. 2012. iPSCs 
were passaged at high density using Versene from Lonza so the cells would be 
maintained as clusters. After twenty-four hours the SMAD inhibitors 1µM 
Dorsomorphin and 10µM SB (Sigma) were added to each well in 50% N2 medium 
(N2 supplemented in DMEM/F12 and 1% glutamax) and 50% B27 medium (B27 
supplement in neurobasal medium with 1% glutamax) (all from Life 
Technologies). The N2/B27 media and SMAD inhibitors were replaced every day 
for the first seven days. After this, cells were dissociated using Accutase and 
replated in N2/B27 media containing 10µM Y-27632 Rock inhibitor (Abcam). 
Neuronal progenitors were plated onto wells coated in laminin for terminal 






containing 10µM DAPT and 10µM Rock inhibitor. After 48 hours from induction, 
the media was replaced with B27 media, the cells were maintained in this media 
and underwent a 50% media change every three days.  
 
4.3.1.3 Generation of Human iPSC-Derived Microglia 
In this section I will describe the methods used to culture, maintain and 
differentiate iPSCs into microglial cells. 
 
4.3.1.3.1 iPSC Culture 
iPSCs were cultured at 37oC with 5% CO2 under feeder free conditions. iPSCs 
were cultured on 6-well plates (Nunc) that had been coated with matrigel (BD 
Biosciences) prior to plating and were maintained in 2mL Oxford Essential-8 (Ox-
E8) media (made in house). Colonies were passaged when the culture reached 
approximately 80% confluency. To passage the cells the media was removed 
and the cells were washed with PBS, and detached using dispase (Life 
Technologies) by incubating at 37oC for three to four minutes. After this time the 
dispase was removed and the cells were gently washed with 2mL pre-warmed 
Ox-E8 media. To remove the cells from the base of the well, they were gently 
scraped and pipetted up and down to break up the colonies, but not to reduce 
them to single cells. The cells were plated at approximately 10,000 cells per cm2, 
after which they were returned to the incubator and left for a minimum of 48 hours 
before handling.  
 
4.3.1.3.2 Embryoid Body Formation by Spinning 
Spin embryoid bodies were formed using AggreWellsTM800 (Stemcell 






five minutes at 37oC in TrypLE Express (Gibco). The cells were mixed into single 
cell suspension in the TrypLE by pipetting up and down, collected into a 15mL 
falcon tube and were diluted 1:10 in PBS. Cells were then counted and spun 
down. After centrifugation the supernatant was removed, and the cell pellet 
tapped loose before being resuspended in mTeSRTM-1 spin-EB medium. The 
mTeSRTM-1 spin-EB medium consisted of mTeSR™-1 (Stem Cell Technologies), 
supplemented with 1mM Rock-inhibitor (Y27632; Calbiochem), 50ng/mL BMP-4 
(Peprotech), 20ng/mL SCF (Miltenyi Biotec), 50ng/mL VEGF (Peprotech). For 
AggreWellsTM800 the plates were prepared by rinsing each AggreWell with PBS 
and aspirating the PBS. Next, 1mL mTeSR™-1 spin-EB medium was added to 
the AggreWells and this was centrifuged at 3,000 x g for one to two minutes to 
remove any microscopic air bubbles. After the plate had been prepared, of 4x106 
cells were added per well. The plate containing the cells was then centrifuged at 
800rpm for three minutes. After centrifugation, the cells in each well were 
examined to make sure they were evenly distributed across the base of the well. 
The plate was then left in the incubator for four days. Each day the EBs were fed 
with spin medium by gently removing 1mL spin medium from the well and gently 
replacing it by pipetting it in a drop wise manner down the side of each well using 
a pipette. To harvest the EBs on day four the contents of the wells were pipetted 
up and down several times using a 5mL serological pipette to dislodge the EBs 
from the microwells. The contents were taken up and transferred onto a 40µM 
cell strainer that was inverted over a 50mL falcon tube. The contents were 
washed out of the well several times with PBS and transferred onto the same cell 
strainer to collect and wash all EBs on the strainer. This way the EBs remained 
on top of the inverted strainer and the media/PBS passed through the strainer 






gently transferred and inverted over a new 50mL falcon tube so that the EBs were 
now on the underside of the strainer and could be collected into the new 50mL 
falcon tube, by passing differentiation media (contents described below) through 
the strainer. EBs could then be counted by transferring 50uL sample to a 96 well 
plate under a microscope. 
 
4.3.1.3.2 Directed Differentiation to Produce Microglial Precursors 
For differentiation, approximately ten EBs were transferred to one well of a six 
well plate in 3mL medium, two thirds of the medium were replaced every five 
days. The medium consisted of X-VIVOTM15 (Lonza) supplemented with 
100ng/mL M-CSF (Invitrogen), 25ng/mL IL-3 (R&D Systems), 2mM Glutamax 
(Invitrogen) 100U/mL penicillin and 100µg/mL streptomycin (Invitrogen) and 
0.55mM β-mercaptoethanol (Invitrogen). Once precursors were visible in the 
supernatant of the cultures (two to three weeks post differentiation beginning), 
the non-adherent cells were harvested weekly from the supernatant of the EB 
cultures.  
 
4.3.1.3.3 Microglial Culture and Maturation  
Microglia were plated onto treated six well plates (Corning) at a density of 1.5x106 
cells per well. They were maintained in media consisting of RPMI 1640 (PAA) 
with 10% fetal bovine serum (PAA), or in X-VIVOTM15 (Lonza) where specifically 
stated. The medium was supplemented with 100 ng/mL (approx. 1.7×104 
units/mL) recombinant human M-CSF (R&D Systems), as well as 2 mM glutamine 
(PAA), 100 U/mL penicillin and 100 µg/mL streptomycin (PAA). Monocytes were 







4.3.1.4 Treatment of iPSC-derived Neurons and Microglia with Epigenetic 
Modulators  
Cells were plated out into 36 wells of 6 or 12 well plates at a density of 7.5x105 
cells per well for the iPSC-derived microglia and 3x105 for iPSC-derived neuronal 
cells. All compounds were used at a final concentration of 3µM (chosen due to 
the specificity and on-target effect in cells at this concentration) and were 
incubated on the cells for twenty-four hours. After this twenty-four hour period, 
each well was washed two times with PBS, which was then aspirated. The plates 
were then stored at -80oC until required for DNA extraction. The compounds used 
can be broadly split into five categories: bromodomain inhibitors, histone 
methyltransferase inhibitors, histone lysine demethylase inhibitors, methyl lysine 
reader inhibitors and WD40 containing protein inhibitors (table 4.1). Further 
details about each compound is available at: https://www.thesgc.org/chemical-
probes.  
 
An illustration detailing the experimental workflow can be found in figure 4.1 and 



















Figure 4.1. Diagram illustrating the experimental workflow. 
 
iPSC-derived neurons and microglia were plated out at densities of 300,000 and 750,000 
cells per well, respectively. Both cell types were treated with 29 compounds at 3µM or a 
DMSO control for 24 hours. Following incubation cells were washed twice in PBS and cells 
were collected and DNA extracted. Following extraction DNA methylation was quantified 







Class Compound Name Protein Target Description 
BRD 
(+)-JQ1 BET family Potent, selective BET bromodomain inhibitor 
BAY 299 BRPF2/TAF1 Potent and selective BRD1 and TAF1 inhibitor 
BAZ2-ICR BAZ2A/2B Selective BAZ2 inhibitor 
BI 9564 BRD9/7 Potent and selective BRD9 and BRD7 inhibitor 
GSK2801 BAZ2A/2B Selective BAZ2A and BAZ2B inhibitor 
I-BRD9 BRD9 Potent and selective BRD9 inhibitor 
I-CBP 112 CREBBP/EP300 Selective CBP/p300 BRD inhibitor 
NI 57 BRPF1/2/3 Potent and selective BRPF bromodomain inhibitor 
NVS-CECR2-1 CECR2 Potent and selective inhibitor of CECR2 
OF 1 BRPF1/2/3 Selective BRPF1B and BRPF2 inhibitor 
PFI 3 SMARCA2/4 Potent and selective SMARCA2/4 and polybromo 1 inhibitor 
TP 472 BRD: BRD9/7 Potent BRD9/7 inhibitor 
HKDM 
GSK LSD 1 dihydrochloride LSD1 Potent and selective LSD1 inhibitor 
GSKJ4 JMJD3/UTX Histone KDM inhibitor 
KMR 
A 395 EED EED inhibitor 
UNC 1215 L3MBTL3 Potent inhibitor of L3MBTL3 Kme reader domain 
MT 
A 196 SUV420H1/H2 SUV420H1 and H2 inhibitor 
A 366 G9a/GLP Potent and selective G9a/GLP inhibitor 
BAY 598 SMYD2 SMYD2 inhibitor 
GSK343 EZH2 EZH2 inhibitor 
GSK591 dihydrochloride PRMT5 Potent and selective PRMT5 inhibitor 
MS 023 dihydrochloride PRMT type 1 Potent and selective type I PRMT inhibitor 
MS049 oxalate salt PRMT4/6 Potent and selective PRMT4 and PRMT6 inhibitor 
RPFI 2 hydrochloride SETD7 Potent and selective SETD7 inhibitor 
SGC 0946 DOT1L Highly potent and selective DOT1L inhibitor 
SGC 707 PRMT3 Potent and selective allosteric inhibitor of PRMT3 






UNC 0642 G9a/GLP Potent and selective G9a and GLP inhibitor 
UNC 1999 EZH2/H1 Potent and selective EZH2/EZH1 inhibitor 
WD40 OICR 9429 WDR5 High affinity and selective WDR5 antagonist 




Listed for each compound is the compound name, its protein target, a description of its action, the supplier it is available from and 
corresponding catalogue number where available. All compounds in this chapter were used at a concentration of 3µM and were incubated on 
the cells for 24 hours. Where BRD = bromodomain, KDM = histone lysine demethylase, KMR = methyllysine reader, HMT = histone 
methyltransferase and WD40 = WD repeat protein family. All compounds are available to buy from Tocris with the exception of A 395 and 






4.3.1.4 DNA Extraction and Methylomic Profiling and Quantification 
Please refer to section 2.2 for information on DNA extraction, section 2.3 for details on 
bisulfite conversion and section 2.4 or figure 2.2 for a detailed outline of the EPIC array 
protocol. 
 
4.3.2 Data QC 
For an outline of the QC and normalisation methods used in this chapter please see 
section 2.4.2. All data analyses in this chapter were performed using R version 3.4.3. 
Signal intensities were imported into R using the methylumi package [262]. Initial QC 
checks were conducted using functions within the methylumi and wateRmelon 
packages [198, 262]. Using the default settings of one percent within “pfilter”, no 
samples and 2,332 neuronal probes and 2,674 microglial probes were flagged for 
removal. 
 
4.3.3 Data Analysis 
Outlined in this section are the analysis steps conducted in order to assess and 
quantify the DNA methylation changes occurring when iPSC-derived neurons and 
microglia are treated with different compounds known to affect epigenetic 
mechanisms. 
 
 4.3.3.1 PCA 
In order to look at variation within the dataset, PCA was used. Using the “prcomp” 
function within the default statistics package within R the top principal components 
were identified. These principal components were then correlated to known variables 






replicate, cell culture plate and the wells within the cell culture plate using spearman 
correlations. 
 
 4.3.3.2 Removing Confounding Variation using Combat 
Using the “combat” function within the sva package [332] variation attributed to 
“replicate” within the microglial samples was removed as this was identified as a 
significant confounder using PCA (further details are provided below in section 4.4.2.6). 
For this analysis the batch covariate was replicate number and parametric adjustments 
were allowed. 
 
4.3.3.3 Identifying DMPs associated with treatment 
Linear regression was used to identify DMPs for each drug treatment by comparing 
each treatment individually to the control treatment (N=810,201 probes that passed 
QC). In order to investigate whether there was any overlap in differential DNA 
methylation between compounds with similar functions I used Pearson correlations to 
compare the effect sizes of the top 100 most significant probes for a given compound 
to their effect sizes for other compounds in that category using the “cor.test” function 
in R. Similarly, to explore whether there was an enrichment for the same direction of 
effect I used a sign test (an exact binomial test). I was also interested to investigate 
whether similar DNA methylation changes were induced by the compounds in the two 
different cell types. To this end, I used the sign test and Pearson’s correlations to 
compare the effect sizes of the top 100 most significant DMPs treated with a given 







4.3.3.4 GO Enrichment Analysis 
Pathway analysis was used to give biological meaning to nominated CpG sites using 
the “gometh” function from the missMethyl package [265] alongside the GO repository. 
The “gometh” function was chosen as it adjusts for the number of CpGs per gene. This 
was only done in the microglial samples as there were too few consistently 
differentially methylated probes in the neuronal data. Given the low number of 
replicates no DMPs reached genome-wide significance. As such, I used a nominal p-











4.4.1 Outcome of the QC Pipeline 
This section outlines the results of the QC process undertaken in order to ensure the 
data was of sufficient quality before undertaking any subsequent analyses.  
 
4.4.1.1 Median Methylated and Unmethylated Sample Intensities 
To ensure that the signal intensities for each sample were above background level the 
methylumi package was used to quantify the fluorescent intensities for each probe 
[262]. The median methylated and unmethylated intensities were then plotted against 
one another for each sample colouring them according to either their ChipID (figure 
4.2), their position on the BeadChip (figure 4.3), or which plate they were assayed in 
(neuronal samples only – figure 4.4).  It appears that the BeadChip and the position 
within the Chip that the sample was run on do impact the median intensities, with the 
position on the BeadChip having a greater effect. In particular both the neuronal and 
microglial samples run at position R08C01 have the lowest median unmethylated 
intensities. However, the effect is not large enough to consider removing samples as 
all samples have median intensities above 1,000 and therefore were not excluded 
























Figure 4.2. Median signal intensities plotted by BeadChip ID. 
Intensities for each sample were imported using the methylumi package [262] and the median methylated and unmethylated sample intensities 





















Figure 4.3. Median signal intensities plotted by position on the BeadChip. 
Intensities for each sample were imported using the methylumi package [262] and the median methylated and unmethylated sample intensities 






















Figure 4.4. Median signal intensities plotted by plate processed in.
Intensities for each sample were imported using the methylumi package [262] and the median methylated and unmethylated sample intensities 
were calculated for each plate that the neuronal samples were processed in. Shown are (A) a scatterplot of the median signal intensities 
coloured by plate, median (B) methylated and (C) unmethylated signal intensities plotted by plate represented as a boxplots. As all of the 
microglial samples were all assayed on the same plate it was not necessary to check the association between plate and methylation intensity. 






4.4.1.2 Bisulfite Conversion Efficiency of Samples 
Bisulfite is the process that converts unmethylated cytosines into uracils and therefore 
allows them to be distinguished from methylated cytosines on the EPIC array. Within 
the EPIC array BeadChip there are several fully methylated control loci, which allow 
for the bisulfite conversion efficiency to be calculated. Using the “bscon” function within 
the R wateRmelon package [198] it is possible to convert the fluorescence intensity of 
these probes for each sample into an easy to understand percentage conversion 
efficiency. The lowest generally accepted bisulfite conversion efficiency is 80%, any 
samples which have a percentage conversion less than this should be removed. All of 
the samples within this study have a bisulfite conversion efficiency of greater than 92% 
and therefore do not need to be removed based on this metric (figure 4.5). 
 
4.4.1.3 Neuronal and Microglial have a Bimodal Beta Density Distribution 
To ensure our data fell within this metric the β-values for each sample were plotted as 
a beta density plot. It is clear that for the majority of loci within each sample this holds 
true (figure 4.6). Interestingly, it appears that the neuronal samples in general are more 




















Figure 4.5. Bisulfite conversion efficiency for samples in the study.
Using the fully methylated probes within the array the bisulfite conversion efficiency of each sample was calculated using the “bscon” function 













The DNA methylation level at each locus was determined using β-values, which are the 
ratio of fluorescence signal intensity for the methylated and unmethylated beads.  The β-
values of each probe in the (A) neuronal and (B) microglial samples were plotted on a beta 






4.4.1.4 No Samples are Removed by P-filtering 
The final stage of the QC pipeline is to filter samples and probes based on their 
detection p-value. Using the “pfilter” function within the wateRmelon package [198] 
samples that contained more than one percent (by default) probes above the 0.05 
detection p-value threshold and probes with any samples having a beadcount less 
than three or more than one percent above the p-value threshold were removed. Using 
the default setting of one percent 524 sites that had a beadcount of less than three in 
five percent of samples and 1,708 sites having one percent with a detection p-value 
greater than 0.05 were removed from the neuronal samples. Similarly, 499 sites with 
a low bead count and 2,175 sites with a greater than one percent detection p-value 
were removed from the microglial samples. However, no whole samples were 
recommended for removal from either the neuronal or microglial samples.  
 
4.4.2 Data Analysis 
In this section I have described the results of the main analyses undertaken in this 
chapter. 
 
4.4.2.1 iPSC-Derived Neurons have a Lower Epigenetic Age  
Using the latest version of the epigenetic age calculator (available from: 
https://dnamage.genetics.ucla.edu/home) I assessed the epigenetic ages of the 
neuronal and microglial cells after the treatments with the different epigenetic 
modulators. Overall the iPSC-derived microglia (figure 4.7B) have a significantly 
higher epigenetic age than the neurons (p=4.88x10-3, figure 4.7A), although all of the 
epigenetic ages are still representative of immature cells, with the highest epigenetic 






significant difference between treatments within the same cell type as the differences 
seen between treatments are very small and there are large variations between 
replicates (neurons: p=0.182 and microglia: p=0.780). There are a couple of 
exceptions to this, for example the treatment UNC0642 has less variation in epigenetic 
age between replicates in both the neurons and microglia. There are also some 
treatments that seem to have a greater effect in the neuronal samples, for instance 
TP472 decreases epigenetic age in the neurons but not in microglia, where there is 
an increase in variation. Finally, it is also worth note that UNC1999 seems to cause 
the greatest consistent decrease in epigenetic age in the neuronal cells. Unfortunately, 





















Figure 4.7. iPSC-derived neurons are epigenetically younger than iPSC-derived 
microglia. 
Using the latest iteration of the Horvath epigenetic age calculator [126] the biological or 
epigenetic ages of each sample were derived. The estimated epigenetic age for each 
treatment in the (A) neuronal and (B) microglial samples were then plotted as a boxplot. 






4.4.2.2 iPSC-Derived Microglia have Undergone more Cell Divisions 
Using the coefficients of the MiAge calculator created by Youn and Wang [199] I 
estimated the number cell divisions each of the neuronal and microglial samples had 
gone through. It is clear that overall the microglial cells (figure 4.8B) had undergone 
significantly more rounds of cell division than the neuronal cells (p=5.00x10-3; figure 
4.8A). The microglial control cells have undergone approximately 990 replications on 
average whereas the neuronal control cells have only been through approximately 450 
divisions, less than half that of the microglia. There is also more variation within the 
microglial cells with some treatments, such as BAY598, causing there to be a 400 cell 
division spread, although this does seem to be driven by one replicate (figure 4.8B). 
Due to the large amount of variation in the microglial data it appears that the treatments 
have a more specific effect on the number of cell divisions in the neurons. For example, 
A395, GSK LSD1, MS023 and OF1 cause very little variation with there only being a 
difference of 12, 6, 11 and 7, respectively between the highest and lowest number of 
cell divisions within each treatment group. However, none of the treatments 























Using the coefficients of the MiAge calculator [199] the mitotic ages of each sample were 
derived. The estimated number of cell divisions for each treatment in the (A) neuronal and 






4.4.2.3 Dasen Normalisation 
To make it possible to make meaningful comparisons between the data, the “dasen” 
normalisation function within the wateRmelon package [198] was used. Dasen 
involves quantile normalisation, which normalises the data by type I and type II probe 
background levels first. After dasen normalisation, the median methylated and 
unmethylated signal intensities have a smaller range and are therefore consistent 
across samples (figure 4.9). Through plotting the normalised β-values it is possible to 
see that they still have a bimodal distribution and that the unmethylated (β-value 
between 0 and 0.2) and methylated (β-value between 0.8 and 1) peaks are much more 
consistent, and this is especially true of the fully methylated probes.  
 
By splitting the probes based on whether they are a type I or type II probe it is clear 
that for both the neuronal and microglial samples the type I probes contribute more to 
the unmethylated peak (β-value of less than 0.2; figure 4.10A and C) and the type II 
probes contribute more to the methylated peak (figure 4.10B and D). The type II 
microglial fully methylated peak (figure 4.10D) is also a lot smaller than that of the 
neuronal type II methylated peak (figure 4.10B). This would appear to be because 
there is an increase in hemi-methylation in the microglial type II probes. Finally, there 
is a split within the microglial type II fully methylated peak with there being two distinct 






















Figure 4.9. Median methylated and unmethylated sample intensities after dasen normalisation. 
Quantile normalisation was performed using the dasen function within the wateRmelon package [198] to generate the normalised median 
methylated and unmethylated signal intensities. Graphical representation of median signal intensities relative to each other for the (A) neuronal 






















Figure 4.10. Median methylated and unmethylated sample intensities for type I and II probes after dasen normalisation.
Quantile normalisation was performed using dasen [198] to generate the normalised median methylated and unmethylated signal intensities. 
Probes were separated based on whether they were type I or type II probes and plotted individually. Density plots for (A) neuronal type I, (B) 






4.4.2.4 There is More Hemi-Methylation in the iPSC-Derived Microglia 
Following dasen normalisation, neuronal and microglial probes that were hemi-
methylated (having a β-value between 0.2 and 0.8) were extracted and plotted (figure 
4.11). From this is it clear that there are a larger proportion of hemi-methylated probes 
in the microglial samples than that of the neuronal samples. Specifically, there are 
512,850 hemi-methylated microglial probes and 476,870 hemi-methylated neuronal 
probes. In addition, the hemi-methylated probes have a lower β-value in the microglia 
samples than the neuronal samples, which could account for the smaller type II fully 







































After dasen normalisation probes containing β-values between 0.2 and 0.8 (hemi-
methylated probes) were then plotted, where blue represents the iPSC derived-neurons 






 4.4.2.5 PCA Identifies Variation within Data 
Using the “prcomp” function within the default statistics package in R, principal 
components (PCs) that account for variation within each dataset were identified. The 
first five PCs were then correlated to known variables. From this it was determined 
that for the neuronal samples PC1 and PC3 correlate with the array plate the samples 
were run on, PC2 and PC4 correlate with the position on the BeadChip, and PC5 
correlates with ChipID (figure 4.12A). PC1 accounts ~4.11%, PC2 accounts for 
~2.72% and PC3 for ~1.92% of variation within the neuronal dataset (table 4.2). Within 
the microglial samples PC1 and PC2 both correlate with replicate and PC3 and PC4 
correlate with position on BeadChip (figure 4.12B). In the microglial samples PC1 
accounts for ~42.5%, PC2 for ~12.1% and PC3 for ~1.89% of variation within the data 
(table 4.3). 
 
Following this, PC1 was plotted against PC2 for both the neuronal and microglial 
samples with each point being coloured by its corresponding replicate (figure 4.13). 
This further demonstrates that PC1 and PC2 are associated with replicate in the 
microglial samples, as the data points group together by replicate (figure 4.13B). There 












  PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 
Standard deviation 4.55 3.70 3.36 3.11 2.88 2.77 2.74 2.68 2.59 2.53 
Proportion of Variance 0.04 0.03 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 
Cumulative Proportion 0.04 0.07 0.09 0.11 0.13 0.14 0.16 0.17 0.18 0.19674  
 




  PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 
Standard deviation 20.30 10.83 14.28 3.03 2.93 2.76 2.74 2.68 2.66 2.58 
Proportion of Variance 0.42 0.12 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
Cumulative Proportion 0.42 0.55 0.56 0.57 0.58 0.59 0.60 0.61 0.61 0.62 
 
Table 4.3. Variance explained by the first ten PCs in the microglial dataset. 
 
Shown for each PC is the standard deviation, proportion of variance explained and the cumulative proportion explained.  






Figure 4.12. Variation in each dataset is identified using principal component analysis. 
Using the “prcomp” function within the default statistics package the principal components accounting for variation within the dataset were 
identified. The first five principal components were then correlated and plotted against known variables for both (A) neuronal and (B) microglial 
samples. The known variables were treatment, ChipID, position on Chip, array plate (neurons only), replicate, cell culture plate and well within 
the cell culture plate. Where blue indicates a positive correlation, red indicates a negative correlation, *=p<0.001, **=p<1e-8 and ***=p<1e-10. 







Figure 4.13. PC1 clusters by replicate when plotted against PC2 in the microglial samples.
After PCA, PC1 and PC2 were plotted against one another for the (A) neuronal and (B) microglial samples to look for clustering within the 






4.4.2.6 Combat Analysis Reduces Variation Induced by Replicate 
Using the “combat” function within the SVA package [332] it was possible to reduce 
the variation in the microglial dataset that was caused by replicate. Following combat 
analysis it is clear that PC1 and PC2 no longer correlate with replicate (figure 4.14A) 
and that the samples no longer cluster by replicate when PC1 is plotted against PC2 
(figure 4.14B). The proportion of variation accounted for by each PC was also reduced 
with PC1 accounting for ~5.03%, PC2 for ~2.08% and PC3 for ~1.88% variation in the 












  PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 
Standard deviation 4.65 2.99 2.84 2.83 2.58 2.53 2.47 2.45 2.39 2.37 
Proportion of Variance 0.05 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0 .01301 
Cumulative Proportion 0.05 0.07 0.09 0.11 0.12 0.14 0.15 0.17 0.18 0.19 
Table 4.4. Variance explained by the first ten PCs in the microglial dataset after combat analysis. 
Shown for each PC is the standard deviation, proportion of variance explained and the cumulative proportion explained after the microglial 






Figure 4.14. Variation caused by replicate in microglial samples is reduced.
Using the “combat” function within the SVA package the variation induced by replicate in the microglial samples was removed from the dataset. 
(A) Following combat analysis the new principal components were calculated and correlated to known variables including treatment, ChipID, 
position on the Chip, replicate, cell culture plate and the well within the cell culture plate. (B) Scatterplot of principal component one plotted 
against principal component two. *=p<0.001, **=p<1x10-8 and ***=p<1x10-10. The colour intensity and size of the circle are proportional to the 






4.4.2.7 Epigenetic Modulators have Cell Type Specific Effects on Methylation 
I used linear regression to identify DMPs associated with each treatment in each cell 
type separately. Due to the low number of replicates I did not identify any Bonferroni-
significant loci but did identify a number of DMPs at a more relaxed p-value threshold 
of 5x10-4. As a number of compounds have related functions I wanted to identify 
whether the same probes were differentially methylated across all treatments of the 
same compound class. To do this I extracted the significant probes (i.e. p<5x10-4) from 
one modulator (the first alphabetically) and extracted the probes that were nominally 
significant (p<0.05) in all other modulators of that same compound class, with this 
performed for each cell type separately. Interestingly, whilst there were consistent 
methylation changes seen with compound class in the microglia (BRD: 427, HMT: 429, 
HKDM: 387, KMR: 369 and WD40: 422 probes nominally significant across all 
compounds in a class; table 4.5) the same cannot be said of the neuronal samples, 
as there was only consistent changes in the compound groups with the fewest number 
of modulators in the group (BRD: 0, HMT: 0, HKDM: 144, KMR: 120 and WD40: 330 
significant across all compounds in a class; table 4.5). 
 
To add further meaning to the consistent DNA methylation changes seen in the 
microglial samples, a pathway analysis was performed on the probes that were 
consistently differentially methylated across treatments in each compound class. 
Although few pathways reached FDR significance, several demonstrated nominally 
significant alterations in specific pathways in cells treated with compounds in the 
categories of treatment. First, the significant DMPs associated with BRD inhibitor 
treatment seem to be associated with pathways relating to receptor internalisation 






and ureteric bud morphogenesis (table 4.6). The pathways associated with HMT 
inhibitor treatment related to protein targeting to the vacuole, mRNA processing and 
the AV node (table 4.7). HKDM treatment was related to tight junctions and GTPase 
activity and regulation (table 4.8). KMR treatment was related to the regulation of 
chromatin organisation, receptor binding and cell signalling and RNA related process 
(table 4.9). Finally, WD40 treatment was associated with pathways relating to 
























  Number of consistently DMPs across compound class 
Cell Type BRD HMT HKDM KMR WD40  
Neurons 0 0 144 120 330 
Microglia 427 429 387 369 422 
Table 4.5. Number of consistent DMPs across all compounds of the same type. 
 
Number of consistent nominally significant DMPs across the same compound class in the 
neurons or microglia. Loci were identified by extracting the significant DMPs (p<5x10-4) from 
one compound in a given class (the first compound alphabetically) and then noting if they 
were also nominally significantly (p<0.05) differentially methylated in all of the other 












DMPs P-value FDR Genes 
GO:0002090 regulation of receptor internalization BP 51 5 2.74x10
-4 1.000 EGF; ANGPT1; LRRTM1; LRPAP1; NUMB 
GO:0005768 endosome CC 862 20 4.66x10-4 1.000 NISCH; NIPA1; ATP11A; CCDC22; SNX10; EHD4; HLA-DQB1; KIFC1; LRPAP1; OCRL; C11orf59; VAC14; PRKCZ; SPPL2B; C11orf2; RABEP2; FAM108A1; RILP; NUMB; VAMP8 
GO:0043393 regulation of protein binding BP 217 9 0.001 1.000 ANGPT1; LRPAP1; PAX7; PPP2CA; CTNNBIP1; TGFBR3; TIAM1; CFHR5; ARHGEF7 
GO:0001658 
branching involved in 
ureteric bud 
morphogenesis 
BP 60 5 0.001 1.000 FGF1; HOXB7; PKD2; CTNNBIP1; SIX1 
GO:0099010 modification of postsynaptic structure BP 17 3 0.002 1.000 CTNNA2; STAU1; TIAM1 
GO:0060675 ureteric bud morphogenesis BP 65 5 0.002 1.000 FGF1; HOXB7; PKD2; CTNNBIP1; SIX1 
GO:0072171 mesonephric tubule morphogenesis BP 66 5 0.002 1.000 FGF1; HOXB7; PKD2; CTNNBIP1; SIX1 
GO:0051098 regulation of binding BP 368 11 0.002 1.000 EGF; ANGPT1; LRPAP1; PAX7; PPP2CA; CTNNBIP1; EBF2; TGFBR3; TIAM1; CFHR5; ARHGEF7 
GO:0016323 basolateral plasma membrane CC 213 8 0.002 1.000 CTNNA2; DLG2; DSP; PKD2; SLC2A9; NDRG4; NUMB; MAP7 
GO:0005942 phosphatidylinositol 3-kinase complex CC 26 3 0.002 1.000 PIK3R5; NRBF2; VAC14 
GO:0044431 Golgi apparatus part CC 915 19 0.003 1.000 
YIF1A; GPC5; MAPK8IP3; ATP11A; HLA-DQB1; LRPAP1; OCRL; PODXL2; RAB6B; 
SERPINA1; A2BP1; VAC14; NSFL1C; SPPL2B; ST3GAL1; C11orf2; AGPAT9; TRAPPC9; 
ASAP2 
GO:0060415 muscle tissue morphogenesis BP 82 5 0.003 1.000 DSP; IGSF22; PAX7; TGFBR3; TNNC1 
GO:0005769 early endosome CC 336 10 0.003 1.000 NISCH; NIPA1; ATP11A; EHD4; KIFC1; OCRL; VAC14; RABEP2; NUMB; VAMP8 
GO:0072078 nephron tubule morphogenesis BP 74 5 0.003 1.000 FGF1; HOXB7; PKD2; CTNNBIP1; SIX1 





BP 95 5 0.003 1.000 EGF; ANGPT1; LRRTM1; LRPAP1; NUMB 
GO:0072088 nephron epithelium morphogenesis BP 76 5 0.003 1.000 FGF1; HOXB7; PKD2; CTNNBIP1; SIX1 
GO:0036379 myofilament CC 31 3 0.003 1.000 IGSF22; TNNC1; TNNT3 
GO:0099563 modification of synaptic structure BP 22 3 0.003 1.000 CTNNA2; STAU1; TIAM1 






GO:0048644 muscle organ morphogenesis BP 88 5 0.004 1.000 DSP; IGSF22; PAX7; TGFBR3; TNNC1 
GO:0072028 nephron morphogenesis BP 78 5 0.004 1.000 FGF1; HOXB7; PKD2; CTNNBIP1; SIX1 
GO:0061333 renal tubule morphogenesis BP 78 5 0.004 1.000 FGF1; HOXB7; PKD2; CTNNBIP1; SIX1 
GO:0071556 
integral component of 
lumenal side of 
endoplasmic 
reticulum membrane 
CC 27 3 0.004 1.000 HLA-DQB1; PKD2; SPPL2B 
GO:0098553 
lumenal side of 
endoplasmic 
reticulum membrane 
CC 27 3 0.004 1.000 HLA-DQB1; PKD2; SPPL2B 










Shown are the top 25 most significant pathways after the iPSC-derived microglia were treated with compounds known to inhibit proteins 
containing bromodomains. Shown for each pathway is the GO ID, the pathway descriptor, the ontology of the pathway, the number of genes 
in the pathway, the number of DMPs in the pathway, p-value significance, FDR value and the list of significantly differentially methylated 











DMPs P-value FDR Genes 
GO:0086016 AV node cell action potential BP 11 3 5.39x10
-4 1.000 RYR2; CACNA1C; CACNB2 
GO:0086027 AV node cell to bundle of His cell signaling BP 11 3 5.39x10
-4 1.000 RYR2; CACNA1C; CACNB2 
GO:0086067 AV node cell to bundle of His cell communication BP 12 3 6.68x10
-4 1.000 RYR2; CACNA1C; CACNB2 
GO:0019934 cGMP-mediated signaling BP 33 4 7.07x10-4 1.000 EDNRB; ADNP; KCNC2; NPR1 
GO:1900363 regulation of mRNA polyadenylation BP 16 3 7.51x10
-4 1.000 CPEB3; RDBP; CPSF7 
GO:0005089 Rho guanyl-nucleotide exchange factor activity MF 76 6 0.001 1.000 FGD5; MCF2L; PLEKHG5; TRIO; ARHGEF6; ARHGEF10 
GO:0097066 response to thyroid hormone BP 27 3 0.002 1.000 GAS2L1; SIX1; TOMM20 
GO:0031440 regulation of mRNA 3'-end processing BP 27 3 0.003 1.000 CPEB3; RDBP; CPSF7 
GO:0086014 atrial cardiac muscle cell action potential BP 20 3 0.003 1.000 RYR2; CACNA1C; CACNB2 
GO:0086026 atrial cardiac muscle cell to AV node cell signaling BP 20 3 0.003 1.000 RYR2; CACNA1C; CACNB2 
GO:0086066 
atrial cardiac muscle cell to 
AV node cell 
communication 
BP 20 3 0.003 1.000 RYR2; CACNA1C; CACNB2 
GO:0030016 myofibril CC 216 8 0.003 1.000 SYNM; SYNE1; RYR2; SPTBN1; TNNI1; CACNA1C; SQSTM1; PDE4DIP 
GO:0072665 protein localization to vacuole BP 55 4 0.003 1.000 VTI1A; SH3BP4; PIK3R4; VPS13D 
GO:0019388 galactose catabolic process BP 10 2 0.004 1.000 GALK2; PGM1 
GO:0043292 contractile fiber CC 227 8 0.004 1.000 SYNM; SYNE1; RYR2; SPTBN1; TNNI1; CACNA1C; SQSTM1; PDE4DIP 
GO:0032414 
positive regulation of ion 
transmembrane transporter 
activity 
BP 95 5 0.004 1.000 CFTR; KCNC2; NLGN3; RYR2; CACNB2 
GO:0006623 protein targeting to vacuole BP 30 3 0.004 1.000 VTI1A; PIK3R4; VPS13D 
GO:0019935 cyclic-nucleotide-mediated signaling BP 213 7 0.006 1.000 ADRA2A; EDNRB; ADNP; PCLO; KCNC2; NPR1; BAI3 
GO:0050808 synapse organization BP 381 12 0.006 1.000 DSCAM; EPHA7; PDZRN3; ADNP; PCLO; PALM; PFN2; NLGN3; BAI3; PTPRF; SIX1; CACNB2 
GO:0032411 positive regulation of transporter activity BP 103 5 0.006 1.000 CFTR; KCNC2; NLGN3; RYR2; CACNB2 







attachment of mitotic 
spindle microtubules to 
kinetochore 
BP 13 2 0.006 1.000 ZNF828; MAD1L1 
GO:0031256 leading edge membrane CC 166 7 0.007 1.000 FGD5; WWC1; SH3YL1; KCNC2; PALM; PSD; SPTBN1 
GO:0035023 regulation of Rho protein signal transduction BP 131 6 0.007 1.000 FGD5; MCF2L; PLEKHG5; TRIO; ARHGEF6; ARHGEF10 
GO:0006012 galactose metabolic process BP 14 2 0.007 1.000 GALK2; PGM1 
 










Shown are the top 25 most significant pathways after the iPSC-derived microglia were treated with compounds known to inhibit histone 
methyltransferases. Shown for each pathway is the GO ID, the pathway descriptor, the ontology of the pathway, the number of genes in the 
pathway, the number of DMPs in the pathway, p-value significance, FDR value and the list of significantly differentially methylated genes 











DMPs P-value FDR Genes 
GO:2000810 regulation of bicellular tight junction assembly BP 20 4 4.22x10
-5 0.372 NPHP4; PRKACA; PRKCH; FZD5 
GO:1901888 regulation of cell junction assembly BP 87 6 4.90x10
-4 1.000 DAPK3; NPHP4; WNT4; PRKACA; PRKCH; FZD5 
GO:0043087 regulation of GTPase activity BP 464 13 0.001 1.000 
AGAP11; EPHA4; PLEKHG4; RACGAP1; NTF3; WNT4; RASIP1; PTPRN2; 
TSC2; PREX2; SYNGAP1; MTSS1L; TBC1D5 





BP 26 3 0.002 1.000 JSRP1; PRKACA; CAMK2D 
GO:0120192 tight junction assembly BP 54 4 0.002 1.000 NPHP4; PRKACA; PRKCH; FZD5 
GO:0120193 tight junction organization BP 57 4 0.002 1.000 NPHP4; PRKACA; PRKCH; FZD5 
GO:0015662 
ATPase activity, coupled to 
transmembrane movement 
of ions, phosphorylative 
mechanism 





MF 69 4 0.003 1.000 MPST; CHST8; TST; HS3ST3B1 
GO:0090075 relaxation of muscle BP 31 3 0.003 1.000 C5orf20; ATP2A1; CAMK2D 
GO:0043297 apical junction assembly BP 62 4 0.003 1.000 NPHP4; PRKACA; PRKCH; FZD5 
GO:1903779 regulation of cardiac conduction BP 58 4 0.003 1.000 ATP2A1; ATP2B1; PRKACA; CAMK2D 
GO:0097546 ciliary base CC 33 3 0.004 1.000 NPHP4; PRKACA; PRKAR1B 
GO:0006040 amino sugar metabolic process BP 38 3 0.004 1.000 CSGALNACT1; LARGE; GFPT2 
GO:1903312 negative regulation of mRNA metabolic process BP 71 4 0.004 1.000 CIRBP; DHX9; SFRS8; RBM42 
GO:0043547 positive regulation of GTPase activity BP 389 10 0.005 1.000 
AGAP11; PLEKHG4; RACGAP1; NTF3; WNT4; TSC2; PREX2; SYNGAP1; 
MTSS1L; TBC1D5 
GO:0051279 
regulation of release of 
sequestered calcium ion 
into cytosol 
BP 80 4 0.007 1.000 JSRP1; PRKACA; PRKCE; CAMK2D 
GO:0009101 glycoprotein biosynthetic process BP 316 8 0.008 1.000 
C3orf21; GALNT9; CSGALNACT1; CHST8; B3GNT9; LARGE; GFPT2; 
HS3ST3B1 
GO:0033017 sarcoplasmic reticulum membrane CC 38 3 0.008 1.000 JSRP1; ATP2A1; CAMK2D 






GO:0071333 cellular response to glucose stimulus BP 126 5 0.010 1.000 OPA1; PRKACA; PRKCE; PTPRN2; ZNF236 
GO:0090630 activation of GTPase activity BP 83 4 0.010 1.000 PLEKHG4; NTF3; MTSS1L; TBC1D5 
GO:0071331 cellular response to hexose stimulus BP 128 5 0.011 1.000 OPA1; PRKACA; PRKCE; PTPRN2; ZNF236 
GO:0030145 manganese ion binding MF 53 3 0.011 1.000 C3orf21; PRKACA; LARGE 
GO:0071326 cellular response to monosaccharide stimulus BP 129 5 0.011 1.000 OPA1; PRKACA; PRKCE; PTPRN2; ZNF236 











Shown are the top 25 most significant pathways after the iPSC-derived microglia were treated with compounds known to inhibit histone lysine 
demethylases. Shown for each pathway is the GO ID, the pathway descriptor, the ontology of the pathway, the number of genes in the 
pathway, the number of DMPs in the pathway, p-value significance, FDR value and the list of significantly differentially methylated genes 











DMPs P-value FDR Genes 
GO:0031057 negative regulation of histone modification BP 40 6 3.12x10
-6 0.027 PHF1; KDM3A; SKI; TWIST1; UCN; H2AFY 
GO:1905268 negative regulation of chromatin organization BP 60 6 9.74x10
-6 0.043 PHF1; KDM3A; SKI; TWIST1; UCN; H2AFY 
GO:0031056 regulation of histone modification BP 138 7 3.70x10
-4 1.000 PHF1; WDR70; KDM3A; SKI; TWIST1; UCN; H2AFY 
GO:0008307 structural constituent of muscle MF 44 4 8.54x10
-4 1.000 IGSF22; PLEC1; TTN; ACTN2 
GO:1902275 regulation of chromatin organization BP 174 7 8.74x10
-4 1.000 PHF1; WDR70; KDM3A; SKI; TWIST1; UCN; H2AFY 
GO:2001251 
negative regulation of 
chromosome 
organization 
BP 142 6 0.001 1.000 PHF1; KDM3A; SKI; TWIST1; UCN; H2AFY 
GO:0005104 fibroblast growth factor receptor binding MF 26 3 0.001 1.000 FGF2; NPTN; KL 
GO:0031061 negative regulation of histone methylation BP 20 3 0.001 1.000 PHF1; KDM3A; H2AFY 
GO:0016072 rRNA metabolic process BP 237 7 0.001 1.000 NGDN; PELP1; UTP11L; H2AFY2; USP36; RPS2; H2AFY 
GO:0010996 response to auditory stimulus BP 23 3 0.002 1.000 USP53; UCN; NRXN1 
GO:0030506 ankyrin binding MF 20 3 0.002 1.000 ATP1A1; PLEC1; SPTBN1 
GO:0031430 M band CC 29 3 0.002 1.000 IGSF22; SPTBN1; TTN 
GO:0045595 regulation of cell differentiation BP 1747 28 0.002 1.000 
PQBP1; VAX1; ACAP3; C20orf123; UNC5D; FGF2; NPTN; GLI2; HOXA7; HOXB8; 
HSPA1A; KDR; MIR9-1; PPP2CA; H2AFY2; KDM3A; PRKCI; CTNNBIP1; PTHLH; 
PRDM16; SEMA3F; SKI; TPH1; TWIST1; ARHGEF7; BRSK2; NEURL; H2AFY 
GO:0044449 contractile fiber part CC 212 7 0.002 1.000 SYNE1; IGSF22; PLEC1; SPTBN1; TTN; CACNA1C; ACTN2 





BP 39 3 0.003 1.000 HOXA7; H2AFY2; H2AFY 
GO:0033120 positive regulation of RNA splicing BP 35 3 0.003 1.000 ERN1; HSPA1A; NCBP1 
GO:0043292 contractile fiber CC 227 7 0.004 1.000 SYNE1; IGSF22; PLEC1; SPTBN1; TTN; CACNA1C; ACTN2 
GO:0051393 alpha-actinin binding MF 31 3 0.004 1.000 IGSF22; TTN; CACNA1C 
GO:0000805 X chromosome CC 10 2 0.004 1.000 H2AFY2; H2AFY 
GO:0040011 locomotion BP 1812 27 0.004 1.000 
NCKAP1; VAX1; CHRM4; ACAP3; UNC5D; FGF2; GCET2; NPTN; GLI2; HOXA7; 
KDR; LCK; RERE; PRKCI; PTPRK; TRIM27; SEMA3F; SKI; SPTBN1; TWIST1; 





















nucleolar large rRNA by 
RNA polymerase I 
BP 13 2 0.005 1.000 H2AFY2; H2AFY 
GO:0031672 A band CC 40 3 0.005 1.000 IGSF22; SPTBN1; TTN 
GO:0098787 
mRNA cleavage 
involved in mRNA 
processing 
BP 14 2 0.005 1.000 ERN1; NCBP1 
Shown are the top 25 most significant pathways after the iPSC-derived microglia were treated with compounds known to inhibit proteins 
containing methyl lysine readers. Shown for each pathway is the GO ID, the pathway descriptor, the ontology of the pathway, the number of 
genes in the pathway, the number of DMPs in the pathway, p-value significance, FDR value and the list of significantly differentially methylated 











DMPs P-value FDR Genes 
GO:0043649 dicarboxylic acid catabolic process BP 17 3 0.001 1.000 ACOT4; ALDH1L2; GAD1 
GO:0048172 
regulation of short-term 
neuronal synaptic 
plasticity 
BP 13 3 0.001 1.000 GRIK2; SYP; PPFIA3 
GO:0006110 regulation of glycolytic process BP 41 4 0.001 1.000 ESRRB; GAPDHS; PRKAG2; HDAC4 





BP 48 4 0.002 1.000 ESRRB; GAPDHS; PRKAG2; HDAC4 
GO:2001169 regulation of ATP biosynthetic process BP 50 4 0.002 1.000 ESRRB; GAPDHS; PRKAG2; HDAC4 
GO:0032786 
positive regulation of 
DNA-templated 
transcription, elongation 
BP 30 3 0.002 1.000 BRD4; ELL3; CCNT1 
GO:1902547 
regulation of cellular 
response to vascular 
endothelial growth 
factor stimulus 
BP 22 3 0.002 1.000 DLL1; MYO1C; ADAMTS12 
GO:0051196 regulation of coenzyme metabolic process BP 55 4 0.003 1.000 ESRRB; GAPDHS; PRKAG2; HDAC4 
GO:0043065 positive regulation of apoptotic process BP 626 15 0.003 1.000 
CYP1B1; DAPK3; AES; DFNA5; FAP; TNFAIP8; GRIK2; FBXW7; TRIM39; PRDM11; 
RPS6KA2; TFDP1; ZBTB16; ARHGEF6; HDAC4 
GO:0043068 positive regulation of programmed cell death BP 630 15 0.003 1.000 
CYP1B1; DAPK3; AES; DFNA5; FAP; TNFAIP8; GRIK2; FBXW7; TRIM39; PRDM11; 
RPS6KA2; TFDP1; ZBTB16; ARHGEF6; HDAC4 
GO:0019359 nicotinamide nucleotide biosynthetic process BP 105 5 0.004 1.000 ESRRB; GAPDHS; PRKAG2; CARKD; HDAC4 
GO:0019363 pyridine nucleotide biosynthetic process BP 105 5 0.004 1.000 ESRRB; GAPDHS; PRKAG2; CARKD; HDAC4 
GO:0019369 arachidonic acid metabolic process BP 49 3 0.004 1.000 MGLL; CYP1B1; TBXAS1 
GO:0000083 
regulation of 
transcription involved in 
G1/S transition of 
mitotic cell cycle 





BP 108 5 0.005 1.000 ESRRB; GAPDHS; PRKAG2; CARKD; HDAC4 
GO:0032653 regulation of interleukin-10 production BP 45 3 0.005 1.000 DLL1; BCL3; TNFSF4 






GO:1903578 regulation of ATP metabolic process BP 71 4 0.006 1.000 ESRRB; GAPDHS; PRKAG2; HDAC4 
GO:0032613 interleukin-10 production BP 47 3 0.006 1.000 DLL1; BCL3; TNFSF4 
GO:1900371 
regulation of purine 
nucleotide biosynthetic 
process 
BP 71 4 0.006 1.000 ESRRB; GAPDHS; PRKAG2; HDAC4 
GO:0010942 positive regulation of cell death BP 681 15 0.006 1.000 
CYP1B1; DAPK3; AES; DFNA5; FAP; TNFAIP8; GRIK2; FBXW7; TRIM39; PRDM11; 
RPS6KA2; TFDP1; ZBTB16; ARHGEF6; HDAC4 
GO:0030808 regulation of nucleotide biosynthetic process BP 72 4 0.006 1.000 ESRRB; GAPDHS; PRKAG2; HDAC4 
GO:0008047 enzyme activator activity MF 504 12 0.007 1.000 
TOM1L1; SH3D20; RASA3; ARHGEF15; RACGAP1; ARF1; PRKAG2; RIN2; ARHGEF10L; 
CCNT1; STARD13; ARHGEF6 
GO:0051193 regulation of cofactor metabolic process BP 73 4 0.007 1.000 ESRRB; GAPDHS; PRKAG2; HDAC4 
Table 4.10. Pathways altered upon WD40 inhibitor treatment. 
 
Shown are the top 25 most significant pathways after the iPSC-derived microglia were treated with compounds known to inhibit proteins 
containing WD40 domains. Shown for each pathway is the GO ID, the pathway descriptor, the ontology of the pathway, the number of genes 
in the pathway, the number of DMPs in the pathway, p-value significance, FDR value and the list of significantly differentially methylated 






4.4.2.8 There is Significant Correlation of Top DMPs between Compound 
Types 
As there was little consistency in the nominally significantly DMPs identified across 
compound classes in the neuronal samples I wanted to check whether the treatments 
within each class were having a consistent effect, in terms of effect size and direction 
of effect, as due to the limited number of replicates in the study it could be 
underpowered. When comparing the direction of effect and effect size within each drug 
class within the neuronal samples it is clear that the direction of effect of the top 100 
probes is consistent within the treatments of the same type and that the effect sizes of 
these top probes also correlate strongly with one another (table 4.11 and figure 4.15). 
This is also the same within the iPSC-derived microglia, which again show a significant 
enrichment for the direction of effect and a significant correlation of effect sizes for the 
top 100 DMPs identified within each drug class (table 4.12 and figure 4.16). 
 
4.4.2.9 There is no Correlation of Top DMPs between Cell Types 
To determine whether the treatments had a similar effect in both cell types the top 100 
DMPs for each treatment in the neuronal samples were extracted and a sign test and 
correlation test were performed against the same loci in the microglia treated with the 
same compound. These analyses highlighted that there is no consistent direction of 
effect or correlation of effect size in the same drug in both the neurons and microglia 
(table 4.13 and figure 4.17), suggesting that they are effecting different genes in the 














BRD (+)-JQ1 - - - 
BAY299 4.83x10-13 0.80 <2.20x10-16 
BAZ2-ICR 2.61x10-12 0.80 <2.20x10-16 
BI 9564 4.83x10-13 0.82 <2.20x10-16 
GSK2801 3.32x10-18 0.77 <2.20x10-16 
I-BRD9 2.61x10-12 0.71 <2.20x10-16 
I-CBP 112 2.54x10-16 0.81 <2.20x10-16 
NI 57 1.31x10-11 0.72 <2.20x10-16 
NVS-CECR2-1 1.91x10-15 0.81 <2.20x10-16 
OF 1 8.28x10-14 0.78 <2.20x10-16 
PFI 3 2.61x10-12 0.75 <2.20x10-16 
TP 472 1.31x10-11 0.81 <2.20x10-16 
HKDM GSK LSD 1 dihydrochloride - - - 
GSKJ4 2.54x10-16 0.83 <2.20x10-16 
HMT A 196 - - - 
A 366 2.70x10-10 0.72 <2.20x10-16 
BAY598 5.64x10-7 0.75 <2.20x10-16 
GSK343 1.31x10-11 0.72 <2.20x10-16 
GSK591 dihydrochloride 8.28x10-14 0.72 <2.20x10-16 
MS 023 dihydrochloride 3.06x10-17 0.77 <2.20x10-16 
MS049 oxalate salt 4.83x10-13 0.63 3.56x10-12 
RPFI 2 hydrochloride 1.31x10-14 0.78 <2.20x10-16 
SGC 0946 8.28x10-14 0.78 <2.20x10-16 
SGC 707 1.31x10-14 0.82 <2.20x10-16 
TP 064 4.83x10-13 0.78 <2.20x10-16 
UNC 0642 3.06x10-17 0.85 <2.20x10-16 
UNC 1999 1.31x10-11 0.77 <2.20x10-16 
KMR A 395 - - - 
UNC 1215 3.32x10-18 0.80 <2.20x10-16 
 
Table 4.11. Correlation of effect size and direction of effect for the top 100 most 
significant DMPs identified in neuronal samples. 
 
 
Shown are the correlations of effect size for the top 100 most significant DMPs in one 
compound (the first alphabetically) in a given category, to other compounds in that same 
drug class within the iPSC-derived neurons. The drug class, compound name, sign test p-
value and Pearson correlation are shown for each drug treatment. The compounds that do 
not have p-values or correlations were the drugs used to assess correlations within the 
other treatments of the same class. Where BRD=bromodomain inhibitors, HKDM=histone 
lysine demethylase inhibitors, HMT=histone methyltransferase inhibitors and KMR=methyl 
lysine reader inhibitors. (+)-JQ1, GSK LSD1, A196 and A 395 were chosen to test against 





Figure 4.15. The effect size of the top 100 most significant DMPs identified in 
neurons after treatment with one compound are highly correlated with the effect 
size of the same probes in neurons treated with another compound in the same 
drug class. 
To assess whether the compounds of the same class were having a consistent effect on 
DNA methylation, the effect size of the top 100 most significant DMPs identified for one 
compound were compared to the effect size of the same probes in another compound in 
the same category using Pearson correlations. Shown as an example are the correlation 
of effect sizes of two drugs from the (A) BRD inhibitors, (B) HKDM inhibitors, (C) HMT 
inhibitors and (D) KMR inhibitors. For each comparison the correlation (r value) is also 
given. Where BRD=bromodomain inhibitors, HKDM=histone lysine demethylase inhibitors, 





Table 4.12. Correlation of effect size and direction of effect for the top 100 most 





Compound Name Sign Test p-
value 
Correlation r-value Correlation p-
value 
BRD (+)-JQ1 - - - 
BAY299 1.31x10-11 0.75 <2.20x10-16 
BAZ2-ICR 8.28x10-14 0.74 <2.20x10-16 
BI 9564 2.61x10-12 0.78 <2.20x10-16 
GSK2801 1.31x10-11 0.75 <2.20x10-16 
I-BRD9 1.31x10-11 0.75 <2.20x10-16 
I-CBP 112 1.12x10-9 0.73 <2.20x10-16 
NI 57 4.82x10-13 0.78 <2.20x10-16 
NVS-CECR2-1 8.28x10-14 0.78 <2.20x10-16 
OF 1 1.31x10-11 0.71 <2.20x10-16 
PFI 3 8.28x10-14 0.69 1.69x10-15 
TP 472 6.15x10-11 0.72 <2.20x10-16 
HKDM GSK LSD 1 dihydrochloride - - - 
GSKJ4 3.06x10-17 0.80 <2.20x10-16 
HMT A 196 - - - 
A 366 3.06x10-17 0.78 <2.20x10-16 
BAY598 1.67x10-6 0.55 3.93x10-9 
GSK343 2.54x10-16 0.77 <2.20x10-16 
GSK591 dihydrochloride 1.59x1-8 0.73 <2.20x10-16 
MS 023 dihydrochloride 4.83x10-13 0.80 <2.20x10-16 
MS049 oxalate salt 1.91x10-15 0.80 <2.20x10-16 
RPFI 2 hydrochloride 8.28x10-14 0.74 <2.20x10-16 
SGC 0946 1.31x10-14 0.71 <2.20x10-16 
SGC 707 4.34x10-9 0.76 <2.20x10-16 
TP 064 1.31x10-11 0.66 1.04x10-13 
UNC 0642 3.32x10-18 0.85 <2.20x10-16 
KMR A 395 - - - 
UNC 1215 2.70x10-11 0.75 <2.20x10-16 
Shown are the correlations of effect size and direction of effect of the top 100 DMPs in one 
compound (the first alphabetically) in a given category, to other compounds in that same 
drug class within the iPSC-derived microglia. The drug class, compound name, sign test 
p-value and Pearson correlation are shown for each drug treatment. The compounds that 
do not have p-values or correlations were the drugs used to assess correlations within the 
other treatments of the same class. Where BRD=bromodomain inhibitors, HKDM=histone 
lysine demethylase inhibitors, HMT=histone methyltransferase inhibitors and KMR=methyl 
lysine reader inhibitors. (+)-JQ1, GSK LSD1, A196 and A 395 were chosen to test against 





Figure 4.16. The effect size of the top 100 most significant DMPs identified in 
microglia after treatment with one compound are highly correlated with the effect 
size of the same probes in microglia treated with another compound of the same 
drug class.  
 
To assess whether the compounds of the same class were having a consistent effect on 
DNA methylation, the effect size of the top 100 most significant DMPs were compared to 
the effect size of the same probes in another compound in the same category using 
Pearson correlations. Shown as an example are the correlation of effect sizes of two 
compounds from the (A) BRD inhibitors, (B) HKDM inhibitors, (C) HMT inhibitors and (D) 
KMR inhibitors. For each comparison the correlation (r value) is also given. Where 
BRD=bromodomain inhibitors, HKDM=histone lysine demethylase inhibitors, HMT=histone 













BRD (+)-JQ1 0.002 -0.32 0.001 
BAY299 0.617 0.02 0.826 
BAZ2-ICR 1.000 -0.08 0.404 
BI 9564 0.920 0.08 0.451 
GSK2801 0.271 -0.14 0.163 
I-BRD9 0.484 -0.06 0.522 
I-CBP 112 0.271 0.03 0.741 
NI 57 0.193 0.01 0.926 
NVS-CECR2-1 0.133 0.00 0.990 
OF 1 0.920 -0.08 0.428 
PFI 3 0.617 -0.11 0.270 
TP 472 0.271 -0.12 0.250 
HKDM GSK LSD 1 dihydrochloride 0.484 0.10 0.800 
GSKJ4 1.000 -0.03 0.748 
HMT A 196 0.617 -0.19 0.066 
A 366 0.617 -0.06 0.569 
BAY598 0.764 0.01 0.887 
GSK343 0.920 -0.19 0.059 
GSK591 dihydrochloride 0.271 0.01 0.957 
MS 023 dihydrochloride 0.920 0.05 0.617 
MS049 oxalate salt 0.193 0.04 0.691 
RPFI 2 hydrochloride 0.368 0.27 0.007 
SGC 0946 0.271 -0.11 0.288 
SGC 707 0.764 -0.12 0.225 
TP 064 0.484 -0.11 0.276 
UNC 0642 0.920 0.06 0.553 
KMR A 395 0.920 -0.07 0.520 
UNC 1215 0.617 0.03 0.779 
Table 4.13. Correlation of effect size and direction of effect for the top 100 most 
significant DMPs identified in the neurons treated with a compound, with the same 




Shown are the correlations of effect size and direction of effect of the top 100 DMPs 
identified in the neurons given a particular compound, with the same probes in microglia 
treated with the same compound. The compound class, compound name, sign test p-value 
and Pearson correlation are shown for each drug treatment. Where BRD=bromodomain 
inhibitors, HKDM=histone lysine demethylase inhibitors, HMT=histone methyltransferase 






Figure 4.17. There is no correlation of effect sizes for the top 100 most significant 
DMPs identified in neurons treated with a compound, with the same probes in 
microglia treated with the same compound.  
To assess whether each drug was having a consistent significant effect on the top 
100 DMPs identified in the neurons in a particular compound, with the same probes 
in microglia treated with the same compound binomial testing and Pearsons 
correlation were used. Shown as an example are the correlations of effect sizes for 
(A) (+)-JQ1, (B) GSK LSD dihydrochloride, (C) A 196 and (D) A 395 within the 






In this chapter I have undertaken epigenome-wide analyses at base-pair 
resolution of the DNA methylation changes that occur when iPSC-derived 
neurons and microglia are treated with different compounds that are known to 
affect different epigenetic mechanisms. To facilitate this, iPSC-derived neurons 
and microglia were treated with each of the different compounds in triplicate, DNA 
was extracted and then run on the Illumina EPIC array to quantify the DNA 
methylation levels at over 850,000 loci. 
 
One of the first things to be shown in this chapter is that both the stem cell derived 
neurons and microglia have an immature epigenetic or biological age. Consistent 
with previous chapters the epigenetic ages of the neuronal samples are all foetal 
with the control sample ages being approximately ~-0.45 to ~-0.30 years. The 
microglia on the other hand have a significantly higher epigenetic age which for 
the control group, ranged from ~0.20 and ~0.40 years. This suggests that the 
iPSC-derived microglia are older in terms of their epigenetic age but despite this 
are still representative of microglia from an infant. The other marker of “age” used 
in this chapter was the number of cellular divisions the cells had been through. 
Again this was higher for the microglial samples, with the neuronal control 
samples only having undergone ~450 divisions, which is less than half of that of 
the control microglia, which had been through approximately 1000 cellular 
divisions. This suggests that the microglia have undergone more divisions, which 
is likely a reflection of the fact iPSC-derived microglia are proliferative whereas 






Interestingly, none of the treatments seemed to have any effect on either the 
epigenetic or mitotic ages of the neurons or microglia. This lack of effect could be 
due to the short duration of treatment for the two cell types, which was only 24 
hours. Had the cells been exposed to the treatments for longer it is possible that 
there could have been a greater effect on the epigenetic and mitotic ages of the 
cells. Despite the lack of significant effect on maturity some of the treatments do 
seem to have reduced the amount of variation in epigenetic age. For example, 
UNC 0642 reduced the variation in epigenetic age for both neurons and microglia, 
suggesting that UNC 0642 has a more specific effect on the loci used to calculate 
the epigenetic age in both cell types than other treatments. Alongside this, other 
compounds seemed to have a cell type specific reduction in variation. For 
example, UNC 1999, MS 049 and A 196 reduced the variation in the neuronal 
samples yet A 366 OF1 and TP 064 reduced variation in the microglial epigenetic 
ages. This could suggest that the treatments are having cell type specific effects 
and that again the loci used to derive the epigenetic age clock are most 
susceptible to these compounds. Although, as there are few replicates per 
treatment it is difficult to truly assess the effect of treatments on variation. In terms 
of mitotic age, the neuronal samples have less variation in terms of number of 
cellular divisions, which is likely a consequence of all the replicates for the 
neuronal being plated and processed at once whilst the microglial replicates were 
plated and processed separately. Aside from GSK 591 the treatments do not 
seem to reduce the variation in any of the microglial samples. Whereas in the 
neuronal samples A 395, GSK LSD1 dihydrochloride, MS 023 and OF1 seem to 
reduce variation. In the future to combat the variation seen in the microglial 
samples it will be important to plate and collect the replicates all at the same time 






Using linear regression models I aimed to identify DMPs that were associated 
with each type of treatment. I did not identify any Bonferroni significant DMPs, 
which is likely due to the low number of replicates per treatment group and in the 
future it will be of interest to include more samples. However, given the fact that 
DNA methylation at neighbouring CpG sites is highly correlated, Bonferroni 
correction is likely overly conservative [333]. To this end I did identify a number 
of DMPs at a more relaxed p-value threshold of 5.00x10-4, and particularly within 
the microglial samples a number of these DMPs were also nominally significant 
(p <0.05) in all of the other treatments targeting the same epigenetic mark i.e. 
BRD, HMT, HKDM or KMR. This suggests that within the microglial cells the 
treatments of the same category seem to cause similar methylation changes at 
the same loci. From running pathway analyses on these DMPs it was determined 
that the inhibitors could be affecting pathways relating to receptor internalisation, 
GTPase activity, the regulation of chromatin organisation, the regulation of 
apoptosis and immune relevant pathways. However, it is worth noting that only 
two of the pathways pass the FDR significance threshold and so cautious 
interpretation is required. To validate these pathway analyses findings further 
experimental validation is necessary.  In contrary to this very few common DMPs 
were seen in neurons treated with compounds of the same class. This suggests 
that unlike in the microglia these treatments had a less specific effect on DNA 
methylation as the same loci were not significant across the different treatments. 
This is possibly a reflection of the short treatment time and low number of 
replicates used, as previously discussed in the future it would be of great interest 
to treat the cells for longer and also undertake more replicates in order to try and 






In order to circumnavigate the issue of power I instead decided to look at the 
direction of effect and effect size for each of the compounds in the same class as 
these measures are unaffected by the number of replicates. From this it was 
possible to determine that the compounds of the same class, i.e. BRD, HMT or 
HKDM caused consistent changes in terms of the direction of effect and had 
highly correlated effect sizes for the top 100 DMPs in both the neurons and 
microglia. This demonstrates that despite there not being common DMPs within 
the same treatment groups the treatments are exerting a similar effect on 
methylation at the same CpGs within the neurons.  Interestingly, when the effect 
size and direction of effect were compared between the neurons and microglia 
given the same treatment there was no significant consistency in the direction of 
effect and the effect sizes were not correlated. This infers that the treatments are 
exerting cell type specific effects on the methylation of the top 100 DMPs. In 
general, the compounds may have a more specific effect in the microglial cells 
and this is why there are consistent changes seen across compound categories 
despite there being little overlap with the top 100 DMPs of the neuronal samples.  
 
Another possibility is that the lack of correlation between the treatments in the 
different cell types is a result of the different genetic backgrounds of the cell types. 
A consequence of the neurons and microglia being generated in different labs is 
that they are derived from different people. It is possible that the differential effect 
of methylation seen in the different cell types is a reflection of the genotypic 
differences between them. In order to determine whether this is indeed the case 
it would be of interest to repeat this experiment using neurons and microglia that 





on the data presented in this chapter, moving forward it would appear that the 
iPSC-derived microglia are a more interesting model in which to study the effects 
of these epigenetic modulators. The discordancy between the DNA methylation 
changes in neurons and microglia potentially demonstrates that the microglia 
could be the more interesting cell type to further study the effects of the epigenetic 
modulators. This is because within the microglial samples there are loci which 
are consistently differentially methylated in all compounds of the same type 
suggesting that the compounds of the same type have a similar effect in terms of 
the pathways they are potentially altering.   
 
Alongside assessing methylation it would also be interesting to identify the 
transcriptomic changes and changes to the specific histone modifications 
themselves (i.e. histone acetylation or methylation) that are associated with each 
of the treatments. Having both transcriptomic and DNA methylomic information 
in both cell types and for all treatments would make it possible to determine 
whether the cellular pathways associated with the differentially expressed genes 
are similar to the differentially methylated pathways I identified in microglia in the 
current study. The RNA for these samples has been collected but it wasn’t in the 
remit of this PhD to run the sequencing experiments and undertake the data 
analysis. Another interesting avenue in which this study could be taken further is 
to study other epigenetic mechanisms such as histone modifications as a number 
of the treatments are known to interact with or cause changes to the modifications 
of histones. Finally, it would be interesting to relate both the DNA methylomic and 
transcriptomic changes to the loci and pathways that are already known to be 
altered in the brain or blood of individuals with various diseases known to have a 






One caveat of this study is that the replicates for the microglial samples were 
plated out and collected at different times whereas the neuronal replicates were 
all plated and collected at the same time. By collecting the replicates at different 
time it introduced variation into the data, which I was able to detect using PCA. 
As a result of this, and in order to remove the effect of replicate on the data, 
combat analysis was used. Whilst it is possible to control and reduce this variation 
it is not the ideal situation as you could potentially also be eliminating variation 
that is a result of the treatments. When you have very small sample 
numbers/replicates in the first instance removing any variation could potentially 
obscure the effect of treatment therefore introducing false negatives.  
 
Finally, in the future it will be important to expand this study to include different 
drug concentrations and different treatment times. A concentration of 3µM was 
chosen as all the inhibitors have been shown to have >30-fold selectivity versus 
other subfamilies and have been demonstrated to have on-target effects in cells 
at this concentration. Alongside this as this study is exploratory and only the initial 
effects the modulators have on DNA methylation were to be studied a treatment 
time of 24 hours was deemed acceptable. However, as modulators such as these 
could evoke a bi-phasic change within the cell lines used it will therefore be 
important in the future to determine the effect the compounds have at both 










In this chapter I have characterised the genome-wide patterns of DNA 
methylation that are associated with the treatment of iPSC-derived neurons and 
microglia with different compounds known to affect epigenetic mechanisms. I 
have again shown that iPSC-derived cells have a foetal or immature epigenome 
and that the short treatment with the epigenetic modulators does not affect their 
epigenetic or mitotic age. Within the microglial samples similar DNA methylation 
changes were observed with compound within the same category, suggesting 
that the same loci are being affected by related compounds in microglia, which 
was not the case for the neurons. Alongside this within both the neuronal and 
microglial samples the compounds of the same type exerted a similar effect in 
terms of the effect size and direction of effect on DNA methylation. However, 
when comparing the effect size and direction of effect for the same compound in 
the two different cell types there was no significant correlation suggesting that the 
effects of each compound are cell type specific and this warrants further 
investigation. Through these analyses it is clear that there are large numbers of 
loci within both the neurons and microglia whose DNA methylation profile is 
altered upon treatment with the different epigenetic modulators.  
 
Overall, I have identified DNA methylomic variation within iPSC-derived neurons 
and microglia that is associated with compounds known to regulate epigenetic 
mechanisms. I have demonstrated that these changes happen in a cell type 
specific manner and that there are more consistent effects seen within the 
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5.1.1 Microglial Biology and Response to Immune Challenge 
Despite being originally believed to be immune privileged, the CNS is now known 
to be able to have immunological capability, which differs from that of other 
peripheral tissues. These immune reactions depend on specialised innate 
immune cells such as microglia, which are the most common type of CNS-
resident immune cells. Unlike other brain cell types, microglia arise from EMPs in 
the yolk sac [54]. Resting microglia in the adult brain have a small cell body with 
many highly ramified processes (figure 1.3), a morphology which distinguishes 
them from other immune cells such as macrophages [58]. Microglial cells have a 
number of different functions and are critical in neurodevelopment [334-336], 
synaptogenesis [337-339] and responding to CNS immune challenges [340-342]. 
Under homeostatic conditions microglial cell bodies remain stationary whilst their 
processes move and scan the surrounding extracellular space communicating 
with astrocytes, neurons and blood vessels [343]. However, resting microglia can 
be activated by a number of CNS challenges including injury, infection, 
neurodegeneration and protein aggregates [344]. On detecting these insults 
microglial morphology changes rapidly and they become less ramified, begin to 
express more inflammatory markers and produce inflammatory mediators. For 
example, microglia have been shown to express toll like receptors [340] and 
release cytokines (IL-1β [345], IL-6 [346], TNF-α [347]), chemokines [348] and 
nitric oxide (NO) [341, 349]. This enables them to recruit other immune cells and 






5.1.2 Neuroinflammation and AD 
Despite extensive research, it is still unknown what mechanisms lead to the onset 
of pathological Aβ and Tau aggregates in the brain in sporadic AD. Recent 
evidence has suggested that immune mechanisms may play a key role in AD risk 
and pathogenesis [80, 82]. One common theory surrounding the involvement of 
microglia in AD is through the recurrent/chronic activation of microglia during 
ageing or in the presence of Aβ plaques. These recurrent exposures, whether it 
be to AD related proteins or inflammatory molecules, can trigger morphological 
changes, leaving the microglia less ramified, and expressing cell surface antigens 
that are usually reminiscent of activated cells [58-60].  Once activated microglia 
have a heightened response to inflammatory stimuli, releasing more inflammatory 
molecules which can be neurotoxic [67]. 
 
A number of large scale GWAS studies have identified genetic variation in 
immune-related genes in LOAD. These GWAS studies have indicated that LOAD 
is a multifactorial disease with many different SNPs contributing to disease onset 
[80, 81, 350-354]. These GWAS studies have also revealed that many of the 
SNPs that are associated with AD reside in genes involved in microglial biology 
[80, 352, 353]. This includes common variants such as CLU, CR1, CD33, ABCA7, 
EPHA1 and MS4A and more rare variants identified from exome-sequencing 
studies such as TREM2 [90, 350, 351, 353, 354]. In recent years there have been 
several functional studies conducted in order to try and determine the role these 
variants may play in disease aetiology and to establish the role microglia play in 
AD onset and progression. For example, TREM2 has been shown to play a role 
in regulating microglial phagocytosis [355], and that missense mutations in 





TREM2 in the cerebrospinal fluid of AD patients [356]. However, in contrast to 
this in several mouse model of AD, TREM2 deficiency in microglia was shown to 
promote survival of microglia and also enhance phagocytosis [357-359]. These 
findings suggest that the role of TREM2 in modulating neuroinflammation in AD 
is complex and therefore further investigation is required, as is the case for many 
other immune-related AD variants. In general, microglia are thought to regulate 
the amount of Aβ in the brain through phagocytosis [360]. One interesting feature 
of microglia in AD brain is that they adopt a polarised morphology and cluster 
around fibrillar Aβ and extend hypertrophic processes towards the plaques [361]. 
This provides a physical barrier around the plaques and stops the deposits 
extending further, promoting the creation of compact plaque micro regions that 
have little affinity for soluble Aβ1-42 [361, 362]. On the other hand regions of the 
brain that aren’t covered by microglial processes are ‘hotspots’, with high levels 
of soluble Aβ1-42 leading to markedly concentrated protofibrillar Aβ1-42 plaque 
regions [361]. These ‘’hotspots’’ are neurotoxic given that adjacent axons develop 
a greater extent of dystrophy compared to those covered by microglia [362]. 
 
Alongside GWAS, studies investigating inflammation induced cognitive 
dysfunction have also linked inflammation seen in the periphery to delirium and 
acute cognitive impairment resembling that seen in AD [363, 364]. Cytokines are 
key mediators in the response to inflammation and it is thought that the pro-
inflammatory cytokine IL-1β may regulate both the response to infection and be 
responsible for inflammation induced cognitive decline [365, 366]. In accordance 
with this, IL-1β has been associated with delirium in patients with septic 
encephalopathy [367]. The high prevalence of inflammation induced cognitive 





inflammation can have particularly in those who are older and already cognitively 
impaired [368, 369]. Alongside this it is now apparent that infection can also 
increase the long term risk of developing dementia [370, 371] or accelerate its 
progression [372, 373]. 
 
5.1.3 Microglial In Vivo Models of AD Neuroinflammation 
Microglia make up approximately 15% of the total number of cells in the CNS, yet 
despite this, microglial RNA only makes up < 0.1% of total CNS RNA [374, 375]. 
This relatively low proportion of total transcripts has made it quite difficult to detect 
the microglial molecular phenotype from that of neurons, astrocytes and 
oligodendrocytes in human post-mortem tissues. In order to combat this issue 
several in vitro and in vivo model systems have been created. These include 
immortalised human and rodent cell lines, primary rodent cultures, in vivo rodent 
models and more recently human stem cell models.  
 
In the AD research field, there has traditionally been a large focus on using 
transgenic mice to model FAD. This is because a lot is understood about murine 
genetics and there is a wealth of genetic manipulation techniques that are 
available to develop new mouse models. The vast majority of murine AD models 
reflect familial AD, with mice expressing human APP and PSEN genes bearing 
autosomal dominant mutations [376-381]. However, other mouse models have 
been developed that express human genes bearing SNPs associated with 
sporadic AD.  The TREM2 R47H mutation has been shown through whole 
genome sequencing (WGS) to increase AD risk three fold [382] and so is an 
important mutation to study in order to understand the role of the immune system 





developed, for example mice expressing human TREM2 or with TREM2 knocked 
out [383-385]. In mice expressing wild type human TREM2 microglia have been 
shown to cluster around Aβ plaques forming a physical barrier between the 
plaques and neurons [357, 359, 362, 386]. However, in TREM2 deficient mice 
the number of plaque-associated microglia is significantly reduced with there 
being a concomitant increase in the number of dystropic neurites surrounding the 
plaques [359, 386].  
 
5.1.4 Microglial In Vitro Models of AD Neuroinflammation 
Whilst murine in vivo models provide three dimensional interactions between 
microglia and other brain cell types similar to that of the human brain, microglial 
cultures in vitro undoubtedly also provide a useful model for studying 
neuroinflammation. In particular, in vitro models have proven useful for 
elucidating the basic aspects of neuroinflammation, including intracellular 
signalling and gene transcription. One example of this was the discovery of the 
involvement of p38 mitogen-activated protein kinase (MAPK) in the release of 
inflammatory mediators from microglia. Using BV-2 cells (immortalised mouse 
microglia), Bachsetter et al demonstrated that upon LPS stimulation, the BV-2 
cells produced more IL-1β and TNF-α, but that this could be inhibited in a 
concentration dependent manner by a p38 MAPK inhibitor [387]. This study 
demonstrated the involvement of MAPK signalling in the response to LPS 
immune challenge and the potential to modulate cytokine overproduction through 
the inhibition of this pathway.  
 
Microglial cell culture models have also been useful in disentangling the role of 





that LPS induced an increase in both inducible nitric oxide synthase (iNOS) 
reactivity and NO production, but that this could be prevented by parthenolide 
[388], a pro-inflammatory molecule known to bind and inhibit the cytokine 
signalling kinase IκB kinase β (IKKβ) [389]. Alongside this, in neuronal-microglial 
co-cultures LPS has been shown to induce neurotoxicity and cellular dysfunction 
through the activation of the COX-2 and NOS pathways, resulting in a dramatic 
increase in prostaglandin and NO production [390-394].  
 
5.1.5 LPS Mechanism of Action 
LPS constitutes a large proportion of the outer membrane of gram-negative 
bacteria and is frequently used in vitro and in vivo to mimic the presence of an 
infection. Interestingly, one study has shown that the blood levels of LPS are 
three times higher in AD patients than that of control populations [395]. Studies 
have also shown the presence of gram-negative microbes in the erythrocytes of 
AD patients [396]. LPS cannot itself under physiological conditions enter the 
brain, therefore it is likely in vivo that there are other mechanisms that allow 
systemic LPS to induce central inflammation, for example degradation of the 
blood brain barrier (BBB), ischaemia or peripheral cytokines [397, 398]. There is 
a proposed mechanism of action for LPS induced injury in the AD brain, which is 
that LPS binds to toll like receptor 4 (TLR4) or CD14 expressed on microglia 
within the brain [399]. This TLR4 activation then leads to NFκB mediated 
induction of cytokines including IL-1, IL-6 and TNF-α [400-402]. Very high levels 
of pro-inflammatory cytokines such as IL-1 and IL-6 can cause myelin injury and 
can also increase the accumulation of Aβ and APP [403]. This Aβ then can also 
act on TLR4 causing a feedback loop, further exacerbating the problem [403]. 





the amount of Aβ being able to leave the brain [398]. Finally, LPS is also known 
to induce Tau hyperphosphorylation, another protein whose accumulation is a 
characteristic hallmark of AD [404-406]. Taken together the combination of all 
these factors could cause or amplify the neurodegeneration seen in AD. 
 
 
5.1.6 Identifying Methylomic Variation in Microglia following LPS Stimulation 
It has previously been demonstrated that there is both epigenetic dysfunction 
[121, 407-410] and neuroinflammation in AD [60, 61, 68, 411]. As stated above 
one mechanism through which neuroinflammation and neurodegeneration may 
be mediated is through recurrent stimulation and activation of microglia by 
immune activators such as LPS, and this could be mediated via epigenetic 
mechanisms. With microglial cells representing a relatively small proportion of the 
cells in the brain it has been difficult to assess the methylomic signature of human 
microglia in vivo following immune challenge. In order to establish what DNA 
methylomic changes may be occurring following acute exposure to LPS and 















5.2 Hypothesis and Aims 
As bacterial infection and neuroinflammation are hypothesised to play a role in 
the onset of AD this chapter hypothesises that exposure of microglial cells to 
inflammatory molecules, such as LPS, will have methylomic consequences, that 
some loci will be more susceptible to this exposure and that these methylomic 
changes will be associated with changes to biological pathways.  
 
To address this hypothesis the aims of this chapter are: 
1. To perform an EWAS of 5-mC levels following LPS challenge in a microglia 
cell line. 
2. To identify DMPs which are associated with immune stimulation and 
recovery. 




















5.3.1 Cell Culture  
The information in this section contains all the information necessary to grow, 
maintain and passage the microglia cell line used in this chapter. 
 
5.3.1.1 Sources of Cells 
The cells used in this study are a primary human immortalised microglia (SV40 
cell line) which were bought from Accegen Biotech (ABI-TM009).  
 
5.3.1.2 Maintenance and Passaging of Microglia 
Cells were maintained at 37oC and 5% CO2 in a humidified incubator. The SV40 
microglia were maintained in the microglial maintenance medium (MMM) 
provided by accegen which contains essential and non-essential amino acids, 
vitamins, organic compounds, inorganic compounds, vitamins, minerals, 5% 
foetal bovine serum and growth factors necessary for the maintenance of 
immortalised microglia in vitro. The MMM contained 5% HD-fetal bovine serum 
(ABI-TM009-FBS25), 1% penicillin/streptomycin (ABI-TM009-PS5) and 1% 
microglial growth supplement (ABI-TM009-MGS5) in 500mL basal medium (ABI-
TM009). Media was changed every three days until the cells were 70% confluent, 
thereafter it was changed every other day until the cells reached ~90% 
confluency. Once the cells reached approximately 90% confluency they were 
passaged. Before passaging T75 flasks that were pre-coated with collagen I 
(Corning; 354485) were washed twice with sterile water. The coated plates, 
trypsin/EDTA (Fisher scientific; 11580626) solution and trypsin neutraliser 





temperature, disinfected and placed within a laminar flow hood ready for use. 
Used media was removed from the flask and cells were washed with 5mL PBS 
which was then aspirated. A further 5mL PBS was added to the flask before the 
addition of 5mL trypsin-EDTA for three to five minutes at 37oC. The length of time 
they were left was determined by how quickly the cells became rounded. After 
the trypsinisation 5mL of MMM was placed into the flask and the combined 10mL 
solution transferred in to a 50mL falcon tube already containing 10mL MMM. 
Using the base of the hand the flask was gently tapped in order to dislodge cells 
from the base of the flask. 5mL trypsin neutraliser solution was then washed over 
the base of the flask and placed in the 50mL falcon containing the rest of the cell 
suspension. The cells were then pelleted through centrifugation at 1000rpm for 
five minutes. Following this, the number of cells per mL was calculated with a 
TC20TM automated cell counter (Bio-Rad). Once the number of cells per mL was 
known it was possible to calculate the dilution factor needed in order to give a 
density of 10,000 cells/cm2. This was achieved using the following equation: 
𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑦𝑜𝑢 ℎ𝑎𝑣𝑒 (𝑐𝑒𝑙𝑙𝑠/𝑚𝐿)
𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑦𝑜𝑢 𝑤𝑎𝑛𝑡  (𝑐𝑒𝑙𝑙𝑠/𝑚𝐿)
= 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑝𝑒𝑟 𝑇75. 
Once plated, cells were placed back in the incubator to attach.  
 
5.3.1.3 Stimulation with LPS  
Cells were plated out at a density of 10,000 cells/cm2 into four wells of three 
individual six-well plates (i.e. 12 wells in total). Each plate contained the four 
replicates for the three different treatments used in this study. Those treatments 
were: (1) no LPS treatment (control group), (2) 24-hour treatment with 1ug/mL 
LPS (LPS group) and (3) 24-hour treatment with 1ug/mL LPS followed by a 24-





concentrations of LPS (1mg/mL) were diluted 1:1000 into pre-warmed MMM. 48 
hours after plating the LPS and LPS + recovery groups had their normal MMM 
removed and it was replaced with MMM containing 1ug/mL LPS. The control 
group underwent a normal media change. After 24 hours the control group and 
LPS treatment groups were washed twice with PBS and collected as pellets using 
tryspin-EDTA and trypsin neutraliser solution as outlined above. The LPS + 
recovery group were washed twice with PBS and then the media was replaced 
with normal MMM. After a further 24 hours on MMM the LPS + recovery group 
were collected and pelleted using trypsin-EDTA and trypsin neutraliser solution. 



































Figure 5.1. Diagram to illustrate the experimental workflow. 
 
 SV40 immortalised primary microglial cells were plated out in quadruplet for the three conditions at a density of 100,000 cells per well. 48 
hours after plating two of the conditions were treated with 1µg/mL LPS and the cells corresponding to the control condition underwent a 
normal change of media. 24 hours following this first treatment the LPS and control condition cells were pelleted down and frozen at -80oC, 





5.3.2 DNA Extraction and Methylomic Profiling  
DNA was extracted from cell pellets and QC checked as described in section 2.2. 
500ng of DNA was bisulfite treated as described in section 2.3. Subsequently bisulfite-
treated DNA was analysed for DNA methylation using the EPIC array protocol as 
described in section 2.4 and in figure 2.2. 
 
5.3.3 Illumina EPIC Data QC 
For an outline of the QC and normalisation methods used in this chapter please see 
sections 2.4.2. All data analyses in this section were performed using R version 3.5.2. 
Signal intensities were imported into R using the methylumi package [262]. Initial QC 
checks were conducted using functions within the methylumi and wateRmelon 
packages [198, 262].  
 
Using the default settings of one percent with “pfilter”, no samples, 13,207 sites with a 
beadcount less than three and 9,180 sites having 1% of samples with a detection p-
value of greater than 0.05 were flagged for removal. 
 
5.3.4 Data Analysis 
Outlined in this section are the analysis steps conducted in order to assess and 
quantify the DNA methylation changes occurring immortalised primary microglia are 
treated with the known immune stimulant, LPS. 
 
5.3.4.1 PCA 
In order to look at variation within the dataset PCA was used. Using the “prcomp” 





were identified. These principal components were then correlated to known variables, 
which included treatment, which BeadChip the sample was run on (Chip ID) and 
position on the BeadChip using spearman correlations. 
 
5.3.4.2 Identification of DMPs 
Following normalisation, probes with common (>5% minor allele frequency (MAF)) 
SNPs within 10 bp of the single base extension and probes with sequences previously 
identified as potentially hybridizing to multiple genomic loci were excluded [203]. The 
top 20% most variable probes were identified using the median absolute derivation (N 
= 158,310 probes). Subsequently, three linear models were used to identify which of 
these probes were differentially methylated between the three treatment groups 
(control, LPS, LPS + recovery). We identified four patterns of methylation changes in 
probes, corresponding to whether they became hyper- or hypomethylated over the 24 
hours of LPS treatment and then whether these patterns reverted during the recovery 
stage (i.e. were acute changes), or whether they were persistent through the recovery, 
as illustrated in figure 5.2. An arbitrary significance threshold of p < 1x10-3 was used 
to determine whether the probes were differentially methylated between treatment 
groups.  
 
5.3.4.3 GREAT annotation 
Many of the CpG loci covered by the Illumina EPIC array reside in non-coding regions 
of the genome, meaning it can be difficult to infer meaning to the changes in 
methylation observed at these loci. Although UCSC gene annotation [271] is provided 
by Illumina for loci on the EPIC array,  there are many loci that lack annotation. In 





used to annotate each locus to its nearest gene [412]. Using the chromosomal location 
of each CpG probe, GREAT was able to annotate each loci to the single nearest gene 
that is between 1000 kilobases upstream or downstream [412]. Using this annotation 
method, all bar one probe was annotated to a nearby gene. The function of each of 
these genes was then manually searched for and recorded.  
 
5.3.4.4 GO Pathway Analysis 
GO pathway analysis was performed on each of the four different methylation change 
categories (i.e. hypermethylating acute, hypermethylating persistent, hypomethylating 
acute, hypermemethylating persistent). This was performed using the “gometh” 
function with the missMethyl package, which was selected as it adjusts for the number 
of CpGs per gene. [265].  
 
In order to add additional meaning to the pathway analysis outputs the online platform 
REVIGO was used (available at: http://revigo.irb.hr/) [267]. The significantly altered 
pathways (determined by GO ID) and p-value significance values were added to the 
online portal with the GO term database being set to Homo sapiens and the semantic 
similarity measure as Resnik. Once analysed the treemaps for the altered BP, MF and 








Figure 5.2. Diagrammatical representation of how differentially methylated probes were categorised.
Data analysis was undertaken once the samples had been through QC checks and dasen normalisation. Firstly using the median absolute 
deviation, the top 20% most variable probes were identified. These probes where then categorised based on whether they were 
hypomethylated (A) or hypermethylated (B) between the control and LPS groups. Within this, probes were further categorised depending on 
whether the methylation reverted to the control level (acute category) or whether the methylation level deviated further from control levels or 





5.4 Results  
 
5.4.1 Outcome of the QC Pipeline 
The following section outlines the results of the QC process, which demonstrates that 
all the samples were of sufficient quality to take forward to the main analyses. 
 
5.4.1.1 Median Methylated and Unmethylated Signal Intensities 
In order to check that the signal intensities were above background levels the signal 
intensities were imported and assessed using the methylumi package [262]. This 
package extracts and calculates the signal intensities using the fluorescence intensity 
of each probe. Once the intensities were extracted the median methylated and 
unmethylated signal intensities for each sample were calculated (table 5.1) and plotted 
against one another (figure 5.3). The background level of signal intensity is generally 
assigned a value of 1000 although this is by no means a definitive cut off. Only one of 
the samples has a value below 1000, which is one of the LPS + recovery samples 
(LPS_recov_1). As the median unmethylated intensity for this sample was very close 
to the cut off (value was 997), a decision was made not to drop the sample at this 
stage and to instead see how it performed when assessed with the other quality control 
metrics. 
 
Next, I also wanted to see whether there was any variation being introduced by the 
BeadChip the samples were on (Chip ID) or the position on the BeadChip. As such, 
the unmethylated and methylated signal intensities were replotted, with the samples 
coloured both by Chip ID (figure 5.4) and position on the chip (figure 5.5). Although it 





202073200083 were higher than the other BeadChips (figure 5.4), there was no 
difference in methylated values and there was no significant difference in methylated 
or unmethylated intensities between samples run on different chips (methylated 
intensities: p=0.70, unmethylated intensities: p=0.60). Similarly, samples run on the 
first row of the chip had higher median methylated and unmethylated intensities 
compared to samples run on the second row of the chip, which had higher intensities 
than those run on the third row of the chip (figure 5.5). However, this pattern is always 
seen on BeadChips, and there was no significant difference in the ratio of methylated 

















Control_1 1 2565 1860 
Control_2 2 1714 1296 
Control_3 3 1694 1281 
Control_4 4 2059 1852 
LPS 
LPS_1 1 1821 1359 
LPS_2 2 1601 1193 
LPS_3 3 1766 1344 
LPS_4 4 1861 1778 
LPS + Recovery 
LPS_Recov_1 1 1271 997 
LPS_Recov_2 2 2176 1643 
LPS_Recov_3 3 1564 1221 
LPS_Recov_4 4 1705 1669 
 
Table 5.1. Median methylated and unmethylated sample intensities. 
 
 















Using the methylumi package [262] the signal intensities for samples were extracted and 
the medians calculated. Shown is a scatterplot plotting the median methylated and 
unmethylated signal intensities for each sample. Each point is labelled with the 
































Figure 5.4. Median sample intensities coloured by Chip ID. 
Median methylated and unmethylated sample intensities were calculated for each BeadChip 
(A) Median signal intensities coloured by Chip ID represented as a scatterplot. Median (B) 
methylated and (C) unmethylated signal intensities coloured by Chip ID represented as a 





























Figure 5.5. Median sample intensities coloured by position on Chip. 
 
  
Median methylated and unmethylated sample intensities were calculated for each BeadChip (A) 
Median signal intensities coloured by position on chip represented as a scatterplot. Median (B) 
methylated and (C) unmethylated signal intensities coloured by position on chip represented as 






5.4.1.2 All Samples have a Good Bisulfite Conversion Efficiency 
Bisulfite conversion is the process that converts unmethylated cytosines into uracil and 
then thymine on PCR amplification and is the process that allows us to distinguish 
between methylated and unmethylated positions on the array. This therefore allows 
one to determine how methylated or unmethylated a specific loci is. Therefore, it is 
important that the bisulfite conversion efficiency of each sample is high. On the EPIC 
array there are several loci known to be fully methylated, which can be used as 
controls for bisulfite conversion; it is the fluorescence intensity of these loci that allows 
us to determine the bisulfite conversion efficiency using the “bscon” function in the 
wateRmelon package [198]. The lowest generally accepted bisulfite conversion 
efficiency is 80%. All the samples within this study are well above this cut off with the 
lowest conversion efficiency being 93.3% (figure 5.6).  
 
5.4.1.3 Beta Density Plot  
To determine the methylation at each locus on the EPIC array β-values were 
generated, which is the ratio of fluorescence signal intensity for the methylated and 
unmethylated beads. As the value is a ratio all β-values lie between zero and one, where 
zero indicates that the locus is completely unmethylated and a β-value of one indicates 
that the locus is fully methylated. The β-values for our samples have a bimodal 
distribution with most probes being either almost fully methylated or unmethylated, 











Figure 5.6. Bisulfite conversion efficiency and beta density plot. 
Using data from probes on the EPIC array known to be fully methylated, the bisulfite 
conversion efficiency of each sample was calculated and is represented in a histogram, 











The DNA methylation level at each locus was determined using β-values, which are the 
ratio of fluorescence signal intensity for the methylated and unmethylated beads.  The beta-





5.4.1.4 No Samples are Removed by P-filter 
The final stage in the QC pipeline is to filter samples and probes by their detection p-
value. The “pfilter” function in the wateRmelon package [198] highlights samples or 
probes that should be removed from the analysis, including samples that contain more 
than one percent (by default) probes above the 0.05 detection p-value threshold and 
probes with any samples having a beadcount less than three or more than one percent 
above the p-value threshold. Using the default settings, 9,180 probes were suggested 
for removal as they have more than one percent above detection threshold, and 
13,207 sites were suggested for removal as there was a beadcount less than three in 
five percent of samples. These probes were removed from the analysis but no whole 
samples were flagged for removal. Therefore, all samples were taken forward for the 
downstream analyses, which are presented in the next section. 
 
5.4.1.5 There Are No Differences in Epigenetic Age between Treatment 
Groups 
Using the latest version of the Horvath epigenetic age calculator (available from: 
https://dnamage.genetics.ucla.edu/home) I assessed the epigenetic ages of the 
samples under the different conditions. Overall there seems to be no significant 
difference between the control, LPS and LPS + recovery groups (table 5.2, figure 5.8), 
although there is a small, non-significant decrease in epigenetic age between the 
control and LPS treated groups.  
 
5.4.1.6 There Are No Differences in Mitotic Age 
Using the MiAge calculator [199] I estimated the number of cellular divisions that the 





number of cell divisions. The MiAge algorithm predicts mitotic age using the DNA 
methylation profile of 268 probes which are on the Illumina EPIC array. There were no 
differences in the mitotic ages of the samples (table 5.2, figure 5.9). This suggests that 




















Treatment Sample ID Replicate Epigenetic Age (years) No. of Cell Divisions 
Control 
Control_1 1 18.579 3001.784 
Control_2 2 31.968 3104.674 
Control_3 3 19.968 2969.018 
Control_4 4 15.912 2801.034 
LPS 
LPS_1 1 15.460 3046.159 
LPS_2 2 14.524 3064.258 
LPS_3 3 19.914 2944.178 
LPS_4 4 15.602 2768.622 
LPS + Recovery 
 
LPS_Recov_1 1 12.076 2839.904 
LPS_Recov_2 2 23.741 3087.382 
LPS_Recov_3 3 16.186 2954.161 
LPS_Recov_4 4 16.117 2731.298 






Using the latest iteration of the Horvath epigenetic age calculator [126] and MiAge calculator [199], the epigenetic or biological age (in years), 
and mitotic age (number of cell divisions) were calculated for each sample. For each sample shown above is the treatment group, sample ID, 












Using the new online epigenetic age calculator created by Horvath and colleagues [126] 
the epigenetic ages of each sample were calculated. Red represents the control group, 
blue the group treated with LPS for 24 hours and green the cells first treated with LPS for 











Using the MiAge calculator [199] the estimated number of cell divisions for each sample 
were calculated. Where red represents the control group, blue the group treated with LPS 
for 24 hours and green the cells first treated with LPS for 24 hours and then given a 24 






5.4.1.7 Dasen Normalisation  
In order to make meaningful comparisons between the samples within the dataset the 
data was transformed using quantile normalisation using the “dasen” function within 
the wateRmelon package [198]. After dasen normalisation, there is a lot less variation 
in the median methylated and unmethylated signal intensities (figure 5.10), with all 
samples having a median methylated intensity between 1863-1865 and a median 
unmethylated signal intensity between 1481-1483. 
 
By plotting the normalised β-values it is evident that there are bimodal peaks, which 
shows that most loci are either fully methylated or fully unmethylated. Across all probes 
the peaks are much tighter following normalisation (figure 5.11B) compared to before 
normalisation (figure 5.11A). This was also evident when looked at the type I probes 











Figure 5.10. Median methylated and unmethylated sample intensities after 
normalisation. 
 
Quantile normalisation was performed using dasen [198] to generate the normalised 
median methylated and unmethylated signal intensities. Graphical representation of 
median signal intensities relative to each other following normalisation. Each point is 






Figure 5.11. Median methylated and unmethylated signal intensities after dasen normalisation. 
Quantile normalisation was performed using dasen [198] to generate the normalised median methylated and unmethylated signal intensities. 






Figure 5.12. Beta density plots of type I probes before and after dasen normalisation. 
Probes were separated based on whether they were type I or type II probes. Beta density plots were generated showing the beta values of 






Figure 5.13. Beta density plots of type II probes before and after dasen normalisation. 
 
Probes were separated based on whether they were type I or type II probes. Beta density plots were generated showing the beta values of 





5.4.1.8 There is no Difference in CpH Hemi-Methylation upon Treatment 
Following dasen normalisation, the hemi-methylated probes (i.e. those with a β-value 
between 0.2 and 0.8) were grouped together based on whether they were annotated 
to a CpG or CpH (where H stands for any base other than cytosine) locus (figure 5.14). 
There was no difference in hemi-methylation at either CpH or CpG probes between 
treatment groups.  
 
5.4.1.9 Principal Component Analysis Identifies Causes of Variation in the 
Data 
In order to identify sources of confounding variation within the dataset I used principal 
component analysis. The “prcomp” function in the default statistics package of R was 
used to detect consistent variation within the dataset and assigned it to different 
principal components. The first ten principal components generated were able to 
account for ~95% of the variation within the dataset, with the first and second principal 
components alone accounting for 22% and 11% of the variation, respectively (table 
5.3). Next, I correlated these principal components to known variables, which could be 
sources of variation in the data. These variables were treatment (plate), the BeadChip 
the sample was on (Chip ID) and the position within the BeadChip. From this analysis 
there were no significant correlations and so I did not need to control for any of the 










Figure 5.14. Beta-values of hemi-methylated CpG and CpH probes is the same 
regardless of treatment. 
 
After dasen normalisation probes were grouped on the basis of whether they were a CpG 
or CpH probe. Shown are box plots of β-value for probes containing beta-values between 
0.2 and 0.8 (i.e. hemi-methylated probes) for each of the treatment groups. Red represents 
the control group, blue the LPS treated group and green the cells that were first treated 







 PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 
Standard deviation 16.46 11.84 10.84 10.41 10.12 9.83 9.49 9.38 8.85 8.82 
Proportion of Variance 0.22 0.11 0.10 0.09 0.08 0.08 0.07 0.07 0.06 0.06 
Cumulative Proportion 0.22 0.34 0.43 0.52 0.60 0.68 0.76 0.83 0.89 0.95 
 







Following dasen normalisation, principal component analysis (PCA) was used to identify sources of variance in the data. This table shows the 







Figure 5.15. Principal component analysis to identify sources of variation with the 
methylation data. 
 
Following dasen normalisation, PCA was performed and then correlated with known 
variables to identify sources of variation in the data. Shown is a PCA plot, showing the 
correlation between treatments, the chip the sample was run on (Chip_ID_coded), and the 
position of the sample within the chip (Pos_coded) with the first five principal components. 
Blue indicates a positive correlation, red indicates a negative correlation, with the colour 
intensity and size of the circle being proportional to the correlation coefficients. None of the 





5.4.1.10 Identifying Acute and Persistent Changes in DNA Methylation 
Associated with Treatment 
In order to identify DNA methylomic variation associated with LPS treatment, I first 
identified the 20% most variable probes across all three treatment groups (N = 158,310 
probes) and removed from my analysis the remaining, non-varying probes. I then 
performed three linear regression analyses on this set of 158,310 probes to identify 
pair-wise differences between the three treatment groups. These probes were then 
grouped in to four categories (figure 5.2) based on whether they became hyper- or 
hypomethylated after LPS, and whether this change was acute (i.e. was not seen in 
the LPS + recovery group compared to controls), or persisted during the recovery. 
Data was analysed in this manner as I hypothesised that probes showing similar 
methylation patterns over time may have similar biological functions or roles. 
Therefore, the categories of probes I analysed were (1) acute hypomethylation (2) 
acute hypermethylation, (3) persistent hypomethylation, and (4) persistent 
hypermethylation.  
 
The largest numbers of significant differences occurred acutely after LPS treatment, 
with 97 and 67 significant loci (p<1x10-3 between control and LPS and p>0.05 between 
LPS and LPS + recovery) being hypomethylated (table 5.4, figure 5.16) or 
hypermethylated (table 5.5, figure 5.17) after initial LPS treatment, which was not seen 
after 24 hours of recovery, respectively. There were fewer persistent significantly 
differentially methylated loci, with eight significant loci persistently hypomethylated 
(table 5.6, figure 5.18) and just one significant persistently hypermethylated locus 






There was greatest variation in DNA methylation in the LPS + recovery group 
compared to the control or the LPS groups, which would explain why I identified 
considerably fewer persistent differentially methylated loci than acute differentially 
methylated loci. This could suggest that the microglia were “recovering” from LPS 
exposure at different rates. Interestingly, there was a pattern of methylation differences 
within the replicate samples in the LPS + recovery treatment group, and for 
hypermethylated loci replicates one and three were more consistently 
hypermethylated than replicates two and four, whilst conversely for hypomethylated 
loci replicates two and four were more consistently hypermethylated than replicates 





     Control vs LPS Control vs LPS+Recovery 
CpG ID Genomic Location UCSC Annotation 
GREAT Annotation 
(distance) Function Δ (%) P-value Δ (%) P-value 
cg00664381 Chr1:229892969 DISC1 URB2 (+130989) Ribosome biogenesis -7.79 8.35x10-6 -1.33 0.467 
cg13642974 Chr11:92611456 - MTNR1B (-91429) GPCR in retina -7.12 1.10 x10-5 -1.90 0.250 
cg18465484 Chr19:16999051 CPAMD8 F2RL3 (-619) Cell signalling -8.67 1.12 x10-5 -5.31 0.085 
cg20564330 Chr1:46924956 EFCAB14-AS1 DMBX1 (-47712) Transcription factor -11.51 1.31 x10-5 -6.74 0.146 
cg14849274 Chr12:51281327 KRT72 METTL7A (-35927) Methyltransferase -8.18 2.04 x10-5 -6.30 0.160 
cg16395123 Chr4:25474382 SEL1L3 ANAPC4 (+95548) E3 ubiquitin ligase -8.48 2.12 x10-5 -6.18 0.069 
cg00252121 Chr13:28773027 MTUS2 PAN3 (+60385) mRNA degradation -9.60 2.36 x10-5 -3.92 0.127 
cg05230522 Chr2:61055411 PUS10 REL (-53244) Transcription factor -8.08 2.91 x10-5 -3.46 0.162 
cg02922817 Chr14:103693366 KIF26A TNFAIP2 (+103569) SNARE binding/cell differentiation -9.65 4.37 x10-5 -2.60 0.597 
cg24112213 Chr17:69220806 - SOX9 (-896354) Transcription factor -6.91 6.03 x10-5 -1.01 0.747 
cg08491105 Chr15:22057479 - OR4M2 (-310998) Olfactory GPCR -8.25 6.33 x10-5 -5.48 0.218 
cg04679277 Chr7:1390554 - MICALL2 (+108583) Actin organistation and cell adhesion -6.71 6.47 x10-5 -4.15 0.275 
cg24839145 Chr8:5016262 - CSMD1 (-164325) Complement control protein -8.67 8.79 x10-5 -3.57 0.073 
cg12429593 Chr14:99691999 DEGS2 BCL11B (+45565) Transcriptional repressor -9.53 1.01 x10-4 -7.13 0.057 
cg01751047 Chr16:87785642 CDH15 KLHDC4 (+13912) Protein binding -8.01 1.11 x10-4 -4.34 0.163 
cg21584495 Chr11:17930141 SERGEF SERGEF (+104567) Guanine nucleotide exchange factor -7.98 1.17 x10-4 -2.46 0.145 
cg23276990 Chr3:113534251 CD200 GRAMD1C (-23013) Cholesterol transporter -17.44 1.24 x10-4 -11.14 0.080 
cg08471790 Chr2:108453832 GCC2 RGPD4 (+10440) Ran GTPase binding -12.60 1.24 x10-4 -3.80 0.180 
cg04413147 Chr21:46399562 FTCD FAM207A (+39638) rRNA maturation -10.23 1.50 x10-4 -7.30 0.076 
cg13097878 Chr1:65452808 AK4 JAK1 (-20622) Signal transduction -6.52 1.75 x10-4 -3.20 0.235 
cg12736406 Chr11:125918532 KIRREL3 CDON (+14654) Cell-cell interactions -6.13 1.88 x10-4 -2.87 0.275 
cg17023193 Chr1:33333181 AZIN2 FNDC5 (+3232) Regulation of brown fat differentiation -5.70 1.92 x10-4 1.92 0.622 
cg01084189 Chr2:134581807 - NCKAP5 (-255777) Microtubule formation -6.30 2.03 x10-4 -5.60 0.074 
cg23645046 Chr11:64338820 - SLC22A11 (+15723) Sodium-independent transporter -5.90 2.15 x10-4 -1.92 0.263 
cg09397963 Chr1:19529973 PQLC2 UBR4 (+6796) E3 ubiquitin ligase -7.22 2.26 x10-4 -7.06 0.175 





cg08694574 Chr16:84569116 - TLDC1 (-30753) mTor signalling -9.36 2.92 x10-4 -4.49 0.377 
cg12558795 Chr7:45945361 - IGFBP3 (+15488) Insulin-like growth factor I binding -8.04 2.93 x10-4 0.63 0.725 
cg09995507 Chr1:21861081 RAP1GAP ALPL (+25217) Phosphatase -5.77 2.97x10-4 -3.60 0.283 
cg26254345 Chr10:2961684 - PFKP (-148027) Glycolysis regulation -8.43 3.03x10-4 -2.65 0.639 
cg17065901 Chr4:90048410 FAM13A TIGD2 (+14443) Nucleic acid binding -5.80 3.06 x10-4 -1.40 0.562 
cg03943459 Chr3:142623215 ZBTB38 PCOLCE2 (-15171) Collagen trimerisation -7.41 3.08 x10-4 -4.39 0.082 
cg16856722 Chr3:9895535 CIDEC RPUSD3 (-9836) Mitochondrial ribosome assembly -8.62 3.36 x10-4 -3.45 0.295 
cg09330885 Chr3:197020882 MUC4 DLG1 (+4564) Signal transduction/cell proliferation -7.10 3.41 x10-4 -4.82 0.403 
cg04196119 Chr10:4507246 - AKR1E2 (-361199) Oxidoreductase -11.84 3.43 x10-4 -5.49 0.212 
cg25970363 Chr1:47423075 PDZK1IP1 CYP4A11 (-15939) Cholesterol synthesis -10.43 3.43 x10-4 -1.26 0.780 
cg14729068 Chr8:135581283 ZFAT ZFAT (+143997) Transcriptional regulator -5.88 3.44 x10-4 -3.06 0.283 
cg03431950 Chr18:55050667 - ST8SIA3 (+32624) Sialyltransferases -6.64 3.60 x10-4 -3.41 0.156 
cg11931360 Chr3:12963820 IQSEC1 IQSEC1 (+45347) EGF signalling -8.58 3.66 x10-4 -0.76 0.816 
cg13001919 Chr7:130842370 PODXL MKLN1 (-170248) Ubiquitin degradation -5.93 3.75 x10-4 -1.23 0.700 
cg01712984 Chr1:244213389 SMYD3 ZBTB18 (-1195) Transcriptional repressor -9.47 3.79 x10-4 -5.66 0.366 
cg19699170 Chr2:109760023 - SH3RF3 (+14027) E3 ubiquitin ligase -6.30 3.98 x10-4 -4.62 0.172 
cg24951151 Chr6:70951241 COL19A1 COL9A1 (+61544) Collagen protein -9.06 3.99 x10-4 -3.79 0.177 
cg07612956 Chr7:124865113 - POT1 (-295079) Telomere maintenance -8.75 4.01 x10-4 -0.06 0.986 
cg09141075 Chr8:874716 - TDRP (-378936) Spermatogenesis -6.09 4.15 x10-4 1.41 0.613 
cg08314156 Chr11:122446897 - UBASH3B (-79485) Protein tyrosine phosphatase -7.92 4.21 x10-4 -5.74 0.086 
cg13522359 Chr15:82176542 ADAMTSL3 MEX3B (+161939) Cell surface interactions -6.39 4.28 x10-4 0.37 0.912 
cg26558809 Chr11:9822265 LOC101928008; SBF2 SWAP70 (+136642)  NF-kappaB Signaling.  -11.08 4.39 x10-4 -8.30 0.052 
cg03544502 Chr14:44467592 KLHL28 FSCB (+508889) Calcium ion binding -5.31 4.40 x10-4 -0.83 0.646 
cg14800299 Chr19:17552465 GLT25D1 TMEM221 (+6910) Transmembrane protein -8.28 4.41 x10-4 -3.27 0.185 
cg03647619 Chr16:65536412 CES2 CDH11 (-380312) Calcium dependent cell-cell binding -9.21 4.55 x10-4 -3.60 0.369 
cg04024417 Chr7:96132284 - SLC25A13 (-180826) Mitochdondrial transport protein -9.29 4.65 x10-4 -2.13 0.557 
cg00426518 Chr5:115721607 - SEMA6A (+189022) Cell-surface receptor signalling -9.18 4.76 x10-4 -7.46 0.093 
cg21459713 Chr8:613688 ERICH1 TDRP (-117908) Spermatogenesis -7.70 4.89 x10-4 -2.50 0.698 





cg06790492 Chr17:75570125 TBC1D16 SEPT9 (+292634) Cytokinesis -6.62 5.02 x10-4 -1.80 0.732 
cg18654931 Chr3:156380895 MME TIPARP (-11738) Enhancer binding -8.23 5.07 x10-4 -0.23 0.923 
cg09451747 Chr4:143761752 INPP4B INPP4B (+5690) Phosphatidylinositol signaling -11.99 5.22 x10-4 -7.33 0.069 
cg06054708 Chr8:37633059 - PROSC (+12949) Regulator of PLP -8.44 5.47 x10-4 -3.13 0.494 
cg11527760 Chr4:107392661 TBCK TBCK (-150010) Actin organisation -7.35 5.67 x10-4 -6.98 0.055 
cg18162371 Chr10:134471866 - INPP5A (+120543) Intracellular calcium signalling -12.43 5.79 x10-4 -3.60 0.150 
cg16141678 ChrX:3274695 MXRA5 MXRA5 (-10014) Cell matrix remodelling -8.67 5.98 x10-4 -1.53 0.615 
cg02187937 Chr1:20877841 KIF17 CDA (-37599) Cytidine deaminase -7.35 6.03 x10-4 -3.37 0.288 
cg24328431 Chr9:14428351 - NFIB (-114686) Transcription factor -9.79 6.09 x10-4 -1.26 0.802 
cg02273079 Chr3:167772015 - GOLIM4 (+41747) Protein transporter in Golgi -13.38 6.15 x10-4 -8.03 0.102 
cg09068998 Chr5:148513916 ABLIM3 ABLIM3 (-7260) Actin binding -6.41 6.23 x10-4 -1.61 0.664 
cg03095244 Chr12:114285006 - RBM19 (+119104) Ribosome biogenesis -6.29 6.30 x10-4 -4.15 0.499 
cg04815049 Chr21:32189266 HUNK KRTAP8-1 (-3697) Keratin associated matrix protein -7.81 6.37 x10-4 -3.56 0.277 
cg26577683 Chr1:17765199 ARHGEF10L RCC2 (+1020) Regulator of small GTPases -10.91 6.98 x10-4 -3.72 0.074 
cg24462058 Chr1:20509731 VWA5B1 UBXN10 (-2846) Tethering factor -7.79 7.01 x10-4 0.40 0.882 
cg21858680 Chr4:85239853 - NKX6-1 (+179749) Transcriptional regulator -9.15 7.04 x10-4 -2.66 0.512 
cg13734043 Chr17:53625197 EPX MMD (-125845) Ion channel protein -8.30 7.06 x10-4 -3.95 0.185 
cg01893571 Chr2:38126388 FAM82A1 RMDN2 (-51217) Regulator of microtubule dynamics -7.59 7.19 x10-4 -0.59 0.936 
cg15361587 Chr18:54198203 NEDD4L TXNL1 (+107672) Protein disulfide oxioreductase -11.91 7.21 x10-4 -6.29 0.255 
cg04407732 Chr10:70142562 - RUFY2 (+24383) Endocytosis regulator -8.50 7.40 x10-4 -7.22 0.144 
cg18509185 Chr6:108039190 SOBP SCML4 (+106325) Transcriptional repressor -8.17 7.58 x10-4 0.58 0.701 
cg20229931 Chr21:46472084 LSS ADARB1 (-22408) Pre-mRNA editing -7.68 7.69 x10-4 -6.62 0.164 
cg05725719 Chr7:150064761 GIMAP5 REPIN1 (-1127) Nucleic acid binding -15.34 7.86 x10-4 -8.16 0.207 
cg08883054 Chr17:58125104 - HEATR6 (+31187) RNA binding -9.35 7.94 x10-4 0.05 0.985 
cg20216726 Chr22:46176691 - ATXN10 (+109013) Akt signalling -7.66 7.98 x10-4 -4.31 0.393 
cg20255272 Chr1:1363541 VWA1 TMEM88B (+2034) PDZ domain binding/signalling -6.94 8.03 x10-4 -3.33 0.500 
cg09759578 Chr19:1864405 SCAMP4; ADAT3 KLF16 (-839) Transcription factor -8.72 8.14 x10-4 -2.52 0.377 
cg13450196 Chr2:126981827 - GYPC (-431681) GYPC -8.39 8.25 x10-4 4.97 0.085 





cg16588731 Chr10:133873546 STK32C JAKMIP3 (-44628) Microtubule binding/formation -10.96 8.49 x10-4 -2.30 0.423 
cg21075278 Chr11:68208663 GAL PPP6R3 (-19574) Protein phosphatase -8.89 8.60 x10-4 -6.68 0.389 
cg16867466 Chr8:117386061 LINC00536 EIF3H (+381998) RNA transport/translation initiation -8.08 9.10 x10-4 -3.12 0.271 
cg01630199 Chr7:66006511 - KCTD7 (-199131) Potassium channel protein -8.99 9.16 x10-4 -2.73 0.597 
cg25681958 Chr2:75484984 - TACR1 (-58159) Vesicle mediated transport -6.58 9.17 x10-4 -4.97 0.083 
cg06823122 Chr3:111008424 - PVRL3 (+217835) Cellular adhesion -9.73 9.30 x10-4 -2.15 0.473 
cg15319438 Chr7:12681101 - ARL4A (-45859) GTP binding protein -5.64 9.36 x10-4 -3.74 0.442 
cg03512076 Chr8:103976253 - ATP6V1C1 (-57037) ATPase component -9.07 9.36 x10-4 -5.20 0.290 
cg03653841 Chr14:36052656 SFTA3 INSM2 (+49409) Transcriptional repressor -8.29 9.52 x10-4 -1.43 0.493 
cg00082939 Chr10:76835299 C10orf41 DUPD1 (-17028) Phosphatase -9.57 9.75 x10-4 -0.55 0.737 
cg25871851 Chr11:113547186 ZBTB16 TMPRSS5 (+29908) Serine protease -6.03 9.81 x10-4 -0.37 0.861 
cg08485684 Chr14:26374866 - NOVA1 (+692093) Neuron specific RNA binding -9.96 9.96 x10-4 -3.90 0.549 
cg08700546 Chr11:47393251 SLC39A13 SPI1 (+6690) Transcription factor -10.79 1.00 x10-3 -3.13 0.510 
Table 5.4. Probes acutely hypomethylated after treatment with LPS.
Shown are the 97 significantly differentially methylated probes that show acute hypomethylation (control to LPS p-value<1x10-3 and LPS to 
recovery p-value>0.05) after treatment with LPS. For each probe is the CpG ID, the genomic location, the UCSC gene annotation of the probe 
from Illumina, the GREAT annotation of the probe, the function of the GREAT gene, and the Δ value (% change in methylation) and p-value 
between both the control to LPS and control to LPS+recovery comparisons. The function of the genes identified through GREAT were found 






Figure 5.16. Loci demonstrating acute hypomethylation of probes after LPS treatment. 
 
 
Box plots showing the top four differentially methylated probes that demonstrate acute 
hypomethylation after LPS treatment, which was not seen after 24 hours recovery. β-values 
for individual replicates are represented by black dots on each of the box plots. Error bars 





     Control vs LPS Control vs LPS+Recovery 
CpG ID Genomic Location UCSC Annotation 
GREAT Annotation 
(distance) Function Δ (%) P-value Δ (%) P-value 
cg00904273 Chr16:657622 RHOT2/WDR90 RAB40C (+18266) Component of E3 ubiquitin ligase 8.92 3.93x10-5 1.56 0.550 
cg26775104 Chr13:45333858 - TSC22D1 (-183158) Transcription factor 7.75 4.34 x10-5 4.96 0.069 
cg11783901 Chr17:44456999 IGF2BP1 ARL17B (-17870) GTP binding protein 9.94 7.12 x10-5 6.36 0.066 
cg06555468 Chr7:2061316 MAD1L1 MAD1L1 (+211561) Spindle assembly 7.84 8.05 x10-5 -1.86 0.406 
cg26826339 Chr8:24421976 ADAM7 ADAM7 (+123438) Protein Interaction and adhesion in sperm-egg fusion 8.88 8.25 x10
-5 3.60 0.425 
cg09076431 Chr1:196155786 LHX9 KCNT2 (+422568) Voltage gated ion channel protein 6.42 9.15 x10-5 5.12 0.053 
cg15358079 Chr8:37378803 - ZNF703 (-174465) Transcriptional corepressor 5.80 1.32 x10-4 4.19 0.214 
cg04695063 Chr11:18371116 LDHA GTF2H1 (+26974) Part of the general transcription and DNA repair factor IIH 7.06 1.33 x10
-4 1.63 0.517 
cg19100169 Chr5:159620781 CCNJL FABP6 (+6408) Fatty acid binding protein 5.53 1.46 x10-4 4.33 0.397 
cg21336373 Chr17:3754061 P2RX1 C17orf85 (-4517) mRNA export 9.78 1.57 x10-4 3.07 0.100 
cg25251543 Chr2:240170336 - HDAC4 (+152306) Histone deacetylase 10.64 1.85 x10-4 0.28 0.942 
cg10139358 Chr18:72763183 ZNF236 ZADH2 (+158119) Oxioreductase 8.73 2.04 x10-4 -0.08 0.985 
cg08631134 Chr9:21751378 - MTAP (-51163) Adenine and methionine salvage 12.38 2.12 x10-4 1.84 0.652 
cg25961805 Chr4:121182403 - MAD2L1 (-194175) Mitotic checkpoint protein 9.46 2.18 x10-4 -0.45 0.834 
cg02557865 Chr16:15435558 C16orf45 NPIPA5 (+36592) Interacts with nuclear pore 16.68 2.29 x10-4 3.93 0.199 
cg08570033 Chr5:58857790 PDE4D PDE4D (+331834) cAMP degradation 9.49 2.44 x10-4 4.45 0.121 
cg01799429 Chr8:142802747 - PTP4A3 (+400655) Protein tyrosine phosphatase 6.42 2.65 x10-4 1.14 0.691 
cg24744928 Chr1:239757484 - CHRM3 (-34888) Muscarinic cholingeric receptor and GPCR 7.85 2.84 x10-4 4.28 0.145 
cg06046580 Chr2:232465658 MIR1471 C2orf57 (+8084) Testis expressed protein - function unknown 10.82 2.86 x10
-4 8.71 0.060 
cg09701702 Chr6:101021723 - SIM1 (-108919) Transcription factor 7.37 3.20 x10-4 0.30 0.950 
cg04398416 Chr10:3588486 - KLF6 (+238980) Transcription factor 8.93 3.31 x10-4 3.20 0.092 
cg12765327 Chr14:105434901 - AHNAK2 (+9792) Nucleoprotein/calcium signalling 9.36 3.32 x10-4 5.94 0.069 
cg16899859 Chr4:34346550 - - - 9.04 3.35 x10-4 2.20 0.256 
cg14525769 Chr5:10745140 DAP DAP (+16243) Positive mediator of cell death 8.03 3.56 x10-4 7.08 0.157 
cg05192293 Chr10:71604092 - COL13A1 (+42405) Alpha chain of collagen 7.64 3.77 x10-4 0.64 0.840 





cg18158658 Chr9:126064834 NEK6 STRBP (-33980) Spermatogenesis 4.70 3.96 x10-4 -1.43 0.639 
cg09696231 Chr19:16346049 EPS15L1 AP1M1 (+37305) Protein sorting in Golgi network 9.59 3.97 x10-4 9.19 0.063 
cg08194969 Chr14:64142766 - SGPP1 (+51990) Dephosphorylates sphingosine 1-phosphate 10.05 4.02 x10
-4 6.78 0.078 
cg20829955 Chr1:22547616 - WNT4 (-78158) Cellular signalling 9.47 4.03 x10-4 1.43 0.589 
cg00023726 Chr1:2829795 - ACTRT2 (-108250) Cytoskeletal organisation 8.75 4.16 x10-4 3.70 0.295 
cg02206323 Chr17:19189661 MIR1180/B9D1 EPN2EPN2 (+49008) Clathrin mediated endocytosis 7.87 4.22 x10-4 5.19 0.063 
cg09425404 Chr21:31641444 TIAM1 KRTAP24-1 (+13831) Keratin associated matrix protein 7.32 4.55 x10-4 -0.10 0.958 
cg13724238 Chr11:2828568 - CDKN1C (+78542) Inhibitor of G1 cyclin/CDK complexes 3.96 4.78 x10-4 -3.95 0.059 
cg24307945 Chr2:65363564 - RAB1A (-6325) Vesicle trafficking in Golgi 6.03 4.80 x10-4 -0.28 0.904 
cg22902550 Chr5:136367959 SPOCK1 SPOCK1 (+467077) Proposed protease inhibitor 12.87 4.82 x10-4 6.18 0.074 
cg05534427 Chr19:50693390 RTN2/FLJ40125/RTN2 MYH14 (-13511) Actin dependent motor protein 6.66 5.11 x10-4 3.53 0.274 
cg02170071 Chr11:59237191 OR10V1 OR4D10 (-7654) Olfactory GPCR 10.37 5.18 x10-4 0.98 0.662 
cg05967001 Chr12:111714030 RPH3A FAM109A (+92894) Endocytic trafficking 6.92 5.31 x10-4 5.99 0.183 
cg19076895 Chr6:7578298 - SNRNP48 (-12133) Gene regulation and mRNA splicing 6.47 5.47 x10-4 4.74 0.145 
cg06673910 Chr10:43224783 HNRNPF BMS1 (-53465) Ribosome biogenesis 7.75 6.24 x10-4 1.45 0.573 
cg00828618 Chr19:7660029 FCER2 CAMSAP3 (-758) Regulation of microtubule dynamics 10.23 6.26 x10-4 2.96 0.212 
cg22667851 Chr16:11313379 - SOCS1 (+36656) Negative regulator of cytokine signalling 7.49 6.27 x10-4 5.71 0.071 
cg05487589 Chr8:25952113 EBF2 EBF2 (-49201) Transcription factor 7.78 6.28 x10-4 6.88 0.117 
cg25654973 Chr8:81355474 - ZBTB10 (-42427) Proposed transcriptional regulator 7.29 6.43 x10-4 7.00 0.142 
cg01736264 Chr1:26320998 PDIK1L PAFAH2 (+3649) Platelet homeostasis 8.58 6.44 x10-4 5.93 0.067 
cg00686823 Chr3:128793728 TPRA1 GP9 (+14119) Platelet activation 13.64 6.66 x10-4 6.52 0.142 
cg21554217 Chr5:138877651 - TMEM173 (-15277) Regulator of innate immune reponse to infection 11.87 6.78 x10
-4 3.89 0.268 
cg23493306 Chr8:22658435 PEBP4 EGR3 (-107621) Transcriptional regulation 6.75 6.78 x10-4 1.52 0.624 
cg21806810 Chr5:35014708 - AGXT2 (+33489) Glyoxylate to glycine conversion 8.03 6.81 x10-4 0.65 0.745 
cg21701994 Chr20:24086020 - GGTLC1 (-116605) Glutathione metabolism 8.31 7.10 x10-4 2.00 0.524 
cg03446846 Chr17:1891356 DPH1/OVCA2 RTN4RL1 (+37282) Cell surface receptor 6.75 7.17 x10-4 0.24 0.934 
cg15731551 Chr3:100164386 - TOMM70A (-44145) Mitochondrial precursor protein import 10.61 7.31 x10-4 5.72 0.250 





cg07740306 Chr18:75347357 NFATC1 GALR1 (+384853) GPCR receptor signalling 7.38 7.95 x10-4 5.73 0.366 
cg26868111 Chr1:116881898 CD58 ATP1A1 (-34590) Component of NA+/K+ ATPase 5.97 8.02 x10-4 0.66 0.732 
cg01450803 Chr4:75070018 - MTHFD2L (+46190) Formate-tetrahydrofolate ligase activity 8.01 8.03 x10-4 4.66 0.197 
cg04186484 Chr17:59319760 - TBX2 (-157496) Transcription factor 7.44 8.40 x10-4 1.77 0.493 
cg06106499 Chr2:1088670 SNTG2 SNTG2 (+142117) Actin/PDZ domain binding 5.81 8.64 x10-4 1.25 0.539 
cg20134175 Chr20:42195557 JPH2 SGK2 (+821) Protein tyrosine kinase/glucose transporter 4.70 8.82 x10-4 0.66 0.703 
cg05050884 Chr3:188050040 ADIPOQ LPP (+119320) Cell-cell adhesion 7.61 8.97 x10-4 6.90 0.082 
cg20682563 Chr5:133488773 TCF7 SKP1 (+23955) Component of ubiquitin ligase complex 9.06 9.21 x10-4 4.70 0.068 
cg27286069 Chr11:117987092 PHLDB1 SCN4B (+36442) Component of voltage gated ion channel 7.85 9.43 x10-4 -0.29 0.880 
cg08066500 Chr3:2381280 CNTN4 CNTN4 (+100768) Axon associated cell adhesion molecule 5.77 9.58 x10-4 -0.07 0.971 
cg12196720 Chr1:160573852 NOS1AP CD84 (-24559) Glycoprotein involved in cellular signalling 5.40 9.62 x10-4 3.90 0.207 
cg11519260 Chr10:42506816 - ZNF33B (+627175) Transcriptional regulation 9.89 9.78 x10-4 3.70 0.369 
cg11003725 Chr14:104420652 KIAA0284 TDRD9 (+25854) ATP-binding RNA helicase 8.09 9.93 x10-4 -1.36 0.590 





Shown are the 67 significantly differentially methylated probes that show acute hypermethylation (control to LPS p-value<1x10-3 and LPS to 
recovery p-value>0.05) after treatment with LPS. For each probe is the CpG ID, the genomic location, the UCSC gene annotation of the probe 
from Illumina, the GREAT annotation of the probe, the function of the GREAT gene, and the Δ value (% change in methylation) and p-value 
between both the control to LPS and control to LPS+recovery comparisons. The function of the genes identified through GREAT were found 







Figure 5.17. Loci demonstrating acute hypermethylation of probes after LPS treatment. 
 
Box plots showing the top four differentially methylated probes that demonstrate acute 
hypermethylation after LPS treatment, which was not seen after 24 hours recovery. β-
values for individual replicates are represented by black dots on each of the box plots. Error 





     Control vs LPS Control vs LPS+Recovery 
CpG ID Genomic Location UCSC Annotation 
GREAT Annotation 
(distance) Function Δ (%) P-value Δ (%) P-value 
cg12698829 Chr4:156874061 GUCY1A3 CTSO (+1007) Cellular protein degradation -7.41 2.02x10-4 -8.63 3.80 x10-2 
cg11543559 Chr2:102139055 IL1R1 RFX8 (-47891) Transcription factor -5.91 2.91x10-4 -10.12 4.76 x10-3 
cg23986404 Chr16:49948713 - ZNF423 (-92064) Transcription factor -8.37 3.27x10-4 -9.66 6.96 x10-3 
cg07022240 ChrX:152694768 PLXNB3 ZFP92 (+10989) Transcriptional regulation -7.87 3.91x10-4 -15.15 7.51 x10-3 
cg20387395 Chr15:56665965 - TEX9 (+8341) Suggested ATP binding protein -7.55 5.29x10-4 -7.58 2.76 x10-2 
cg10110288 Chr5:55309787 IL6ST IL6ST (-18967) Signal transduction -7.34 6.93x10-4 -7.77 4.82 x10-3 
cg05084299 Chr1:244126238 SMYD3 ZBTB18 (-88346) Transcriptional repressor -7.23 7.33x10-4 -7.66 1.28 x10-2 
cg13415481 Chr2:234369420 MROH2A USP40 (+104815) Deubiquitinating enzyme -7.44 7.46x10-4 -7.63 4.13 x10-3 




Shown are the 8 significantly differentially methylated probes that show persistent hypomethylation (control to LPS p-value<1.00x10-3 and 
LPS to recovery p-value<0.05) after treatment with LPS. For each probe is the CpG ID, the genomic location, the UCSC gene annotation of 
the probe from Illumina, the GREAT annotation of the probe, the function of the GREAT gene, and the Δ value (% change in methylation) and 
p-value between both the control to LPS and control to LPS+recovery comparisons. The function of the genes identified through GREAT were 










Box plots showing the top four differentially methylated probes that demonstrate persistent 
hypomethylation after LPS treatment, which was not seen after 24 hours recovery. β-values 
for individual replicates are represented by black dots on each of the box plots. Error bars 





Table 5.7. Probe persistently hypermethylated after treatment with LPS. 
 







(distance) Function Δ (%) P-value Δ (%) P-value 
cg09424348 Chr6:30881549 VARS2 MUC22 (+11278) 
Glycosylated protein in bacterial/fungal 
defence 10.76 4.80x10-4 12.66 0.015 
Shown is the one significantly differentially methylated probe that show persistent hypermethylation (control to LPS p-value<1x10-3 and LPS 
to recovery p-value<0.05) after treatment with LPS. For each probe is the CpG ID, the genomic location, the UCSC gene annotation of the 
probe from Illumina, the GREAT annotation of the probe, the function of the GREAT gene, and the Δ value (% change in methylation) and p-
value between both the control to LPS and control to LPS+recovery comparisons. The function of the genes identified through GREAT were 













Box plots showing the only differentially methylated probes that demonstrate persistent 
hypermethylation after LPS treatment, which was not seen after 24 hours recovery. β-
values for individual replicates are represented by black dots on each of the box plots. Error 





5.4.1.11 Specific functional changes in DNA methylation after LPS treatment 
Using the chromosomal location of each CpG probe GREAT was used to annotate 
each locus to the single nearest gene that is either upstream or downstream. Using 
this annotation method all bar one of the probes was annotated to a nearby gene. The 
function of each of these genes was then manually searched and recorded.  
 
As I was interested in exploring whether there were any common functions of loci that 
featured in the four methylation change categories I performed GREAT annotation to 
determine the genes that are important in the overall response of microglia to LPS. I 
observed a number of transcription related genes such as SOX9, RXF8, ZFP92 and 
TSC22D1. Alongside this there were also several genes involved in cellular signalling, 
for example F2RL3, JAK1, IL6ST and PTP4A3. Finally, there were also numerous 
other genes associated with the innate immune system being differentially methylated, 
including METTL7A, a methyltransferase known to be involved in the innate immune 
response and C17orf85, an mRNA export protein known to play a role in the response 
to cellular stressors such as infections [413].  
 
In addition to manual gene function curation, the “gometh” function within the 
missMethyl package [265] was used to identify pathways being altered by treatment 
with LPS. Although ideally I would have performed pathway analysis on each of the 
four categories of methylation changes separately, given the low number of significant 
loci in some categories this was not possible and so instead all of the significant loci 
from all four categories were combined and assessed together, with the overall aim of 






In terms of biological pathways (table 5.8, figure 5.20), the largest group of pathways 
that were altered were those related to extracellular matrix organisation and the 
regulation of lymphocyte proliferation. Alongside these pathways, there were also 
changes occurring in genes related to tRNA metabolism and fat cell differentiation. 
However, it should be noted that none of the pathways from the pathway analysis were 
FDR significant and therefore it is important to not over interpret the resulting outputs. 
I observed several changes in molecular functions (table 5.9, figure 5.21), including 
enzyme activities such as intramolecular transferase and serine-type endopeptidase 
inhibitor activity, although none of these were FDR-significant. Finally, I also observed 
changes to cellular components (table 5.10, figure 5.22), relating to lipid particles, 
organelle membranes, the endoplasmic reticulum and neuromuscular junctions, 






GO ID Term Ontology No. Genes in Term No. of DMPs P-value FDR Genes 
GO:0010737 protein kinase A signaling BP 30 2 0.004 1 GAL; ADIPOQ 
GO:1903055 positive regulation of extracellular matrix organization BP 20 2 0.005 1 PHLDB1; GLT25D1 
GO:0006399 tRNA metabolic process BP 184 3 0.009 1 
ADAT3; PUS10; 
VARS2 
GO:0050873 brown fat cell differentiation BP 40 2 0.010 1 EBF2; ADIPOQ 
GO:0032370 positive regulation of lipid transport BP 58 2 0.014 1 GAL; ADIPOQ 
GO:0010470 regulation of gastrulation BP 42 2 0.015 1 PHLDB1; ADIPOQ 
GO:1903053 regulation of extracellular matrix organization BP 39 2 0.016 1 PHLDB1; GLT25D1 
GO:0046324 regulation of glucose import BP 55 2 0.017 1 RTN2; ADIPOQ 
GO:0032945 negative regulation of mononuclear cell proliferation BP 69 2 0.017 1 GAL; MAD1L1 
GO:0050672 negative regulation of lymphocyte proliferation BP 69 2 0.017 1 GAL; MAD1L1 
GO:0070664 negative regulation of leukocyte proliferation BP 74 2 0.018 1 GAL; MAD1L1 
GO:0046323 glucose import BP 63 2 0.019 1 RTN2; ADIPOQ 
GO:0010827 regulation of glucose transmembrane transport BP 74 2 0.026 1 RTN2; ADIPOQ 
GO:1905954 positive regulation of lipid localization BP 78 2 0.027 1 GAL; ADIPOQ 
GO:0008033 tRNA processing BP 123 2 0.029 1 ADAT3; PUS10 
GO:0015850 organic hydroxy compound transport BP 254 3 0.038 1 P2RX1; GAL; ADIPOQ 
GO:1904659 glucose transmembrane transport BP 101 2 0.041 1 RTN2; ADIPOQ 
GO:0032368 regulation of lipid transport BP 121 2 0.045 1 GAL; ADIPOQ 
GO:0008645 hexose transmembrane transport BP 108 2 0.046 1 RTN2; ADIPOQ 
GO:0015749 monosaccharide transmembrane transport BP 110 2 0.046 1 RTN2; ADIPOQ 
GO:0034219 carbohydrate transmembrane transport BP 112 2 0.047 1 RTN2; ADIPOQ 
GO:0120162 positive regulation of cold-induced thermogenesis BP 96 2 0.049 1 EBF2; ADIPOQ 
GO:0016999 antibiotic metabolic process BP 147 2 0.050 1 FTCD; EPX 
Table 5.8. Biological processes altered upon LPS treatment. 
 
Shown are the 23 significantly altered GO BP pathways after treatment with LPS and recovery. Shown for each pathway is the GO ID, the 
pathway descriptor, the ontology of the pathway, the number of genes in the pathway, the number of DMPs in the pathway, p-value 


















Figure 5.20. Biological processes altered after microglial treatment with LPS.  
 
GO enrichment analysis was performed on the all loci shown to be differentially methylated on LPS treatment. Treemap illustrating the 
pathways relating to biological processes (BP) is shown. In the treemap, terms relating to the same pathway are grouped together and have 






GO ID Term Ontology No. Genes in Term No. of DMPs P-value FDR Genes 
GO:0016866 intramolecular transferase activity MF 27 2 0.001 1 PUS10; LSS 
GO:0005201 extracellular matrix structural constituent MF 151 4 0.004 1 
MXRA5; MUC4; VWA1; 
ADIPOQ 
GO:0004867 serine-type endopeptidase inhibitor activity MF 92 2 0.018 1 CPAMD8; SPOCK1 
GO:0005179 hormone activity MF 113 2 0.024 1 GAL; ADIPOQ 
GO:0140101 catalytic activity, acting on a tRNA MF 120 2 0.036 1 PUS10; VARS2 
GO:0016853 isomerase activity MF 141 2 0.040 1 PUS10; LSS 





Shown are the 6 significantly altered GO MF pathways after treatment with LPS and recovery. Shown for each pathway is the GO ID, the 
pathway descriptor, the ontology of the pathway, the number of genes in the pathway, the number of DMPs in the pathway, p-value 



















Figure 5.21. Molecular functions altered after microglial treatment with LPS.  
GO enrichment analysis was performed on the all loci shown to be differentially methylated on LPS treatment. Treemap illustrating the 
pathways relating to molecular functions is shown. In the treemap, terms relating to the same pathway are grouped together and have been 






GO ID Term Ontology No. Genes in Term No. of DMPs P-value FDR Genes 
GO:0005811 lipid droplet CC 77 2 0.021 1 LSS; CIDEC 
GO:0031301 integral component of organelle membrane CC 194 3 0.024 1 P2RX1; RHOT2; SLC39A13 
GO:0005783 endoplasmic reticulum CC 1809 11 0.026 1 FTCD; ABCB9; LSS; GIMAP5; RTN2; CIDEC; VWA1; GLT25D1; CES2; SLC39A13; ADIPOQ 
GO:0031300 intrinsic component of organelle membrane CC 216 3 0.032 1 P2RX1; RHOT2; SLC39A13 
GO:1902554 serine/threonine protein kinase complex CC 86 2 0.035 1 GTF2H4; CCNJL 
GO:0072686 mitotic spindle CC 100 2 0.039 1 FAM82A1; MAD1L1 
GO:0031594 neuromuscular junction CC 76 2 0.041 1 CDH15; SPOCK1 
GO:0015630 microtubule cytoskeleton CC 1166 8 0.045 1 FTCD; FAM82A1; WDR90; MTUS2; KIF26A; B9D1; KIAA0284; MAD1L1 
GO:0016528 Sarcoplasm CC 75 2 0.047 1 RTN2; SPOCK1 
Table 5.10. Cellular components altered upon LPS treatment 
. 
Shown are the 9 significantly altered GO CC pathways after treatment with LPS and recovery. Shown for each pathway is the GO ID, the 
pathway descriptor, the ontology of the pathway, the number of genes in the pathway, the number of DMPs in the pathway, p-value 



















Figure 5.22. Cellular components altered after microglial treatment with LPS.  
GO enrichment analysis was performed on the all loci shown to be differentially methylated on LPS treatment. Treemap illustrating the 
pathways relating to cellular components is shown. In the treemap, terms relating to the same pathway are grouped together and have been 





In this chapter I have used the Illumina EPIC array to undertake epigenome-wide 
analyses of DNA methylation changes occurring upon microglial cell activation 
and then recovery by a known immune stimulant. This was achieved by treating 
an immortalised microglial cell line with either LPS for 24 hours, treating with LPS 
for 24 hours followed by a 24-hour recovery period or undergoing no treatment 
(control), as outlined in figure 5.1. Once the treatments were completed the cells 
were collected, DNA was extracted and then run on the EPIC array to provide 
information on DNA methylation at over 850,000 loci across the genome.  
 
One of the first things that has been shown by this study is that there are no 
changes to either epigenetic age or mitotic age upon stimulation. This could have 
numerous explanations. Firstly, as this is an immortalised cell line the process of 
immortalisation could have made the cells more robust and therefore less 
susceptible to stimulation. What is of interest is that the epigenetic age of these 
cells does not reflect the biological age of the person the cells were originally 
derived from, which was a middle-aged male. This would suggest that the 
immortalisation process has changed the methylation profile of the cells therefore 
making them appear epigenetically rejuvenated. Another reason there are no 
changes upon stimulation could be because the cells were only treated once and 
for 24-hours. During life and throughout disease course the human body will be 
exposed to numerous infections and it is possible that it is this repeated exposure 
to immune stimulation that is causing the robust methylation changes that are 
found upon post-mortem investigation. In order to test whether these are the 
reasons there are no significant changes in epigenetic or mitotic age it would be 




use recurrent exposures and recoveries to LPS. One example could be to 
repeatedly expose iPSC-derived microglia or just treat them once with LPS to see 
if there is any association of repeated exposure to these measures of maturity. 
Finally, although I showed there were no differences in epigenetic age using the 
current Horvath age calculator [126], it is worth noting that there are many 
different epigenetic age clocks [125, 236, 237] and calculators that have now 
been developed. These all have different advantages and disadvantages, 
depending on the dataset that they have been developed in. I decided to use the 
Horvath age calculator in this chapter as I had used it in my previous chapters, 
as it had demonstrated in chapter 4 that my samples were cortical neurons. It 
could perhaps be possible that the other epigenetic clocks that are available may 
be more sensitive to changes in immortalised cell lines, and so future studies 
could explore the epigenetic age predicted by these different algorithms. 
 
By categorising DMPs into four different categories based on their pattern of 
methylation change (e.g. acute and persistent hypo and hypermethylated 
probes), I was able to look at which loci are more susceptible to long term 
changes in methylation and the associated functions of these loci. This allowed 
me to infer the cellular functions that are perhaps the most affected by immune 
stimulation. Firstly, as there are many more genes in both of the acute categories 
it is clear that the majority of differentially methylated loci were more susceptible 
to short term changes, which had largely disappeared in the recovery group. 
Again, this could reflect the short term and non-recurrent nature of the stimulation 
and it would be interesting to see whether the changes in methylation at these 
loci become more long term upon multiple treatments with LPS. In addition, the 




the fact that there was more variation in methylation in the LPS + recovery group 
samples, compared to the other treatment groups. In the future profiling additional 
samples per treatment group could reduce this variation, or could demonstrate 
that this is driven by differences in recovery between samples. It is worth noting 
that due to the low number of replicates per treatment group (N = 4) and as I only 
tested a one-off stimulation, none of the loci I identified were Bonferroni-
significant. As such I decided to use a more relaxed arbitrary significance 
threshold of P=1x10-3. Therefore, further replication of results is required. Owing 
to the fact that the EPIC array profiles ~850,000 methylation sites, and many of 
these are highly correlated it has been previously shown in previous methylomic 
studies on the Illumina arrays that Bonferroni significance is overly stringent for 
EWAS [414], although the field has not yet identified the best p-value threshold 
for the EPIC array to account for this [415]. 
 
Across all of the categories of methylation pattern changes, one type of gene that 
consistently feature were that of transcriptional regulators. Within the persistent 
hypomethylation category half of the significant loci were known transcription 
factors or transcriptional regulators, inferring that changes to transcription are 
affected more long term. As decreased methylation is generally associated with 
increases in gene expression it would suggest that immune stimulation is causing 
an increase in expression of these transcriptional regulators. This would therefore 
cause expression changes of the targets of the regulators. These changes in 
DNA methylation are intuitive as exposure to LPS is known to cause immune cell 
activation which will be regulated and brought about by changes to gene 
expression. It is however worth noting that the relationship between DNA 




methylation also associated with gene silencing and alternative splicing, 
depending on the context. In the future it will therefore be of interest to profile 
mRNA levels of the genes I have shown are differentially methylated following 
LPS, to establish this relationship. 
 
Another category of genes that had altered DNA methylation following LPS were 
those encoding signalling proteins or proteins involved in signalling pathways. 
The fact that the levels of methylation were both increasing and decreasing 
depending on the locus would suggest that some signalling pathways become 
activated, whilst other become less active following LPS exposure. As microglia 
undertake a variety of different roles in addition to response to LPS/bacteria (e.g. 
phagocytosis, synaptic pruning [416]), then it is not surprising that changes in the 
activity of different signalling pathways are observed after LPS. It would again be 
of interest in the future to explore the levels of gene expression of the differentially 
methylated genes.  
 
In order to get a better idea of the pathways that were changing upon LPS 
treatment GO pathway analysis using the missMethyl package was used. As 
there were not enough loci within each category to do this analysis for the 
categories individually all significant loci across the categories were pooled. By 
pooling the loci together, it was possible to determine which pathways were 
possibly impacted following LPS irrespective of the direction or duration of 
change. Using the REVIGO treemap generator the changing pathways were 
grouped into biological pathways, molecular functions and cellular components 
and then further grouped according to their specific function and summarised. 




altered in genes involved in extracellular matrix organisation, enzyme activity, 
signalling and organelle function. One limitation of this analysis is the small 
number of DMPs used to perform the pathway analysis. Ideally, pathway analysis 
would be performed on more than 1000 loci, but despite pooling of DMPs there 
were still only 173 DMPs used. This low number of loci resulted in none of the 
resulting pathways being FDR significant and therefore cautious interpretation is 
advised. Another limitation for this analysis was the pooling of the genes in the 
different categories of methylation changes, as ideally this would be performed 
on the separate categories. In order to address both of the limitations it could 
have been an option to analyse the top 1000 DMPs per group. However, as this 
could introduce a lot of false negatives into the results I decided not to do this.  
 
Looking to the future I feel it is important to take these results further and 
interrogate DNA methylation upon LPS treatment in more relevant models and 
more comprehensively. As previously mentioned, this could be undertaken in 
iPSC-derived microglial lines. Using these cells it would also be of interest to 
explore the effects of recurrent exposure to LPS and whether there are any loci 
that are susceptible to persistent changes in DNA methylation upon recurrent 
stimulation. Using iPSC lines, it would also be possible to look at the effect of 
genotype on methylation and whether having a microglial relevant mutation, such 
as those in TREM2, CLU or CD33 for example, would affect the changes seen in 
methylation. As the data generated using this system would be human data it 
would be possible to look at the overlap in post-mortem brain data, perhaps in 





Finally, alongside investigating changes in methylation, it will be important to 
profile gene expression as well as undertaking more functional assays to assess 
the effects of LPS on phenotype. It would be particularly interesting to undertake 
these experiments in the presence of AD relevant proteins such as Aβ, as I am 
particularly interested in cellular phenotype in the context of AD.  This would allow 
us to confirm that microglial cells are less able to perform phagocytosis of Aβ 
after stimulation with LPS [417]. Looking at morphological changes and staining 
for proteins known to have increased expression on immune activation would 
provide more information on how functionally relevant the assay is. To look at 
response to injury scratch assays could be used or phagocytosis could be tracked 



































In this chapter I have characterised genome wide patterns of DNA methylation in 
microglia in order to further understand the epigenomic changes that are 
occurring upon microglial stimulation with LPS. I have shown that despite 
treatment and recovery there are no changes in either epigenetic, or mitotic age, 
which is perhaps a reflection of the cell line used, the low replicate number and 
the one-off nature of the treatment. In order to understand the functional 
implications of LPS stimulation, I used both manual and computational 
assessment of the pathways and cellular functions that were changing. Through 
these analyses it is clear that there are large amounts of loci undergoing DNA 
methylation changes on treatment, which is potentially affecting gene regulation, 
matrix organisation and signalling within the microglial cells. In the future it will be 
important to expand upon these results by assessing genotype dependent 
recurrent LPS-induced methylation and functional changes in an iPSC-derived 
microglial cells. 
 
Overall, I have shown there is methylomic variation occurring upon the stimulation 
of microglial cells with LPS.  This includes increasing and decreasing methylation 
changes that are short and longer lived. Moving forward it would be of benefit to 
expand this study further using a different cell line, with more recurrent exposures 













































The primary aim of thesis was to characterise and expand the existing knowledge 
about the epigenetic landscape in neuronal and microglial cell lines, in particular 
the methylomic changes occurring with AD-relevant events, such as time in 
culture, drug treatment or immune challenge.  This discussion will summarise the 
key findings from each chapter of this thesis and the limitations present within 





6.2 Key Findings from this Thesis 
 
6.2.1 Chapter 3: Characterisation of DNA Methylomic Signatures in iPSCs 
during Neuronal Differentiation 
As it is known that epigenetic mechanisms, including DNA methylation, play a 
role in cell fate, this chapter aimed to demonstrate that there are DNA methylation 
changes occurring during differentiation and that these changes impact on 
neuron-related cellular pathways. Using the Illumina EPIC array it was possible 
to assess the DNA methylation status of over 850,000 loci across the genome at 
numerous time points throughout the differentiation of iPSCs into neurons. 
 
The first key finding in this study is that the iPSC-derived neurons have a foetal 
epigenetic age, with the highest age of any sample being -0.41 years. This will 
be important to bear in mind for future studies, especially when using stem cell 
derived neurons to study the epigenetic changes occurring in age related 
diseases. However, it is worth noting that the algorithm used to determine the 
epigenetic ages of these samples was not trained on foetal brain data. Therefore, 
it is important that the epigenetic ages of the samples are interpreted with some 
caution. In the future it will be of interest to test a range of different epigenetic age 
calculators to explore whether these may demonstrate different ages. However, 
in the current study it is still interesting that despite not being trained on foetal 
data that the epigenetic ages of all samples were negative.  
 
Following on from this I performed WGCNA, pathway analysis and trajectory 
inference modelling to determine the consequences of the DNA methylation 




relating to pathways involved in neuronal development or the regulation of gene 
expression. The trajectory inference model identified probes that that were 
becoming progressively hypo- or hypermethylated with time, and similarly these 
probes were also largely annotated to genes involved in gene regulation and 
processes that are important in becoming a neuron. One of the advantages of 
using two different methods to analyse the data (WGCNA and TI modelling), 
which identified similar pathways is that we can be more confident that the results 
seen are genuine and the cells we are generating are neurons. 
 
Finally, to explore the interconnectivity of the probes identified in the trajectory 
model gene-gene interaction analyses were performed. This identified 2,352 
unique genes, of which 602 of those genes formed a network containing 1,158 
interactions. Within this network there were 50 highly connected genes, of which 
72% were involved in transcriptional regulation and 14% were shown to be 
involved in epigenetic regulation. Many of the transcription factors identified, 
including STAT3, TDF7L2 and LHX2 have been shown to be important for 
neuronal survival and function [280-282, 418]. The implication of these genes in 
the network adds more evidence to suggest that there are many neuronal genes 
that are highly influential in the development and differentiation of neurons.  
 
One caveat of this study is the fact that it was only undertaken in one iPSC cell 
line and that there were relatively few replicates per group. Having few replicates 
affects the power in the study and means that it is not possible to detect small 
changes in DNA methylation. Only using one cell line means that whilst we can 
say the changes seen here are characteristic of this cell line it is not possible to 




study it will be important to repeat the study in several different cell lines, ideally 
with more replicates; this way we could create a lineage trajectory that is 
characteristic of all iPSC lines rather than just the one.  
 
6.2.2 Chapter 4: Determining the Utility of Epigenetic Modulators to Treat AD 
The aim of this chapter was to characterise the methylomic changes occurring 
when iPSC-derived neurons and microglia are treated with compounds known to 
effect epigenetic mechanisms. Whilst the targets of the drugs used in this chapter 
are known, and have been shown to modulate various epigenetic mechanisms, 
the consequence on epigenetic markers, such as DNA methylation have never 
been investigated. This was achieved using the Illumina EPIC array to assess 
DNA methylation patterns across the genome.  
 
As demonstrated in chapter 3, the iPSC-derived neurons in this chapter all have 
a foetal epigenome, with the highest epigenetic age of any sample being ~-0.2 
years. In addition to this the epigenetic ages of iPSC-derived microglia were also 
assessed. Whilst the majority of microglial samples did not have a foetal 
epigenetic age, the age they were predicted to be was still immature and ranged 
from ~0 to 0.7 years. This suggests that whilst still young the microglia are 
epigenetically older than the neuronal samples, which may reflect that they still 
proliferate once generated. Interestingly, none of the treatments in either of the 
cell types had an impact on the epigenetic age of the samples. This could be a 
result of the short nature of treatment or show that the epigenetic modulators do 
not affect the methylation levels of the loci that are used to calculate epigenetic 




assessing the epigenetic age and methylation changes that occur after a longer 
term treatment with these compounds. 
 
Using linear regression modelling I tried to identify DMPs in the neurons and 
microglia that were nominally consistently significant across the drugs of the 
same class, i.e. BRD, HMT, HKDM or KMR inhibitor. Whilst there were consistent 
nominally significant changes seen across the drug classes in the microglial 
samples (BRD: 427, HMT: 429, HKDM: 387 and KMR: 369) the same was not 
true in the neurons BRD: 0, HMT: 0, HKDM: 144 and KMR: 120), where the only 
consistent nominally significant changes that were seen were in the groups 
containing the fewest modulators. This suggests that the modulators are having 
a much more constant effect on DNA methylation in microglia than in neurons, or 
that there is more variation in the neurons than the microglia, meaning there are 
less significant changes in the neurons. However, it is worth noting that although 
I saw little overlap in the number of nominally significant methylation changes in 
neurons, I did observe similar effect sizes for compounds in the same drug class. 
For example, when I compared the effect size of the 100 most significant DMPs 
identified in neurons for one compound in a class, to other compounds in that 
class I saw a significant correlation and enrichment of direction of effect. Similarly, 
when I performed the same tests in the microglia I also observed significant 
correlations and enrichments of direction of effect.  Interestingly, when I 
compared the effect size and direction of effect of the top 100 DMPs in one 
treatment in the neuronal samples to the same treatment in the microglial 
samples there was no correlation or enrichment for a direction of effect. This 





One caveat of this study is that it was underpowered, and therefore it was not 
possible to find any methylation changes that reached genome-wide (Bonferroni) 
significance. As power is linked to the number of replicates, in the future the 
replicate number would need to be increased in order to detect DMPs and DMRs 
that are Bonferroni significant. It may also be possible to see more significant 
changes if the treatments were delivered for longer than 24-hours. As previously 
mentioned drugs used to treat chronic diseases are seldom given as a one off 
and so it would be valuable to assess the long term effects these drugs would 
have on DNA methylation. 
 
Another potential pitfall in this study is that the neurons and microglia were 
generated from different cell lines. As a result of this, the different cell types will 
have different genetic backgrounds and this could affect the way the treatments 
alter the DNA methylome. In the future it will be of interest to repeat these 
experiments using neurons and microglia generated from the same iPSC line to 
eliminate the different genotypes as a confounder. Similarly, it will be of interest 
to explore this in multiple iPSC lines to ensure any findings are consistent across 
different genetic backgrounds.  
 
Finally, in the future it would be interesting to assess other epigenetic markers 
other than DNA methylation. As a lot of the targets of the drugs are known to 
interact with histone-related proteins it, looking at histone modifications and 
chromatin accessibility would provide more information on the epigenetic 
consequences of these modulators. Alongside this looking at the corresponding 
gene expression changes within the cells would allow us to determine whether 




pulled out by the transcriptomic data. Being able to take a multi-omics approach 
would also mean we could determine whether the methylation changes are 
causing gene expression changes therefore further disentangling the cellular 
effects of the modulators.   
 
6.2.3 Chapter 5: DNA Methylomic Variation Induced by LPS Challenge in a 
Human Microglial Cell Line 
The aim of study was to determine DNA methylation changes that occur when 
microglial cells are exposed to known immune stimulants such as LPS and the 
cellular consequences that these changes have. This was achieved by treating 
immortalised human primary microglia for 24 hours with LPS, 24 hours with LPS 
followed by a 24 hour recovery period or no treatment (i.e. control), the genome 
wide DNA methylation changes were then profiled using the Illumina EPIC array. 
 
One of the first results of this study demonstrated that neither treatment nor 
treatment and recovery from LPS stimulation affects the epigenetic or mitotic age 
of the microglial cells. As previously discussed, there are several reasons this 
could be. Firstly, the immortalisation of the cells is likely to have impacted the 
methylome of the cells and could have therefore made them less susceptible to 
LPS-induced methylation changes. Secondly, the treatment and recovery periods 
may have been too short. As the treatment and recovery periods were both only 
24 hours it is possible that this was not a long enough time for significant changes 
to manifest. To improve this study in the future it would be interesting to assess 





In order to determine the probes that were susceptible to long term changes to 
methylation and the associated functions of these loci I categorised the DMPs 
into four categories based on their methylation changes (i.e. acute or persistent 
hypo- and hypermethylated probes). This approach allowed me to infer the 
cellular pathways and functions that were more susceptible to immune 
stimulation. As there are more probes in both of the acute groups it is clear that 
the majority of DMPs were more susceptible to short term changes that largely 
disappear during the recovery period. This may be due to the short term nature 
of the treatment period, and in the future it would be interesting to see if any of 
these loci become persistently differentially methylated after longer or recurrent 
treatment. Across the four categories there was one type of gene that was more 
consistently differentially methylated, these were transcriptional regulators. In fact 
half of the DMPs in the persistent hypomethylation category were transcription 
factors or transcriptional regulators. As decreased methylation is generally 
associated with increased transcription it would suggest that there is increased 
expression of transcriptional regulators upon LPS stimulation. However, as the 
relationship between DNA methylation and gene expression is context dependent 
it would also be interesting to study the mRNA changes associated with LPS 
treatment to see if the expression of these regulators is in fact decreasing.  
 
As there weren’t enough loci in each individual category to perform pathway 
analysis separately the four categories of DMPs were pooled to get a general 
view of the pathways potentially impacted by LPS treatment irrespective of the 
direction or duration of the change. These analyses demonstrated that DNA 
methylation changes are particularly observed in genes involved in extracellular 




these pathways are changing functional experiments are required. One limitation 
of analysing the data in this way is the small number of DMPs put into the pathway 
analysis. Ideally >1,000 DMPs would be used for each category and each 
category would have been run separately. However, in the current study I did not 
use this approach as taking the top 1,000 DMPs for each group would have 
introduced a lot of false negatives, which could have made the data more difficult 
to interpret. 
 
One of the largest limitations of this study is the small number of replicates used. 
The low sample number in conjunction with the short treatment time are likely the 
reasons it wasn’t possible to detect any Bonferroni significant loci. This lack of 
power means that further replication of the results in the future is necessary. In 
addition to this adding more replicates to this study should also counteract some 
of the large variation seen in some of the results. For instance the variation seen 
in the LPS + recovery group suggests that some of the replicates are recovering 
from treatment faster than others and could be the reason I identified fewer 
persistently differentially methylated loci. By adding more replicates into the study 
I would be able to reduce this variation and determine whether there is a genuine 
difference in the recovery rates of samples. 
 
Finally looking to the future I think it will not only be important to increase the 
treatment length or use recurrent treatments to assess LPS-induced methylation 
changes. However, one issue with recurrent exposure to LPS is cells can become 
tolerant to the treatment [419-421], so in addition to LPS, it would also be 
interesting to look at the methylation changes occurring upon Lipoteichoic acid 




relevant cellular model and profile the changes more comprehensively. This 
could include the use of iPSC-derived microglial lines containing different relevant 
mutations, such as TREM2, CLU or CD33. Using these non-immortalised human 
lines it would then be possible to see if there is any overlap with human post 
mortem data, perhaps in people who were known to have an infection at time of 
death. In addition, I believe it would also be of interest to profile the DNA 
methylation changes observed in iPSC-microglia upon stimulation with 






















6.3 General Discussion, Limitations and Future Perspectives 
 
6.3.1 Biological Implications of the Key Findings 
Through each chapter of this thesis I have demonstrated that there are 
methylomic changes occurring in neuronal and microglial cell lines that have been 
exposed to AD-relevant exposures such as time in culture, drug treatment and 
immune stimulation. As DNA methylation is known to regulate gene expression 
[99, 422-424] and there are many loci at which the methylation levels are 
changing it is likely that each of these exposures are causing changes gene 
expression changes at numerous loci therefore potentially impacting certain 
cellular pathways.  
 
One of the most consistent changes seen throughout this thesis is changes to 
methylation at loci associated with transcriptional regulation. In chapter 3, 72% of 
the loci within the gene-gene interaction network were known transcriptional 
regulators and ten of the MFs identified through pathway analysis using the loci 
becoming progressively hypermethylated with time were related to transcription 
regulatory region DNA binding. Similarly, in chapter 5 half of the loci in the 
persistent hypomethylation category were found to be involved in transcriptional 
regulation through manual curation. As hypomethylation is generally associated 
with increases in gene expression it would suggest that LPS treatment is causing 
an increase in the expression of these regulators. Due to the nature of the 
treatments in these chapters, i.e. differentiation (chapter 3) and immune 
challenge (chapter 5) it is not surprising that transcriptional regulation is affected. 
Expression changes to some of the loci identified in these chapters have 




order to assess the true biological impact the exposures are having more 
experiments will need to be performed, these could include quantitative 
polymerase chain reaction (qPCR) to look at gene expression changes and 
assays to look at changes to cellular function. 
 
Another broad category of proteins affected consistently throughout this thesis is 
that of signalling proteins. In chapter 3 six of the BPs identified through pathway 
analysis using the loci becoming progressively hypermethylated with time were 
related to cell-surface receptor signalling. Alongside this two of the compound 
classes in microglia were shown to affect the methylation of loci known to be 
involved in cell signalling pathways; these include the BRD inhibitors which 
affected loci associated with protein tyrosine kinase activity and the KMR 
inhibitors which affected loci associated with phosphatidylinositol 3-kinase 
signalling. Finally, LPS treatment in chapter 5 was associated with changes to 
methylation at loci involved in protein tyrosine kinase A signalling and 
serine/threonine kinases. These data taken together suggest that AD relevant 
exposures are associated with changes in cellular signalling, which has been 
previously demonstrated using different methods [430-433]. However, although 
associated it is important to note that without undertaking specific functional 
assays the changes to these signalling pathways is not certain in these conditions 
in these cell lines.  
 
Finally, although there is commonality in regards to the types of loci undergoing 
methylation changes as the work has been undertaken in cell lines grown in 2D 
culture these results likely only reflect a small proportion of the changes occurring 




disease it would be interesting to compare them to post-mortem human brain 
data or data generated from organoid co-culture models.  
 
6.3.2 Limitations 
As outlined above there are numerous limitations associated with the chapters of 
this thesis and with studying epigenetic changes. In this section I will outline the 
limitations that are common to most chapters and what could be done in the future 
to address these limitations.  
 
6.3.2.1 Low Sample Number 
One consistent limitation throughout this thesis and is often a common problem 
for cell culture based studies, is that of the low number of samples. Whilst it is 
possible to use a lower number of replicates for in vitro studies as it is possible to 
eliminate confounders such as sex, medication, or age that are common caveats 
in studies using human samples, having a low sample number does often mean 
that statistical significance, particularly in -omics based studies are not often 
reached. This is due to the relationship between p-value, sample size and the 
power to detect changes in methylation [434-436]. By increasing the sample size 
in further studies it will be possible to more accurately determine whether there 
are type I or II errors being introduced into the results therefore possibly leading 
to misinterpretation of findings. It will also possible to use the data in the chapters 
of this thesis to undertake power calculations in order to determine the ideal 
samples sizes moving forward. Power calculations were not performed before 
undertaking the experiments presented in this thesis as they represent the first 
DNA methylomic studies in this context and so no preliminary data was available 




on direction of effect and the correlation of effect size in some cases, in addition 
to a more relaxed arbitrary significance threshold chosen. It has previously been 
demonstrated that due to the high degree of correlation between the probes on 
the Illumina EPIC array the Bonferroni significance threshold is likely too stringent 
and therefore likely to introduce type II errors. Owing to this it was deemed 
acceptable to use more relaxed thresholds in my studies, but to note that further 
replication of results is required before solid conclusions can be drawn. 
 
6.3.2.2 Use of Different Cell Lines 
It is critical to note that there is a different cell line used in each of the chapters of 
this thesis. Whilst this was not originally planned due to issues with building 
management and power failures I have had to rely upon collaborators to provide 
iPSC-derived cells to use in each chapter. The first issue to occur was due to lack 
of communication between the technical staff in the Hatherly laboratories. As a 
result of the mis-communication the liquid nitrogen tanks storing the vast majority 
of the neuronal lines I had developed, evaporated and meant all of the cell stored 
in the tank were destroyed. Following this loss it took numerous months to get 
stocks of the various lines from collaborators and to regenerate the iPSC-derived 
neurons. Owing to the lack of redundancy in the liquid nitrogen facilities at the 
Hatherly laboratories whilst cell lines were being re-acquired I decided to move 
my tissue culture work to the RILD building, as that is where our research group 
is primarily based. Unfortunately, a year later within the RILD building there was 
a power failure overnight and the backup generators failed. This power outage 
affected the tissue culture facilities and resulted in the incubators cooling down 
to ~12oC. Whilst the cells were still alive the next morning I decided the cells could 




likely have affected the methylome of the cells. As a result of this second system 
failure I lost iPSC-derived neurons which had been maturing in culture for 
approximately six months and cell lines of different genetic background. A further 
four months of work was lost later that year whilst I was away at a conference 
and my cells were being looked after by someone else. Unfortunately all of these 
issues were beyond my control, and has meant that we have used different lines 
for different chapters, with substantially less replicates than originally planned. 
However, ideally all of the experiments in this thesis would have been undertaken 
in cells of the same genetic background with substantially more replicates.  
 
6.3.2.3 Caveats of EWAS Studies and Profiling Cytosine Modifications 
The Illlumina platform has become one of the most popular ways to interrogate 
DNA methylation across the genome and has been used extensively to study 
methylomic variation within AD [120, 121, 437]. However, despite its extensive 
use there are limitations which should be taken into account. Firstly, standard BS 
conversion does not allow you to distinguish between DNA methylation and 
another cytosine modifications (DNA hydroxymethylation). As a result of this, the 
results from the array are a combination of both these cytosine modifications 
rather than just 5-mC. As 5-hmC is a DNA modification that in particular has been 
shown to be elevated in the brain and during development [438, 439]  and the 
majority of cells used in this thesis are iPSC-derived neurons, which I have shown 
to be epigenetically foetal or immature then it would be of interest to profile this 
modification in isolation in the future.  It is now possible to simultaneously profile 
5-hmC and 5-mC, by adding an oxidation step prior to bisulfite treatment, which 
converts 5-hmC to 5-fC. Following BS treatment the 5-fC is converted to a uracil 




protected from the conversion and therefore will remain as cytosine. 
Subsequently, running oxidative-BS samples on the array generates a measure 
of 5-mC in isolation, and by running a matched BS sample in parallel you can 
subtract the oxidative-BS signal from the BS signal generating a 5-hmC value for 
each locus. In order to determine whether the methylation changes detected 
(particularly in chapters 4 and 5) are indeed changes to DNA methylation rather 
than hydroxymethylation it would be of interest in the future to also run oxidative 
BS converted DNA on the EPIC array to disentangle the relationship between 
cellular maturity, drug treatment and hydroxymethylation changes. 
 
6.3.2.4 Determination of Age 
Looking to the future, I think it will be important to further explore the epigenetic 
age of the iPSC-derived neurons and microglia used in this thesis. The 
methodology used to generate the epigenetic or biological age of the samples 
used in this thesis was the most up to date version of Horvath’s epigenetic age 
calculator [126]. However, it is worth noting that the algorithm used to calculate 
epigenetic age was not trained on foetal data. As the DNA methylation profile is 
dynamic throughout brain development [440], the epigenetic ages presented in 
each chapter should not be interpreted as a robust read out of age. The 
interpretation of this should be that despite not being trained on foetal or infant 
data the epigenetic ages of the sample in this thesis are still predicted to be foetal. 
In the future it will be of interest to explore other epigenetic age calculators and 
to culture cells for a long period of time to investigate whether this impacts their 
epigenetic age. It will also be of interest to examine the epigenetic age of iNs 
under the different treatments outlined in each chapter, as iNs have been shown 





In order to combat this other metrics of cellular maturity or ways of measuring the 
biological age of iPSC-derived cells should be considered in the future in addition 
to epigenetic age. One way in which this could be achieved in through the use of 
RNA-sequencing and measuring the expression of genes known to increase or 
decrease throughout development. This could include the measuring the 
expression level of pluripotency genes such as NANOG, mature neuronal 
markers such as β-III-Tubulin or subtype specific markers such as choline 
acetyltransferase to determine the type of neuron being generated. As 
telomerase is known to be active in iPSCs [442, 443] determining the telomere 
length of the resultant iPSC-derived neurons and relating it healthy human post 





















Overall the data outlined in this thesis has provided evidence that it is possible to 
generate iPSC-derived neurons and that there are epigenetic changes occurring 
in neuronal and microglial cell models that are exposed to AD-relevant exposures 
such as time in culture, drug treatment and immune challenge. However, despite 
this there are still several questions which remain unanswered. These include: 
1. What is the best way to mature iPSC-derived cells in culture and the best 
way of measuring cellular age? 
2. Whether longer treatment with the epigenetic modulators used in chapter 
4 could alter epigenetic age or be used to reverse the epigenetic changes 
seen in disease. 
3. Whether recurrent exposure to LPS or other relevant pathological proteins 
will have a more profound effect on resulting cells.  
Looking to the future using multi-omics approaches and different conditions 
throughout neuronal differentiation and maturation will offer the best tools in 
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Alzheimer’s disease
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder and accounts for approximately 60–80%
of all dementia cases worldwide [1]. Dementia is estimated to affect 46.8 million people worldwide, with this set
to double every 20 years reaching 131.5 million in 2050 [2]. The disease is characterized by the accumulation of
amyloid beta (Aβ) plaques, intracellular neurofibrillary tangles of hyperphosphorylated tau [3] and loss of synaptic
connections [4]; taken together these lead to neuronal cell death. This is accompanied by cognitive and behavioral
changes, such as memory impairments, language disturbance and hallucinations. The early cognitive decline in AD
can be attributed to the degeneration of cholinergic neuronal cells found in the cortical and limbic brain regions
such as the hippocampus [5] and the basal forebrain [6].
The deposition of senile plaques and tangles does not occur at random, but follows a distinct and characteristic
pattern [7–10], starting in the neocortex and then the hippocampus [11], while other regions, such as the cerebellum,
remain relatively unaffected [12]. This specific topographical distribution correlates with, and explains, the character-
istic symptoms of AD; the hippocampus and neocortex are well known for being involved in controlling emotions,
memory and higher brain function [13,14]. The cerebellum on the other hand is responsible for coordination, motor
and voluntary movements, and there are far fewer aberrations in these in AD patients when compared with the
prevalence of other symptoms [15]. There is already considerable pathology before the disease is diagnosed [16], with
the onset of symptoms sometimes occurring at least 10 years after Aβ is first deposited [17]. This apparent delay in
the appearance of symptoms is caused by there being a threshold of cholinergic loss before the brain can no longer
compensate and ameliorate the deficit [11]. Although, much progress has been made in understanding the cellular
pathology of AD, the treatments currently available only temporarily alleviate some symptoms and do not modify
the underlying pathology.
Genetic variation associated with AD
Given, the high heritability estimates (∼60–80%) for AD based on quantitative genetic studies [18], initial etiological
studies have focused on identifying a genetic basis for disease. Although some AD cases are caused by autosomal
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Table 1. Summary table of single nucleotide polymorphisms (SNPs) associated with Alzheimer’s disease (AD), which reach
genome-wide significance in Lambert et al. (2013).
SNP Chr: position Closest gene Odds ratio
rs6656401 1:207692049 CR1 1.18
rs6733839 2:127892810 BIN1 1.22
rs10948363 6:47487762 CD2AP 1.10
rs11771145 7:143110762 EPHA1 0.90
rs9331896 8:27467686 CLU 0.86
rs983392 11:59923508 MS4A6A 0.90
rs10792832 11:85867875 PICALM 0.87
rs4147929 19:1063443 ABCA7 1.15
rs3865444 19:51727962 CD33 0.94
rs9271192 6:32578530 HLA-DRB5– HLA-DRB1 1.11
rs28834970 8:27195121 PTK2B 1.10
rs11218343 11:121435587 SORL1 0.77
rs10498633 14:92926952 SLC24A4 RIN3 0.91
rs8093731 18:29088958 DSG2 0.73
rs35349669 2:234068476 INPP5D 1.08
rs190982 5:88223420 MEF2C 0.93
rs2718058 7:37841534 NME8 0.93
rs1476679 7:100004446 ZCWPW1 0.91
rs10838725 11:47557871 CELF1 1.08
rs17125944 14:53400629 FERMT2 1.14
rs7274581 20:55018260 CASS4 0.88
Chr: Chromosome.
Data taken with permission from [25].
dominant mutations in three genes (APP, PSEN1, PSEN2), these account for less than 5% of AD prevalence and
are early-onset, occurring before the age of 65 years. Most AD cases are late-onset (>65 years) and sporadic, with
no defined etiology. However in recent years, large cohort collections and the relatively inexpensive cost of assessing
genetic variation through genome-wide association studies (GWAS) has allowed the identification of common
variants associated with risk of developing AD. These studies have demonstrated that late-onset Alzheimer’s disease
(LOAD) is thought to be multifactorial with many different genes and single nucleotide polymorphisms (SNPs)
being implicated in, and contributing to, disease onset and progression [18]. The most robustly associated gene
with LOAD is APOE, which encodes a polymorphic glycoprotein that is involved in the transport of cholesterol
and other lipids [19] alongside neuronal growth [20] and tissue repair [21]. There are three isoforms of APOE: ε2,
ε3 and ε4, which can be distinguished by cysteine to arginine substitutions at the amino acid positions 112 and
158 [22]. The ε4 variant confers increased risk of developing LOAD, with each additional copy of the risk allele
lowering the mean age of onset [23]. While APOE ε4 accounts for approximately 20% of genetic risk for developing
LOAD it cannot explain all of disease incidence, as not everyone who is homozygous for ε4 actually develops
AD [24]. Aside from APOE there are numerous other risk loci SNPs that have been implicated in AD. The most
recent meta-analysis of nearly 75,000 individuals nominated 19 common genetic variants, of which 11 were novel
disease loci [25] (Table 1). Interestingly, many of the GWAS loci that have been nominated for AD can be linked
to amyloid processing or inflammation. While risk variants that have been identified from GWAS only confer a
relatively modest effect size, with odds ratios between 0.73 and 1.22 per loci investigated [26], it is thought that
these could act cumulatively to cause the onset of degeneration. Scientists have generated polygenic risk scores
(PRS) for AD, which combine the effects of many disease-associated SNPs to predict disease risk [27] and recently
it has been reported that the PRS prediction captures nearly all common genetic risk for AD [28]. However, another
study has demonstrated that collectively common SNPs for AD only account for a third of phenotypic variance in
AD [29]. Recent efforts to explain the missing heritability of AD have used sequencing approaches to identify rare
variants, with a larger effect size, with SNPs in PLD3, TREM2, TM2D3 and PICALM being nominated in recent
years [30–34].
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Despite the fact that GWAS and sequencing efforts have been successful in identifying novel genes involved in
AD, the majority of SNPs lie outside of coding regions of the genome. These variants are thus unlikely to have
direct structural or functional effects on their gene’s protein product, and are more likely to affect gene regulation
at other loci. By integrating genetic variation with transcriptomic measurements in the same samples, for example
from microarray or RNA sequencing experiments, it is possible to correlate disease associated genetic variants with
changes in gene expression to identify expression quantitative trait loci (eQTLs). Such disease-associated eQTLs
can occur both within the same gene (in cis) or distally within another gene (in trans). Recent research indicates that
SNPs may change expression by initially altering the binding ability of one ‘pioneering’ transcription factor (TF),
which then recruits other TFs. This was shown to occur at a CTCF motif, which if disrupted affects the binding of
five different TFs [35]. However, if there are two or more variants in perfect linkage disequilibrium (LD) with one
another, the nonrandom association of loci at different genomic locations, then it is not possible to distinguish which
variant is acting as the eQTL. To further complicate matters, many eQTLs act in a cell-type-specific manner [36].
This is particularly relevant when studying heterogeneous tissues such as the brain or blood, or in a disease such as
AD, where cellular abundance is known to be altered [37,38]. In the context of AD, one recent study demonstrated
enrichment for monocyte-specific eQTLs at disease-associated loci, suggesting a role of the innate immune system
in AD pathology [39]. In support of this, Karch et al., tested whether GWAS LOAD SNPs act as cis-eQTLs for
LOAD GWAS genes [40]. They were able to show the AD SNP rs1476679 in ZCWPW1, was significantly associated
with the expression of PILRB and GATS in most brain regions, including the hippocampus. Interestingly, PILRB
acts as a binding partner for TYROBP, both of which can be found on microglia [41]. The expression of TYROBP
is restricted to cells of the immune system such as microglia, and has been shown to be upregulated in the brains of
patients with LOAD. In a recent gene-regulatory network analysis TYROBP was shown to be a key causal regulator
of a microglial/immune module highlighted as the module most associated with pathophysiology of LOAD. This
microglia/immune module was also shown to contain a number of AD GWAS risk loci, such as CD33, MS4A4A
and MS4A6A [39]. Furthermore, TREM2, which has been recently nominated from sequencing studies, is known
to interact and signal through TRYOBP [39]. Taken together many network level analyses have highlighted a role
for microglia and neuroinflammation in AD risk [39,40,42,43].
A role for epigenomic dysfunction in AD?
Recently, increased understanding about the functional complexity of the genome has led to growing recognition
about the likely role of nonsequence-based ‘epigenetic’ variation in AD [44]. Epigenetic processes mediate the
reversible regulation of gene expression, occurring independently of DNA sequence, acting principally through
chemical modifications to DNA and nucleosomal histone proteins (Figure 1). The most widely studied epigenetic
modification in human studies is that of DNA methylation, given it is the most stable and longest lasting change.
In general, in vitro studies have suggested that there is a trend toward global DNA hypomethylation in AD. For
example, one study demonstrated global hypomethylation in a glioblastoma cell line with the APPSWE mutation,
which occurs in familial AD [45]. Likewise, it was shown that there are lower DNA methylation levels in brain
microvascular endothelial cells that were exposed to high levels of synthetic Aβ1–40 [46]. However, in contrast to this
a more recent study using neuroblastoma cells exposed to synthetic Aβ1–40 showed no significant change in DNA
methylation levels [47]. In the context of human postmortem brain samples there are also some conflicting results;
contrasting studies have shown decreased levels of global DNA methylation in AD-associated brain regions such as
the entorhinal cortex [48] and hippocampus [49], while others report no change [50,51] or even increased levels in the
frontal cortex [52] and hippocampus [53].
In recent years, advances in genomic technology have allowed the first genome-scale studies of DNA methylation
in AD [54,55]. To date, all published studies have utilized the Illumina Infinium 450 K Methylation Beadarray
(450 K array) to examine DNA methylation changes at >485,000 loci in postmortem brain samples. Although,
these epigenome-wide association studies (EWAS) have been performed on independent sample cohorts, in a
range of anatomically distinct cortical brain regions, a number of consistently differentially methylated genes have
been identified [56]. Most notably one such gene to be robustly hypermethylated in AD cortex is ANK1 [54,55].
Interestingly, disease-associated ANK1 hypermethylation has been observed in a tissue-specific manner, with brain
regions affected by AD pathology (entorhinal cortex, superior temporal gyrus and prefrontal cortex) showing
significant hypermethylation, while the cerebellum, a region largely unaffected by pathology, and premortem blood
show no disease-associated changes. The majority of genes identified by EWAS are distinct from those nominated
in GWAS with the exception of BIN1. However, despite different genes being identified with the two approaches
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Figure 1. Diagram to illustrate the different epigenetic mechanisms that have been identified. (A) Regulation of
chromatic structure through post-translational modifications to histone proteins. This can include: acetylation,
methylation, SUMOylation, ubiquitylation, citrullination and ADP-ribosylation. (B) Addition of chemical tags to DNA
to the 5’ end of a cytosine nucleotide. This creates 5mC – the most commonly studied epigenetic mark, 5hmC, 5caC
and 5fC. (C) Small RNA molecules, such as microRNA can also affect gene expression either through degrading mRNA
or altering protein translation.
5caC: 5-carboxylcytosine; 5fC: 5-formylcytosine; 5hmC: 5-hydroxymethycytosine; 5mC: 5-methylcytosine.
many of these do reside in common pathways [57]. Since the publication of the initial EWAS analyses, there
have been additional studies identifying additional differentially methylated genes in AD, including CRTC1 [58],
APOE [59] and TREM2 [60].
To date, the majority of AD EWAS have focussed on DNA methylation, with histone modifications considerably
less well studied. However, one study has shown that the histone deacetylase (HDAC) inhibitor, sodium butyrate,
can improve cognitive function, synaptic density and plasticity in mouse models with inducible overexpression
of p25 protein [61]. P25 has been shown to be linked to numerous features of AD such as amyloid and tau
pathology alongside memory loss and neurodegeneration [62–64]. Similarly, another study has shown improved
memory function in transgenic APPPS1–21 mice after treatment with sodium butyrate [65]. Furthermore, memory
improvements were seen even when it was administered at the latest stages of amyloid pathology and were associated
with increased expression of genes implicated in associative learning. Other studies have also shown HDACs to
have therapeutic utility, such as Depakote [66], phenylbutryic acid [67] and trichostatin A [68]. While these studies
are encouraging and show the potential utility of HDACs as therapeutic agents there are, however, a couple of
considerations with this approach. First, most models, including the ones we describe, are models of familial AD,
which use small numbers of animals and, as such, results should not be over interpreted. Alongside this, these
studies use pan-HDAC inhibitors, which are all known to affect multiple HDACs. While, it is useful to know
that there may be some involvement of histone modifications or HDACs in AD initiation or progression, these
studies do not highlight specifically which ones are implicated. In order to address this, a number of groups
have crossed APPPS1–21 mice with those lacking certain HDACs. APPPS1–21 mice that lack HDAC5 show
exaggerated memory impairment [69], while those lacking HDAC6 have improved memory, but this is achieved
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without changing amyloid deposition [70]. Another HDAC that could have potential as a therapeutic target is
HDAC2, as mice with reduced HDAC2 show increased memory and synaptic plasticity [71]. Therefore, it appears
that only specific HDACs show promise as potential drug targets. When using certain HDACs it is important
to be aware that they can also affect DNA methylation. For instance, it has been shown that Depakote can cause
extensive DNA methylation changes including demethylation changes at specific genes such as MMP2, MAGEB2
and WIF1, which have been implicated in tumor growth and metastasis [72]. This study supports the concept that
various epigenetic marks are in a dynamic relationship with one another and that you cannot necessarily target
one without affecting another. Finally, as with any potential drug that is tested on model systems, such as mice,
it is important to remember that these rarely translate effectively into humans. One good example of this comes
from studies which demonstrated the utility of anti-amyloid antibodies [73]. In these APP-transgenic mice, just one
injection of m266, an anti-APP mouse antibody, was able to reverse cognitive deficits without reducing amyloid
plaque burden [73]. However, when taken to Phase III clinical trials, the human antibody, Solanezumab, did not
reduce cognitive decline in those with mild dementia due to AD [74].
Induced pluripotent stem cells: new models for late-onset Alzheimer’s disease?
To fully understand and elucidate the mechanisms of disease etiology, extensive modeling must take place. Tra-
ditionally, this has been achieved by a number of methods, including both animal (murine) models and primary
patient cell lines. While both of these approaches have their own merits, they can prove inconvenient and do not
completely and accurately reflect human disease. At present, the AD research field has had a heavy focus on disease
modeling through the use of transgenic mouse models [75], as there is a well-developed understanding of genetic
manipulation techniques in this organism. Furthermore, mice are more phylo-genetically related to humans than
other simpler model organisms such as Drosophila melanogaster and Caenorhabditis elegans, although these do allow
for more experimental control than mice. Due to the close relation of mice and humans they also have good utility
for studying familial AD, through the use of transgenic mice containing mutations in the APP and PSEN genes.
This has led to advances in our understanding of multiple aspects of AD, in particular amyloid pathology and the
differential effects of the various Aβ peptides. However, despite the extensive use of these transgenic models to study
AD, they do not accurately recapitulate AD, as the mice do not display overt neurodegeneration [76–78] or have
amyloid plaques [79]. While proven useful for modeling autosomal disease, such as familial AD, the mouse models
do not have extensive utility for studying sporadic AD, which has both polygenic and environmental components.
Even if it was possible to model the genetics of sporadic AD in transgenic mice the effect sizes of each associated
variant would be small and therefore difficult to determine phenotypic outcome. However, there have been murine
studies that have targeted replacement of the endogenous murine Apoe gene with human APOE-ε4. These mice
demonstrated reduced spatial learning and a reduction in dendritic spine density in the medial entorhinal cor-
tex [80]. In another study, where APOE (both ε3/ε3 and ε4/ε4) mice were crossed with mice containing a mutant
human form of APP, the APOE-ε4xAPP mice displayed significantly worse spatial memory performance than their
APOE-ε3xAPP counterparts, but this was also associated with insulin dysfunction [81].
A more promising avenue for modeling SNPs in complex diseases, such as sporadic AD, is through the use
of stem cell technology. Embryonic stem cells (ESCs), which are derived from the inner cell mass of an embryo
(blastocyst), have the ability to differentiate into any cell in the body [82]. Due to their inherent plasticity, and
as genomic variation can be assessed relatively inexpensively through PCR, microarray, or sequencing technology,
there is the potential that they could be used to study the effect of disease-associated SNPs on the functionality
of specific cell types. However, while being useful, the ethical issues implicated with using embryo-derived ESCs
are numerous. Recent advances in stem cell technology have allowed the production of stem cells derived from
adult tissue, such as blood, urine and keratinocytes [83]. These induced pluripotent stem cells (iPSCs) have almost
identical characteristics to ESCs: they share the same morphology, can differentiate into any cell type in the body,
have unlimited growth and have the same expression pattern of genes [84]; potentially making them a very powerful
tool in research.
There are, however, a number of caveats when utilizing iPSCs to model complex diseases that must be considered.
Associated with inducing pluripotency are the global cellular epigenetic changes that allow the cells to alter gene
expression in order for them to be functionally identical to ESCs. Despite, being functionally identical, several
groups report that iPSCs have different DNA methylation profiles and gene expression patterns to ESCs [85–88].
Some groups attribute this variation due to an ‘epigenetic memory’ where iPSCs show residual DNA methylation
patterns that are typical of the tissue they originate from [89]. These differentially methylated regions (DMRs) were
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shown to affect the differentiation potential of the newly formed iPSCs. For example, iPSCs derived from neural and
fibroblast progenitors maintained DNA methylation marks at sites associated with hematopoietic lineages, which
decreased the potential for these iPSCs to form blood cells. Subsequently, it is possible to reverse these restricting
methyl marks by increasing the cells passage number or treatment with chromatin modifying compounds [89]. This
treatment is associated with a decrease in DNA methylation at hematopoietic loci and therefore an increase in blood
cell fate potential. Therefore, although it would appear that this epigenetic memory can affect the differentiation
potential of cells initially, this effect is actually only transient. It has also been observed that certain subsets of
cells can become stuck in a partially reprogrammed state. This is due to inefficient DNA demethylation at certain
sites or the incomplete repression of TFs [90]. Despite this, these aberrations can be rectified using RNA inhibition
of TFs or treatment with DNA methylase inhibitors. Another potential source of epigenetic variation between
ESCs and iPSCs is the microenvironment in which the iPSCs have been generated. Cooper and Newman have
demonstrated that there is some correlation between cells’ gene expression patterns and the laboratory the cell
lines are derived from [91,92]. This demonstrates that the environment can affect the epigenome and therefore,
downstream gene expression of cell lines. To fully assess the differences in the epigenomes between iPSCs and
ESCs, Lister et al., utilized a shotgun bisulphite sequencing technique (MethylC-seq) to look at the whole-genome
DNA methylome at single base-pair resolution [93]. This demonstrated that, overall, ESCs and iPSCs are similar,
but that there are some inherent differences between their DNA methylomes. The reprogramming of somatic cells
generated hundreds of DMRs that could be attributed to both memory from the somatic cell and iPSC specific
DNA methylation patterns that are susceptible during the reprogramming process as many DMRs were consistent
across independent iPSC lines [86]. All of these studies demonstrate that there are fundamental differences in both
the epigenome and gene expression patterns of ESCs and iPSCs. However, there are ways to rectify some of these
differences meaning that iPSCs still have utility as disease models, although the differences must be taken into
account when interpreting results.
Since, the introduction of iPSC technology there have been increasingly more studies utilizing iPSCs for
disease modeling and small molecule testing as, theoretically, iPSCs are an exact genetic match of the patient
they are derived from. To accurately model AD using iPSCs, the generation of specific neuronal populations are
usually necessary, particularly iPSC derived cortical and cholinergic neurons. Generating these requires certain
factors, including SB431542 and LDN-193189 [94], which act as inhibitors of TGF-βI and BMP type I receptors
respectively. This inhibition prevents SMAD phosphorylation, suppressing cellular renewal and promoting cortical
differentiation [95,96]. A good iPSC model of AD would not only be the correct cell type of interest, but also
show the neuropathological features and characteristics of the disease. There have been several studies that have
reported that iPSCs show certain disease features [97–100]. More specifically, in AD iPSCs have also been used to
show Aβ-induced synaptotoxicity [101]. In this study, Nieweg et al. demonstrated not only that Aβ altered AMPA
receptors postsynaptically and impaired axonal vesicle clustering, but also increased the phosphorylation status
of tau, another key characteristic hallmark of AD. Alongside aberrations in tau phosphorylation, degeneration of
cortical neurons is also a very prominent clinical feature of AD, and it is believed that this causes the onset of
symptoms. Therefore, to truly understand AD as a disease, being able to recapitulate this neuronal cell death is
vital. One recent study has shown that iPSC-derived basal forebrain cholinergic neurons heterozygous for APOE
(ε3/ε4) are more susceptible to glutamate-mediated cell death, while also showing an increased Aβ42/Aβ40 ratio
when compared with basal forebrain cholinergic neurons generated from healthy age matched control patients [102].
One of the major utilities for using iPSCs to study AD is the ability to examine the effects of genetic variants with a
relatively small effect size on phenotype. One study that took advantage of this has demonstrated that iPSC-derived
neurons carrying genetic variants in SORL1, which increase LOAD risk, have reduced response to BDNF treatment.
This not only manifests at the level of SORL1 expression but also impacts APP processing [103]. Furthermore,
given that AD has a polygenic component; it is also possible to assess the effect of different combinations of
disease-associated SNPs. As it is possible to use iPSCs to generate patient specific neuronal cells, there is the
potential to generate libraries of cells with varying combinations of LOAD-associated SNPs and therefore, different
susceptibilities to disease. Interestingly, two studies have demonstrated this variability in susceptibility using LOAD
iPSC-derived neurons [104,105]. In the first, undertaken by Israel et al., they found that neurons from one patient, but
not from another, showed AD-associated phenotypes. This included altered levels of secreted Aβ1–40, higher aGSK3
levels and had significantly increased p-tau/total tau [104]. The second study, conducted by Kondo et al., showed
differential intracellular Aβ oligomer accumulation, inducing endoplasmic reticulum and oxidative stress [105].
Taken together these studies show how different genetic backgrounds can alter disease initiation and progression as
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well as the complex genetic interplay there is in LOAD. However, being able to investigate the effects of different
PRS on living and developing neuronal populations will provide more valuable insight into the role genetic variants
play in terms of physiological/cellular aberrations and disease progression in LOAD. Importantly, data that is
generated through the usage of iPSCs can therefore be compared and contrasted with data collected from molecular
studies in human postmortem tissue to potentially elucidate the disease-specific effects.
Using genetic editing to elucidate the functional consequence of disease-associated variation
Using iPSCs and recent advances in epigenetic editing technology, it is becoming possible to start teasing apart the
underlying mechanisms that may be driving AD pathogenesis. Clustered regularly interspersed short palindromic
repeats (CRISPR) uses RNA-guided Cas9 nucleases to introduce DNA breaks which can be repaired through
homologous recombination, indel mutations or with a vector carrying a desired mutation [106]. CRIPSR can be
used provided that the sequence of interest is unique compared with the rest of the genome and is upstream of
a protospacer adjacent motif (PAM) sequence. The PAM sequence is typically three to five nucleotides long and
serves as a binding region for the Cas9 to bind. Unfortunately, this is a requirement of the method and can be
technically challenging. Despite, the PAM sequences being relatively common throughout the human genome they
can often be in the incorrect location relative to the sequence of interest and can make modifying the gene difficult.
Furthermore, if the target locus has high homology to another region in the genome then there is the potential for
off-target effects resulting in inadvertent mutations [107,108].
The main advantage of the CRISPR-Cas9 system is that you can create isogenic control lines that only show
genetic variation at your disease-specific loci. One recent example of this in the AD field comes from Pires et al.,
who successfully corrected the A79V PSEN1 mutation in a patient AD iPSC cell line [109]. These types of control
lines are extremely beneficial for studying disease-associated genetic variation, as they enable the minimization of
genetic variability as both disease and control lines have the same genetic background. Such isogenic lines have been
recently used to study familial AD [105,110,111]. One study has shown iPSCs harboring the APPSWE and PSEN1
M146V mutations have increased total Aβ production, and up to a three-fold increase in the Aβ42/Aβ40 ratio when
compared with their isogenic controls. These changes have been shown to correlate to neuronal identity, maturity
and mutation load [112].
While, it proves relatively simple to use this technique to study the effects of causative mutations, such as those in
familial AD, other genetic variants like SNPs associated with sporadic AD are more problematic to model. This is
due to the fact that they may only be relevant to diseases such as AD in specific combinations. As an extension to the
CRISPR system, it is possible to alter multiple loci using CRISPR-multiplexing [113]. In this system, multiple guide
RNAs are assembled into the same vector and transfected into the cells allowing the targeting of multiple loci. This
tool will undoubtedly prove incredibly useful for LOAD research as it will allow researchers to modify up to seven
loci. By modifying multiple disease-associated SNPs, one could investigate the effects of various combinations on
cell physiology, protein expression and aggregation. This approach would work very well for the LOAD risk SNPs
BIN1, CLU and PICALM, for example, as these have all been shown to interact with Aβ/tau [114–117]. Therefore, by
altering these specific SNPs one could investigate how tau and Aβ pathology changes over time. Another interesting
point is that this methodology would allow one to investigate the interaction between disease-associated SNPs
with reported relationships, for example PICALM and the APOE ε4 allele. In a previous study of familial AD
patients, a homozygous PICALM genotype (rs3851179) was shown to modulate prefrontal cortex volume and
cognitive impairment in carriers of the APOE ε4 allele [118]. As both proteins are involved in the same Aβ clearance
pathway [119,120], it is thought that alterations in the endocytic functions of PICALM may synergistically affect
APOE ε4. This could mean there is a higher likelihood of Aβ remaining in the brain and therefore increasing plaque
formation.
Establishing causality
An important step for research is to establish whether disease-associated variation is causing disease. This is simpler
to test when examining genetic variation, as we know that the SNP has been present in an individual throughout
their life course, prior to disease onset. However, when investigating the functional effects of disease-associated
epigenetic variation, the relationship is less clear, and it is difficult to determine whether epigenetic changes are a
cause, or a consequence, of the disease process. While previous postmortem brain studies have provided valuable
physiologically relevant information about epigenetic changes occurring at later disease stages it is difficult to
establish if those alterations actually initiated disease, or are secondary to the disease process, therefore making it
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difficult to infer causality. First, because this is crucial for the design of effective drug therapies to combat disease,
and second, because AD neuropathology generally occurs at least 10 years before symptomatic onset, it is important
to understand the root causes to be able to monitor and diagnose the disease in its very earliest stages. iPSCs have
real utility for determining whether associations identified in EWAS analyses could represent a secondary effect of
disease, or could be driving disease progression. Using a modified version of the CRISPR-Cas9 technology it has
become possible to alter DNA methylation at specific loci. By fusing the Cas9 protein with the enzymatic domains
of TET1 or DNMT3A it is possible to remove, or add methyl groups to DNA respectively [121]. This method
builds on previous work [122,123] where Tet1 and Dnmt3a were fused to TALE proteins to achieve the same effect.
By being able to manipulate the epigenetic landscape of cells, particularly at loci associated with disease it will
enable researchers to establish whether disease-associated epigenetic variation is causative. These techniques have
already been utilized in diseases such as cancer [124,125], but to our knowledge have not yet been reported in AD
research. The epigenetic status of genes such as ANK1, which have robust changes in AD, would be an excellent
initial target for this new methodology. It has the potential to reveal whether the DNA methylation changes seen
are truly causative and precede disease initiation, or whether they are a consequence of progression. Even if, it is the
latter and it is found that these alterations do not cause disease, but occur in the earliest stages of the disease, they
could potentially be used as a biomarker for diagnosis prior to symptomatic onset. Alongside this, such changes also
tell us something about the disease process and its progression. Given that recent studies have demonstrated robust
epigenetic alterations in AD, iPSCs could become a valuable tool in which these studies could be taken further.
However, to undertake epigenetic studies in these cells it will be very important to fully understand the epigenetic
landscape of the iPSCs themselves, both throughout differentiation and at maturity.
Current challenges to progress
While it is possible to create disease-relevant cells using iPSCs, as with any model, iPSCs also have their limitations.
A large concern when using iPSC-derived neurons to model disease is that the resulting neurons represent an
immature and fetal population [126–129]. This is of particular concern when studying diseases of aging, such
as LOAD. However, efforts are being made to overcome this particular issue. For example, by expressing a
mutant form of LMNA, which is known to cause premature aging. By expressing progerin in the iPSC-derived
dopaminergic neurons, it was possible to create phenotypes that were resultant of both the induced aging and
genetic susceptibility [130]. The aged Parkinson’s disease neurons had marked dendrite neurodegeneration, reduced
tyrosine-hydroxylase expression and displayed epigenetic markers of aging that were not present in the control
populations. Another study directly reprogrammed fibroblasts into neurons, skipping iPSC pluripotency stages, in
an attempt to overcome iPSC immaturity [131]. As this protocol does not induce pluripotency the inducible neurons
display both age-related epigenetic and transcriptomic signatures, showing age-associated decreases in RanBP17, a
nuclear transport receptor. While these neurons would prove useful for studying diseases of aged cells, such as AD,
it is difficult to make large amounts of primary material as these cells cannot be propagated, unlike the iPSCs.
Future perspective
Since, the pioneering work by Takahashi and Yamanaka in 2006, the use of iPSCs has been able to significantly
advance complex disease research. They have enabled researchers to more accurately recapitulate disease phenotypes
in a cell culture system. While iPSCs are far from being used therapeutically, they have proven useful for investigat-
ing the molecular and genetic underpinnings of LOAD. Once there have been more extensive investigations into
the effects of SNP burden and their molecular targets, iPSCs can be used to test the effectiveness of new therapeutic
interventions. Although, at present iPSC generation and differentiation are costly and time consuming, differentia-
tion protocols are quickening, and the use of an individual’s own iPSCs to select their appropriate treatment would
be a first step toward personalized medicine, potentially improving the patient’s life.
While, it is still unknown whether the global epigenetic changes that occur during iPSC generation affect
the end epitype of cells, there is still promise that these cells could be used to study the epigenetics of complex
diseases. If epigenetic aberrations do prove to be an issue, then these will have to be taken into account during
experimental design and analysis. However, before identified changes can be targeted for therapeutic intervention,
it will be important to determine whether they are causal; with the recent advances in genetic and epigenetic editing
technology this will soon be possible. Finally, while there are many questions that still remain unanswered and
many challenges ahead when addressing these, with the correct model and methodologies these will hopefully be
overcome.
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Executive summary
Alzheimer’s disease! Most prevalent neurodegenerative disorder causing 60–80% of dementia cases worldwide.! Characterized by extracellular depositions of amyloid β-protein and intracellular neurofibrillary tangles of paired
helical filaments of tau.
Genetic variation associated with Alzheimer’s disease! Through the use of genome wide association studies (GWAS) a number of single nucleotide polymorphisms
(SNPs) have been associated with late onset Alzheimer’s disease (AD).! Many GWAS loci implicated in disease have been linked to amyloid processing and inflammation.
A role for epigenomic dysfunction in Alzheimer’s disease?! Recent epigenome wide association studies (EWAS) have identified a number of loci that are differentially
methylated in disease.! The majority of genes identified by EWAS are distinct from those nominated in GWAS with the exception of BIN1.
Induced pluripotent stem cells: new models for late-onset Alzheimer’s disease?! Through somatic cell reprogramming, it is possible to generate induced pluripotent stem cell (iPSC) derived
neuronal cells.! These iPSC-derived neuronal cells have been shown to reflect some disease features.! iPSC-derived neuronal cells can be used to assess the effect of polygenic risk on physiological/cellular changes
and disease progression.
Using genetic editing to elucidate the functional consequence of disease-associated variation! Clustered regularly interspersed short palindromic repeats (CRISPR) uses RNA guided Cas9 nucleases to introduce
modifications in the genome.! CRISPR-multiplexing can be used to edit multiple loci within the genome.
Establishing causality! iPSC models have utility in determining whether loci identified from GWAS and EWAS are causative in the
disease process.! Using CRISPR, the epigenetic landscape of cells can be altered to establish whether DNA methylation changes
associated with disease are causative.
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Alzheimer’s disease is the most common form of dementia, it is estimated to affect
over 40 million people worldwide. Classically, the disease has been characterized by
the neuropathological hallmarks of aggregated extracellular amyloid-β and intracellular
paired helical filaments of hyperphosphorylated tau. A wealth of evidence indicates a
pivotal role for the innate immune system, such as microglia, and inflammation in the
pathology of Alzheimer’s disease. The over production and aggregation of Alzheimer’s
associated proteins results in chronic inflammation and disrupts microglial clearance of
these depositions. Despite being non-excitable, microglia express a diverse array of ion
channels which shape their physiological functions. In support of this, there is a growing
body of evidence pointing to the involvement of microglial ion channels contributing
to neurodegenerative diseases such as Alzheimer’s disease. In this review, we discuss
the evidence for an array of microglia ion channels and their importance in modulating
microglial homeostasis and how this process could be disrupted in Alzheimer’s disease.
One promising avenue for assessing the role that microglia play in the initiation and
progression of Alzheimer’s disease is through using induced pluripotent stem cell derived
microglia. Here, we examine what is already understood in terms of the molecular
underpinnings of inflammation in Alzheimer’s disease, and the utility that inducible
pluripotent stem cell derived microglia may have to advance this knowledge. We outline
the variability that occurs between the use of animal and human models with regards
to the importance of microglial ion channels in generating a relevant functional model
of brain inflammation. Overcoming these hurdles will be pivotal in order to develop new
drug targets and progress our understanding of the pathological mechanisms involved
in Alzheimer’s disease.
Keywords: microglia, Alzheimer’s disease, ion channel, stem cells, iPSCs
INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder and accounts for
approximately 60–80% of all dementia cases worldwide (Alzheimer’sstatistics, 2016). Initial studies
focussed on trying to identify a genetic basis to the disease (Gatz et al., 2006). Although some
AD cases are caused by defined mutations in one of three genes (APP, PSEN1 and PSEN2) these
account for fewer than 10% of all cases and occur before 65 years of age. The majority of cases
are sporadic, have no defined etiology and occurs at or after a mean age of 65. Our understanding
has progressed through evidence obtained from large cohort studies identifying genetic variants
which are associated with and potentially result in the late onset form of AD (LOAD). These
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genome wide association studies (GWAS) have demonstrated
that LOAD is a multifactorial disease with many different genes
and single nucleotide polymorphisms contributing to disease
onset (Gatz et al., 2006). The most strongly associated gene
with LOAD is Apolipoprotein E (APOE), which encodes a
polymorphic glycoprotein that is involved in cholesterol and
other lipid transport (Poirier, 2005) alongside tissue repair
(Huang, 2010) and neuronal growth (Nathan et al., 1994).
There are three isoforms of APOE, ε2, ε3, and ε4 that all
correspond to cysteine to arginine substitutions at the amino acid
positions 112 and 158 (Zlokovic, 2013). The ε4 variant confers
increased risk of developing LOAD, and each additional copy
of the ε4 allele lowers the mean age of onset (Corder et al.,
1993). Neurodegenerative diseases such as AD were traditionally
considered to be ‘’neurocentric,” however recent findings are
challenging this view, implicating glia as primary targets. GWAS
studies reveal there have been a number of single nucleotide
polymorphisms that are associated with AD which reside in
genes involved in microglial biology. These include common
variants such as CR1 (complement receptor 1), CD33 (sialic
acid binding Ig-like lectin 3), CLU (clusterin), ABCA7 (ATP-
binding cassette, sub family A, member 7), MS4A (membrane-
spanning 4-domain family, subfamily A) and EPHA1 (ephrin
type-A receptor 1) (Bertram et al., 2008; Harold et al., 2009;
Hollingworth et al., 2011; Naj et al., 2011; Lambert et al., 2013;
Zhang et al., 2013), and also more rare coding variants in genes
such as TREM2 (triggering receptor expressed on myeloid cells
2) (Guerreiro et al., 2013; Jonsson et al., 2013). TREM2 is a
cell surface receptor of the immunoglobulin superfamily that
is expressed on microglia (reviewed by Colonna and Wang,
2016). Several variants within TREM2 appear to significantly
increase the risk of developing AD (Jin et al., 2014; Song
et al., 2017), in particular rs75932628, an SNP that confers
an arginine to histidine change at amino acid 47 (R47H)
(Guerreiro et al., 2013; Jonsson et al., 2013). Although TREM2
polymorphisms are associated with a risk of late-onset AD
(Guerreiro et al., 2013), their role in neurodegenerative diseases is
controversial. Indeed, recent evidence proposes that the TREM2-
APOE pathway induces a microglia phenotypic switch from a
homeostatic to neurodegenerative phenotype (Krasemann et al.,
2017). One of the main functions of TREM2 is regulating
microglial phagocytosis (Hsieh et al., 2009), and as a ligand for
TREM2 in microglia, APOE binds to dead neurons and increases
Trem2-mediated phagocytosis (Atagi et al., 2015). Interestingly,
Kleinberger et al. (2014) showed that missense mutations in
TREM2 resulted in impaired phagocytic activity with a reduced
level of soluble TREM2 in cerebrospinal fluid (CSF) of AD
patients. Indeed TREM2 deficiency has been shown to alter
microglial function in both primary microglial cultures and in
mouse models of AD where a decrease in plaque-associated
microglia are observed alongside an increase in apoptosis of both
resting and activated microglia and reduced phagocytosis (Ulrich
et al., 2014; Jay et al., 2015, 2017). These findings suggest that
the role of TREM2 in modulating inflammation may be more
complex than previously appreciated and may be dependent on
the cell type in which it is expressed and the inflammatory context
in which it is studied. For a more in depth discussion we refer
the reader to the following very comprehensive review articles
(Colonna and Wang, 2016; Ulrich et al., 2017; Li and Zhang,
2018).
Microglia are thought to regulate the degree of Aβ deposition
by phagocytosis with potentially protective impact on AD
progression (Lee and Landreth, 2010). One striking feature of
the behavior of microglia in the AD brain is their marked
clustering around fibrillar Aβ deposits and they adopt a polarized
morphology with hypertrophic processes extending toward
plaques (Condello et al., 2015). This aids as a protective physical
barrier mechanism through which the Aβ fibrils cannot extend,
promoting the formation of highly compact plaquemicro regions
that have minimal affinity for soluble Aβ1−42 (Condello et al.,
2015; Yuan et al., 2016). Conversely, areas not covered by
microglia processes display “hotspots” with very high soluble
Aβ1−42 affinity, leading to markedly concentrated protofibrillar
Aβ42 plaque regions (Condello et al., 2015). These “hotspots” are
neurotoxic given that adjacent axons develop a greater extent of
dystrophy compared to those covered by microglia (Yuan et al.,
2016).
On the other hand, most studies in TREM2- deficient AD-
like mice have shown reduced number of microglia around Aβ
plaques (Jay et al., 2015; Wang et al., 2015). Similar reports
suggest that in R47H human mutants, microglial processes were
also unable to form a robust barrier, resulting in a decreased
Aβ fibril compaction (Yuan et al., 2016). With the decrease
in microglial number, there are less compact Aβ fibrils and a
higher ratio of Aβ1−42 plaques (Yuan et al., 2016; Ulland et al.,
2017), therefore a deficient rather than an exacerbated microglial
response could give rise to the development of sporadic AD.Once
activated by pathological triggers, like neuronal death or protein
aggregates, microglia extend their processes to the site of injury,
migrate to the lesion and initiate an innate immune response
(Heneka et al., 2015). Mounting evidence from polymorphisms
linking microglial dysfunction to AD could have a causal role in
disease onset and progression and are not just a consequence of
neuropathological hallmarks that are characteristic of AD.
THE INNATE IMMUNE SYSTEM IN AD
Of increasing interest is the involvement of the innate immune
system in AD, particularly the role of microglia. Microglia are
the resident immune cells in the brain and spinal cord, and
play important roles in neurodevelopment, immune surveillance,
disease and homeostasis (Nayak et al., 2014). Unlike neurons and
other glial cell types, microglia are of haematopoietic lineage,
arise early during development (Hutchins et al., 1990), and are
derived from erythromyeloid progenitors (EMPs) in the yolk sac
(Ginhoux et al., 2010).
Microglia can exist in several morphological/phenotypic states
depending on the environment they are in or the factors they
are stimulated by. From a highly processed state, the microglia
become more amoeboid with increased numbers of intracellular
vesicles in preparation for engulfment of foreign particles. These
differential states have been termed accordingly as “classical
activation,” “alternative activation,” and “acquired deactivation”
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(Colton, 2009; Colton and Wilcock, 2010). Previous studies
defined these states as separate from one another, a profiling
index of M1 or M2 phenotyping suggesting a pro- or anti-
inflammatory state respectively. More recently it has become
more apparent that this is derived from the idea that microglia
are central macrophages and so must follow by the same “kill
or cure” switch seen in these cell types. However, microglia can
exist in multiple phases with the same cell producing markers
of both pro- and anti- inflammatory components depending on
stimulus. Usage ofM1/M2 profile terminology fails to capture the
heterogeneity of microglia which is a vital to their local and global
physiological responses (Mosser et al., 2017).
Classical activation, considered to be pro-inflammatory, is
stimulated by IFN-γ and is associated with the production of
cytokines such as TNF-α and IL-1β and nitric oxide production
(Li et al., 2004; Block et al., 2007). On the other hand, alternative
activation, is defined by the release of anti-inflammatory
cytokines IL-4 and IL-13 and arginase 2. This results in gene
expression to promote tissue repair and extracellular matrix
reconstruction (Ponomarev et al., 2007; Colton, 2009). Acquired
deactivation, is mainly seen in the presence of apoptotic cells and
is characterized by the release of IL-10, TGF-β, IL-6, and CSF1
and the production of scavenger receptors (Sawada et al., 1999;
Colton, 2009; Colton and Wilcock, 2010; Saijo and Glass, 2011).
Microglial phagocytosis relies on specific receptors expressed
on the cell surface and their downstream signaling pathways to
instigate engulfment of harmful particulates (Figure 1).
Microglia mediate the innate immune response of the brain
and are involved in the phagocytosis and clearance of debris,
pathogens, and toxins. Their dysfunction and increased Aβ
accumulation is universal to AD patients and not just those
with familial APP mutations. This suggests that Aβ build-up
is due to poor clearance and not APP proteolysis. Microglia
will secrete both pro- and anti-inflammatory factors, which can
either be beneficial or detrimental in neurodegenerative diseases.
Here exists extensive literature showing that inflammation
is integral to AD progression, facilitating Aβ deposition,
neuronal loss and cognitive deficits. Brains from AD patients
and those from murine models of Aβ pathology uniformly
display high expression of pro-inflammatory cyto- and chemo-
kines including TNFα, IFNγ, IL-1β, and IL-6 (Zheng et al.,
2016). IL-1β and TNFα can impair neuronal function by
suppression of long-term potentiation of synaptic transmission
(LTP) (Rowan et al., 2007). Multiple interactions as well as
elevated expression of additional cytokines/chemokines and
innate immune receptors favor a pro-inflammatory activation
state in AD.
Accumulating evidence demonstrates that inflammasomes,
which cleave precursors of interleukin-1β (IL-1β) and IL-18
to generate their active forms, play an important role in the
inflammatory response in the CNS and in AD pathogenesis. The
inflammasome is an inducible, high molecular weight, protein
complex consisting of the antigen sensor protein NLRP3, adaptor
protein ASC, and pro-caspase 1 (Heneka et al., 2015). The
complexing of these three components results in cleavage of
caspase 1 and instigates a cascade of pro-inflammatory cytokine
activation of the IL-1b family. Inmurinemutants where APP/PS1
was crossed with NLRP3-/- mice, a decrease in cC1 and IL-1β is
observed (Heneka et al., 2013).
Conversely an anti-inflammatory profile of microglia also
contributes to Aβ pathology. In murine models where IL-10
was either knocked down or knocked out in the APP/PS1
model, a decrease in Aβ load, increases phagocytosis and
reduces microglial APOE expression was observed (Chakrabarty
et al., 2015). Further studies showed that this was due to
preventing downstream pathways involving Jak1/Stat3 and
consequential transcription factor activity (Guillot-Sestier et al.,
2015). Additionally, primary microglia treated with fibrillar
Aβ1−42 and recombinant IL-10 showed that fibrillar Aβ1−42
is prevented from inducing a pro-inflammatory response of
cytokine release including CCL5, CXC10, and TNFα, suggesting
a push to an anti-inflammatory profile (Chakrabarty et al., 2015).
Therefore, it is pertinent to think that the Aβ activates
microglia and results in an innate immune response. Indeed, it
has been shown that exposure of microglia to fibrillar Aβ by
CD36, a class B scavenger receptor (Coraci et al., 2002), causes
the formation of a heterodimer of the TLR4 and TLR6 through
NF-κB signaling (Stewart et al., 2010). However, on deletion
of MyD88, an adaptor protein essential for downstream TLR
signaling, there was a significant decrease in both Aβ load and
microglial activation in APP/PS1 mice (Lim et al., 2011). Despite
this the MyD88 deletion only resulted in minor improvements in
cognitive functions (Lim et al., 2012).
Microglial activation by Aβ does not necessarily only occur
after Aβ deposition but can also occur before plaques are even
formed. Maezawa and colleagues have shown that nanomolar
concentrations of Aβ oligomers activated microglia and that
they required another scavenger receptor, SR-A, and the Ca2+-
activated potassium channel KCa3.1 (Maezawa et al., 2011).
Another group has also shown microglial activation precedes
Aβ aggregation in APP[V717I] transgenic mice and that this
coincides with increased BACE1 activation (Heneka et al., 2005).
Intracellular neurofibrillary tangles of hyperphosphorylated
tau are another pathological hallmark of AD. However, the
exact mechanisms which lead to the hyperphosphorylation of
tau are still unclear. Previously, it has been demonstrated that
neuro-inflammation positively correlates with tau aggregation,
hyperphosphorylation and neurodegeneration in several models
(Sheng et al., 1997; Sheffield et al., 2000; Bellucci et al., 2004, 2011;
Ikeda et al., 2005; Yoshiyama et al., 2007).
Microglial activation also precedes tau pathology in the
P301S tauopathy model (Yoshiyama et al., 2007). In the triple
transgenic model of AD, lipopolysaccharide administration
significantly increased tau phosphorylation through toll like
receptor 4 signaling (Kitazawa et al., 2005). Interestingly,
one paper has demonstrated that microglia may be involved
in the propagation of tau pathology through non-synaptic
transmission in mammals (Asai et al., 2015). Asai et al.
(2015) used two different tau mouse models to show that tau
propagation is mediated through microglia which phagocytose
tau-positive neurons or synapses and secrete tau protein in
exosomes, efficiently transmitting tau to neurons. They also
demonstrated that this propagation is sensitive to microglial
depletion and inhibition of nSMase2 activity. On the other
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FIGURE 1 | Morphological phenotype of Microglia. An illustration depicting the different phenotypic states. These are “classical activation,” “alternative activation,”
and “acquired deactivation.” Classical activation, otherwise considered to be the M1 phenotype and so is pro-inflammatory, is stimulated by IFN-γ and is associated
with the production of cytokines such as TNF-α and IL-1β. Subsequently the alternative activation, or M2 phenotype, defined by the release of anti-inflammatory
cytokines IL-4 and IL-13. The third activation phenotype, acquired deactivation, is thought to be a subtype of the M2 phenotype, releases IL-10 and TGF-β. Activation
does not inclusively mean a phagocytic phenotype in microglia. For this to occur, antigen sensing receptors are made available on the cell surface to allow pathogen
recognition. In Alzheimer’s disease, the best known of these is TREM2 but others include Toll-like receptors and members of the complement system.
hand, significant ablation of microglia in a mouse model of
amyloidopathy indicated that Aβ formation, maintenance and
associated neuritic dystrophy was not depended on microglia
(Grathwohl et al., 2009). Interestingly, (Krabbe et al., 2013)
reported that Aβ may directly affect microglial function. This
in vivo study detected a significant inverse correlation between
Aβ plaque burden and microglial phagocytic activity (Krabbe
et al., 2013). They found that microglial dysfunction develops
early during AD in an Aβ-dependent fashion and can be restored
by interventional anti-Aβ approaches, such as Aβ vaccination
(Krabbe et al., 2013).
MICROGLIA PHYSIOLOGY AND ION
CHANNELS
Studies have highlighted the importance of microglia in brain
ionic homeostasis (Annunziato et al., 2013; Szalay et al.,
2016; Shibata and Suzuki, 2017). For example, depletion of
microglia results in the loss of potassium chloride induced
neuronal depolarisation (Szalay et al., 2016) and the microglia
KCa3.1 channel has been proposed as a valid therapeutic
target for modulating cortical spreading depression (Shibata
and Suzuki, 2017). Therefore ion channels and transporters,
regulating ionic flux, are essential regulators of a variety
of microglial functions, including proliferation, morphological
changes, migration, cytokine release and reactive oxygen species
production (Schilling and Eder, 2015). Ion channel expression in
microglial cells is tightly regulated, with the expression of most
ion channel types noticeably depending on the cells’ functional
state (Eder, 1998, 2005, 2010; Kettenmann et al., 2011). Despite
being non-excitable cells, the plethora of voltage-gated ion
channels present in microglia suggests they play a prominent
role in both physiological as well as pathological states. Brain
inflammation is a characteristic of AD and numerous studies
have demonstrated that microglia can directly interact with
neurons to induce inflammation (Hashioka et al., 2012). Due to
this interaction, the study of microglial ion channels may shed
light on brain inflammation seen in neurodegenerative diseases
such as AD (Silei et al., 1999). In this review, we have summarized
the most prominent ion channels involved in microglial cells
which may contribute to AD pathology, as demonstrated in
Figure 2.
POTASSIUM CHANNELS
Potassium channels are present in all cells within the body and
have many diverse functions. In particular, they are capable
of regulating cell excitability and influence action potential
waveform. To identify therapeutic targets to modulate microglial
activation, numerous studies are addressing the contributions
of several K+ channels. Based on both their structural and
functional properties, K+ channels have been subdivided into
specific families. They have transmembrane helices (TMs)
spanning the lipid bilayer (Kuang et al., 2015). The largest of
these consist of K+ channels that are activated by membrane
depolarisation, with subsequent families consisting of channels
that are activated by altered intracellular Ca2+ ions and others
that are constitutively active. Based on the structure and function,
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FIGURE 2 | Illustration depicting presence of ion channels observed in microglial models and which of these have confirmed activity in Alzheimer’s disease associated
microglia. Strength of evidence is depicted in bold to un-bold text. In addition each channel is pre-fixed with the species in which they have been investigated:
h, human; m, mouse; r, rat.
the channels are categorized into three major classes: the voltage-
gated (Kv) (six TMs), inwardly rectifying (Kir) (two TMs), and
tandem pore domain (K2P) (four TMs) channels (Kuang et al.,
2015). K+ channels are particularly important in microglia since
their activation can induce membrane hyperpolarisations, which
are essential for driving Ca2+ influx through inward rectifying
Ca2+-Release-Activated-Ca2+ channels (CRAC) (Kraft, 2015;
Nguyen et al., 2017a) ATP-activated P2X receptors (Burnstock,
2015) and other Ca2+-permeable cation channels (Kettenmann
et al., 2011).
Voltage-Gated Potassium Channels
Kv channels form an exceedingly diverse group, their structure
consists of six TMs, of which the first four helices (S1–S4) form
the voltage sensor domain (VSD) (Jiang Y. et al., 2003; Long et al.,
2007). The last two helices (S5–S6, corresponding to the outer
and inner helices in KcsA, respectively) form the pore-forming
domain. The VSD senses the membrane potential alteration, and
is followed by a conformational change that is coupled to gate the
pore-forming domain (Long et al., 2005). In more general terms
Kv currents can be classified into showing A-type (inactivating)
or delayed rectifier behavior (non-inactivating). The Kv channels
present inmicroglia to date have been summarized inTable 1 and
mainly comprises of delayed rectifier Kv channels.
Kv1.2, Kv1.3, and Kv1.5 transcripts and protein have been
detected in both primary rat and mouse microglia (Kotecha
and Schlichter, 1999; Khanna et al., 2001; Fordyce et al., 2005;
Pannasch et al., 2006; Li et al., 2011). Microglia are widely
distributed throughout the brain; however some regions express
much higher levels than others (Lawson et al., 1990). The
hippocampus, an area particularly affected by AD, is rich with
microglia and is especially sensitive to cerebrovascular insults
which have been shown to rapidly activate microglia (Wu and
Ling, 1998). The reasons for the highly variable expression
of Kv channels and the role this plays in non-excitable cells
such as microglia are not well understood. It is now known
that microglia in culture can express different proteins when
compared to microglia in situ in brain slices or in vivo (Boucsein
et al., 2003; Butovsky et al., 2014; Yamasaki et al., 2014; Gosselin
et al., 2017). Earlier studies mostly used cultured microglia from
enzymatically dissociated tissue, thus removing cell– cell contacts
and key secretory products such as growth factors affecting Kv
channel expression itself (Kettenmann et al., 1990; Ganter et al.,
1992; Draheim et al., 1999). In vitro studies are currently the
only way to stimulate microglia in isolation in order to elucidate
similarities and differences in how different species respond (Lam
et al., 2017).
It is becoming more apparent that altered expression of Kv
channels could trigger the mechanisms underlying microglial
polarity and could characterize these microglial states (Saijo and
Glass, 2011; Maezawa et al., 2012). In a study on freshly isolated
microglial cells, Kotecha and Schlichter (1999) found both
Kv1.3 and Kv1.5, the former being associated with proliferating
cells and the latter with non-proliferating cells. This shift in
microglial activation also results in changes in the physiological
properties of the cells (Kotecha and Schlichter, 1999). Resting
microglia express Kv1.5 channels and upon activation and
proliferation they upregulate Kv1.3 and down-regulate Kv1.5
channels (Pannasch et al., 2006). Kv1.3 channels migrate to the
cell surface while Kv1.5 channels are internalized, making Kv1.3
channels not only functionally relevant but highly susceptible
to pharmacological manipulation through selective channel
blockers. As we have highlighted, majority of microglial studies
use animal models, in particular rodents. Lam et al. (2017)
found distinct variability between the different rodent models
in expressing different Kv channels. It is also apparent that
Kv channel expression of microglial cells in brain slices from
juvenile mice (P5-P9) differs to some extent from that of cells
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in adult mice (Boucsein et al., 2003; Schilling and Eder, 2007;
Menteyne et al., 2009; Arnoux et al., 2013, 2014). The passive
membrane properties and Kv channel expression of microglial
cells undergo substantial changes upon aging (Schilling and
Eder, 2015). In comparison with microglia of young adult mice,
microglial cells of aged mice are characterized by more negative
resting membrane potentials, decreased input resistances and
upregulated expression of inward rectifier and outward rectifier
Kv channels. Interestingly, the outward rectifier Kv channel
current is strongly age-dependent both in vitro and in vivo
(Schilling and Eder, 2015). It is clear from the literature that the
way in which we study Kv channel physiology in microglia varies
dramatically and depends on the methodology used (Lam et al.,
2017).
Further complications include the potential for strain
differences in rodents (Becker, 2016), and genetic polymorphisms
and epigenetic changes in humans (Boche and Nicoll, 2010).
There is considerable debate as to how closely mouse models
resemble human responses in inflammatory diseases (Seok et al.,
2013; Takao and Miyakawa, 2015). A better understanding
of microglial K+ channel regulation and expression patterns
in neurodegenerative states could also yield targets for drug
development using K+ channel blockers.
Voltage-Gated Potassium Channels and AD
Microglia are the key inflammatory cells in AD that mediate
neuro-inflammation, and Kv channels are key regulators of
microglial function, in particular Kv1.3 (Rangaraju et al., 2015).
In animal models of AD, Aβ-induced priming of microglial
NADPH oxidative activity depends on Kv1.3 channels, however
the exact mechanisms that contribute to this priming is still
poorly explored (Kotecha and Schlichter, 1999; Schilling and
Eder, 2011). It is thought that the activity of Kv channels
lead to membrane hyperpolarization, this Kv1.3 channel-induced
membrane hyperpolarisation could enhance Ca2+ influx through
Transient receptor potential (TRP) channels (see section Calcium
Channels; Schilling and Eder, 2011) aiding in the translocation
of PKC and therefore leading to NADPH oxidative priming.
Franciosi et al. (2006) demonstrated that the broad spectrum Kv
channel inhibitor 4-aminopyridine (4-AP) suppressed microglial
activation in vivo and reduced microglia-induced neuronal death
(Franciosi et al., 2006). This inhibition using 4-AP, which also
blocks Kv1.3 channels, could attribute to inhibition of microglial
priming and subsequent reduction ofmicroglial ROS production,
supporting a role for Kv1.3 channels as a therapeutic target in AD
(Schilling and Eder, 2011). More recently immunohistochemistry
experiments on human brain cortices revealed the presence
of Kv1.3 channels in cortical microglia at levels higher than
non-AD controls (Rangaraju et al., 2015). This particular study
also revealed a “plaque-like” pattern of Kv1.3, suggesting that
it may be possible for Aβ to interact with Kv1.3. Interestingly,
Aβ1−42 oligomers, but not soluble Aβ, accelerate the activation
and inactivation kinetics of Kv1.3 channels in lipid bilayers
without altering channel conductance (Lioudyno et al., 2012). It
is possible that altered channel conductance of Kv1.3 channels
could affect calcium fluxes in neurons and microglia, however
the relevance of this potential Aβ-Kv1.3-interaction remains to
be clarified. Another study by Chung et al. (2001) also confirmed
that Aβ was capable of upregulating Kv1.3 as well as the Kv1.5
channel current density. More recently, low levels of soluble
oligomeric Aβ have been reported to upregulate primary cultured
microglial activity as well as Kv1.3 at transcript and as protein
levels (Maezawa et al., 2017). Electrophysiological studies using
whole-cell patch clamp also revealed enhanced outward rectifier
current, characteristic of homotetrameric Kv1.3 channels.
Pharmacological characterization revealed that the currents were
sensitive to the Kv1.3 specific blockers ShK-186 (Tarcha et al.,
2012), margatoxin (Garcia-Calvo et al., 1993) and the selective
Kv1.3 blocker PAP-1 [5-(4-phenoxybutoxy) psoralen (Schmitz
et al., 2005). Oligomeric Aβ further induced a significant increase
in Kv1.3 current density compared to unstimulated microglia
(Maezawa et al., 2017). Following long-term treatment of an
APP/PS1 mouse model, the selective Kv1.3 blocker PAP-1
mitigated some key AD-like phenotypes such as reducing Aβ
deposition as well as restoring hippocampal synaptic plasticity.
The observation that pharmacological targeting of Kv1.3
channels in microglia with the selective inhibitor PAP-1 supports
PAP-1 as a promising potential for neuro-immunomodulation
therapy and the treatment of neurodegenerative diseases such
as AD.
The age-dependent changes in microglial Kv1.3 noted in
5xFADmice followed a similar trend—initially an age-dependent
increase, then a substantial decrease between 10 and 15 months
of age. We suspect that these changes in K+ channel expression
form part of the age-related changes in microglial function,
documented by several lines of investigation, such as altered
responses to Aβ aggregates or downregulation of “sensome”
genes (Hickman et al., 2008; Cameron et al., 2012; Heneka et al.,
2013; Hickman and El Khoury, 2013; Johansson et al., 2015)
ever, this downregulation is not reflected in a human study in
which Kv1.3 expression remains robust in microglia, particularly
in the later stages of AD (Rangaraju et al., 2015). More recently
transcriptomic data from Rangaraju et al. (2018), revealed that
Kv1.3 plays a distinct role in disease-associated-microglia in the
5XFAD mouse model (Rangaraju et al., 2018). It is pertinent to
say that the evidence presented here from the existing human and
rodent studies, show Kv1.3 could be a therapeutic target even at
the late stage of the disease. Similar to what we have previously
discussed, it appears that the current transgenic models of AD
do not replicate the patterns of microglia activation in human
AD. Many potential treatments identified in rodents have failed
in human clinical trials. To narrow this translational gap, it is
essential to investigate and acknowledge species similarities and
differences. With the promises of stem cell therapy and use of
iPSCs to model diseases in a dish, pharmacological manipulation
on a more directly available human source may reveal further
species differences.
Other Potassium Channels
Recent evidence has suggested that two-pore domain K+
(K2P) channels may play a role in microglia physiology
(Madry et al., 2018). Functional investigations provide data to
support the involvement of THIK-1 in the cytokine release
of microglia in situ. This study revealed two functionally and
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mechanistically distinct modes of microglial motility. THIK-1
regulates microglial ramification, surveillance and interleukin-
1β release (Madry et al., 2018). This is the first study of its kind
to implicate K2P channels in microglia physiology. Future work
will provide a better understanding of its role in vivo as well as
neuro-inflammatory responses. The impairment of motility of
microglial processes that occurs in some pathological conditions,
e.g., in models of Alzheimer’s disease with Aβ plaque deposition
(Koenigsknecht-Talboo et al., 2008; Krabbe et al., 2013; Condello
et al., 2015) raises the question of whether the dependence of
surveillance on THIK-1 activity can be employed therapeutically
for the treatment of AD (Madry et al., 2018). Currently there has
been no direct experimental evidence linking THIK-1 to AD.
Another important K+ channel that has been shown to
play a key role in microglia activation by modulating Ca2+
signaling and membrane potential is calcium-activated KCa3.1
(also known as IK1, SK4 or KCNN4) channels (Maezawa et al.,
2012). This channel is predominantly expressed in microglia and
has been a potential target for both industry and academia as
a potential drug target for AD (as reviewed by Maezawa et al.,
2012).
The strong inwardly rectifying K+ (Kir) channel belong to a
family of K+ channels that have only two membrane-spanning
domains and are responsible for stabilization of the resting
membrane potential (Vrest) near to the K+ equilibrium potential
(EK) (Kettenmann et al., 1990; Tsai et al., 2013). Blocking Kir
channels depolarizes the cell and decreases the driving force for
inwardly transported Ca2+ in microglia. In a study by (Tsai et al.,
2013), addition of the AD drug memantine suppressed Kir as
well as depolarized the membrane potential of BV-2 cells. This
block of Kir2.1 channels could represent one of the important
mechanisms underlying its actions on the functional activities of
microglial cells. It remains unclear what the in vivo function of
Kir are, an area showing significant promise for AD.
Interestingly, in the transgenic mouse model of AD (5xFAD)
(Wendt et al., 2017) reported that the impairment in phagocytic
function of microglia was due to altered purinergic signaling.
They found evidence of altered physiological phenotype
only of microglia in 5xFAD mice that were located close to
Aβ plaques (Wendt et al., 2017). Supporting the idea that
functional and pathological alterations of microglia in AD
may be a consequence of their association with Aβ plaques.
Their detailed study on the 5xFAD model revealed an initial
induction of Kir current, followed by subsequent activation
of outwardly rectifying currents at a later age. Therefore
the induction of Kir current could be considered a first
response followed up with outward K+ current developing at
a later stage of microglial activation, similar to their previous
studies (Boucsein et al., 2000; Kettenmann et al., 2011). This
data supports the fact that microglia can undergo chronic
changes in physiological properties in a disease model over
a prolonged period. It appears from the literature that Kv1.3,
KCa3.1, and Kir 2.1 inhibitors seem to constitute relatively
general anti-inflammatory effects and it could therefore be
useful to preferentially target detrimental pro-inflammatory
microglia functions associated with neuro-inflammation,
such as AD (Nguyen et al., 2017b). A more recent study
investigated the effects of Aβ plaque-dependent morphological
and electrophysiological heterogeneity of microglia in the
AD mouse model, TgCRND8. Plescher et al. (2018) revealed
increased K+ currents in plaque-associated but not plaque
distant microglia. They believe that this electrophysiological
heterogeneity is likely to reflect the different functional states of
the microglia in TgCRND8 (Plescher et al., 2018). Their finding
that outwardly rectifying currents (Kv 1.3) were confined to
a subset of plaque associated microglial cells emphasizes the
potential of specific ion channel inhibitors to target only specific
(i.e., detrimental) subtypes of microglia in AD (Plescher et al.,
2018).
VOLTAGE-GATED SODIUM CHANNELS
Sodium voltage channels (NaV) are formed of one pore-α-
subunit associated with one/more β-subunits. The α-subunit
acts as the “voltage sensor” being activated by changes in
membrane potential (Payandeh et al., 2011). The β-subunits have
multiple roles, from modulating channel gating and regulating
channel expression, to interacting with the cytoskeleton and the
extracellular matrix, as cell adhesion molecules (Brackenbury
and Isom, 2008). It is now known that there are nine pore
forming α-subunits of sodium channels, Nav1.1-Nav1.9, encoded
by genes SCN1A-SCN11A (Catterall et al., 2005), which associate
with one or more non-pore-forming β- subunits encoded by
SCN1B-SCN4B (Brackenbury and Isom, 2011). In addition to
being expressed in cells capable of generating action potentials,
sodium channels have also been identified in cells that have not
traditionally been considered to be electrically excitable (“non-
excitable cells”), leading to speculation as to their functional
role (Pappalardo et al., 2016). Sodium channels contribute
to multiple, varied cellular functions in these cells including
phagocytosis (Carrithers et al., 2007), migration (Kis-Toth et al.,
2011), and proliferation (Wu et al., 2006). Voltage-gated sodium
channels have been documented in immune cells such as
macrophages (Schmidtmayer et al., 1994; Carrithers et al., 2007,
2009, 2011; Black et al., 2013).
Patch-clamp recordings have since confirmed the expression
of functional sodium channels in microglia (Korotzer and
Cotman, 1992; Nicholson and Randall, 2009; Persson et al., 2014).
A number of voltage-gated ion channels have been identified in
microglia, in particularly, voltage-gated Na+ channels isoforms
(VGSC): Nav1.1, Nav1.5, and Nav1.6 (Craner et al., 2005; Black
and Waxman, 2012).
In vitro, microglia derived from mixed glial cultures from
neonatal rats, exhibit immunolabeling for Nav1.1, Nav1.5, and
Nav1.6, which is most prominent, while Nav1.2, Nav1.3, Nav1.7,
Nav1.8, and Nav1.9 are not detectable above background levels
(Black et al., 2009). Whole-cell voltage clamp experiments on
cultured rat microglia revealed that, depolarization-induced
sodium currents were elicited and then completely blocked
by 0.3µM TTX, consistent with the presence of functional
TTX-S sodium channels (Persson et al., 2014). Similarly,
microglia within normal CNS tissues exhibit low levels of Nav1.6
immunolabeling in situ (Black and Waxman, 2012).
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There is a handful of electrophysiological studies of cultures
of human microglia derived from native tissue which reports the
presence of Na+ currents (Nörenberg et al., 1994b; Nicholson
and Randall, 2009), however, these are not observed in every
laboratory (McLarnon et al., 1997). Na+ currents have also been
reported in rat microglia (Korotzer and Cotman, 1992). A study
in mice provides evidence that Nav1.6, plays a central role in
the infiltration and phagocytosis of microglia in experimental
autoimmune encephalomyelitis. Furthermore, the same channel
is reported to be up-regulated in macrophages and microglia in
the lesions of multiple sclerosis patients (Craner et al., 2005).
To date there is no direct evidence for the involvement of
microglial VGSC in AD. This same group, however, also report
the presence of Nav1.1 and Nav1.5 in cultured rat microglia
and demonstrate their function in many key microglial processes
(Black et al., 2009). Although Aβ is a known activator for
microglia, treatment of the human microglial cell line with
Aβ (12 h, 10µM) there was no significant change in Na+
current or Nav1.5 expression (Nicholson and Randall, 2009).
Although there is clear involvement for VGSC in microglial
function its role in AD remain less well defined. This could
be due to a number of different contributing factors such as
species variation, individual laboratory protocols, as well as




Transient receptor potential (TRP) channels are non-selective,
non-voltage gated cation channels, ubiquitously expressed
in mammalian cells. The TRP gene was initially discovered
in Drosophilla where mutant gene expressing animals
showed impaired vision due to dysregulated Ca2+ influx into
photoreceptor cells. TRP channels play important physiological
role in cells by their regulation of temperature, chemoception,
mechanoception, and nocioception. There are 30 known
members of the mammalian superfamily, which can be
divided up into six subfamilies, based on amino acid sequence
homology. These are: TRPA (Ankyrin); TRPC (Canonical);
TRPM (Melastatin); TRPML (Mucolipin); TRPP (Polycystin);
and TRPV (Vanilloid). TRP channels are tetramers made of
monomeric subunits that include a six trans-membrane (TM)
domain with a pore-forming loop between TM 5 and 6. In
addition, their C- and N-termini are intracellular. Functionally,
they act by changing cytoplasmic free Ca2+ concentrations via
Ca2+ permeable pore or by modulating ionic movement via
changes to the membrane potential. Microglia are evidenced to
express some TRP subfamily members, including those of the
TRPC, TRPM, and TRPV families.
TRPA
The smallest of the TRP subfamilies. Its only mammalian
member is TRPA1, a mechano- and chemo-sensor. Its name
is derived from the 14 N-terminal ankyrin repeats. To date
there is no evidence that it is present in microglia, although it’s
silencing in dorsal root ganglion results in reduced microglia
activation following hyperalgesia (Meotti et al., 2017). Similarly,
there is no evidence of the presence of TRPML nor TRPP
channels being expressed in nor influencing function of
microglia.
TRPC
The TRPC subfamily consists of seven homologs (C1-7), with
TRPC2 being exclusively expressed in mouse. TRPC members
share a structural motif in the COOH-terminal tail, TRP box,
located close to the intracellular border of TM6. In addition, they
contain three or four N-terminal ankyrin repeats.
TRPC channels are activated via the stimulation of GPCRs
and receptor tyrosine kinases, leading to phospholipase C,
inositol 1,4,5-triphosphate, and diacylglycerol production. This
stimulation results in a biphasic Ca2+ release with a first phase ER
release, followed by sustained Ca2+ influx across the membrane.
TRPC channels are known mostly as store operated Ca2+ entry
(SOCE) mediators.
In microglia, all seven members have shown RNA expression
in in vitro cell line models, although only C1 and C3 have been
reported in vivo. TRPC1 is a non-selective Na+/Ca2+ permeable
channel with known function in cell survival and proliferation.
Their expression is commonly on organelle membranes such
as ER and intracellular vesicles. TRPC1 negatively regulates the
ORAI1 Ca2+ channel resulting in suppression of NKkB, JNK and
ERK1/2 signaling from microglia (Sun et al., 2014).
TRPC3 is widely expressed in the CNS where it has
modulation via the growth factor BDNF to induce axonal
guidance, neuronal survival, and postsynaptic glutamate
transmission. In microglia, pre-treatment with BDNF inhibits
NO and TNF-α upregulation, via sustained Ca2+ influx through
upregulated TRPC3 channels at the plasma membrane. Effects
were reversed using the siRNA against TRPC3 (Mizoguchi et al.,
2014).
TRPM
The TRPM subfamily has eight mammalian members. Unlike
TRPA/C there are no N-terminus anykin repeats, instead having
functional protein domains, in addition to the TRP box, in the C-
terminus. TRPM’s are non-selective cation channels with a verity
of cellular functions including temperature sensing, osmolarity,
redox, Mg2+ homeostasis, proliferation, and cell death. These
channels can be subdivided further into four groups: M1/3;M4/5;
M6/7; M2/8. M1, 2, 4, and 7 have all been reported as present in
microglia.
TRPM1 was the first to be cloned, in 1998 (Harteneck,
2005), however its function and activation remains unknown.
TRPM1 has a high capacitance for splice variance, similarly so
with TRPM3-with whom M1 shares strong sequence homology.
In murine models of AD (5XFAD/MHCII+) high levels of
Aβ plaque burden correlated to an increase in TRPM1 gene
expression compared to age matched control animals (Yin et al.,
2017).
M2 contains an adapted adenosine 5′-diphosphoribose ribose
(ADPR)-recognizing Nudix box domain at its c-terminus. It
is a redox modulator, activated by reactive oxygen species,
Frontiers in Neuroscience | www.frontiersin.org 10 September 2018 | Volume 12 | Article 676
Thei et al. Ion Channels, Alzheimer’s and Microglia
ADP ribose, NAD+ and Ca2+. M2 will mediate the release of
lysosomal Zn2+ stores in response to reactive oxygen species,
leading to increased cytosolic Zn2+ levels, leading to regulation
of cell motility and actin remodeling. Additionally, Ca2+ influx
via TRPM2 leads to increased intracellular insulin release in
pancreatic β-cells (Uchida et al., 2011). A number of studies, both
in vitro and in vivo confirm TRPM2 expression and activity in
microglia.
In a TRPM2 KO mouse model, microglia show an
abolishment of Ca2+ influx after LPS or IFNγ stimulation.
Activation by these stimuli results in Pyk2-mediated activation
of p38 MAPK and JNK signaling as well as an increase in
nitric oxide production (Miyake et al., 2014). Similarly studies
of MCAO-induced hypoxia in TRPM2 KO mice saw reduced
MG activation, reduced cytokine expression and increased brain
volume after damage (Huang et al., 2017). Lastly, TRPM2
channels are functionally expressed in the murine microglia cell
line BV2. Here these channels have been shown to be involved
in LPC-induced p38 MAPK phosphorylation. LPC-induced
intracellular Ca2+ increase and inward currents dependent on
TRPM2 channels (Jeong et al., 2017).
TRPM4 are non-selective cation channels with a greater
affinity for Na2+ over Ca2+. TRPM4 are activated by increased
intracellular Ca2+ due to changes in cell membrane potential,
ATP, PKC-dependent phosphorylation and calmodulin (CaM)
binding to the channels C-terminal CaM domain (Nilius et al.,
2005). Functional channels were detected in the mouse primary
microglia, both quiescent and active. Here they are thought to
mediate membrane depolarisation, in correlation to Ca2+ influx
(Beck et al., 2008). Sulfonylurea receptor 1 activates TRPM4
channels inmouse primarymicroglia. Receptor binding regulates
NOS andNO transcription onmicroglia activation via LPS action
at TLR4 (Kurland et al., 2016).
TRPM7, like TRPM6, is a channel-enzyme. It is Mg2+, Zn2+,
and Ca2+ permeable with a strong outward rectifying current-
voltage relationship. In addition to its ionic pore, it contains a
tyrosine kinase domain on its N-terminal. Activity at both pore
region and kinase domain are implemented to be involved in the
channels activity. For example, in rat brain microglia there is a
strong increase of intracellular Mg2+ via the channel, however
the currents generated were kinase activity-dependant and not
due to pore, nor cell, activation (Jiang X. et al., 2003). TRPM7
also plays a role in cell motility. Migration and invasion of M1
(pro-apoptotic) microglia was observed in rat primary and MLS-
9 microglia after priming with LPS (Siddiqui et al., 2014). In
addition, flow cytometry and Ca2+ imaging studies in neonatal
mouse microglia saw an increase in intracellular Ca2+ with cell
activation by Polyl:C. Increased Ca2+ led to a correlated increase
in TNFα and P38, in a TRPM7-dependent manner.
TRPV
The final sub-family are the vanilloids, the largest (1-6) and most
in depth studies of the TRP channel families. All TRPVs are
highly selective to Ca2+. The most well-known is TRPV1 for its
actions as a thermosensor (temperatures >43C). V1 mediates
heat response and inflammation in addition to nociceptive
responses to capsaicin, the main “heat” compound of chili
peppers. In addition, application of compounds with a pH <5.9
will shift the temperature gated threshold of these channels
to 20–23C. Heat-mediated activation is shared quality with
other TRPV members, specifically 2, 3, and 4. However, these
channels are insensitive to capsaicin and pH. V5 and V6
are not thermosensors but have enhanced selectivity to Ca2+
over other monovalent cations. Lastly, all TRPV channels are
functionally regulated by their insertion, or retention to the
plasma membrane.
TRPV1 has a high protein expression in microglia, with
the majority of these channels showing co-localisation to
organelles including the golgi, ER, lysosomes, and mitochondria.
Interestingly, at resting state there is very little expression
at the plasma membrane (Miyake et al., 2015). In a model
of rat spinal cord injury, activation of TRPV1 channels,
via I.V injection of capsaicin, gave increased expression of
SOD1 and pro-inflammatory cytokines from spinal microglia
(Talbot et al., 2012). Similar influence on pro-inflammatory
markers were observed in retinal microglia where activation
of TRPV1 resulted in increased IL-6 and NFkB expression
(Sappington and Calkins, 2008). Expression of TRPV1 protein
and function was confirmed in HMO6 human microglial
cell line. Application of capsaicin resulted in increased
intracellular Ca2+, and subsequently cytochrome C and
cleaved caspase 3 release (Kim et al., 2006). Together this
suggests a strong role of TRPV1 in the pro-inflammatory profile
of microglia.
Little is known about the other TRPV channels in microglia,
although an RNA-based analysis by Raboune et al. (2014).
showed upregulation of TRPV1-4 in BV2 cells following cell
activation by N-acyl amide.
Microglial TRP Channels in AD
Aβ accumulation, one of the major hallmarks of AD, commonly
results in excitotoxicity and cell death via the disruption of
normal Ca2+ homeostasis and release of pro-inflammatory
factors such as ROS, NO, and cytokine release. The previous
section highlights the role of TRP channels in intracellular Ca2+
regulation as well as differentially switching the phenotype of
microglia between M1 (pro-apoptotic) and M2 (pro-survival).
Despite this there is little research into glial TRP channel activity
in AD, with most of the focus being on neuronal responses.
Aβ treatment of BV-2 cells gave an upregulation of protein
and mRNA for TRPC6 that is dependent on NFkB activity.
When these cells had TRPC6 knocked down via siRNA, the
condition media was neuroprotective to cultured hippocampal
cells compared to sham BV2 cells. Neuronal influence of
TRPC6 activates via an upregulation of COX2 downstream
(Liu et al., 2017). By using familial AD mouse models- APP23
and 5XFAD, plaque associated microglia from these animals
were homogenized and run through flow cytometry to observe
upregulated genes. From these TRPM1 was pulled out, however
its role in AD remains unclear (Yin et al., 2017). BV2 cells
treated with either fibrillary or soluble Aβ saw high levels of ROS
which was attenuated with simultaneous application of TRPV1
via I-RTX (Schilling and Eder, 2011).
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CALCIUM CHANNELS
Plasma membrane calcium channels are subdivided into three
main groups according to their manner of activation; the voltage-
gated calcium channels (VGCCs), the store-operating calcium
channels (SOCs) and the receptor-operated calcium channels
(ROCs). VGCCs specifically, play a vital role in maintaining
calcium homeostasis, with important roles in cellular processes
such as neurotransmission, control of gene expression, hormone
secretion and cell apoptosis (Ertel et al., 2000; Valerie et al.,
2013). Therefore, developing therapeutics that target these
channels may be of benefit in treating various diseases of
the CNS, such as AD. Structurally VGCCs consists of the
α1 pore-forming subunit consisting of four transmembrane
domains, the cytoplasmic β subunit, the peripheral α2δ and
occasionally the γ accessory subunit (Ertel et al., 2000).
VGCCs are divided into subfamilies according to their pore-
forming subunit; the high voltage-activated channels known
as Cav1 (Cav1.1-1.4) and Cav2 (Cav2.1-2.3), and the low
voltage-activated Cav3 channels (Cav3.1-3.3) (Ertel et al.,
2000).
Voltage-Gated Calcium Channels
To date, evidence suggesting the existence of microglial VGCCs
and their involvement in AD is limited. Although numerous
studies, mainly via electrophysiology and Fura-2 calcium
imaging, have proven that various agents such as Aβ, ATP, and
K+, cause an increase in intracellular Ca2+, the mechanism by
which this phenomenon occurs is still under debate (Korotzer
et al., 1995;McLarnon et al., 1999; Valerie et al., 2013). Thus, there
is no clear indication of the existence of microglial VGCCs or
whether the increase in intracellular Ca2+ is due to other factors
such as ion exchange transporters or opening of intracellular
stores (Korotzer et al., 1995; McLarnon et al., 1999; Valerie et al.,
2013).
The majority of human studies, have investigated the presence
and functionality of VGCCs in human glioblastoma cell lines,
consisting of a mixed culture of glial cells, including astrocytes
and microglia. Therefore, a major limitation of human in vitro
studies, is that identifying VGCCs in glioblastoma cells does
not necessarily indicate the presence of these channels in
microglia. For instance, Valerie et al. (2013), demonstrated that
pharmacological inhibition via the calcium channel blocker
(CCB)mibefradil, or siRNA-induced downregulation of the Cav3
channel (T-type current) in human glioblastoma cell lines, led to
cell apoptosis. Additionally, Nicoletti et al. (2017) demonstrated
that Cav2.1 and Cav2.2 are involved in glial proliferation,
through using of pharmacological tools (Nicoletti et al., 2017).
Furthermore, via the use of an Iba-1 antibody, a marker of
inflammation, and immunohistochemistry, in an in vivo rodent
glioblastoma model (GL261 glioma cells), it was revealed that the
degree of Iba-1 positive microglia had increased following N-type
inhibition. This highlights a role of microglial VGCCs not only
in cell proliferation and microglial survival, but also in inducing
their pro-inflammatory action (Nicoletti et al., 2017). Evidence
from human glial cells, demonstrates that VGCCs are expressed
in human microglia, and that microglia VGCCs may also have
a role in neurotoxicity (Hashioka et al., 2012). Prior to 48-h
treatment with LPS and IFN-γ to induce inflammation, primary
human microglial cells were treated with the L-type blocker
nimodipine, significantly reducing neuronal toxicity induced by
the microglia (Hashioka et al., 2012). In contrast to other studies,
Hashioka et al. (2012) provided more conclusive evidence in
indicating the presence of microglial VGCCs due to the use
of primary human microglia and not a cell line consisting of
a mixed glial population. A 1999 study demonstrated a more
direct involvement of microglia VGCCs with progression of AD
by investigating how Aβ25−35 alters Ca2+ signaling in human
microglia (Silei et al., 1999). Incubation with Aβ caused an
increase in microglia proliferation and additionally an increase
in intracellular Ca2+ levels (Silei et al., 1999). As no significant
increase in microglial intracellular Ca2+ levels were observed
when microglia were incubated in Ca2+ -free media, it was
suggested that this change was due to VGCC-mediated Ca2+
influx (Silei et al., 1999). This was verified via co-incubation
of microglia with Aβ and the CCBs verapamil, nifedipine and
diltiazem which lead to a half-reduction in intracellular levels
(Silei et al., 1999). Moreover, incubation of peptide-treated
microglia with nifedipine not only lead to a reduction in
intracellular Ca2+, but also significantly prevented the increase
in microglia proliferation induced by the peptide. Therefore,
this study proposes that Aβ has the ability to increase microglia
number and also induce their activation and consequently
inflammatory action, through a VGCC manner (Silei et al.,
1999).
In contrast to human studies, the majority of studies using
animal models, have not provided conclusive evidence to indicate
the existence and activity of VGCCs in microglia (Toescu et al.,
1998; Silei et al., 1999).
A possible explanation for this, could be that microglial
VGCC expression and activity is species-dependent. For instance,
studies have shown that rodent microglia can express very low
levels of VGCC activity which may even remain undetected
(Toescu et al., 1998). Toescu et al. (1998), demonstrated that
adding ATP to microglia isolated from murine cortex lead to a
significant increase in intracellular Ca2+ levels. In contrast, KCl
induced microglial depolarisation, did not lead to an increase
in intracellular Ca2+ thus it was proposed that increased Ca2+
levels involved VGCC independent pathway (Toescu et al.,
1998). Prolonged elevation in intracellular Ca2+ levels can
activate pathways involved in regulation of gene expression
such as the Ca2+-calmodulin pathway, and therefore altered
Ca2+ signaling in microglia may occur as a pathway for
microglia activation and may even induce the progression of
various pathological conditions such as AD (Toescu et al.,
1998).
Although the majority of animal model studies have not
definitively proven the existence of the channels in microglia,
a few were able to provide some evidence indicating their
existence. In a study carried out in 2014 by Saeugusa and
Tanabe, where rodent lines were created where expression of
Cav2.2 was suppressed, they indicated dynamic modulation of
microglia Cav2.2 in regulation of pain related behavior. (Saegusa
and Tanabe, 2014). Saeugusa and Tanabe also highlight neuronal
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and microglial crosstalk, in controlling response to pathology
(Saegusa and Tanabe, 2014). A more recent study investigated
how microglial activation, verified by immunostaining and
morphological changes, alters the activity of the L-type currents
in an in vivo animal model for neurodegeneration, and in
the in vitro BV2 cell line (Espinosa-Parrilla et al., 2015).
Comparison of microglia before and after LPS and IFNγ
stimulation revealed differences as seen via immunostaining
and molecular approaches such as western blotting and PCR
(Espinosa-Parrilla et al., 2015). Additionally, as depolarisation
of LPS/IFNγ treated microglia demonstrated changes in
intracellular Ca2+ by treatment with either nifedipine or Bay
K8644 (agonist), it was suggested that VGCCs, may form part
of the mechanism involved in the activation of microglia,
inducing their pro-inflammatory action (Espinosa-Parrilla et al.,
2015).
To summarize, even though human microglia studies have
proposed the existence of functional VGCCs, the majority of the
studies were carried out in mixed glial cell lines. Additionally,
animal studies have either demonstrated very low expression of
VGCCs in microglia or were not able to prove their existence,
either at a functional or expression level (protein and mRNA).
Thus, due to the limited and contradicting evidence on human
and rodent microglial VGCC existence, the use of human
induced pluripotent stem cells (iPSCs) may allow amore effective
study of microglial ion channel role in neuro-inflammation
observed in neurodegenerative diseases such as AD.
CHLORIDE CHANNELS
Chloride channels are a diverse superfamily of channels proteins,
incorporating the volume regulated chloride channels, the ClC
proteins, Ca2+ activated chloride channels, CFTR and maxi
chloride channels (Alexander et al., 2017). Studies have identified
Cl− channels in rat (Visentin et al., 1995; Schlichter et al., 1996),
bovine (McLarnon et al., 1995) and human microglia (McLarnon
et al., 1997). These have mainly been based on pharmacological
studies using a range of Cl− channel blockers (e.g. nifluemic
acid). Pharmacological modulation of Cl- channels indicates a
role for in the regulation of microglia process outgrowth (Hines
et al., 2009). However, the lack of specific pharmacological tools
has hindered our progress in identifying specific channel entities,
and indeed their contribution to microglia physiology. This
is backed up with a lack of experimental evidence as to the
molecular identity of the channels that have been suggested to be
responsible for experimental observations. While the molecular
identity remains to be resolved, evidence indicates that is a
similar fashion to Cl− currents within lymphocytes, microglia
Cl− conductance are responsive to stretch (Lewis et al., 1993;
Steinert andGrissmer, 1997). Interestingly CLIC1 an intracellular
chloride channel has received some attention with relation to
amyloid pathology (Novarino et al., 2004; Milton et al., 2008;
Paradisi et al., 2008). This suggests a role for modulation
of chloride conductances in microglial generation of reactive
oxygen species, but robust evidence for this is lacking in relevant
in situmodels of microglia.
VOLTAGE GATED PROTON CHANNELS
(HV1)
Voltage-gated proton channels (Hv1; Alexander et al., 2017)
reportedly consist of 4 proton sensitive transmembrane domains
which are sensitive to both membrane depolarisation and
transmembrane pH gradient (DeCoursey, 2008; Capasso et al.,
2011). There is widespread expression of these channels within
the central nervous system, highlighting both regional and
cellular variation (Eder et al., 1995; McLarnon et al., 1997).
Functional evidence comes from both studies carried out on
murine microglia (Eder et al., 1995; Klee et al., 1998, 1999), rat
(Visentin et al., 1995), and human microglia (McLarnon et al.,
1997). There is also evidence to link Hv1 to both microglia
polarity and brain responses to stroke (Wu et al., 2012; Tian et al.,
2016). This could be pertinent given the link between hypoxia
and Alzheimer’s disease (Peers et al., 2007). However, one
drawback from these studies is the use of culture preparations.
This is pertinent given that work on brain slices was unable to
detect any H+ conductance in situ (De Simoni et al., 2008). This
again raises the question about membrane properties in cultured
preparations in contrast to in situ set ups. In addition there
are questions around the physiological role of these channels
when present in microglia (Eder and Decoursey, 2001) It is well
established that microglial reactive oxygen species contribute to
neuronal cell death in AD (see review Block et al., 2007). This
process likely involved the build-up of protons within microglia,
which will impact on the flux through Hv1 channels. However, a
direct demonstration of the involvement of HV1 in this process is
lacking. There is greater evidence to indicate the involvement of
other channels (e.g., Kv1.3) which are discussed elsewhere in this
article.
MODELING MICROGLIAL INVOLVEMENT
To fully understand a disease and its etiology it is necessary
that extensive modeling takes place. By tradition this has
been through the use of a number of different model systems
including both animal (murine) models and primary patient
cell lines. Currently in AD research there is a large focus
on the use of animal models, particularly transgenic mice
(McGowan et al., 2006), as a lot is understood about their genetics
and the availability of well-characterized genetic manipulation
techniques in this organism. Not only this, mice are more closely
phylo-genetically related to humans than other model systems
such as Caenorhabiditis elegans or Drosophila melanogaster. The
genetic similarities between humans and mice means that they
have utility in studying the familial aspect of AD by using
transgenic mice that contain mutations in the APP and PSEN
genes. There are over 100 different transgenic mouse models
available to study the familial aspect of AD, with some models
containing five different mutations in the APP and PSEN genes
(Oakley et al., 2006).
As it is widely accepted that Aβ plaques and neurofibrillary
tangles cause neuro-inflammation, models which overexpress
mutant human versions of APP have been shown to present
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microglial activation (Bornemann et al., 2001; Wright et al.,
2013). In addition to this it was shown that there were significant
increases in CD38-positive microglia before Aβ deposition which
also correlated with neuronal cell death in the CA1 region
of the hippocampus (Wright et al., 2013). The inflammatory
processes of in another APP mouse model, Tg2576, were
investigated by looking at individual microglial cells using in vivo
multiphoton imaging. Meyer-Luehmann and his colleagues
showed that Aβ plaques can form within days and once formed
it only takes 1–2 days before microglial cells begin to aggregate
around the depositions. Alongside this accumulation ofmicroglia
is accompanied by changes to neurite morphology (Meyer-
Luehmann et al., 2008). Whilst these have their advantages, they
also have a number of limitations. These types of models do not
accurately recapitulate human pathology as they do not develop
the robust tauopathy or neuronal cell death that is seen in human
disease without the addition of extra transgenes such as tau (Ribé
et al., 2005).
The triple-transgenic model of AD, which contains the
APPSWE, Presenilin-1 (PSENM146V) and tau mutations (tauP301L)
offers the advantage that they develop Aβ plaques, tau tangles,
synaptic dysfunction and LTP deficits which all manifest in
an age-related manner (Oddo et al., 2003). Janelsins et al.
demonstrated that this model shows a 14.8 fold increase of TNF-
α and 10.8 fold increase in MCP-1 mRNA in 6 month old triple
transgenic mice when compared to 2 month old mice. However
these increases were only seen in the entorhinal cortex and could
not be replicated in the hippocampus, suggesting that different
cell types or environments may be responsible for the differential
transcript levels and inflammatory responses in these disease
relevant brain regions (Janelsins et al., 2005).
Mouse models containing just tau mutations have also been
investigated in terms of neuro-inflammatory response and they
too also display microglial changes (Wes et al., 2014; Cook
et al., 2015). For example, the P301S tau model whose neurons
develop bundles of hyperphosphorylated tau also have significant
increases in inflammatory molecules such as IL-1β and COX-
2 within the tau-positive neurons. Alongside this they also
demonstrated that there were activated microglia throughout
the brain and spinal cord, but that these microglia could
be predominantly found surrounding the tau-positive neurons
(Bellucci et al., 2004). Interestingly, this microglial activation
was shown to begin before neurofibrillary tangle formation,
but could be ameliorated using an immunosuppressive drug,
FK506, early in life increasing life span and attenuating tau
pathology (Yoshiyama et al., 2007). One important thing to bear
in mind that mutations in tau do not cause AD but instead
cause frontotemporal dementia. So whilst these models can
provide useful information about how mutations in tau can
cause cellular dysfunction and neurodegeneration they do not
completely replicate AD in terms of other pathological markers
(Wolfe, 2012).
Whilst proven useful for modeling autosomal disease, such as
the familial form of AD, as previously mentioned, these murine
models do not accurately recapitulate AD. A more promising
avenue for modeling complex diseases, such as sporadic AD, is
through the use of stem cell technology. Embryonic stem cells
(ESCs) are derived from the inner cell mass, or blastocyst, of an
embryo and can differentiate into any cell in the body (Evans and
Kaufman, 1981). Despite their many potential uses, the ethical
issues surrounding the use of embryo-derived cells are numerous.
However, recent advances in stem cell technology have meant
that it is now possible to derive stem cells from differentiated
adult cells/tissue. Takahashi et al. showed it was possible to use
ectopic transcription factors to induce pluripotency and ESC
properties (Takahashi and Yamanaka, 2006). These transcription
factors were known for being important in the long term
maintenance of ES cell phenotype (Oct3/4 and Sox2) and
pluripotency (c-myc and Klf4) (Takahashi and Yamanaka, 2006).
These iPSCs are almost identical to ESCs in terms of their
characteristics. They are able to differentiate into any cell type
in the body, have infinite potential to grow, share the same
morphology and have the same expression pattern of genes
(Yamanaka, 2009); making them a potentially very powerful tool
for complex disease research.
Primary microglia cultures are often used to study neuro-
inflammation, they can be derived from rat ormouse brain before
birth or early on in development. In addition, human microglia
cultures have also been established from fetal brain (McLarnon
et al., 1997). One method of generating these cells was developed
by Giulian and Baker (1986) and involving a specific process of
adhesion and agitation. These cells are often used as they show
similarities to microglial cells in vitro, however, the process of
extraction and culture itself alters microglial phenotype (Caldeira
et al., 2014). Given the degree of variability in ion channel
distribution during development and aging (Harry, 2013), using
this type of model for investigating neurodegeneration is less
than ideal. Another method to study microglia is through the
use of retroviral-immortalized cell lines, such as the mouse and
rat microglial cell lines N9 and BV-2 respectively (Righi et al.,
1989; Blasi et al., 1990). These cell lines offer an advantage in
the fact that they are fast to grow, and large numbers of cells can
be generated quickly. However, as they have been immortalized
using oncogenes whichmeans they differ from primary microglia
as they have increased adhesion and proliferation and can vary in
terms of their morphology (Horvath et al., 2008).
Until recently, being able to generate iPSC-derived microglia
has been elusive, with previous attempts being met with
skepticism as the microglia were made from induced
hematopoietic stem cells (HSCs). HSCs have the potential
to give rise to other cell types such as blood derived macrophages
and as already stated microglia arise from EMPs. In order
to generate EMPs from the iPSCs, Muffat and his colleagues
developed a serum free media that contains high levels of
IL-34 and colony stimulating factor 1 (CSF1) (Muffat and Li,
2016). These conditions were chosen as the media mimics the
brain cerebrospinal fluid and the factors have been shown to
be necessary for microglia differentiation and maintenance.
Under these conditions they found that the cells soon formed
rope-like structures that when plated onto low adherence plates
gave rise to highly adherent pluripotent stem cell–derived
microglia-like cells (pMGLs). These cells express many of
the markers that would be expected from microglia, such as
TMEM119, P2RY12/13, HEXB and GPR34. Alongside this they
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are also highly phagocytic and gene transcriptomic analysis
demonstrated they resemble human primary fetal and adult
microglia (Muffat and Li, 2016). This is not the only protocol that
has been published which describes the derivation of microglia
from iPSCs, subsequently there have been four more protocols
released. In fact the next two papers described the generation
of iPSC-derived microglia going through a hematopoietic
progenitor cell (HPC) stage. Both methodologies use defined
media systems that contain a number of growth factors including
IL-3, BMP4 and L-ascorbic acid to generate HPCs (Abud et al.,
2017; Pandya et al., 2017). Both protocols take about 10 days to
generate HPCs at which point they were checked for markers
of the hematopoietic lineage such as CD43 before differentiating
for a further 2 weeks using another media to form induced
microglia like cells (iMGLs). One way in which these protocols
differ is that Pandya et al. (2017) co-culture the HPCs with
astrocytes to enhance microglial differentiation. This is not the
only protocol that uses co-culture to generate iPSC-derived
microglia, a paper released by Walter Haenseler also uses
co-culture but neuronal microglial co-culture instead (Haenseler
et al., 2017).
Whilst iPSC-based models offer a number of advantages to
modeling complex diseases there are a number of limitations that
should also be considered. Firstly, the cells which are derived
from iPSCs have been found to display the functional and
epigenetic signatures of fetal neurons and do not maintain the
features, such as telomere length and mitochondrial metabolism,
of the cells from which they were originally derived (Lapasset
et al., 2011). One of the current major stumbling blocks for iPSC
research (control and those derived from patients with specific
neurodegenerative disorders), is the lack of standard culturing
or differentiation methods (Wen et al., 2016). Resulting in the
unavailability of established protocols to generate entirely pure
populations of a specific cell type, therefore making cross lab
comparisons particularly difficult. However, more recently the
availability of human tissue as well as iPSCs have provided new
opportunities for academic and industry-based researchers to
identify optimal cell types and culture conditions to efficiently
generate stable, defined and reproducible cell types for their
specific research–with limited variability. Whilst this may not be
an issue for some studies, when trying to investigate diseases of
aging such as AD it could pose more problems as cells may not
show age related phenotypes or degeneration. One way in which
it may be possible to overcome this is throughmaintain and aging
the cells in culture for as long as possible.
One of the challenges to date has been modeling sporadic
AD in both rodent and human models of disease, with familial
AD mutations accounting for only 5–10% of all AD cases (Kim
et al., 2017). Excitingly, Lin et al. (2018) describes the first
experiments in which CRISPR/Cas9 technology has been used
to generate isogenic APOE4 iPSC-derived microglia. In this
study the APOE4-like microglia exhibited altered morphology
correlating to the reduced Aβ phagocytosis seen in rodent
models. They found that consistently converting APOE4 to
APOE3 in brain cell types from sporadic AD iPSCs was sufficient
to diminish multiple AD-related pathologies (Lin et al., 2018).










Human iPSC KCNA5, KCNK13,
KCNN4
SCN5A TRPM2, TRPM4, TRPM8,
TRPV1, TRPV2
CACNA1S HVCN1, CLIC1 Haenseler et al.,
2017




Not determined TRPC1, TRPC2, TRPM2,
TRPM3, TRPM4, TRPM7,
TRPMV1, TRPV2, TRPV4
Not determined HVCN1, CLIC1 Gosselin et al.,
2017
Human Purified from post-mortem
dorsal lateral pre-frontal
cortex
KCNN4 Not determined TRPM2, TRPV2 Not determined CLIC1 Olah et al., 2018









HVCN1, CLIC1 Olah et al., 2018
Human Purified from post-mortem
right parietal cortex
KCNK13, KCNN4 Not determined TRPC2, TRPV2, TRPV4 Not determined CLIC1 Galatro et al.,
2017
Human Purified from post-mortem
right parietal cortex
KCNN4 Not determined Not determined CACNA1F Not determined Galatro et al.,
2017
Mouse Primary microglia culture KCNA3, KCNK13,
KCNN4
Not determined TRPM4 CACNA1A,
CACNA1D
Not determined Gosselin et al.,
2017
Mouse Collated Meta-Analysis KCNA1, KCNA2,
KCNN1, KCNN3




Not determined HVCN1 Olah et al., 2018
Rat Primary microglia culture KCNK13, KCNN4 Not determined TRPC4, TRPC6, TRPM2,
TRPM4, TRPV1
Not determined CLIC1 Bohlen et al., 2017
Regulation threshold was set at a 3-fold change over all studies. Anything below this is referred to as not determined.
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They also showed that in their iPSC-derived microglia, TREM2
was positively correlated to the APOE4 genotype. This data
is consistent with reports showing increased levels of soluble
TREM2 in cerebrospinal fluid of AD patients (Heslegrave et al.,
2016). Similarly, protocols for microglia differentiated from
patients carrying missense mutations in TREM2 (that are causal
for frontotemporal dementia-like syndrome and Nasu-Hakola
disease). These studies found subtle effects on microglia biology,
consistent with the adult onset of disease in individuals with
these mutations (Brownjohn et al., 2018). These particular
studies establish a reference for human cell-type-specific changes
associated with the risk of developing AD, providing critical
insight into potential treatments for sporadic AD.
As more is understood about the developmental origin and
unique identity of microglia, recent studies have attempted to
circumvent this issue by deriving microglia from iPSCs in order
to study human and cell-type-specific biology and disease (Muffat
et al., 2016; Abud et al., 2017; Douvaras et al., 2017; Haenseler
et al., 2017; Pandya et al., 2017; Takata et al., 2017; Brownjohn
et al., 2018; Lin et al., 2018). At the whole-transcriptome level,
microglia generated by the methods reported here most closely
resemble cultured primary microglia (Brownjohn et al., 2018).
Due to a lack of unique surface markers, it has historically
been difficult to distinguish microglia from other macrophages
and cells of myeloid lineage. It is only recently that a distinct
transcriptomic profile of microglia has emerged (Hickman et al.,
2013; Butovsky et al., 2014; Holtman et al., 2015; Bennett et al.,
2016; Gosselin et al., 2017; Keren-Shaul et al., 2017; Krasemann
et al., 2017). In this review we have highlighted the similarities
between rodent and human microglia transcriptomics and have
identified key ion channels prominent in human iPSC-derived
microglia, some of which we have already been highlighted earlier
in this review as prominent targets associated with AD (Table 2)
including KCNK13, KCNN4, TRPV2, HVCN1, and CLIC1.
Indeed, the ion channels found from iPSC-derived microglia to
date mirror those found in aged-human tissue (Olah et al., 2018).
Finally, the characterization of the electrophysiological
properties of neurons derived from iPSCs are extremely
limited and even fewer reports on the functional properties
of iPSC-derived glia (microglia and astrocytes). However, with
the development of standardized methods and differentiation
protocols and, importantly, broader functional characterization
of the complex collection of ion channels and receptors expressed
in defined glial and neuronal subtypes from iPSCs, their
significance in drug discovery and neuroscience will become
increasingly valuable.
CONCLUDING REMARKS
Microglial research has expanded dramatically in the last 5 years,
this combined with the lack of new therapeutic options for
treating complex neurological conditions highlights the potential
of these cells to provide a viable alternative. For this to be
realized a clearer picture of human microglial physiology needs
to be established. The development of iPSC technology has been
a great advance in these efforts, but robust protocols are still
in their infancy (Douvaras et al., 2017; Haenseler et al., 2017;
Brownjohn et al., 2018). With microglia being dependent in situ
environments the need to generate more complex 3D models is
even greater. While the development of 3D scaffolds continues
at pace (Saliba et al., 2018), some initial research indicates the
possibility of 3D microglia cultures (Cho et al., 2018). The
challenge will now be to incorporate the diverse range of cells into
these cultures with the ability to provided measurable outcomes
(e.g. electrophysiology). Establishing robust and reproducible
protocols will also allow us to progress into addressing the
role of microglia in pathological states. This is vital if we are
to achieve a therapeutic purpose for targeting microglia ion
channels.
The role of ion channels is extensive within the central
nervous system, however as non-excitable cells microglia
channels often get overlooked. Here we have examined the
microglia ion channel landscape and the evidence that supports
the involvement in Alzheimer’s disease pathogenesis. While there
is still work to be done as highlighted above, this review indicates
that microglia ion channels play a pivotal role in their physiology
and can contribute to the fight against dementia.
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Characterization of DNA Methylomic signatures in induced pluripotent stem cells 




In development, inducing pluripotency and differentiation into different cell types results 
in global epigenetic changes, although the extent this occurs in induced pluripotent stem 
cell (iPSC)-based neuronal models has not been extensively characterized.  
Methods 
iPSC colonies (33Qn1 line) were differentiated and collected at four time-points. DNA 
methylation was assessed using the Illumina EPIC array. After dimensionality reduction, 
we identified dynamic changes during differentiation using a data-driven trajectory 
inference method. 
Discussion 
We identified 5,866 Bonferroni-significant loci during differentiation. A gene-gene 
interaction network analysis identified 50 densely connected genes that are influential in 
the differentiation of neurons, with STAT3 being the gene with the highest connectivity. 
Conclusions 
We have profiled DNA methylation during iPSC-derived neuronal differentiation and 
identified an epigenetic trajectory signature associated with maturation. 
 
Keywords:  
Aging; DNA methylation; EPIC array; Epigenetics; Epigenome-wide association study 




DNA methylation is the most widely studied epigenetic change, as it is the most stable 
and long-lasting modification; there is a vast array of literature linking DNA methylation 
changes in various cell types with aging [239, 242, 243, 260, 430, 431]. Changes to the 
epigenome occur throughout the life course in all tissues and cell types [432-435].  In 
humans, these changes begin very early, with dynamic DNA methylation changes 
reported across fetal development [426], and further changes throughout the life course 
as we age [436].  
In recent years, owing to advances in genomic technology, a number of epigenome-wide 
association studies (EWAS) of DNA methylation have been undertaken in various age-
related complex diseases, including, for example, Alzheimer’s disease (AD) [405, 407, 
437]. Whilst these studies have provided considerable insight into the epigenomic 
landscape of the disease, they were performed on post-mortem brain tissue and so only 
offer a snapshot of what is occurring at the end stages of disease and provide no 
evidence for epigenetic causality. In order to better understand the molecular 
mechanisms underlying disease onset and progression, it is necessary to monitor 
epigenetic changes at multiple time points throughout the disease course. However, this 
is not possible in human studies of inaccessible tissues such as the brain.  
One promising avenue for longitudinal modeling of neurological diseases is through the 
use of induced pluripotent stem cell (iPSC)-derived neuronal cells, as iPSCs are derived 
from human tissue, can be monitored over time and in theory can be transformed into 
any cell type in the body [1]. In recent years iPSC-derived neurons have been 
increasingly used to model various neurological diseases by, for example, utilizing a 
patient line bearing a specific disease-associated genetic mutation [438, 439]. 
Furthermore, through recent advances in epigenetic editing technology it is now feasible 
to model disease-associated DNA methylomic variation. However, there are some 
potential caveats with this approach; whilst differentiated iPSC-derived neurons have 
mature electrophysiological features, including spontaneous electrical activity, 
regenerative induced action potential train activity and hyperpolarized resting membrane 
potentials [273], they do not retain their age-related transcriptomic profile [285]. This lack 
of transcriptional maturity has led researchers to question whether iPSC-derived neurons 
are an appropriate model to study age-related diseases such as AD. Furthermore, much 
like the erasure and re-establishment of epigenetic marks after fertilization, there are 
global DNA methylation changes that occur upon inducing pluripotency [440], which are 
essential for efficient reprogramming [441]. However, to our knowledge, no studies have 
yet longitudinally profiled DNA methylation patterns and the epigenetic “age” of iPSC-
derived neurons during differentiation and maturation. This is an important area to 
address before utilizing these to model neuroepigenetic changes in neurological 
diseases, particularly those that are associated with aging. In this study, we have 
differentiated iPSCs into cortical neurons and assessed their DNA methylation profile at 
different time points during differentiation and maturation to identify DNA methylomic 
trajectories of neuronal aging. 
MATERIALS AND METHODS 
iPSC culture and neuronal differentiation 
This study was performed using one extensively characterised feeder-free human iPSC 
line (33Qn1), originally derived from human fibroblasts by transfection of episomal 
plasmid vectors expressing the six transcription factors Oct4, Sox2, Klf4, cMyc, Nanog, 
and Lin28) [442]. Differentiation was achieved using the SCM1/2 protocol outlined in 
[273]. Briefly, iPSCs were maintained on vitronectin coated plates in Essential 8 flex 
medium, passaged using dispase according to the manufacturer’s instructions (Stem 
Cell Technologies) and were collected four days after initial plating for DNA extraction 
(Day 0 - iPSCs). Neuronal differentiation was started at approximately 70% confluency. 
Differentiation into neuronal precursors was achieved using SLI media (Advanced 
DMEM:F12 (with Glutamax); 1 % Penicillin/Streptomycin (all from Life Technologies); 10 
µM SB431542 (Abcam, Cambridge, Cambs. U.K.); 1 µM LDN 193189 (Stemgent, 
Cambridge, MA, U.S.A); 1.5 µM IWR1 (Tocris Bioscience, Abingdon, Oxon., U.K.), and; 
2 % NeuroBrew-21 without RA (Miltenyi Biotec: Bisley, Surry, U.K) for the first eight days 
followed by LI media for another eight days (Advanced DMEM:F12, 2 mM L-glutamine, 
1 % Penicillin/Streptomycin, 200 nM LDN 193189, 1.5 µM IWR1, and: 2 % NeuroBrew-
21 without RA), after which neuronal precursor cells (NPCs) were collected for DNA 
extraction (Day 16 – NPCs). The remaining neuronal precursors were then terminally 
differentiated and matured as described previously [129] using the sequential addition of 
the SCM1 for seven days (SCM1 contained: Advanced DMEM:F12 (with Glutamax); 1 
% penicillin/streptomycin; 2 % NeuroBrew21 (Miltenyi Biotec); 2 µM PD0332991 
(Selleckchem); 10 µM DAPT (Sigma-Aldrich); 0.6 mM CaCl2 (to give 1.8mM total CaCl2 
in final complete medium, (Sigma-Aldrich)), 200 µM ascorbic acid (Sigma-Aldrich), 10 
ng/mL BDNF (Miltenyi Biotec); 1 µM LM22A4 (Tocris Bioscience); 10 µM Forskolin (FSK, 
Tocris Bioscience), 3 µM CHIR 99021 (Tocris Bioscience), and; 300 µM GABA (Tocris 
Bioscience)) and then SCM2 for the remainder of the maturation period for a further 37 
and 58 days (SCM2 contained: 1:1 Advanced DMEM/F12 (with Glutamax): Neurobasal 
A (Life Technologies); 1 % penicillin/streptomycin (Life Technologies), 2 % NeuroBrew21 
with RA (Miltenyi Biotec); 2 µM PD0332991 (Selleckchem); 3 µM CHIR 99021 (Tocris 
Bioscience); 0.3 mM CaCl2 (to give 1.8 mM total CaCl2 in final complete medium (Sigma-
Aldrich)); 200 µM ascorbic acid (Sigma-Aldrich); 10 ng/mL BDNF (Miltenyi Biotec)). At 
these time points the cells were collected for DNA extraction (Day 37 and Day 58 – 
mature neurons). At each time point cells were collected separately from four wells, 
representing four technical replicates. All collected cells were washed with PBS, pelleted 
down, frozen and stored at -80°C 
Genome-wide quantification of DNA methylation 
DNA was extracted from the 16 cell pellets using a standard phenol chloroform protocol. 
Subsequently, 500ng of genomic DNA was sodium bisulfite converted using the Zymo 
EZ 96 DNA methylation kit (Zymo Research) according to the manufacturer’s 
instructions. Samples were profiled using the Illumina Infinium Human Methylation EPIC 
BeadChip (Illumina) and the Illumina HiScan System (Ilumina).  
All data analysis was done in R version 3.5.2 (Eggshell Igloo). The methylumi package 
[443] was used to extract signal intensities for each CpG probe and perform initial QC, 
with data normalization and pre-processing using the WateRmelon package [153]. 
Additional QC checks were performed using the p-filter function within the methylumi 
package, assessing bisulfite conversion efficiency, and the median methylated and 
unmethylated sample intensities as previously described [437]. Two iPSC samples failed 
the p-filter checks and had low median (un)methylated sample intensities. As a result, 
they were removed from the study. For the remaining 14 samples the data were 
normalized with the dasen function from the wateRmelon package [444]. Prior to any 
analyses, probes with common (>5% minor allele frequency [MAF]) single nucleotide 
polymorphisms (SNPs) within 10 bp of the single base extension and probes with 
sequences previously identified as potentially hybridizing to multiple genomic loci were 
excluded [445], resulting in a final dataset of 847,103 probes. For each of the 14 samples 
the mitotic age and epigenetic age were calculated [154, 155]. Epigenetic age was 
calculated using the latest iteration of the Horvath et al age calculator using the online 
portal; available at: https://dnamage.genetics.ucla.edu/new. 
Probe filtering and dimensionality reduction 
Median absolute deviation (MAD) was computed as a robust measure of variability for 
each CpG site across the four cell stages and the upper fifth percentile value was used 
as a cut-off to determine the most variably methylated loci (41,811 loci). Principal 
component analysis (PCA) without scaling the probes by their variance was then applied 
to obtain a lower-dimensional feature subspace, representing the information explaining 
most of the variance in the dataset.   
Pseudotime trajectory analysis 
A pseudotime trajectory through the cell stages was inferred and plotted using the 
“infer_trajectory” and “draw_trajectory_plot” functions in the SCORPIUS package, 
respectively [270]. The first two principal components of the DNA methylation data was 
subjected as coordinate of the samples to  ‘infer_trajectory’ function which performs k-
means clustering, calculates distance matrix between cluster centres and finds the 
shortest path connecting all cluster centres using a custom distance function, and finally 
fits a curve to the given data using principal curves [270]. 
Next, to identify the loci with the largest contribution to the trajectory inference, we 
regressed each CpG site’s methylation values on the pseudotime variable that had been 
inferred by trajectory analysis, using a general additive model (GAM). This allowed the 
detection of non-linear methylation patterns throughout neuronal differentiation.  The loci 
that remained significant after Bonferroni correction for 41,811 tests were considered as 
robust markers of neuronal differentiation and subjected to further downstream analyses.  
Gene Ontology and pathway enrichment analyses 
We performed Gene Ontology (GO) pathway analysis using the missMethyl R package 
[277], which adjusts for the number of CpGs per gene. 
Gene-gene interaction network analysis 
We used Metacore (Clarivate Analytics) to obtain a set of directed functional regulatory 
interactions between the unique genes annotated to the CpG sites with the largest 
contribution to the trajectory inference. The MetaCore database contains a compilation 
of manually curated and experimentally validated directed gene-gene interactions based 
on existing literature. Its high level of manual curation ensures the creation of highly 
confident interaction network maps. The network reconstruction was restricted to 
interactions reported in humans from the categories “transcriptional regulation”, 
“influence on expression”, “co-regulation of transcription”, and “regulation”, with the 
interaction type (i.e. activation or inhibition) provided when available. Subsequently, the 
R package igraph (version 1.1.2) [446] was used to extract the strongly connected 
component (SCC) from the network obtained through Metacore. The ‘network analyzer’ 
tool from Cytoscape (version 3.4.0) [281] was used to conduct a network topological 
analysis in order to identify key genes with high centrality and connectivity in the network. 
RESULTS 
iPSC-derived neurons have an immature epigenome 
One concern when using iPSC-derived neurons to study diseases of advanced age is 
the biological age of the neurons. We used the Horvath epigenetic age calculator to 
predict epigenetic age based on DNA methylation profiles assessed by the EPIC array 
[154]. The epigenetic age of the iPSCs was negative (i.e. fetal), with the age then 
increasing through differentiation and maturation (Figure 1A). However, even the most 
mature neurons we studied (Day 58) still had a negative epigenetic age (~-0.4 years).  
Another important metric of aging is the number of cell divisions, which is particularly 
interesting to assess in our study as differentiated neurons are post-mitotic. Using the 
MiAge calculator [155] we observed an increase in mitotic age from the iPSC stage to 
the NPC stage and to Day 37 mature neurons (Figure 1B). However, this then plateaued 
in the Day 58 mature neurons. This suggests that whilst the cells are differentiating into 
NPCs and, for at least the first 37 days post terminal differentiation, the cells are still 
replicating. However, at some point after 37 days post terminal differentiation the cells 
stop dividing and become senescent. 
Cell trajectory modeling highlights methylation patterns during differentiation 
In order to further explore how DNA methylation levels change throughout neuronal 
differentiation and maturation, we generated a cellular lineage trajectory signature to 
identify groups of loci that become progressively hyper- or hypomethylated throughout 
differentiation. First, we reduced the dimensionality of the dataset containing the most 
variable CpG probes (41,811 loci), to 14 principal components (PCs), of which the first 
two explained 78% of the variation in that dataset. These two PCs were used as 
coordinates of samples to cluster them according to stage of differentiation/maturation 
(Figure 2A). Samples within each cellular stage clustered together, with the exception 
of one Day 37 neuron sample, which clustered with the Day 58 neuron samples.  This 
could indicate that this sample had aged quicker than the others in the same group; 
however, when we checked the “epigenetic age” of this sample, it was surprisingly the 
second youngest of the four Day 37 neuronal samples. To ensure this sample was not a 
general outlier we clustered all 14 samples based on Euclidean distance (prior to the 
trajectory inference analysis). This highlighted that this Day 37 sample was not an outlier 
in general and clustered together with the Day 58 samples (Supplementary Figure 1). 
Using the pseudotime generated in the trajectory analysis as a predictor, a GAM was 
fitted to the 41,811 probes in order to identify the loci that contributed the most to the 
trajectory inference model. In total we identified 5,866 of the 41,811 loci that showed 
Bonferroni-significant variation in methylation across the cell stages (Supplementary 
Table 1, Figure 2B), which we termed the “epigenetic trajectory signature”. An example 
of the large scale DNA methylation changes occurring through differentiation is 
highlighted by the cg00908292 probe, which is intergenic and located closest to the 
CCR7 gene PBonf= 7.16x10-9. This locus is hemi-methylated in iPSCs, becoming 
progressively de-methylated over time and is largely unmethylated in the terminally 
differentiated mature neurons (Figure 2C).  
Pathway analysis of loci contributing to cell trajectories implicates development, 
signalling and transcription 
We used GO enrichment analysis to identify the pathways that are changing most 
significantly throughout neuronal differentiation. We took the 5,866 loci that comprised 
the epigenetic trajectory signature and grouped these according to whether they were 
becoming gradually hypermethylated (N=1,661) or hypomethylated (N=4,205) over time. 
The progressively hypermethylated loci resided in genes that featured in pathways 
relating to head development, signalling, cell surface receptor signalling, transcriptional 
activity and cell-cell junctions. (Supplementary Table 2, Supplementary Figure 2). The 
progressively hypomethylated loci were associated with neuron projection development, 
synaptic activity and gated channel activity (Supplementary Tables 3, Supplementary 
Figure 3).   
Transcriptional regulation is a highly interconnected process throughout differentiation 
To explore the connectivity between key genes that display progressive DNA methylomic 
changes through differentiation, we performed gene-gene interaction analyses on the 
2,352 unique genes that were annotated (Illumina [UCSC] annotation) to the 5,866 loci 
comprising the epigenetic trajectory signature. The prior knowledge network (PKN) 
obtained from MetaCore contained 602 genes and 1,158 interactions. Only one strongly 
connected component (SCC) existed in this network (i.e. there is only one sub-network 
in which every gene can be reached through any other gene in the same sub-network), 
comprised of 50 genes and 138 interactions between them (Supplementary Table 4, 
Figure 3). The conducted topological network analysis highlighted the key genes in this 
SCC with outstanding topological characteristics, including out-degree (set of target 
genes it regulates), in-degree (set of upstream regulating genes), betweenness centrality 
(most influential genes based on their shortest paths to other genes in the network), and 
clustering coefficient (a measure of gene tendency to cluster with other genes in the 
network). STAT3 was the gene with the highest connectivity (Neighbourhood 
Connectivity = 9.43, Clustering Coefficient = 0.02) in the SCC, according to its in-degree 
(9) and out-degree (62), suggesting it may play a key regulatory role in this SCC. 
Previously, alterations in STAT3 signalling have already been observed to be associated 
with age-related changes in different cell types [447, 448]. 
DISCUSSION 
In this study we have used the Illumina Infinium EPIC array to profile DNA methylation 
in iPSCs and throughout their differentiation and maturation into neurons. One of the 
concerns regarding using iPSC-derived neurons to study diseases of aging is that they 
have been reported to lose their age-associated transcriptomic signatures [285]. 
Similarly, in our study we have shown that iPSCs, NPCs and post-terminally 
differentiated neurons have an immature epigenomic profile according to the Horvath 
epigenetic age calculator. This is particularly interesting given that these iPSC-derived 
neurons have been previously shown to be functionally mature at these time points [273]. 
Mertens and colleagues showed that although neurons derived from iPSCs lose their 
age-related transcriptional profiles and were comparable to embryonic or immature 
neurons, this was not the case with inducible neurons (iNs), which are neurons 
generated directly from fibroblasts that do not go through the intermediate stem cell 
phase [285]. Alongside the age-related transcriptomic profiles of iNs, they also exhibit 
age-dependent nucleocytoplasmic compartmentalisation and maintenance of epigenetic 
age, unlike iPSC-derived neurons. In the future, it will be of interest to assess the mitotic 
age and epigenetic trajectories of iNs.  It will also be important to utilize a number of 
different iPSC lines and to culture the iPSC-derived neurons for longer than 58 days, to 
explore how this affects the epigenetic age and epigenetic trajectory. Another important 
point to consider is that the epigenetic age calculator is reported to be inaccurate in 
juvenile samples, presumably because DNA methylation changes are more dynamic in 
children [449]. As all of the samples used in our study were estimated to have an 
epigenetic age <1 year, it is possible that these predictions are inaccurate, and the 
biological age of the samples is greater than predicted. Another important marker of 
aging for cells is their number of divisions, which is particularly interesting in the context 
of our study as the differentiated neurons (Day 37 and 58) are post-mitotic and therefore 
should no longer be dividing. We showed that although the mean mitotic age increased 
from the iPSC stage through to 37 days post-differentiation, this plateaued at day 58, 
indicating that the neurons had become post mitotic. This decrease could be due to 
imperfect differentiation in some of the day 37 samples, causing there to be 
contamination of proliferating non-neural cells. The fact that the mitotic and epigenetic 
age show different patterns across differentiation/maturation, with the epigenetic age still 
increasing at day 58, corroborates previous findings that epigenetic age does not reflect 
mitotic age [247].  
One interesting observation from the creation of the cell lineage network was that one of 
the day 37 terminally differentiated neuron samples clustered more closely with the day 
58 terminally differentiated neuron samples, than with other samples of the same cellular 
stage. We considered that this sample may have “aged” faster than the other day 37 
neurons however, upon further investigation this sample actually had the second lowest 
epigenetic age and has the lowest mitotic age of the day 37 group. This could therefore 
suggest that the probes used to determine epigenetic age are not contributing to the 
epigenetic trajectory signature we identified that distinguished between the different 
cellular stages.  
Our pathway analysis highlighted that probes comprising the epigenetic trajectory 
signature are largely involved in gene regulation and neural development. The gene-
gene interaction network analysis of the epigenetic trajectory signature identified a highly 
connected, epigenetically altered sub-network of 50 genes, featuring 138 interactions. 
STAT3 was the most connected gene in the SCC subnetwork. This gene is known to be 
involved in neuronal survival and function, for example, STAT3 and other members of 
the JAK/STAT pathway have been shown to play key roles in the control of neuronal 
proliferation, survival and differentiation [292, 293]. Primary neuronal and SH-SY5Y cells 
have been shown to be highly susceptible to treatment with the STAT3 inhibitor 
tryphostin, with a significant percentage of both cell types (80-100%) dying even at low 
concentrations [292]. The fact that STAT3 was identified as a key gene by the network 
analysis highlights its importance in the epigenetic trajectory signature, which is further 




In this study, we have characterized genome-wide patterns of DNA methylation and 
identified an epigenetic trajectory signature of 5,866 loci that become progressively 
hypermethylated or hypomethylated during the course of neuronal differentiation and 
maturation from iPSCs. These loci reside in genes that were over-represented in 
processes related to gene regulation and transcription.  
 
FUTURE PERSPECTIVE 
Since the creation of iPSCs they have been increasingly used to study neurological and 
neurodegenerative diseases. However, to date iPSC-derived neurons have not been 
usedto study the epigenetic aberrations known to be associated with various age-related 
disease. Here we have investigated DNA methylation changes occurring throughout 
iPSC-derived neuronal differentiation in order to better understand iPSC-derived 
neurons as a model system in the context of the epigenome. One caveat of our study is 
that we have examined only one iPSC line (33Qn1). Looking into the future, it will 
therefore be important to explore whether our epigenetic trajectory signature is 
reproducible in neurons derived from other iPSC lines. Similarly, it will be of interest to 
compare iPSC-derived neurons to iN-derived neurons, and to profile neurons beyond 58 
days post-terminal differentiation. Another important logical next step for the future will 
be the profiling of other types of epigenetic markers, such as histone modifications and 
general chromatin accessibility. Ultimately, different types of epigenetic information will 
need to be integrated with matched transcriptomic data in order to deconvolute the role 




Induced pluripotent stem cells (iPSCs) 
• Through the introduction of pluripotency factors into differentiated adult cells it is 
possible to create iPSCs. 
• Induction of pluripotency leads to global epigenetic changes. 
Epigenetic and mitotic age change throughout neuronal differentiation 
• Epigenetic age increases as iPSCs differentiate into neurons. However. even 
day 58 neurons have a fetal epigenetic age.  
• Mitotic age increases initially during differentiation but after terminal 
differentiation plateaus. 
DNA methylation changes occur at a large number of loci 
• Bonferroni significant changes to DNA methylation changes occurred at 
5,866 loci. 
• 1,661 of these loci became progressively hypermethylated during 
differentiation 
Gene-gene interaction analysis nominates STAT3 as a key gene in 
differentiation 
• A gene-gene interaction analysis identified 50 genes, with 138 
interactions, with STAT3 being the most connected gene. 
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Figure 1: The predicted biological ages of iPSC-derived neurons through differentiation. As two iPSC samples did not pass the quality control 
checks there are only two samples in the iPSC group of each graph. (A)  The estimated epigenetic age (Y-axis) of the four cellular stages (X-axis) 
increased throughout differentiation, with the Day 58 neurons having the highest epigenetic age, although the mean age was still <0.5 years.  (B) The 
estimated mitotic age (number of cell divisions - Y-axis) of the four cellular stages (X-axis) increased until 37 days post-terminal differentiation, after 
which point it plateaued suggesting the day 58 neurons had become senescent.  
 
 
Figure 2: Trajectory inference modelling identifies a signature of 5,866 probes that distinguish cell stage. (A) To create the trajectory model 
dimensionality reduction was first performed, using PCA, followed by estimating pseudo-time to model the lineage trajectory. The different samples 
grouped together based on the first two principal components. (B) Using the pseudo-time estimation a generalised additive model was used to determine 
which of the 5,866 probes were becoming hypomethylated (blue) or hypermethylated (red) over time. The patterns of hypomethylation and 
hypermethylation could distinguish the different cell stages. (C) The DNA methylation patterns occurring at the most significant probe throughout 


























Figure 3: A subnetwork of 50 genes constituting the strongly connected component (SCC) in the gene-gene interaction network. Directed 
gene-gene interaction network was constructed for 2,352 unique genes that were annotated to the 5,866 loci comprising the epigenetic trajectory 
signature. The prior knowledge network (PKN) obtained from Metacore contained 602 genes and 1,158 interactions. Only one strongly connected 
component (SCC) in this network, comprising of 50 genes and 138 interactions between them was identified, blue nodes indicate genes becoming 
progressively hypomethylated, red nodes indicate genes becoming progressively hypermethylated and grey ovals indicate genes that have more than 















Supplementary figure 1: Clustering of 14 samples based on Euclidean distance prior Trajectory inference analysis. One sample from Day 37 






Supplementary figure 2: Pathway analysis of loci becoming progressively hypermethylated throughout differentiation. Gene ontology (GO) 
enrichment analysis was performed on the 1,661 loci shown to become progressively hypermethylated throughout neuronal differentiation. Treemaps 
illustrating the pathways relating to (A) biological pathways (BP), (B) cellular components (CC) and (C) molecular functions (MF) that are changing 
throughout differentiation are shown. For each treemap, terms relating to the same pathway are grouped together and have been given the same 
colour, the term that summarizes the grouped pathways is at the centre of each section and is written in bold text.  
Supplementary figure 3: Pathway analysis of loci becoming progressively hypomethylated throughout differentiation. Gene ontology (GO) 
enrichment analysis was performed on the 4,205 loci shown to become progressively hypomethylated throughout neuronal differentiation. Treemaps 
illustrating the pathways relating to (A) biological pathways (BP), (B) cellular components (CC) and (C) molecular functions (MF) that are changing 
throughout differentiation are shown. For each treemap, terms relating to the same pathway are grouped together and have been given the same 
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